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Abstract 
Intellectual disability (ID) is devastating condition which is defined using three 
criteria: reduced intellectual ability, deficit in two or more adaptive behaviours, 
and diagnosis before the age of 18 years. ID can have various causes, but 
genetic factors are thought to be responsible for up to 50% of cases. ID is a 
heterogeneous and complex disorder, and more than 800 genes have been 
implicated in its pathology. Schizophrenia (SZ) is another complex 
neurodevelopmental condition that also affects the brain and has a partially 
overlapping genetic basis with ID. This thesis describes work carried out into the 
genetic basis of ID and SZ. 
 
The ID project was focused on ID in consanguineous families recruited in Oman. 
Next generation sequencing allowed the identification of apparently causative 
mutations in three out of the six families recruited. The mutations are all novel, 
although some of them occur in previously associated ID genes. The known ID 
genes in which novel mutations were identified are TUSC3 (NM_006765: 
exon2:c.222delA, p.R74 fs) and NHS (NM_198270:exon8: c.C4385G, 
p.S1462C). A novel LHFPL5 variant (NM_182548:exon2:c.T575C, p.L192P) was 
also identified in an ID family with hearing loss. In one ID family, mutations in two 
genes not previously associated with ID were found: ANKRD2 
(NM_001129981:exon8:c.C883T, p.R295W) and PDZD8 (PDZD8:NM_173791: 
exon5:c.2197_2200del, p.733_734del). 
 
The SZ project was focused on two SZ families recruited in the UK. Preliminary 
work on these families had suggested the involvement of homozygosity for 
genetic variants in the DFNB31 gene and in a region of Chr13q in the 
pathogenesis of schizophrenia. Further experiments to validate the initial findings 
included testing the overexpression of the DFNB31 variant (R450C) in the SH-
SY5Y cell line, pull-down assay and transcript analysis of the genes located at 
Chr13q. 
 
Identification of the causative mutated gene is an important step in understanding 
more about the biology of ID and SZ. It also facilitates carrier testing and genetic 
counselling, and identifies a pathway for potential therapeutic intervention. 
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Chapter 1: General Introduction 
1.1 Preface  
The human brain regulates many of the highly complex life processes and 
controls the unique behaviours associated with human thought, memory and 
ingenuity, including feeling, thinking, reasoning and perception. Our brains not 
only work when we are awake, they are also active while we sleep (Walker and 
Robertson, 2016). This impressive organ has a cohesive structure involving 
specialized cells called neurons which are the basic units responsible for 
processing and transmitting signals and sensory information rapidly throughout 
the central nervous system (Melillo and Leisman, 2010). Neuronal cells do not 
look exactly alike as they have different structural themes but they generally 
share the basic structure of the cell body, dendrites and axons (Figure 1.1). 
Dendrites are specialised branched projections found at the end of neurons and 
their function is to receive and propagate the incoming information from other 
neurons. The information is received as signals at the synapse where the 
neurotransmitters convey the message. It is then the role of the axons, which are 
slender-forming cable-like extensions throughout the nervous system, to 
broadcast the neuronal impulse to other cells (Qu et al., 2017). There are about 
100 billion neurons in the adult brain and each of them has the ability to establish 
up to 10 thousand synaptic connections with other neurons (Herculano-Houzel, 
2009).  
 
The dense wiring of the interconnected network makes the brain a highly efficient 
and complex system, but its soft and delicate tissues make the brain vulnerable 
to trauma. Because of that, the brain is highly protected by the hard skull bones 
and also surrounded by the cerebrospinal fluid which provides structural support 
and extra protection. The number of genes involved in neurodevelopment is more 
than required to build any other organs like heart or liver. The precise number 
genes is not actually known but studies suggest that 80% of genes in the human 
genome are expressed in the brain (Jain, 2013). 
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Figure 1.1. Structure of neurons: schematic and real-tracing images. On the left is 
a picture of a neuron with its multiple branched dendrites. This neuron is firing into 
another neuron through the axon which forms the synapse. To the right is an outlining of 
a real neuron when visualised after labelling it with molecules of biocytin, as described 
by Lee Christian R and Tepper (2007). The body cell and the dendrites are shown in 
black. The axon is shown in red. (Adapted from Striedter (2015) with written permission).    
 
Not all the genes are expressed at the same time; different genes are expressed 
at specific developmental stages (Harris, 2015). Pre-natal and post-natal 
environmental factors can also have important effects on the development of the 
brain (Homberg et al., 2016). The pre-natal factors include nutrition, infection, and 
maternal stress during pregnancy (Wingenfeld and Wolf, 2011). After birth, the 
brain becomes more plastic at different stages of neurodevelopment (Figure 1.2) 
(Hensch and Bilimoria, 2012). A complex interaction of environmental influences 
and genetic factors plays a role in the process of neurodevelopment. Given the 
many genes involved in neurodevelopment and the importance of genetic factors 
in the maturation and development of the human brain, it is not uncommon for 
neurodevelopment to be disrupted by genetic errors. 
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Figure 1.2 Intervals of external inputs essential in enhancing brain plasticity. After 
birth, there are sensory inputs which include hearing and seeing effects. Subsequently, 
the motor/language inputs occur and these mainly incorporate perception, movement 
and speech skills. The third input is crucial to supporting the brain circuit related to 
developing higher cognitive functions and problem solving. There are no distinct borders 
between these inputs in which the brain has peaks of plasticity. (Adapted from Hensch 
and Bilimoria (2012), no permission required). 
 
Most genetic mutations seem to affect the ability of neurons to send signals to 
other neurons (Grant, 2012; Picker and Walsh, 2013) but there are multiple ways 
by which brain function can be impaired. Depending on the genes involved and 
the types of mutation, the impairment of neurodevelopment can range from mild, 
to moderate, to severe, with or without additional co-morbid clinical features. For 
example, nonsense mutations in the CRBN gene (Cereblon OMIM 609262) 
cause mild intellectual disability (ID) with no other abnormalities (Kaufman et al., 
2010; Xu Guoqiang et al., 2013) whereas mutations in the PHF6 gene (Plant 
HomeoDomain (PHD)-like finger 6, OMIM 300414) cause Borjeson-Forssman-
Lehmann syndrome (BFLS), which is characterized by a severe type of ID, 
especially in males, with other manifestations including several dysmorphic 
features, underdeveloped genitalia and obesity (Berland et al., 2011; Gecz et al., 
2006; Jahani-Asl et al., 2016). Sometimes, the gene variants do not directly affect 
general cognitive ability but disrupt particular thought processes and perception, 
resulting in psychiatric symptoms such as delusion and hallucination. Examples 
include mutations in NRG1 (Neuregulin 1, OMIM 142445), which is linked to 
schizophrenia, major depressive disorder and bipolar disorder (Barz et al., 2015; 
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Wen Zujia et al., 2016) and C4, which was recently associated with schizophrenia 
(Mayilyan et al., 2008; Sekar et al., 2016). 
 
Identification of the causative genes underlying rare familial forms of these 
disorders will provide a better understanding of disease pathogenesis and will 
inform our understanding of the possible causes of more common, sporadic forms 
of these conditions. For example, the application of linkage analysis to families 
with Alzheimer’s disease (AD) in the 1990s led to the key finding that mutated 
APP (Amyloid Beta a4 Precursor protein OMIM 104760) and PSEN1 (Presenilin 
1, OMIM 104311) are responsible for the development of AD. Without this 
discovery, it would not have been possible to formulate the prevailing “amyloid 
cascade hypothesis” which explains the plaque formation in AD pathogenesis 
(Mohamed et al., 2016). Similarly, the mapping and discovery of SNCA 
(Synuclein, Alpha, OMIM 163890) variants in Parkinson’s disease (PD) families 
(Polymeropoulos et al., 1996; Polymeropoulos et al., 1997) was a milestone in 
finding an early understanding of the molecular changes associated with PD. With 
more research and advances in technology, mutations in many other genes, such 
as LRRK2 (Leucine-Rich Repeat Kinase 2, OMIM 609007), PRKN (Parkin, OMIM 
602544),  MAPT (Microtubule-Associated Protein Tau, OMIM 157140), EIF4G1 
(Eukaryotic Translation Initiation Factor 4-Gamma 1, OMIM 600495) and PINK1 
(Pten-Induced Putative Kinase 1, OMIM 608309) have been implicated in PD 
pathogenesis (Bekris et al., 2010; Trinh and Farrer, 2013) which resulted in a 
better understanding of PD. 
 
A better understanding of pathogenic processes will also allow new potential 
therapeutic targets to be identified. Despite the availability of some educational 
and management plans to support families with neurodevelopmental disorders, 
there is much scope for more efficient therapies. A major challenging issue 
related to the success of the available therapy in neurodevelopmental disorders 
is the need to identify them very early since they usually begin before birth. Even 
when applying a particular process to correct an associated phenotype, there are 
still some complications. For example, it was found that using posterior spinal 
fusion with unit rod instrumentation could resolve the twisted spinal cord 
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(scoliosis) in Rett syndrome (RTT, OMIM 312750), one of the syndromic ID 
caused by mutations in MECP2 (Methyl-CpG-Binding Protein 2, OMIM 300005),  
but a high rate of postoperative medical complications is normally expected 
(Gabos et al., 2012).  It is true that some studies on FMR1 knock-out mice  have 
shown worthy amendments in several abnormalities of FXS (Fragile X Syndrome, 
OMIM 300624) when using mGLuR5 (Metabotropic glutamate receptor subtype 
5) inhibitors (Dölen et al., 2007; Michalon et al., 2012) but phase 2 clinical trials 
with the mGluR5 inhibitors basimglurant and mavoglurant reported no 
improvement in the clinical phenotype of patients with fragile X syndrome (Scharf 
et al., 2015). 
 
The search for an effective treatment for neurodevelopmental disorder is 
accelerating and various techniques are still on trial phases in animal as well as 
in humans. Progress has already been achieved in some of the conditions with 
intellectual disabilities.   For example, Eisengart and colleagues (Eisengart et al., 
2013) found that introducing enzyme replacement therapy (ERT) intravenously 
could assistance the cognitive ability of patients with Hurler syndrome 
(Mucopolysaccharidosis type IH, OMIM 607014), which is caused by deficiency 
in α-L-iduronidase. Furthermore, various trials of different therapeutic approaches 
to improve cognitive impairment of neurodevelopmental diseases are also 
ongoing and these include microRNA, stem cell and gene therapy (Picker and 
Walsh, 2013). More details about the different therapeutic strategies, that have 
been carried out to find a promising treatment, can be found in chapter 5 (Section 
5.4).   
 
Consanguineous families have been good sources to study the genetics of 
inherited diseases. A consanguineous family is one that results from marriage 
between two individuals belonging to a recent common ancestor.  Because of 
different reasons including economic benefit, educational level as well as cultural 
causes, consanguineous marriages have been practiced since the early 
existence of modern humans (Fuster and Colantonio, 2004; Hamamy, 2012; 
Na’amnih et al., 2014). Modell and Darr (2002) mention that 20% of the world 
population lives in communities with a preference for consanguineous marriage. 
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According to (Bittles and Black, 2010), not less than one billion individuals in the 
global population live in societies with a preference for consanguineous marriage.  
 
In Arab populations, consanguinity is a long tradition that is a deeply rooted 
custom because of socio-cultural factors among Muslim communities (Bittles, 
2008; Bittles and Black, 2010; Na’amnih et al., 2014). A study by (Sharkia et al., 
2016), carried on Arab community in Israel, found the highest rate of 
consanguineous marriage was among Muslims, followed by Druze, with the 
lowest rate in Christians. Compared with its very small ratio in the Western 
population (~1%), Arabs have much higher percentage range consanguineous 
marriages, which is between 25% and 55% (Sharkia et al., 2016). Many Arab 
countries display some of the highest rates of consanguineous marriage in the 
world, specifically first cousin marriages, which are the most common type of 
consanguineous union. According to Al-Gazali et al. (2006), despite the 
increased risk of autosomal recessive diseases, congenital malformations and 
mental retardation, the overall opinion in the Middle East remains in favour of 
consanguineous marriage. 
 
Oman, which is the second largest territory in the Arabian Peninsula, has a 
relatively high rate of consanguineous marriage compared with other countries of 
the world (Rajab Anna et al., 2013). One large scale survey, which included all 
sections of the Omani population, found that 24.1% of all marriages were 
between first cousins and 11.8% were between second cousins, while a further 
20.4% of marriages were contracted within specific tribal groupings  (Rajab A and 
Patton, 2000).  Another study, by Al-Gazali et al. (2006) comparing the rate of 
first-cousin marriages among Arab countries, found that Oman has a high rate of 
about 25%. The offspring of consanguineous families are normally at a higher 
risk of inherited disorders, so this type of family is of great importance in studying 
the underlying genetics. Consanguineous marriage increases the chance that 
both members of a couple will carry any recessive variant that is being transmitted 
in their family, and that this will manifest in the homozygous state in their children 
(Modell and Darr, 2002).  
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1.2 Intellectual disability (ID) 
 1.2.1 ID overview 
There are different overlapping terms for intellectual disability including mental 
handicap, mental retardation, developmental delay and learning disability. The 
term “mental retardation” has been widely used in the literature to describe 
individuals with significantly impaired intellectual functioning, but was seen as 
disparaging, and now “intellectual disability (ID)” is preferred by most researchers 
(Lai et al., 2012). The brains of individuals with ID do not function within the 
normal range for their ages. Affected individuals cannot meet the personal and 
social demands expected of them. They have a significantly reduced ability with 
regard to intellectual reasoning and adaptive skills (Huang Jichong et al., 2016a). 
School age children with ID may struggle with memory, problem solving, 
attention, reading, language, mental arithmetic and visual comprehension. They 
usually develop more slowly than their peers and soon fail to achieve 
developmental milestones in some, or all, of the developmental domains 
(Goharpey et al., 2013; Kok et al., 2016). 
 
ID is a major health issue among young adults, with a worldwide estimated 
prevalence of about 2-3% (Maulik et al., 2011). It tends to be more common in 
developing countries due to the effect of environmental factors such as poor 
medical care, infection and malnutrition (Emerson and Hatton, 2007; Lakhan, 
2015; Maris et al., 2013). ID is defined using three criteria: reduced intellectual 
ability, deficit in two or more adaptive behaviours and diagnosis before the age 
of 18 years (Carulla et al., 2011). 
 
There has been a gender bias in the prevalence of ID and other 
neurodevelopmental disorders: more boys are diagnosed than girls by about 30-
50% (Abikoff et al., 2002; Polyak et al., 2015; Richardson S. A. et al., 1987). In a 
study of Taiwanese children aged 3-17 years between 2004 and 2010, it was 
found that 59.2% of ID patients were boys and 40.8% were girls (Lai et al., 2012). 
This difference could be partially due to the high contribution of X-linked 
disorders, as up to 10% of the known genetic causes of ID are located on the X 
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chromosome (Gandomi et al., 2014; Niranjan et al., 2015). It is also reported that 
more boys are affected with Fragile X syndrome than girls (Polyak et al., 2015; 
Saldarriaga et al., 2014) but the alternative intact X-chromosome in females 
participates in compensating the deficiency (Raymond, 2006).  
 
 1.2.2 ID types 
The Intelligence quotient (IQ) is the main measure that is used to quantify the 
severity of intellectual impairment. It is a statistical assessment of the thinking 
and reasoning ability of a person compared with individuals of the same age. 
Average IQ within each age group is set at 100, and a person with an IQ below 
70 is recognised as having intellectual disability (Webb and Whitaker, 2012). 
Different systems have been used for IQ tests but the most commonly used ones 
are the Stanford-Binet intelligence scale and the Wechsler Adult Intelligence 
Scale (WAIS) (Silverman et al., 2010). Based on IQ score, the Diagnostic and 
Statistical Manual of Mental Disorders (DSM) divides ID into the following 
categories: mild, moderate, severe and profound (Carulla et al., 2011; Katz and 
Lazcano-Ponce, 2008; Schuchardt et al., 2010). Table 1 gives more details of 
each category. 
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ID type IQ score 
Description of  functional level and 
support needed 
Approximate proportion 
Mild 50-69 
Intermittent support needed during 
transitions or periods of uncertainty 
85% 
Moderate 36-49 
Acquire some communication and self-help 
skills, require limited support in daily 
situations 
10% 
Severe 20-35 
Acquire only basic self-help and 
communication skills, require extensive 
support for daily activities 
3.5% 
Profound <20 
Require highly structured and supervised 
living conditions for every aspect of daily 
routines 
1.5% 
 
 
Table 1.1. Classification of ID based on IQ score as described by Boat and Wu (2015).
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Sometimes, the mode of inheritance is also cited beside the ID to indicate its type. 
Although the genetics of ID is separately highlighted in a subsequent section 
(1.2.4), some of the genetics are mentioned here to explain the classification 
point.  X-linked ID (XLID, OMIM 309530) is caused by mutations in genes on the 
X chromosome. Over 150 syndromes have been described (Lubs et al., 2012) 
but the most common example is fragile X syndrome (FXS), which is caused by 
an expanded trinucleotide repeat (CGG) in the FMR1 gene (Fragile X Mental 
Retardation Protein, OMIM 309550). Unaffected people have between 6 and 54 
copies, whereas FXS patients have over 200 copies (Willemsen et al., 2011). 
Nance-Horan syndrome (NHS, OMIM: 302350) is one of the rare X-linked 
disorder which is thought to be under diagnosed and not fully evaluated (Toutain, 
2003). The condition is characterized by congenital cataracts, teeth anomalies as 
well as  intellectual disability, and it was first described by two independent 
studies (Horan and Billson, 1974; Nance et al., 1973). The bilateral cataract is 
normally severe in the affected males and would require an early surgical 
intervention in order to stop profound vision loss (Burdon et al., 2003). Other 
reported ocular abnormalities include small eyes (microphthalmia), small cornea  
(microcornea), recurrent eye movements (nystagmus) and absence of bilateral 
alignment during object focus  (strabismus) (Hong et al., 2014).  
 
The characteristic teeth anomalies which have been described in Nance-Horan 
syndrome include screwdriver or cone-shaped incisors, supernumerary maxillary 
incisors (mesiodens) and increased gap between teeth (diastema) (Stevenson et 
al., 2012; Walpole et al., 1990). About 30-50% of individuals with NHS have 
intellectual disability (Brooks et al., 2010). In some of the cases, additional 
specific facial phenotypes have also been reported like inclination in the external 
part of the ear (anteverted pinnae), shortening in any of the five bones of the hand 
(metacarpals), and long face (Coccia et al., 2009). The severity of the above-
mentioned symptoms would significantly differ from person to person even within 
members of one affected family. Carrier heterozygous females have been 
reported with some milder forms of these related manifestations but intellectual 
disability tends to less likely to occur in those females (Ding et al., 2009; Tug et 
al., 2013; Zhu D et al., 1990). The reported NHS mutations are, so far, not less 
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than 33 and most of them are either nonsense mutations or InDels (insertions 
and deletions) but CNVs (copy number variations), missense and splice site 
mutations are few (Tian et al., 2017).  
 
The autosomal recessive intellectual disability (ARID, OMIM 611093) forms have 
not been well studied as the search for the underlying causes has been largely 
hindered by the scarcity of big consanguineous families in the Western 
communities (Kuss et al., 2011). Joubert Syndrome (JBTS, OMIM 213300) with 
related disorders (JSRD) (Brancati et al., 2010) and Bardet-Biedl syndrome 
(BBS1, OMIM 209900) (Forsythe and Beales, 2013) are examples of autosomal 
recessive ID. JSRD are a group of developmental disabilities and various 
congenital abnormalities but an essential diagnostic hallmark to distinguish this 
group is the presence of molar tooth sign (MTS), which is a unique cerebellar and 
brainstem marker visible on brain imaging (Brancati et al., 2010; Romani et al., 
2013). Bardet-Biedl syndrome (BBS) is characterized by defects in multiple organ 
systems but its main features are rod-cone dystrophy, obesity, hypogonadism, 
postaxial polydactyly, renal dysfunction and intellectual disability (Zaghloul and 
Katsanis, 2009).  
 
The autosomal dominant ID (ADID, OMIM  614563) are not commonly seen due 
to the fact that patients with intellectual disability rarely reproduce 
(Winnepenninckx et al., 2003). The conditions of autosomal dominant ID are 
mainly reported with de novo mutations (Khan Muzammil Ahmad et al., 2016) 
and one example is chromosome 2q23.1 deletion syndrome (Van Bon et al., 
2010). In fact, duplication of this 2q23.1 region has also been described 
(Mullegama et al., 2014) to cause a similar effect. Although the autosomal 
dominant Marfan Syndrome (MFS, OMIM 154700) (Hofman et al., 1988) is a 
disorder of mainly connective tissue with involvement of  cardiovascular, skeletal, 
ocular and pulmonary systems, some cases of intellectual debility have also been 
described (Ades et al., 2006; Hoffjan, 2012). 
 
There is also a different ID classification based on whether other clinical features 
are also present. When low IQ is the sole clinical feature and the only 
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manifestation of ID, this is classified as non-syndromic ID. Syndromic ID is 
characterised by learning disabilities in the presence of other, co-morbid clinical 
features, such as large, protruding ears, long face and adult macro-orchidism of 
Fragile X syndrome, or the stunted growth, atypical fingerprints and eyelid crease 
of Down syndrome (DS, OMIM 190685). Other examples of syndromic ID include 
Rett syndrome (RTT, OMIM 312750), Angelman syndrome (AS, OMIM 105830) 
and Prader-Willi syndrome (PWS, OMIM 176270). Distinguishing between 
syndromic and non-syndromic forms of ID is sometimes difficult because the co-
morbid features may be subtle (Miclea et al., 2015). Some researchers believe 
that the same genes are sometimes involved in both syndromic and non-
syndromic ID, suggesting that there might be no strict boundaries between these 
forms (Beaulieu et al., 2013; Birk et al., 2010; Frints et al., 2002; Tejada et al., 
2011). 
 
1.2.3 Environmental causes of ID 
ID can have various causes, but genetic factors are thought to be responsible for 
up to 50% of cases (Karam et al., 2015; Kaufman et al., 2010). A wide range of 
environmental insults occurring during pregnancy, childbirth or infancy may 
account for the other half of cases. Exposure of the fetus to drugs or alcohol is 
the most common cause of ID during pregnancy. A significant contributor to the 
non-genetic causes of ID, with a general prevalence of 1-2 in every 1000 babies, 
is Fetal Alcohol Syndrome (FAS), in which the fetal brain is affected by alcohol 
crossing the placenta (Aronson and Hagberg, 1998; Cesconetto et al., 2016; 
Miller, 2014; Senturias and Asamoah, 2014). A wider range of 
neuropsychological impairments is associated with Fetal Alcohol Spectrum 
Disorder (FASD), another consequence of fetal exposure to alcohol. FASD is a 
major contributor to ID in the Western world and the different levels of FASD 
affect about 2-5% of the population (May et al., 2013). In the UK, there are 7000 
babies born every year at high risk of FAS and FASD (Larcher and Brierley, 
2014). The behaviour of these babies is determined by different factors, including 
the amount of consumed alcohol, maternal metabolism and developmental stage 
of the fetus during exposure (Basavarajappa and Subbanna, 2016). 
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Environmental causes of ID that might take place during birth are preterm birth, 
oxygen deprivation and brain trauma. There have been various reports describing 
different degrees of risk of ID and attention deficit in preterm babies (Anderson 
Peter J, 2014; Hutchinson et al., 2013; Litt et al., 2005; Soleimani et al., 2014). A 
UK study by Johnson and coworkers (Johnson et al., 2016), involving 161 
children born extremely preterm (EP) and 153 term-born controls, showed that 
the prevalence of ID was 47% in EP children compared with only 4.6% in the 
controls. ID is known to occur as a result of hypoxia or oxygen shortage 
(Sigelman and Rider, 2014), due to inadequate delivery of oxygen to cells. In 
cases of hypoxia, lysophosphatidic acid (LPA) receptors are activated, leading to 
overactivation of signalling pathways. As a result, the mitotic neural progenitor 
cells (NPCs) are driven to migrate from their normal specific regions within the 
developing brain into more superficial areas and thus fail to grow properly (Herr 
et al., 2011). 
 
Brain trauma occurring before, during or after birth can also cause long-
lasting/permanent harm to the brain (Carone, 2014; Foreman, 2009). A 
retrospective study was carried out to investigate the intellectual capability of 63 
children aged less than 15 years, who had experienced severe traumatic brain 
injury (TBI) (Chevignard et al., 2016). IQ tests carried out 7-8 years after the injury 
showed that the children with TBI performed significantly worse than age and 
ethnicity matched healthy controls (p=0.016). 
 
Other environmental causes of ID that can occur in early childhood include severe 
malnutrition and some infections. The diet is known to have an important effect 
on brain function and cognition (Gillette‐Guyonnet et al., 2013; Mangialasche et 
al., 2013). Deficiencies in any of the essential micronutrients have been 
associated with the development of various functional deficits (Kuper et al., 2015). 
For example, Waber and colleagues reported impaired IQ in adulthood as a result 
of malnutrition during infancy (Waber et al., 2014), while Swaminathan and co-
workers reported that reduced cognitive and physical performance in Indian 
children was related to a shortage in vitamin B and folate intake (Swaminathan 
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et al., 2013). The mechanism by which nutrition affects the development of the 
brain is complex. The processes of metabolism, enzyme production, energy 
control, neurogenesis, neurotransmission and synaptic plasticity are all affected 
by diet (Dauncey, 2014). Certain prenatal infections, like rubella, cytomegalovirus 
or Toxoplasma gondii, can disturb development of the fetus, and are also 
plausible risk factors for brain damage (Spreen et al., 1995). Various studies 
suggest that such infections can cause cognitive impairment and autistic 
spectrum disorders but the evidence is inconsistent (Bilder et al., 2013; Meyer et 
al., 2007). A study of a big cohort of individuals born in Sweden between 1984 
and 2007 to mothers who were diagnosed with infection during pregnancy 
provides evidence that infections during pregnancy increase the risk of children 
having Autism spectrum disorder (ASD, OMIM 209850) (Lee Brian K. et al., 
2015). Another study which checked children with ASD and ID for CMV infection 
concluded that congenital CMV infection is a potential contributor to ASD, 
particularly if the condition is also combined with ID (Engman et al., 2015). 
 
1.2.4 ID genetics 
The precise proportion of ID cases caused by gene mutations is unknown, but 
the literature states proportions ranging from 15 to 50% (Karam et al., 2015; 
Kaufman et al., 2010; Moeschler and Shevell, 2006). It is not unexpected for 
genes to have such a significant contribution in ID aetiology, as mutations could 
affect any of the numerous genes that are crucial for early brain development. 
The chromosomal aberration in Down’s syndrome (DS), trisomy 21, is considered 
to be the leading genetic cause of ID, as it alone accounts for up to 20% of 
worldwide cases (Lakhan and Kishore, 2016). Other chromosomal abnormalities 
frequently associated with ID include trisomy 13 and trisomy 18 (Miclea et al., 
2015). The triplet repeat expansion (CGG) in the FMR1 gene causing fragile X 
syndrome (FXS) is the major monogenic cause of ID, accounting for 5% of cases 
(Inaba et al., 2014; Moeschler et al., 2014). 
 
There have been various monogenic genetic causes identified for ID and they are 
generally related to dysfunction in neurodevelopmental processes or in synaptic 
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organisation. The processes that regulate neural development during the 
embryonic stage work in a tightly controlled and organised cascade, resulting in 
the proliferation of neurons from neuronal precursor. The process of neural 
proliferation and production of fully differentiated neurons is called neurogenesis, 
a sophisticated process involving many transcription factors and regulatory genes 
(Busskamp et al., 2014; Stiles and Jernigan, 2010). Neurogenesis begins very 
early during embryogenesis, with the neuronal tube being formed about 15 days 
after fertilization. Neurogenesis continues in most brain regions until early 
postnatal stages, but the dynamic production of new neurons carries on into 
adulthood in the ventricular-subventricular zone and the subgranular zone of the 
dentate gyrus. Adult hippocampal neurogenesis is important in the formation of 
new memories (Sahay et al., 2011; Urbán and Guillemot, 2014). 
 
Disruption within any steps of neurogenesis could have a significant impact on 
the cognitive ability of an individual. For example, defects in genes involved in 
controlling the production of neurons could lead to an imbalance between forming 
more progenitor cells and forming end differentiated neurons giving rise to 
microcephaly (OMIM 152950) which is characterized by reduced head 
circumference at birth and various degrees of ID (Chavali et al., 2014). 
Microcephaly is a heterogeneous neurodevelopmental disorder, in which 
mutations have been found in the following genes: MCPH1 (Microcephalin, OMIM 
607117),  WDR62 (WD Repeat-Containing Protein 62, OMIM 613583), 
CDK5RAP2 (CDK5 Regulatory Subunit-Associated Protein 2, OMIM 608201), 
CASC5 (Cancer Susceptibility Candidate Gene 5 Protein, OMIM 609173), ASPM 
(Abnormal Spindle-Like, Microcephaly-Associated, OMIM 605481),  CENPJ 
(Centromeric Protein J, OMIM  609279), STIL (Scl/Tal1-Interrupting Locus, 
OMIM 181590), CEP135 (Centrosomal Protein, 135-KD, OMIM 611423), 
CEP152 (Centrosomal Protein, 152-KD, OMIM 613529), ZNF335 (Zinc Finger 
Protein 335, OMIM 610827), PHC1 (Polyhomeotic-Like 1, OMIM 602978) and 
CDK6 (Cyclin-Dependent Kinase 6, OMIM 603368) (Faheem et al., 2015). 
Problems associated with neuronal migration, restricting the ability of nerve 
precursor cells to travel from their origin into the cortical plate, have been reported 
to cause psychomotor disorders, including epilepsy and ID. Disorders that occur 
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due to mutations in genes involved in neural migration include lissencephaly, 
polymicrogyria and periventricular heterotopia (Dyment et al., 2013; Filippi, 
2015). 
 
The human brain contains a quadrillion (1015) synapses (Srivastava and 
Schwartz, 2014), which provide communication between neurons. Synapses are 
very complex junctions that are stabilised by adhesion molecules. Each synapse 
is made up of three main components: a presynaptic terminal, a post-synaptic 
terminal, and a cleft, measuring 20-25 nm, between them (Ho Victoria M. et al., 
2011b). Communication between neurons through the synapses is activated 
when an action potential initiates an electrical impulse within the presynaptic 
terminal, which in turn triggers the release of various neurotransmitters. Neuron 
to neuron communication is achieved by these neurotransmitters, which diffuse 
through the synaptic cleft until they reach the post-synaptic terminal, where they 
attach to specific receptors. If the structure of synapses is disrupted, this could 
lead to dysfunction of the signalling network, as has been found in many brain 
disorders (Finnema et al., 2016). An illustration of the extreme complexity of the 
synapse, with some proteins encoded by genes implicated in ID pathogenicity, is 
shown in Figure 1.3. Miclea et al. (2015) have categorised ID genes based on 
their involvement in mechanisms and pathways, such as metabolic pathways, 
neurogenesis, neuronal migration, synaptic function, intracellular signalling, or 
epigenetic regulation of transcription. Examples of the different genes found in 
each group are given in Table 2. 
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Figure 1.3. Synaptic Complexity and some ID involved proteins. This cartoon 
represents the presynaptic terminal, the cleft and the postsynaptic components of the 
glutamatergic synapse in the brain. It shows multiple proteins which are available to 
propagate the messages through connecting the transmembrane and membrane-
associated protein complexes with the underlying actin cytoskeleton. These include 
some adhesion molecules (like Neurexin, Neuroligin and Cadherins), and scaffolding 
proteins (like PSD-95, Cask and Shank). Many of the illustrated proteins (such as 
Neurexin, Cask and Shank) have also been implicated in other neuropsychiatric 
disorders like ASD. Disruption in any of these proteins would result in a failure to transmit 
the signals efficiently. (Adapted from Banerjee et al. (2014), no permission required). 
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Pathway Genes encoding proteins implicated in ID 
Metabolic Pathways 
Organic acid metabolism (ALDH5A1, L2HGDH) Polysaccharide metabolism (NAGLU, SGSH) 
Protein glycosylation (POMGNT1, POMT1, POMT2, FKTN, 
FKRP, LARGE) 
Purine metabolism (ADSL) 
Monocarboxylate transporter (SLC16A2) Creatine transporter (SLC6A8) 
Neurogenesis Mitotic spindle regulation (ASPM, CDK5RAP2, CENPJ) DNA repair and mitotic arrest (MCPH1) 
Intracellular 
Signalisation 
Ras-MAPK-ERK pathway (SOS1, RAF1, BRAF, SHOC2, 
HRAS, KRAS, PTPN11, SPRED1, MAP2K1, MAP2K2, 
NF1, DYRK1A, RPS6KA3) 
PI3K-AKT-mTOR pathway (TSC1, TSC2, 
PTEN) 
Neuronal Migration 
Microtubule subunits (TUBA1A, TUBB2B) Microtubule regulation (DCX) 
Microtubule associated proteins (PAFAH1B1) Transcription factors (ARX) 
Presynaptic Function 
Vesicle traffic (RAB3GAP1, STXBP1, GDI1, RAB39B) Exocytosis inhibition (IL1RAPL1, CASK) 
Adhesion between pre- and postsynaptic membranes (NRXN1, CDH15) 
Postsynaptic Function 
Adhesion between pre- and postsynaptic 
membranes (CNTNAP2, NLGN3, NLGN4) 
Neurotransmitter receptor interaction with 
membrane proteins (SHANK2, SHANK3) 
Regulation of postsynaptic proteins (UBE3A, 
UBE2A, UBR1; HUWE1, CUL4B) 
Subunits of NMDA receptor (GRIN2A, GRIN2B) 
Transport of mRNA from the nucleus to the cytoplasm (FMR1) 
Epigenetic Regulation 
of Transcription 
Histone acetyl-transferase (CREBBP, EP300) Histone deacetylase (HDAC4) 
Histone methyltransferase (NSD1, EHMT1, MLL2) Histone demethylase (KDM5C) 
Transcription factors (TCF4, RAI1, ZNF711, ZNF41, 
ZNF674, ZNF81, PHF6, PHF8) 
DNA replication (SETBP1) 
DNA methyltransferase (DNMT3B) Chromatin modification (ATRX, BRWD3) 
Repression of transcription factors (BCOR, MECP2) 
 
 
Table 1.2. Types of ID genes. 
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Based on the fact that ID is more common in males than in females, it was 
hypothesised that X-linked ID would account for at least 25% but data suggests 
only 10-20% (Ropers H. and Hamel, 2005; Winnepenninckx et al., 2003). So far, 
mutations in more than 100 genes located on the X chromosome have been 
implicated in ID (Lubs et al., 2012), which is consistent with the fact that the 
human X chromosome has a large amount of brain-specific transcripts that are 
crucial for learning and memory (Ross et al., 2005). The full figure of X-linked ID 
genes remains unknown but studying more of the large sample cohorts would 
help investigating all the other genes reside on the X chromosome. On the other 
hand, it is believed that the number of genes behind the autosomal forms of ID 
should not be less than 800-850 genes (Ropers H, 2010). In fact, a more recent 
study (Maris et al., 2013) suggests that total number of autosomal genes involved 
in ID could run into thousands, but  about 400 of them have already been linked 
to ID (Lubs et al., 2012; Raymond, 2006). Based on the various performed studies 
on the non-syndromic ID, 51 loci and 34 genes have been identified with the 
majority of them residing on either chromosome 6 or 19 (Khan Muzammil Ahmad 
et al., 2016).  
 
The completion of the human genome sequencing project (Little et al., 2003) has 
been the  milestone which revolutionized the work in biology and medicine. 
Although it took more than 10 years and 3 billion USD to elucidate the first human 
genome (Von Bubnoff, 2008), the introduction of next generation sequencing 
(NGS) technologies has made it possible to do whole genome sequencing with 
only 1,000 USD (Moens et al., 2014). About a decade ago, around 60% of ID 
cases had an unknown aetiology, but this percentage has dropped with the 
introduction and wide usage of next generation sequencing (Vissers Lisenka E. 
L. M. et al., 2016). The number of identified ID genes is continuously increasing 
and the figure of 600 genes that was mentioned before (Martínez et al., 2016) 
has now gone up to 800 genes (Chiurazzi and Pirozzi, 2016). 
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1.3 Schizophrenia (SZ) 
1.3.1 SZ overview 
The term “psychosis” refers to an abnormal condition of the mind in which thought 
and emotions are so impaired that contact is lost with external reality (Gaebel and 
Zielasek, 2015). In schizophrenia (SZ, OMIM181500), psychosis is a descriptive 
term for the hallucinations, delusions and impaired insight that may occur. It is a 
heterogeneous disorder that affects around 1% of the human population 
worldwide. The onset of SZ is usually in late adolescence or early adulthood 
(Whiteford et al., 2013) but it can strike at any time of life. Most affected 
individuals continue to suffer varying degrees of difficulty throughout their lifetime, 
with a major impact on their quality of life (Hooley, 2010). 
 
About €93.9 billion is spent every year to provide health care for individuals 
affected with SZ in Europe, while €16.7 billion is spent in the UK alone 
(Gustavsson et al., 2011). Schizophrenia affects the thoughts, emotions and 
behaviour of affected individuals, and is often described in terms of positive and 
negative symptoms. Positive symptoms are those that most individuals do not 
normally experience, but are present in people with schizophrenia. They can 
include delusions, hallucinations and paranoid thoughts, typically regarded as 
manifestations of psychosis. Negative symptoms are deficits of normal emotional 
responses of other thought processes, and are less responsive to medication. 
They commonly include apathy (lack of interest), anhedonia (inability to enjoy) 
and social withdrawal. Deficits in cognitive abilities are also widely recognized as 
a core feature of schizophrenia (Leigh, 2013; Zhang Jing et al., 2016a). Figure 
1.4 summarizes the core symptoms of SZ and also shows their overlaps with 
other psychiatric disorders. 
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Figure 1.4. Core schizophrenia symptoms and their overlaps with other disorders. 
The five core symptoms within the coloured circle are expected to be present in SZ 
patients for at least one month to warrant a diagnosis of schizophrenia. There is a range 
of overlaps with other psychiatric disorders, listed outside the segments of the circle. 
(Adapted from Corvin (2011), no permission required).  
 
Another form of major mental illness is bipolar disorder (BPD), formerly manic 
depression, which is characterised by episodes of abnormally elevated arousal 
(mania) and episodes of depression. In severe cases, the individual may develop 
symptoms of psychosis. When a patient has features of both SZ and a mood 
disorder—either bipolar disorder or depression—but does not strictly meet 
diagnostic criteria for either alone, this is called schizoaffective disorder 
(Craddock et al., 2009). 
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There has not been a single effective therapy for SZ but antipsychotic drugs have 
become the cornerstone for the treatment of the associated symptoms 
(Lieberman  et al., 2005). The first-generation antagonists of dopamine D2 
receptors have been introduced and used since 1950s to treat SZ symptoms and 
they are commonly known as conventional antipsychotics or traditional 
antipsychotics. Despite their acceptable effect, they were found to cause some 
extrapyramidal side effects such as muscle contractions, tremor and irregular 
movements and thus many patients have preferred to stop using these drugs 
after a period of time (Hartling et al., 2012). The introduction of the second-
generation antipsychotic drugs or what is called as atypical antipsychotics, like 
the ones that target serotonin and norepinephrine, was made in 1980s to get a 
better treatment with less of these nasty side effects. Unfortunately, these drugs 
have also been reported to cause the unwanted side effects plus their high cost 
makes it difficult for patients to afford buying them (Davies et al., 2007; 
Rosenheck et al., 2006). One of the commonly used atypical antipsychotic is 
clozapine (sold under different brand names including Clozaril, Leponex, 
Denzapine, Zaponex, Versacloz and others)  which is considered to be the gold-
standard treatment especially for resistant SZ cases which show no response 
when using two or more antipsychotics (Siskind et al., 2016; Taylor, 2017). Since 
their introduction, neither first generation nor the second generation 
antipsychotics have proved their efficacy and consistency in treating the 
symptoms of SZ (Hartling et al., 2012; Leucht et al., 2009). 
 
Because glutamatergic dysfunction has been linked to the SZ pathogenesis 
(Olney and Farber, 1995), increased interest has been focused recently on the 
use of N-methyl-D-aspartate receptor (NMDAR) to treat this disorder (Merritt et 
al., 2013). Memantine (sold under different brand names Originally, Axura, Ebixa, 
Namenda, Namenda XR and others) which  is a non-competitive NMDARs 
antagonist, has been the drug of choice to treat the negative symptoms and 
prevent further cognitive failure in young patients (Di Iorio et al., 2017). An 
alternative approach therapy, using cognitive remediation (CR) technique with 
visualization and narrative structure, has also been a promising method to 
improve the cognitive functions of the disorder (Hegde, 2017).  
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1.3.2 SZ types 
Depending on the main diagnostic and prominent symptoms, SZ has been 
classified into different classic subtypes, according to the Diagnostic and 
Statistical Manual of Mental Disorders version IV (DSM-IV). It is not uncommon 
for the same affected person to change from one subtype to another with time 
(Mcglashan and Fenton, 1991). The paranoid SZ subtype is when the affected 
individual feels extremely suspicious and experiences auditory hallucinations with 
repetitive delusions about certain persecutions or conspiracies that have been 
unfairly made against them. As indicated by its name, the main characteristic of 
the disorganised SZ subtype is disorganization of the patient’s thought. 
Impairment in thinking processes leads to incoherent speech and thus an inability 
to communicate effectively. In the catatonic SZ subtype, the movement of the 
patient is affected such that voluntary movements cannot be performed. This 
subtype is usually associated with a strange and uncomfortable body 
position/appearance and a tendency to repeat certain pointless movements or 
facial expressions. If none of the subtypes matches the diagnosis of an affected 
individual, and different symptoms manifest at different times in a mixed up 
manner, their condition is described as undifferentiated SZ. The term residual SZ 
is used when the disorder is at a chronic stage when no specific symptom is 
prominent but the person has no interest in life. The general features of 
hallucinations/delusions may be still present but to a lesser extent (Buoli et al., 
2013; Dongen et al., 2015; Kito and Suzuki, 2016; Nenadic et al., 2015; Walther 
et al., 2009). 
 
After the introduction of DSM-IV in 1994, there was some debate on the validity 
of these SZ subtypes. Kendler and colleagues carried out a study of 416 SZ 
patients and 1753 of their first-degree relatives in Ireland to see whether there is 
an outcome difference between the subtypes (Kendler et al., 1994). The study 
concluded that the subtypes are not aetiologically distinct syndromes. The clinical 
subtypes of SZ in DSM-IV are not considered to be reliable diagnoses because 
individuals with SZ may have a mixture of different subtypes. Even if one specific 
subtype fits better than the others, the stability is short and there is always a 
fluctuation in the prominent symptoms (Edward and Jhan, 2003). Moreover, the 
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different subtypes are not a great help in terms of prognosis or treatment 
response for the patients (Regier, 2007). In many cases, it has not been possible 
to identify the subtypes as described by DSM-IV, as no essential difference could 
be made between them (Linscott et al., 2010; Peralta and Cuesta, 2003; Picardi 
et al., 2012). Because of their inadequate reliability and due to the fact that no 
distinctive therapeutic approach is used for each subtype, they are absent from 
the new DSM-V (Tandon Rajiv et al., 2013). 
 
According to the recent version of DSM-V (5th edition, 2013), for a diagnosis of 
schizophrenia, the individual must have at least two of the following symptoms: 
delusions; hallucinations; disorganized speech; grossly disorganized or catatonic 
behaviour; or negative symptoms. These symptoms need to be there for a 
significant portion of a one-month period, with signs of disturbance for 6 months. 
Different schizophrenic individuals experience different periods of constant 
symptoms and symptom-free periods (Erritty and Wydell, 2013). The new 11th 
edition of the International Classification of Diseases (ICD) has also been 
updated, with the subtypes being replaced by the following symptom specifiers: 
positive, negative, depressive, manic, and psychomotor symptoms, and cognitive 
impairment (Gaebel et al., 2013; Sachdev et al., 2015). 
 
1.3.3 SZ causes 
Schizophrenia is a genetically complex disorder which has been shown to run in 
families. The risk of developing schizophrenia is higher when close relatives also 
have the disorder (Gottesman I. I. and Erlenmeyer-Kimling, 2001). We do not yet 
have a complete understanding of the biological changes taking place in 
schizophrenia, but some theories and supportive findings have been made. For 
example,  various studies nowadays are suggesting that an abnormal abolition of 
excess neuronal synapses could be behind the pathology of SZ (Boksa, 2012; 
Hayashi-Takagi et al., 2011) and synaptic pruning has become an interesting 
target for therapeutic intervention in patients with schizophrenia (Sekar et al., 
2016). There is also accumulating and clear evidence for the involvement of both 
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environmental and genetic factors in the pathology of SZ (Brown Alan S., 2011; 
Tsuang, 2000).  
 
The fact that concordance of schizophrenia in monozygotic twins (which have 
identical genomes) is only about 50% raises the potential importance of 
environmental factors (Owen et al., 2005). Various environmental risk factors 
have been implicated in schizophrenia, including maternal nutritional deficiency, 
birth during late winter or early spring, and cannabis use during adolescence 
(Tandon R. et al., 2008). Infections such as influenza and Toxoplasma have also 
been identified as environmental risk factors for schizophrenia (Fatemi and 
Folsom, 2009). 
 
Immigration and change of cultures have also been found to increase the risk of 
developing schizophrenia (Hollander et al., 2016). People who leave their home 
and settle in other places or countries would normally experience a different 
atmosphere that affect wide aspects of their life including custom culture, religious 
practice and social support. Such changes and their associated challenges would 
collectively participate to express  a stressed condition, that can impact their 
mental well being (Bhugra and Becker, 2005).  According to Shekunov and 
colleagues (Shekunov, 2016), there is an   average increase in SZ by  about 2.5 
times with immigration, but the exact ratio would vary based on ethnicities and 
settings. There is also a strong evidence suggesting  the persistence of 
schizophrenia into the immigrants’ descendants (Cantor-Graae and Selten, 2005; 
Shekunov, 2016). A meta analysis,  based on 4422 schizophrenia and psychosis 
cases from 21 population-based studies published between 1977 and 2008, 
found that the increased risk for schizophrenia and related disorders is also 
extended to the second generation (Bourque et al., 2011). This finding, and 
others (Cantor-Graae and Pedersen, 2007; Corcoran et al., 2009; Selten et al., 
2007), point out to the significant contributions of the post-migration factors and 
the social context in the occurrence of SZ. 
 
Over a long period of time, there have been several theories on the aetiology of 
SZ but the most prominent ones propose a disruption in dopamine (DA) and 
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glutamate (GT) transmission (Howes et al., 2015; Seeman, 2009). The DA and 
GT neurotransmitter systems (Figure 1.5) have been biologically linked to the 
development of the different symptoms of SZ (Mcguire et al., 2008). For example, 
accumulation of DA is hypothesised to cause the positive symptoms of 
hallucinations and delusions (Brisch et al., 2014; Shen et al., 2012) whereas the 
accumulation of GT is associated with negative symptoms and cognitive deficits 
(Merritt et al., 2013). There has also been a recent theory describing synaptic 
pruning and the role of C4  (complement component 4, OMIM 120810) in SZ 
pathology (Sekar et al., 2016), and this will be addressed in the next sub-heading 
about SZ genetics. 
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Figure 1.5. Neurotransmitter systems disrupted in schizophrenia. (a) Dopamine 
neurotransmitter: the increased production of DA (i) from its precursor (tyrosine) leads to 
an increase in its synaptic release (ii). The dopamine transporters would pump some of 
dopamine out of the synapse back into cytosol but some amount would still remain. 
Similarly, the number of DA receptors is unaltered (iii), which means they are not in their 
active state again and thus not functionally ready to receive the high DA, leading to its 
accumulation and development of positive symptoms. (b) Glutamate neurotransmitter: 
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the increased production of glutamate from “messenger-sending” nerve cell causes 
some damage to interneurons (like chandelier cells) and their NMDA receptors (i) 
causing a reduction in the quantity of GABA released onto pyramidal neurons (ii). As a 
compensatory response to GABA shortage, the pyramidal neurons tend to release 
glutamate onto non-NMDA glutamate receptors (AMPA receptors) (iv). Some glutamate 
would be taken up by astrocytes and converted to glutamine but most of it would 
accumulate, causing the negative symptoms and cognitive impairment. (Adapted from 
Mcguire et al. (2008) with a permission from  Elsevier and Copyright Clearance Center, 
License Number: 4077171303111).  
 
1.3.4 SZ genetics 
Relatives of SZ patients have an increased prevalence of SZ compared with the 
general population (Onstad et al., 1991), such that the chance of developing SZ 
is increased 10 times for a child who has a first-degree relative already suffering 
from the disease (Sommer et al., 2016). The SZ concordance rate of monozygotic 
twins is 40-50%, with a heritability rate of up to 80% (Cardno Alastair G and 
Gottesman, 2000; Sullivan et al., 2003). SZ is probably the one first condition at 
which there has been a successful application of polygenic score (Purcell et al., 
2009). The polygenic score is a measurement that uses the total trait-associated 
alleles obtained from genome wide association studies (GWAS) in order to 
predict  a genetic liability to disease risk for an individual (Euesden et al., 2015). 
It was estimated that the SZ polygenic scores are around 50% in first-degree 
relatives and 15% in second degree relatives of SZ patients (Power et al., 2015). 
Relatives of patients with bipolar disorder or depressive disorder also have an 
increased risk of developing SZ (Rasic et al., 2014). 
 
There are basically two opposite models of genetic architecture that have been 
proposed in the literature to explain the common disease susceptibility (Figure 
1.6). Based on epidemiological studies and the estimated risk to relatives, it is 
believed that SZ is caused by a group of susceptibility genes at which their 
proteins interact with each other, under the influence of environmental factors. 
This is compatible with the ‘common disease, common variant (CDCV)’ 
hypothesis, which proposes that SZ is caused by multiple common risk alleles, 
each of low genetic penetrance, under the influence of the environment. The 
penetrance of a disease-causing mutation is the proportion of individuals with the 
mutation who exhibit clinical symptoms. The alternative view is the ‘Common 
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Disease, Rare Variant (CDRV)’ hypothesis, which proposes that rare risk alleles, 
each of high penetrance, comprise the major genetic contribution to disease 
occurrence (Corvin, 2011; Schork et al., 2009). Under this latter model, there is 
thus an important level of heterogeneity, but the genetic variants are expected to 
have clearer functional impact by impairing protein function or production (R). 
 
The high level of SZ heritability (about 80%) suggests the implication of genetic 
factors in the development of this condition. Technological advances in next-
generation sequencing approaches have made it possible to explore the whole 
exome and entire genome of individuals and not only some predefined loci where 
common variants have been detected. Genome-Wide Association Studies 
(GWAS) have been successful at discovering numerous novel associations in 
disease genes that were not suspected to be involved at, demonstrating the role 
of novel cellular processes. One of the largest meta-analysis (Schizophrenia 
Working Group of the Psychiatric Genomics Consortium, 2014), at which GWAS 
was applied to study 37 thousands SZ cases and more than 113 thousands 
controls, identified 128 associations within 108 loci. Majority (75%) of these loci 
contain protein-coding genes and additional 8% are less than 20 kb away from a 
gene. The finding of this above study (Schizophrenia Working Group of the 
Psychiatric Genomics Consortium, 2014) is consistent with the assumption that 
the vast majority of GWAS variants are normally involved with changing the 
expression of the genes rather than altering the organisation of their associated 
proteins (Maurano et al., 2012; Nicolae et al., 2010). Furthermore, it also 
correlates with the findings of exome sequencing studies (Purcell et al., 2014) as 
well as with the reported enrichment of SZ risk loci based on expression 
quantitative trait loci (eQTL) (Richards et al., 2012). Some of the other featured 
findings have also come from The International Schizophrenia Consortium (2008) 
study which showed that the SZ associative candidates are abundant in tissues 
that are brain-specific, like Hippocampus middle and Cingulate gyrus, rather than 
other tissues like kidney and bone. Significant associations were also reported in 
this study for CNVs overlapping with ASD and ID.   
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Figure 1.6. Different genetic risk theories of schizophrenia. The x-axis shows the frequency of a given allele in the population while the y-
axis indicates their penetrance. Zone A contains relatively rare alleles and zone B contains the variants that are more common than variants in 
zone A. The variants at Zone C are also common but their penetrance is low comparing with the ones in zone A and B. Under the CDCV model, 
it is assumed that the major contributors to SZ risk are genetic variants located in zone C and these common variants could be detected with 
Genome-wide association studies (GWAS). On the other hand, the CDRV model assumes that rare genetic variants in Zone A can be involved 
in SZ susceptibility. It is known that the alleles causing Mendelian diseases are located in this zone but there is also a group of alleles that cannot 
be easily identified because of their low frequency and low penetrance. The fast majority cases of schizophrenia alleles are in zone A and C and 
the utilization of whole exome or whole genome sequencing could significantly help in the identification of the underlying alleles (Adapted from 
Corvin (2011), no permission required.) 
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Despite the accumulation of evidence that SZ has a genetic basis, the precise 
mechanisms are unclear. Some studies have observed potential anticipation, 
whereby the onset of the disease occurs at an earlier age with each subsequent 
generation, suggesting the involvement of genes that have trinucleotide repeat 
expansions (Bassett and Husted, 1997; Stöber et al., 1995). SZ has also been 
thought to be caused by damaging de novo mutations affecting a few genes, 
including KLC2 (Kinesin Light Chain 2, OMIM 611729), KIF17 (Kinesin Family 
Member 17, OMIM 605037), SHANK3 (Sh3 and Multiple Ankyrin Repeat 
Domains 3, OMIM 606230) and IL1RAPL1 (Interleukin 1 Receptor Accessory 
Protein-Like 1, OMIM 300206) (Awadalla et al., 2010). Other studies have 
suggested the involvement of larger scale structural variants. An affected mother 
and daughter were found to have disruption of the NPAS3 gene (Neuronal Pas 
Domain Protein 3, OMIM 609430)  as a result of a chromosomal translocation 
t(9;4) (Kamnasaran et al., 2003). The NPAS3 protein has a significant role in 
regulating the differentiation process of cells and also in supporting the growth 
and development of neural cells (Pickard et al., 2005). Subsequent studies have 
confirmed the association of NPAS3 with SZ (Bernier et al., 2014; Macintyre et 
al., 2010). The Disrupted-in-schizophrenia-1 gene (DISC1, OMIM 605210) was 
initially found to be truncated by a chromosomal translocation in an extended 
Scottish pedigree that includes cases of major depression, schizophrenia and 
bipolar disorder. The DISC1 translocation showed more than 70% penetrance for 
mental disorder. DISC1 was then regarded as the most promising candidate gene 
for schizophrenia (Bradshaw and Porteous, 2012). 
 
To achieve a better understanding of the molecular mechanisms of 
schizophrenia, various genetic studies using different strategies in both humans 
and animal models have been carried out (Ayalew et al., 2012). Genome-wide 
association studies (GWAS) have identified various single nucleotide 
polymorphisms (SNP) as genetic risk factors for SZ. One of the strongest findings 
is SNP rs1625579 (G/T), located in an intron of a gene encoding a microRNA 
called MiR-137 (Micro RNA 137, OMIM 614304) (Zhang Ping et al., 2016b). 
Although the first evidence suggesting correlation between MiR-137 and SZ was 
in 2010 (Potkin et al., 2010), many successive independent studies have also 
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reported an association (Lett et al., 2013; Ripke et al., 2014; Whalley et al., 2012). 
Hence, SNPs in MiR-137 are now a well-documented genetic risk factor for SZ. 
A gene called EFNB2 (Ephrin B2, OMIM 600527) has also been considered a 
persuasive candidate gene for involvement in SZ (Zhang Rui et al., 2010). 
Interestingly it has been shown that MiR-137 inhibits EFNB2 expression (Wu et 
al., 2016), suggesting a possible association mechanism involving both of them 
(Tooney, 2016). 
 
C4, the complement component 4 gene which has a function in the immune 
system, has recently been reported to also play a role in brain development, with 
variants of it showing the biggest hit as risk factor for SZ in GWAS (Sekar et al., 
2016). The idea arose from the observation that various markers in the major 
histocompatibility complex (MHC) are strongly associated with schizophrenia 
(Dhindsa and Goldstein, 2016). Sekar and colleagues (Sekar et al., 2016) 
recently showed that the significant association was specifically with certain 
alleles of C4. After analysing SNP data from 28,799 schizophrenia cases and 
35,986 controls, association was found with 7,751 SNPs across the MHC locus. 
The authors reinforced their finding by demonstrating C4 protein localisation in 
neuronal synapses, dendrites and axons. They also showed that C4-deficient 
mice have reduced synaptic pruning, which is consistent with the fact that the 
brains of SZ individuals do not have sufficient synaptic inputs. A plausible 
mechanistic model for the role of C4 in SZ has been proposed by (Ruzzo and 
Geschwind, 2016), as illustrated in Figure 1.7. 
 
Based on the findings of researchers at the Wellcome Trust Sanger Institute who 
performed WES on SZ patients and compared the variants with the ones in 
healthy individuals, loss of function (LOF) variants in SETD1A (Set Domain-
Containing Protein 1A, OMIM 611052) increase the risk to SZ by 35 folds (Singh 
et al., 2016). SETD1A encodes a component of a histone methyltransferase that 
is important for the expression of other genes, particularly those that play roles in 
synaptic and neurotransmission pathways. In fact, a previously published study 
(Takata et al., 2014) already reported that de novo indels in SETD1A could be 
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responsible for SZ, but the recent study of Singh et al. (2016) strengthens the 
implication of this gene in the pathogenesis of SZ. 
 
 
 
Figure 1.7. Model for the role of C4 in SZ. In GWAS, C4 structural alleles show a 
significant association with SZ. The above cartoon is an explanatory model which 
principally links SZ to the increased production of C4A mRNA in the human brain. As a 
result, this increases C3 production which increases synaptic pruning in the neural cells. 
CSMD1 encodes a protein involved in C4 regulation. It also drives the described pathway 
in the same direction and is also associated with SZ in GWAS studies. The model also 
demonstrates the effects of other factors, including environmental insults and possible 
alternative genetic susceptibility factors. (Adapted From Ruzzo and Geschwind (2016) 
with a permission from Nature Publishing Group, License Number 4077180234698).  
 
Although there is little doubt about the positive impact of the recent findings, such 
as the associations of C4 and SETD1A, our understanding of this devastating 
psychiatric illness is still incomplete. Most of the specialists in the field of 
psychiatric genetics are eager for a better future with more concrete findings 
(Curtis, 2016b). 
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1.3.5 Existence of Mendelian SZ alleles 
SZ is a complex disorder with susceptibility resulting from the interaction of 
environmental and genetic factors. However, most of the risk variance associated 
with SZ is genetic, with heritability estimated to be around 80% (Carroll Liam S. 
and Owen, 2009; Girard et al., 2011; Lipina and Roder, 2015). This high level of 
heritability suggests that it should be possible to identify the genetic risk factors 
that contribute to SZ but results from over 40 years of studies have not, 
unfortunately, been very successful (Giusti-Rodríguez and Sullivan, 2013). More 
than a decade ago, it was widely hoped that utilising GWAS would explain the 
genetic basis of SZ as it successfully has done in other genetically complex 
conditions like Age-Related Macular Degeneration (AMD). However, the fact that 
the bulk of the heritability for SZ remains unexplained made it necessary to exploit 
alternative research strategies. Despite the fact that a part of SZ genetic variance 
has been unravelled with hypothesis-free screens of GWAS, the  implicated 
common genetic variants have low odds ratios, and even measured collectively 
they account for no more than 33% of heritability (Lee S. et al., 2012; Sullivan et 
al., 2003) leaving a large portion unaccounted for. Therefore, there is still an open 
gap that needs to be addressed between our current knowledge of SZ genetics 
and the predicted genetic component of the disease. Addressing this should lead 
to better understanding of the development of brain abnormalities as well as the 
cognitive deficit associated with this disorder (Murphy and Benítez-Burraco, 
2016). 
 
By comparing the high heritability of SZ (80%) with the low proportion of the 
revealed variants (33%), it could be stated that there is a missing heritability. This 
missing heritability could in part be due to structural variants missed in existing 
sequencing studies (Kirov et al., 2009; Levinson et al., 2011; Van Dongen and 
Boomsma, 2013), in gene-environment interaction (Lipina and Roder, 2015; Van 
Dongen and Boomsma, 2013) and/or epigenetic factors (Cariaga-Martinez et al., 
2016; Pishva et al., 2014). On the large-scale genome-wide study, by The 
International Schizophrenia Consortium (2008), the underlying rare but highly 
penetrant CNVs were investigated in 3391 SZ patients in Europe after they were 
compared with the ones in 3181 ethnically-matched controls. It was found that 
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CNVs with > 100 kb increase SZ risk by 1.15 folds. Moreover, duplication CNVs 
showed more consistent pattern in terms of the size as well as how far they occurs 
from a gene, in comparison with deletions. Significant associations were also 
reported, for the first time, for 15q13.3 and 1q21.1 regions. However, the 
genome-wide analysis by Stefansson and colleagues (Stefansson et al., 2008), 
which was carried out on 2160 trios of SZ and 5558  parent–offspring pairs, have 
identified 66 de novo CNVs, but  further testing has also highlighted three 
predominant deletions all with significant associations; 1q21.1, 15q11.2 and 
15q13.3.  
 
Additionally, rare variants with a major effect might account for a portion of the 
cases, through the so-called common disease-rare variant hypothesis route. 
These rare variants would be shared by families or small communities, but due 
to their extremely low frequency in patients, broad association studies with 
thousands of unrelated individuals would fail to find them (Van Dongen and 
Boomsma, 2013). The common disease-rare variant hypothesis in psychosis is 
controversial (Craddock et al., 2007; Mcclellan et al., 2007), but the proven 
involvement in SZ of mutations in gene like DISC1 (Millar et al., 2000, Sachs et 
al., 2005) and rare copy number variants with a high susceptibility risk (Sullivan 
et al., 2012) suggest that such rare alleles may indeed play a role in SZ.  
 
Recessive alleles with a major effect that predispose to psychosis are likely to be 
enriched in patients from populations with high levels of consanguineous 
marriage because such progeny will have inherited two copies of the relevant 
mutation (maternal and paternal) from a recent common ancestor (Mansour et 
al., 2010). Evidence for the existence of such alleles comes from the observation 
that SCZ risk increases with genetic relatedness (Cardno A. G. et al., 1999; 
Gottesman Irving I, 1991) and consanguinity (Bener et al., 2012; Mansour et al., 
2010). The chromosomal region surrounding these alleles will be homozygous 
identical-by-descent, so regions of homozygosity in affected individuals from 
consanguineous families are indicators to the mutations involved. Homozygosity 
mapping has already been applied in families with multiple cases of psychotic 
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disorders (Iqbal et al., 2013; Knight et al., 2008), showing evidence of increased 
incidence and provisional genes/chromosome regions of interest. 
 
There are examples in the literature of Mendelian mutations that could account 
for a proportion of cases in apparently complex diseases. Alzheimer’s, 
Parkinson’s and Age-Related Macular Degeneration (AMD) are all diseases 
which are mostly complex but can also be caused by specific, severe highly 
penetrant alleles. For example, highly penetrant mutations in amyloid precursor 
protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) have been shown 
to cause Alzheimer’s disease (Mohamed et al., 2016; Van Cauwenberghe et al., 
2016). Similarly, p.R1441G mutation in leucine-rich repeat kinase 2 (LRRK2) is a 
potent variant causing Parkinson’s disease (Klein Christine and Westenberger, 
2012; Mullin and Schapira, 2015). It is true that AMD has been strongly linked to 
mutations in CFH (Complement Factor H, OMIM 134370), CFB (Complement 
Factor B, OMIM 138470) and HTRA1 (HTRA Serine Peptidase 1, OMIM 602194)  
(Wang Wenqiu et al., 2016), but Mendelian mode has also been reported in this  
genetically-complex disorder. For example, mutations in the tissue inhibitor of 
metalloproteinases-3 (TIMP3)  have been found to cause rare Mendelian macular 
condition known as Sorsby's fundus dystrophy (SFD) (Black and Clark, 2016). 
The impact of Mendelian mutations on our understanding of the pathobiology of 
complex diseases is greatly dependent on the nature of the mutations involved. 
If the mutations involved are rare, highly penetrant, protein damaging variants 
then they can provide valuable insights to the underlying disease mechanisms. 
However, variants that are more common, less penetrant and solely affect 
regulatory processes might not be of significant impact on the pathobiology but 
they tend to be linked to high risk and susceptibility (Lupski James R. et al., 2011). 
 
The fact that complex diseases do not exhibit large proportion of Mendelian 
alleles could be largely due to the shared interaction between both genetics as 
well as environmental factors. However, the involvement of certain variants in 
different pathological conditions and the extent of the genetic change also plays 
a role. For example, carriers of a heterozygous mutation in GBA (Glucosidase, 
Beta, Acid, OMIM 606463), a gene in which homozygous mutations cause 
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Gaucher disease (GD, OMIM 230800), have an increased risk of developing 
Parkinson disease (Goker-Alpan et al., 2004; Sidransky et al., 2009). Similarly, 
carrying heterozygous mutations in CFTR (Cystic Fibrosis Transmembrane 
Conductance Regulator, OMIM 602421) is associated with an increased risk of 
developing idiopathic pancreatitis (Weiss et al., 2005). It has also been shown 
that different genomic changes in a single gene could lead to the development of 
conditions of different complexity. A good example is the FMR1 locus, which 
causes ID when the CGG repeats exceed 200. It has been found that lower CGG 
repeats (down to 50) are associated with fragile X-associated tremor/ataxia 
syndrome (FXTAS) in about 33% of males and 10% of females (Jacquemont et 
al., 2004).  
 
1.4 Genetic overlaps between ID and SZ 
ID and SZ are both complex neuropsychiatric disorders, and are two conditions 
which are part of a group of overlapping disorders. This group also includes major 
depressive disorder, autism and bipolar disorder, all show varying degrees of 
overlap within cases and families over time (Homberg et al., 2016; Lehner and 
Miller, 2016). These disorders are under the influence of multiple genetic and 
environmental factors that interact with each other in complex ways, producing a 
broad spectrum of overlapping symptoms. The environmental influence further 
adds to complexity as this can fluctuate over time. Complex diseases do not 
normally show correlation between the observed phenotypes and their underlying 
genotypes as the genetic determinants of disease in different individuals affected 
by the same disorder will not be the same (Chu et al., 2014; Norbury et al., 2008).  
 
The complexity of these diseases might be explained, in part, by the phenomenon 
of pleiotropy, where a particular allele can cause varying degrees of a number of 
different symptoms (Gratten and Visscher, 2016). The different penetrance levels 
of various risk alleles also add to the complexity. Even in condition when low 
penetrance alleles are involved, they still could cause a disease when they are 
together. Low penetrance alleles could also be supported by the environmental 
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factors in the aetiology of complex diseases (Cooper David N. et al., 2013; Schork 
et al., 2009). 
 
Figure 1.8 shows the striking overlap between some of the genes with variants 
that have been implicated in the well-known neuropsychiatric disorders, based 
on what is called “Hot zone de novo mutations”, an approach defined by Petrovski 
and colleagues (Petrovski et al., 2013). To explain more, this zone was 
established in order to measure the load of de novo mutations in cases of 
neuropsychiatric disorders and compare it with their loads in control individuals. 
The calculation was made using the results of two measurement designs; ≤25th 
residual variation intolerance score (RVIS) and PolyPhen-2 score ≥0.95. The 
RVIS for a particular gene is simply an indicative measure for its functional 
genetic variation in the normal population based on NHLBI-ESP6500 data set. 
Therefore, a gene with very low or negative scores has less functional variation 
and thus will be described as “intolerant” in RVIS. This score has shown great 
capability to rank the protein coding genes that could cause  Mendelian disease 
(Gussow et al., 2016). PolyPhen-2 score, on the other hand, reflects the ability of 
the mutation to  cause change in the function of the produced protein (Adzhubei 
et al., 2010).   
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Figure 1.8. Venn diagram showing the outstanding overlap between many of the 
genes implicated in four neuropsychiatric disorders. This is from a study by Zhu and 
colleagues and was based on the understanding available in 2014, but is missing some 
of the more recently implicated genes described above. Overlaps were determined 
based on “Hot zone” de novo mutations found in four published schizophrenia studies 
(Girard et al., 2011a; Xu et al., 2012; Gulsuner et al., 2013; Fromer et al., 2014) involving 
whole exome sequencing of 512 probands. (Adapted From Zhu et al. (2014) with a 
permission from the Copyright Clearance Center's Rightslink service, License number: 
4074171029655). 
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The idea of shared genetic susceptibility between these complex 
neurodevelopmental disorders is not new. It was first suggested almost half a 
century ago (Ornitz, 1969) and it has been supported by various studies over the 
past 20 years. For example, one study Morrow (2010) describes shared copy 
number variants (CNV) in intellectual disability, autism spectrum disorder (ASD), 
and schizophrenia. In addition, Camacho-Garcia and colleagues have reported 
exonic deletions in the NRXN1 gene on chromosome 2 in patients with 
schizophrenia, autism, or mental retardation (Camacho-Garcia et al., 2012). 
Other examples of overlap between these complex neuropsychiatric disorders 
include the finding that deletion or duplication at 16p11.2 confers a high risk for 
ASD or schizophrenia, respectively (Brownstein et al., 2016). Indeed, 16p11.2 
microdeletions account for 1% of ASD cases (Fernandez et al., 2009). On the 
other hand, the reciprocal microduplication of 16p11.2 is associated with a 14.5-
fold increased risk of psychosis and 16-fold increased risk of schizophrenia 
(Giaroli et al., 2014; Mccarthy Shane et al., 2009). Zhiqiang Li and colleagues 
have reported 17 duplications, with an average length of ~753 kb, at 16p11.2 on 
genome-wide CNV analysis based on 6,588 Chinese patients with schizophrenia 
(Li Zhiqiang et al., 2016). Many genome-wide association studies have also 
reported apparently shared genetic risk factors for bipolar disorder and 
schizophrenia (Craddock et al., 2009). Recently, 3q29 deletion has been 
associated with different phenotypes, including ID, SZ and ASD (Biamino et al., 
2016).  
 
1.5 Gene identification approaches 
Generally, there have been two strategies available for the identification of the 
genes involved in the causation of complex genetic diseases: genome-wide 
association and the candidate gene approach (Zhu Mengjin and Zhao, 2007). 
Genome-wide association is a hypothesis-free approach that involves genotyping 
a large group of unrelated individuals with a particular disease at thousands of 
diallelic SNPs across the genome. By identifying loci at which one of the two 
alleles shows a significantly higher frequency compared with a control group 
without the disease, this technique identifies loci that might alter the risk for 
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certain diseases (Mccarthy I. et al., 2008). Using this method, loci associated with 
type-1 diabetes (Hakonarson et al., 2007; Zeggini et al., 2007), Parkinson’s 
disease (Gandhi and Wood, 2010; Liu Xinmin et al., 2011), breast cancer (Easton 
et al., 2007; Lindström et al., 2014; Turnbull et al., 2010) and psychosis (Cichon 
et al., 2011; Ripke et al., 2013) have been identified. 
 
On the other hand, the candidate gene approach is a hypothesis-driven approach 
that uses prior scientific evidence to select particular ‘candidate’ genes for study 
in relation to the disease in question. Apart from the association studies (see 
above), the evidence for the candidate gene approach could be from linkage 
studies at which patients of a family share a particular variation that is tested by 
specific markers (Kwon and Goate, 2000). It could also come from  expression 
studies, which compare the transcript levels of candidate genes in mRNA 
collected from diseased versus unaffected individuals (Zhu Mengjin and Zhao, 
2007). An example of the candidate gene study approach is found in the report 
by van den Oord and colleagues, which showed a link between a SNP in  
MAMDC1 (MAM Domain-Containing Glycosylphosphatidylinositol Anchor 1, 
OMIM 611128) and neuroticism, a personality trait at which the person has more 
tendency toward negative mood states (Van Den Oord et al., 2008). Another 
example is the implication of HOXB1  (Homeobox B1, OMIM 142968) 
polymorphisms in the development of autism spectrum disorder (Muscarella et 
al., 2010).  
 
1.5.1 Genetic markers 
Genetic alleles or markers that are located on the same chromosome and are 
passed on to the next generation as a DNA unit or block are termed “haplotypes”. 
Various SNPs have been identified and then organised according to their allelic 
haplotypes (Stephens et al., 2001). The use of multiple haplotype markers 
specific to a chromosomal region in order to evaluate its association with a 
phenotype of interest has been extensively employed in genetics, particularly in 
population and gene mapping studies (Crawford et al., 2004; Liu P-Y et al., 2005). 
Advances in genetic mapping have been facilitated by progress in the 
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development of microsatellite and SNP markers (Ball et al., 2010; Hearne et al., 
1991; Nothnagel and Rohde, 2005). 
 
Microsatellites are repeated simple sequences, sometimes referred as short 
tandem repeats (STRs). The abundance of these motif sequences throughout the 
genome, and their high specificity, made microsatellites a valuable tool in the 
early days of genetic mapping. After their discovery in the late 1980s, 
microsatellites soon became the markers of choice in genetic mapping (Ellegren, 
2004). SNPs are specific known genetic changes that take place on average 
every 1-2 thousand bases (Sachidanandam et al., 2001). They do not have a high 
tendency to undergo recurrent mutation and their exact positions in the human 
genome are known. SNPs allow the genetic makeup of studied samples to be 
compared with reference samples (Kidd et al., 2006; Tzvetkov and Von Ahsen, 
2012). Compared with microsatellites, SNP markers are more numerous in the 
genome, are stable in mammals and can more easily be incorporated in highly 
automated systems (Fernández et al., 2013). As a result, SNP arrays have largely 
replaced microsatellites in mapping studies and are now widely used for mapping 
various diseases and conditions (Ku C. S. et al., 2010). This has been facilitated 
by the dramatic improvement in SNP array technology at which the well placed 
SNPs in haplotype blocks allows getting pretty much association across the 
whole genome (Netto and Schrijver, 2015). 
 
1.5.2 Homozygosity mapping 
Over the past two decades, thousands of genes have been implicated in the 
causation of human diseases using this approach. Important work on family 
linkage studies, an approach first proposed in the 1930s (Bernstein and Machol, 
1935; Haldane, 1934; Penrose, 1935), revolutionized our understanding of 
mapping techniques and paved the way for the application of such studies to 
autosomal recessive disorders. However, the idea of studying consanguineous 
families and looking in regions which are homozygous by decent for the causative 
mutations was first proposed by Lander and Botstein in the late 1980s (Lander 
and Botstein, 1987). Homozygosity mapping, followed by next generation 
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sequencing is now a well-established method for the identification of mutations 
that cause Mendelian-inherited disease within consanguineous families (Gilissen 
et al., 2012). Due to the fact that the technique involves identifying regions that 
are autozygous, or identical by decent (IBD) as a result of a consanguineous 
mating, it is also termed “autozygosity” mapping (Mueller and Bishop, 1993). 
 
The main principle of homozygosity mapping (Figure 1.9) is to focus on the 
genetic regions with homozygous stretches which are shared by the affected 
individuals, in order to identify the underlying disease allele. The introduction of 
very high-density SNP genotyping arrays and advances in their analysis allow the 
entire genome to be screened for homozygous regions relatively easily (Carr et 
al., 2011). Nowadays, whole genome SNP arrays allow highly informative SNPs 
to be captured and the most commonly used platforms are from Illumina and 
Affymetrix (Netto and Schrijver, 2015). The technique has been widely used to 
identify various loci/genes underlying autosomal recessive diseases and even 
conditions with extensive genetic heterogeneity in both consanguineous and non-
consanguineous families (Edvardson et al., 2016; El-Asrag et al., 2015; Glöckle 
et al., 2014; Makrythanasis et al., 2016; Ramprasad et al., 2008; Sundaramurthy 
et al., 2016) . 
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Figure 1.9. Representation of the principle of homozygosity mapping. The great 
grandmother in the first generation (I.2) of the family carries a mutation, indicated by the 
red bar, on one copy of one chromosome pair. Colours on the chromosomes denote the 
grandparental origin of each segment. The mutation is passed on to two of the 
grandmother’s children (II.2 & II.3), who inherit not only the mutation but also the 
common ancestral region surrounding it, shown in white. The carrier children could then 
transmit the mutation along with a large portion of the common ancestor regions onto 
their children (III.1 & III.2). If these grandchildren were then to enter into a 
consanguineous marriage (depicted by the double line connecting their symbols) then 
one in four of their children would be expected to inherit two copies the mutation, along 
with a part of the common ancestral region, from the paternal and maternal sides. In the 
instance portrayed, two individuals (IV.1 & IV.2) have inherited both mutated copies, 
resulting in a recessive disease. Examining regions of homozygosity shared by affected 
individuals for the causative mutations is therefore the main concept of homozygosity 
mapping. (Adapted from http://autozygosity.org/about/, no permission required) 
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1.5.3 Next Generation Sequencing, the beginning and current 
time  
The currently-available whole genome sequencing (WGS) has appeared after a 
large amount of resources over a period of not less than six decades. The 
discovery of the double helical structure of DNA in 1953 by James Watson and 
Francis Crick (Watson James D and Crick, 1953) was the first framework on the 
path towards DNA sequencing. With the availability of restriction enzymes at that 
time, various trials were made to sequence the genomes of bacteriophages. 
However, not much progress had been achieved and it was not until 1965, when 
Robert Holley and his colleagues carried the first RNA sequencing (Holley et al., 
1965). At the same time, Frederick Sanger and colleagues were also working 
separately on a related technique and they showed their exceptional progress in 
1977 when they introduced the di-deoxy chain termination method (Sanger, 
1977). In fact, intense work was ongoing around this time and various 
researchers in the field started trying and optimising their techniques. One of the 
significant moves was made by Allan Maxam and Walter Gilbert who replaced 
the laborious 2-D fractionation method with the electrophoresis (Maxam and 
Gilbert, 1977). However, their method involved using some radio-labelled DNA-
cleaving chemicals instead of polymerases and di-deoxy chain terminators, which 
impacted later on it’s wide usage. At this stage, it was the real birth of ‘first-
generation’ DNA sequencing and for this work, which facilitated further 
advancements towards the development of next generation sequencing (NGS), 
Frederick Sanger and Walter Gilbert were awarded Nobel Prizes in 1980 (Barba 
et al., 2014). The method of Sanger is the gold-standard way in DNA sequencing 
and still is used in most laboratories to sequence short DNA of about 200-1000bp. 
 
Various developmental changes then took place gradually for the Sanger 
sequencing method, which led to the replacement of the radiolabelling materials 
with fluorescent chemicals (Ansorge et al., 1986; Kambara et al., 1988). Major 
advances also occurred to the capillary based electrophoresis, which opened the 
gate for the automation in DNA sequencing (Ansorge et al., 1987). The 
introduction of the polymerase chain reaction (PCR) (Saiki et al., 1988) and the 
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subsequent improvement in this technology has participated in the genomics 
revolution. The golden era of first generation sequencing was achieved with the 
development of the dideoxy sequencers, such as the ABI PRISM, produced by 
Applied Biosystems, which at the beginning facilitated the work of the Human 
Genome Project (Venter et al., 2001) .  
 
The second generation DNA sequencing involved improvements in the strategy 
used to identify the nucleotides prior to electrophoresis visualisation. The newly 
introduced method, known as pyrosequencing, is just like Sanger's dideoxy, 
based on the ‘sequence-by-synthesis’ (SBS) techniques. This means that for the 
outcome effect to be detectable, direct action of DNA polymerase is needed (Ju 
et al., 2006). The pyrosequencing is based on using the enzymatic activities of 
ATP sulfurylase and luciferase instead of radioactive or florescent materials. The 
sulfurylase converts pyrophosphate into ATP and the luciferase would then act 
on the produced ATP, developing light proportional to the amount of 
pyrophosphate (Nyrén and Lundin, 1985). Because of the major benefits, which  
include the possibility of using natural nucleotides instead of the heavily-modified 
dNTPs as well as the fact that it allows a direct result observation without the 
need for lengthy electrophoreses, this method gained some popularity (Ronaghi 
et al., 1998). Various improvements were also made to this method especially the 
incorporation of a special type of dNTPs that allow their enzymatic degradation 
when they are not consumed, and thus minimizing the need for lengthy washing 
steps. Pyrosequencing was then licensed to 454 Life Sciences (454; Branford, 
CT, USA; now Roche, Basel) which developed the first next-generation 
technology to reach the market , the 454 Sequencer (Rothberg and Leamon, 
2008).  
 
The great paradigm move offered by the next-generation technology is its ability 
to carry out sequencing reactions for a massive number of DNA segments in 
parallel. With the improvements, the sequencing machines used at that time 
could produce million or so reads at which each of them is about 400-500bp 
(Margulies et al., 2005). After the success of the 454 Sequencer, a number of 
machines have been introduced based on the parallel sequencing techniques 
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and the field of sequencing has gradually undergone extensive developments 
during the past 3 decades resulted in the availability of todays’ NGS platforms.  
 
The most commonly used NGS technologies are from Roche, Illumina and Life 
Technologies. Generally speaking, they all use the same concept, based on 
fragmenting the genome into manageable blocks that can be amplified and 
sequenced in a massively parallel fashion. Millions of genomic DNA segments 
are then read simultaneously (Netto and Schrijver, 2015). In fact, recent 
advances in NGS technology have allowed read length to increase up to 750 bp 
(Barba et al., 2014). The advances have also reduced the cost of sequencing a 
human genome. A full genome can now be sequenced for about US$1,000 
(Christensen et al., 2015), which has allowed this technology to be applied 
routinely in the clinical field. 
 
The available benchtop NGS technologies are either based on sequencing by 
ligation (SBL) or sequencing by synthesis (SBS) technologies (Ho Antoine et al., 
2011a). The technology from Life Technologies (such as SOLiD) is based on 
SBL, in which DNA ligase is utilised to identify which of the dNTPs is available at 
a particular location within a genomic sequence (Liu Lin et al., 2012). On the other 
hand, the technologies from both Roche (Ion Torrent) and Illumina (HiSeq) use 
the SBS approach. According to (Goodwin et al., 2016) Illumina has the top 
market share and sequencing availability in the clinical laboratories. The Illumina 
HiSeq, which was the NGS platform used in this study, uses cyclic reversible 
termination (CRT) and total internal reflection fluorescence (TIRF) microscopy to 
recognise the identity of the nucleotide (Metzker, 2010), as illustrated in Figure 
1.10. The Roche Ion Torrent platform, in contrast, is based on single-nucleotide 
addition (SNA). 
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Figure.1.10. Sequencing by synthesis on Illumina platform. (A) Template enrichment 
step at which the input DNA, which is about 5ug, undergoes fragmentation process 
followed by end repairing and adaptors ligation steps to form the library. (B) Solid-phase 
amplification step where the primers, DNA polymerases and modified nucleotides are 
added to the flow cell. Each nucleotide is specially labelled with cleavable fluorophore 
(F) and when nucleotides are added in each new cycle, each could only be engaged by 
one cluster as the 3′ end of each dNTP is already blocked. An adaptor region is available 
to activate the polymerase binding. (C) Imaging step at which laser channels of the total 
internal reflection fluorescence (TIRF) microscopy are used. The emitted colour from 
each cluster is determined by the type of incorporated base at that cycle. (D) Cleavage 
step where a reducing agent, normally Tris 2-CarboxyEthyl Phosphine (TCEP), is used 
to break the bonds between the nucleotides and fluorophore (F). This step regenerates 
a 3′-OH ready for the subsequent cycle. (Adapted from Goodwin et al. (2016) with a 
permission from the Nature Publishing Group, License number: 4077180975279).
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The utilization of NGS has played an extraordinary role in the field of genetics. A 
tremendous number of studies have been carried out using NGS. The huge 
expansion in the number of the genes identified for ID in recent years can be 
attributed to this revolutionary technology (Carvill Gemma L. and Mefford, 2015). 
NGS technology is also used for applications beyond disease gene identification, 
including a wide spectrum of analyses of various species of animals, plants and 
microbes. For example, the acquisition of 27,120 extra projects to the Genome 
Online Databases (GOLD) by January 2014 was facilitated by NGS technology 
(El-Metwally et al., 2014). 
 
The identification of certain variants is usually followed by an assessment step in 
order to evaluate the possible damage caused by these variants. Various in-silico 
tools are freely available to predict the pathogenicity and significance of found 
variants. They are of great help and becoming more powerful especially in 
accurate prioritization and selection of the top candidates in Mendelian and 
complex diseases (Van Der Velde et al., 2015). Examples of these well-known 
tools are PolyPhen-2, SIFT, mutation taster and CADD. Polymorphism 
Phenotyping version-2 (Polyphen-2) deducts its score mainly from the footnotes 
of UCSC genome browser and the vertebrate genome annotation (VEGA) 
databases. The score of Polyphen-2 ranges from 0 to 1 where higher score 
means probably damaging and closer to 0 suggests a benign change. The 
generated value is based on various logarithmic measures including structural 
features and stability profile in human and vertebrate orthologues (Adzhubei et 
al., 2010) but a higher impact is also made according to the position of the mutant 
allele whether it is at a hyper mutable site or not (Schmidt et al., 2008) . SIFT is 
Sorting Intolerant From Tolerant tool and it uses the annotations of PSI-BLAST 
(Postion-Specific Iterative Basic Local Alignment Search Tool) to generate the 
score based on the conservation of the amino acid residues in multiple species. 
SIFT interpretation is different from Polyphen-2, as higher score indicate 
tolerance and scores of 0.05 and below mean damaging (Ng and Henikoff, 2003). 
Mutation taster integrates groups of databases including 1000 Genomes Project, 
Ensemble, dbSNP and UniPort. This tool provides predication for wide ranges of 
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variants including the intronic changes, synonymous changes and the ones which 
span an intron-exon junction (Schwarz et al., 2014).  
 
CADD is Combined Annotation Dependent Depletion tool that considers a huge 
comparative information from various functional genomic sources like the 
ENCODE project and UCSC genome browser annotations. Its predication utilizes 
63 existing annotations including Ensembl Variant Effect Predictor (VEP), 
PolyPhen-2 and SIFT to produce one indicative measure called a C-score. This 
score is a reflection of the deleteriousness, which is more accurate than the 
pathogenicity score provided by other tools as deleteriousness is not calculated 
based on particular sets of mutations and thus not affected by ascertainment 
biases (Kircher et al., 2014). CADD is a great predictor for substitutions and indels 
and has been used to prioritize and score the variants in this study.  
 
1.5.4 Homozygosity mapping: limitations and the future 
Microsatellites have been used effectively in genetics for more than 30 years. 
However, the use of microsatellites is a labour-intensive process and the analysis 
is time consuming, even with the use of automated programs (Cantarella and 
D’agostino, 2015). Moreover, the allele sizes obtained by different research 
laboratories are sometimes inconsistent (Fernández et al., 2013). 
 
Because SNPs are highly abundant throughout the genome and are amenable 
to high throughput genotyping methods, they have become the most widely used 
markers in genetics research (Lijavetzky et al., 2007). Homozygosity mapping in 
consanguineous families, which uses whole genome SNP arrays, is a very 
powerful tool for the identification of various disease-causing genes. Affected 
progeny of consanguineous marriages normally inherit large blocks of 
homozygous regions, which are likely to harbour the relevant causative gene 
mutation. However, a significant disadvantage of this approach is the rarity of 
consanguineous families, especially in Western societies. Although suitable large 
families can be ascertained from other populations with high endogamy, the 
health care systems in some countries do not always provide a detailed clinical 
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assessment. Developing countries tend to have inadequate resources, well-
trained specialists, and links between health care institutions, which all affect the 
quality of the clinical infrastructure (Verma, 2015). An important point that also 
needs to be considered here is the family size. Big families with multiple affected 
individuals often lead the researcher straight to the gene because of their ability 
to provide a solid evidence that co-occurrence of the variant is not likely to be 
caused by chance but the availability of such families with the DNA from extended 
members are rare (Weber, 2016). More often now we are screening single 
consanguineous cases, hence there is a need for a tailored filtering process.  
 
Another disadvantage of homozygosity mapping is the difficulty in identifying the 
relevant gene, since multiple large regions of homozygosity are often found. 
Bioinformatics prediction tools prioritise the genes in these regions, but selecting 
which genes to pursue is a real challenge, especially when the genes have no 
known function. NGS has facilitated the processes of selecting and identifying the 
genes when coupled with homozygosity mapping. With the application of tailored 
filtering criteria, the success rate of NGS for Mendelian disorders during the past 
few years has been between 60% and 80% (Gilissen et al., 2012). It is now 
possible to bypass the SNP arrays as it is no more the dominant technology, a 
powerful approach would involve doing just WES or WGS and then homozygosity 
mapping on the SNPs that are genotyped in the sequence. Regardless of the 
applied technology, there will always be thousands of variants that require 
filtering. Selection of the best candidate genes would also depend on the minor 
allele frequency (MAF), as rare variants in the population would mean their 
implication in the studied phenotype is higher. Various literatures have already 
discussed the significance of gene allele frequency in epidemiological and 
genetic association studies (Cooper David N. et al., 2013; Goddard et al., 2000; 
Mattei et al., 2009; Taioli et al., 2004; Xue et al., 2012). Selection of the best 
candidate is also based on prior knowledge of the function and expression of the 
genes and of the clinical phenotype in the studied family (Gilissen et al., 2012; 
Tiffin et al., 2009). Checking whether any of the genes is already known to be 
associated with the condition under study might quickly identify the most likely 
causative mutation. Well-established and freely available resources, such as 
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NCBI, UCSC Genome Browser and Ensembl, help to make this process relatively 
straightforward. 
 
Compared with whole genome sequencing (WGS), whole exome sequencing 
(WES) has been more intensively used in clinical diagnostic and research 
settings (Bamshad et al., 2011; Koboldt et al., 2013). This could be due to the 
massive optimisation of WES that has been undertaken in the process of 
detecting thousands of disease-causing variants. The strategy of coupling 
homozygosity mapping with WES has been widely followed (Alkhiary et al., 
2016). However, interest in WGS has increased during the past few years, due 
to its comprehensive coverage that allows the identification of disease-associated 
genetic variants outside protein-coding regions (Hrdlickova et al., 2014). WGS is 
currently more expensive than WES, but costs are quickly dropping to an 
affordable rate with advances in technology (Gilissen et al., 2014b; Van 
Nimwegen et al., 2016). WGS is also able to identify the ~3% of coding variants 
that cannot be detected by WES (Belkadi et al., 2015). However, a major 
drawback of WGS is the huge number of the variants and the difficulty in 
interpreting their potential as causative candidates (Cassa et al., 2013). 
 
The rapid revolution among the sequencing technologies made benchmarking 
the bioinformatics tools of a great necessity. Compared with the widely used 
WES, at which explicit quality characteristics are available, standardising the 
bioinformatic tools for WGS can be more challenging. Despite the availability of 
wide range of bioinformatic tools to facilitate data analysis for next generation 
sequencing, the interpretation of this new kind of data is accomplished with 
different issues of exciting and problematic bioinformatic analysis (Pauwels et al., 
2015). There have been a need for some innovative computational tools, as the 
traditional approaches to the classic bioinformatics could not be effective enough 
to handle this type of data. Moreover, the massively produced raw data by the 
sequencing platforms could not be underestimated, a single genome comprises 
hundreds of gigabytes of base calls and quality scores (Oltvai, 2012). Because 
of that, the huge amount of the generated data implies the need for large data 
storage and thus all healthcare providers need to consider an extremely generous 
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data storage before attempting to provide next generation sequencing facilities 
(Carter Tonia C. and He, 2016; Huang Zhuoyi et al., 2016b). In order to meet the 
huge storage requirement, cloud-based storage solutions have been suggested 
and introduced (Nguyen et al., 2011) but the issue of data security has also been 
raised (Rilak et al., 2014). Security is required for the transfer as well as during 
the storage of the NGS data. It is very crucial for the applied data management 
policy to strictly adhere to the  privacy laws as well as archival need especially 
for a long term storage (Schlosberg, 2016). Different systems and platforms have 
recently been introduced, which have been described to ensure an absolute data 
protection (Bhuvaneshwar et al., 2015; Chae et al., 2013; Onsongo et al., 2014)    
 
The revolution in the sequencing technologies are resulted on various fascinating 
outcomes and one of the major advances is the introduction of the Nanopore 
fourth generation sequencing (Ku Chee Seng and Roukos, 2013; Venkatesan 
and Bashir, 2011). The idea of using nanopore sensors, a fourth generation 
technology, to sequence DNA was first proposed during 1990s (Deamer and 
Akeson, 2000; Kasianowicz et al., 1996). Nanopore sensor technology is based 
on collecting the physical and chemical properties of a molecule under study by 
calculating the blockage of current signals initiated by an ion passing through a 
pore. The flow is influenced by a biased voltage and the properties are mainly 
considered based on the length of signal interruption as well as the generated 
amplitude (Venkatesan et al., 2009). Different types of nanopore sensor have 
been developed and these include biological, solid-state, and hybrid nanopores. 
The great advantage of this technology is the minimal requirement of sample 
preparation, which is normally lengthy step in NGS. The technology also implies 
no amplification and gives results in a much shorter time. It could be the 
sequencing option of choice in the near future, providing that the limitation of a 
high error rate is overcome (Feng et al., 2015). 
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1.6 Project aims 
The research described in this thesis was focused on two main areas: intellectual 
disability (ID) in 6 families recruited in Oman (ID project) and schizophrenia (SZ) 
in 2 families recruited in the UK (psychosis project). The research hypothesises 
that “There are genetic causes of ID/SZ in 8 consanguineous families”. The 
following objectives were investigated: 
 
a. To determine regions of shared homozygosity in the affected 
members of the studied families using SNP array and homozygosity 
mapping technologies.  
b. To apply WES to identify the list of candidate variants and select 
the ones that are homozygous. 
c. To combine the data of homozygosity mapping and WES in order 
to find the list of causative homozygous variants in these families. 
d. To apply various bioinformatics/genotyping methods to filter/select 
most likely mutations identified. 
e. To exclude these mutations if they exist in publically available NGS 
databases. 
f. To Sanger sequence the candidates in the final produced list, so 
that segregation of the variants could be confirmed.   
g. To utilize and carry out certain measures, like position conservation 
and constraint metrics, that would allow supporting the significance 
of the identified mutations.  
h. To screen extra families with phenotype similar to the studied 
families, in order to search for a second hit that validate the 
implication of the identified mutations.    
i. To carry out functional analyses of certain mutations to understand 
more about their implications in the described phenotypes.  
j. To use some of the animal models, like flies and mice, to study 
certain behaviour tasks that are related to learning, memory and 
cognition.  
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Chapter 2: Materials and Methods 
2.1 Ethical approval, patient recruitment and blood/ 
saliva sampling 
This research involved genetic studies of intellectual disabilities (ID) and 
schizophrenia (SZ). The study of Omani families was approved by the Sultan 
Qaboos University Ethical Committee, Muscat, Oman with reference number 
MRE#751. A copy of the approval is attached in Appendix 1. The families were 
recruited through consultants at the Genetic and Developmental Medicine Clinic, 
Sultan Qaboos University Hospital. The main consultants involved in the 
diagnosis and recruitment of ID patients were Dr Fathiya Al Murshedi, Dr Watfa 
Al Mamari and Dr Abeer Al Sayegh. Informed consent, using a process that 
adhered to the tenets of the Declaration of Helsinki, was obtained from the 
parents of the ID patients. Blood or saliva samples were collected from members 
of each family, either at the Sultan Qaboos University Hospital or during field trips 
in different regions of Oman. The collection of blood samples was made by 
antecubital fossa venepuncture by qualified phlebotomists using EDTA 
vacutainer tubes whereas saliva was sampled using Oragene saliva collection 
tubes (DNA Genotek Inc., Ontario, Canada). The collected samples were stored 
at 4oC not more than 3 days before DNA extraction. The Oragene saliva collection 
tubes were also used to collect samples from ethnically-matched Omani controls. 
These controls were recruited from students of the Leeds Omani Society at the 
University of Leeds, using a process approved by the Leeds Central Research 
Ethics Committee. A copy of the approval is attached in Appendix 1. 
 
The study of schizophrenia patients within Pakistani families in West Yorkshire 
was approved by the National Research Ethics Service (NRES) under the title 
“Genetic investigation of schizophrenia in the Pakistani population of West 
Yorkshire” with reference number 10/H/1313/37. A copy is attached in Appendix 
1. The families were diagnosed by psychiatrists Dr Qadeer Nazar (Lynfield Mount 
Hospital, Bradford), Dr Alastair Cardno (Academic Unit of Psychiatry and 
Behavioural Sciences, University of Leeds) and Dr Tariq Mahmood (Leeds and 
 56 
 
York Partnership NHS Foundation Trust). Informed consent was obtained from 
the members of the family to collect blood or saliva. Blood samples from 
ethnically-matched Pakistani controls (n=154) were collected by Ms Salina 
Siddiqui (Eye Department, St. James’s University Hospital, Leeds). Two-hundred 
DNA samples from Caucasian subjects with schizophrenia in Glasgow and the 
West of Scotland were obtained from Dr Catherine Winchester of the University 
of Strathclyde (Winchester et al., 2012). 
 
2.2 DNA extraction 
DNA extraction was done using three different methods, as described below. 
2.2.1 Spin column method 
DNA was extracted from the blood samples using the Qiagen spin column 
method according to the manufacturer’s instructions (Qiagen Ltd., Manchester, 
UK).  In this method, 20l of Qiagen proteinase K was put at the bottom of 
microcentrifuge tubes followed by 200l of EDTA blood and then 200l of Buffer 
AL (lysis solution) before mixing by pulse-vortexing for 15 seconds. The 
homogeneous mixture was then incubated at 56°C for 15 minutes. Brief 
centrifugation was given to the tubes after their incubation in order to remove 
drops from the inside of the lid before adding 200μl ethanol (96–100%) and 
mixing again by pulse-vortexing. This mixture was then applied to a QIAamp Mini 
spin column (in a 2ml collection tube), and centrifuged at 8000rpm for 1 minute. 
After that, the QIAamp Mini spin column was carefully placed into a new 2ml 
collection tube and the tube containing the filtrate was discarded. Two washes 
were then applied and the collection tube containing the filtrate was discarded 
after each wash. The first wash was done using 500l Buffer AW1 with 
centrifugation at 8000rpm for 1 minutes and the second wash using 500l Buffer 
AW2 with centrifugation at 14,000rpm for 3 minutes. For the sake of eliminating 
any possible Buffer AW2 carryover from the previous step, 1 minute 
centrifugation at 14,000rpm was then given to the QIAamp Mini spin column. The 
QIAamp Mini spin column was placed in a new microcentrifuge tube and 200l of 
Buffer AE (elution agent) was added into the column. After 1 minute incubation 
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at room temperature (RT), 1 minute centrifugation at 8000 rpm was given to elute 
all the attached DNA. The DNA samples were then stored at -20°C. 
 
2.2.2 Salt precipitation method 
This method was used to extract DNA from blood samples of the psychosis 
families. It was started by mixing 3ml of blood/EDTA with 9 ml of Red Cell Lysis 
solution (0.32M sucrose, 10mM Tris HCl, 5 mM MgCl2 and  0.75% Triton-X-100) 
in a polypropylene tube and then centrifugation for 10 minutes at 3,200 rpm. After 
careful removal of the supernatant, the pellet was re-suspended in 3ml of White 
Cell Lysis solution (10 mM Tris _HCl, 26 mM EDTA and 0.5% SDS). Multiple and 
gentle pipetting up and down was applied in order to lyse the cells properly. Then, 
1ml of 10M Ammonium Acetate (Protein Precipitation Solution) was added and 
the samples were vortexed for 20 seconds followed by centrifugation at 3,200rpm 
for 10 minutes. A new tube was used to collect the supernatant that contained 
the DNA material. DNA precipitation was done by adding 3ml of isopropanol and 
centrifugation at 3,200rpm for 10 minutes. The precipitated DNA was washed 
twice, each with 500 l of 70% ethanol, and the supernatant was decanted. After 
air drying, the DNA pellet was redissolved in 200μl of 1 x TE buffer (Tris-EDTA 
Solution). In order to make sure that all the DNA dissolved in TE buffer, the 
samples were incubated at 55°C for 4 hours in a shaking water bath and then left 
for 1 hour at RT before storage at -20°C. 
 
2.2.3 Saliva Oragene kits 
Saliva was collected from healthy Omani individuals in Oragene ON-500 tubes 
(DNA Genotek Inc., Ontario, Canada) and DNA was extracted following the 
manufacturer’s protocol. In this method, the saliva tubes were first incubated at 
50°C in a water bath for 1 hour before transferring 750μl of saliva to a 1.5ml tube 
and adding 30μl of PT-L2P solution (purifying agent) supplied with the kit. After 
that, the samples were incubated on ice for 10 minutes followed by centrifugation 
at RT for 10 minutes at 13,000rpm. The clear supernatants of each sample (about 
600μl) were then transferred to fresh tubes and the remaining pellets were 
discarded along with the tubes. Subsequently, 720μl of 100% ethanol were added 
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to the transferred supernatant and the tubes were inverted 10 times. The samples 
were allowed to stand at RT for 10 minutes then centrifuged for 10 minutes at 
13,000rpm. The supernatant was carefully removed from each tube and 
discarded, leaving the pellets which were then washed with 500μl of 70% ethanol. 
After washing, the ethanol was removed without disturbing the DNA pellet and 
the tubes where kept for about 30 minutes at RT for the pellets to dry. Once dry, 
50μl of TE buffer was added to each pellet and the samples were incubated 
overnight at RT to ensure complete rehydration. Finally, 50l DNA was 
transferred to a 1.5ml tube which was later stored at -20°C. 
 
2.3 First strand cDNA synthesis 
This method was used to synthesize complementary DNA (cDNA) from the blood 
lymphocyte RNA, fibroblast RNA as well as the human Total RNA Master Panel 
II (Clontech Laboratories, Inc). The technique was carried out using a first strand 
cDNA synthesis kit (Thermo Scientific) following the manufacturer’s instructions.  
The method involved adding 1l (0.1-5g) of total RNA and 1l of random 
hexamer primer (15-20pmol) to 9l nuclease-free water in a tube on ice. After 
gentle mixing and brief centrifugation, the tube was incubated at 65°C for 5 
minutes and then chilled on wet ice, followed by a quick spin down before being 
placed back on ice. While on ice, another tube was placed on ice to prepare a 
master mix that had 4l of 5X Reaction Buffer, 1l of RiboLock RNase Inhibitor 
(20U/μl), 2μl of 10mM dNTP mix and 2l of M-MuLV Reverse Transcriptase 
(200U/μl). After mixing, 9l of master mix was added to the tube containing the 
RNA and the primer. This tube was then mixed and briefly centrifuged before 
incubation for 5 minutes at 25°C, followed by 60 minutes at 45°C and then heating 
at 70°C for 5 minutes to terminate the reaction. The products of the reverse 
transcription reaction were stored at -20°C until the PCR was done. 
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2.4 Primer design 
All the sequences of the regions of interest were downloaded from the UCSC 
Genome Browser, build hg19 (February 2009). Most of the primers were 
designed using the Primer3 program (http://primer3.ut.ee/) to produce a PCR 
product of 200-800 base pairs (bp). PCR products were designed to amplify 
exons of interest as well as the flanking splice site junctions. The primers 
designed for use in the reverse transcriptase RT-PCR amplification of transcripts 
were synthesised so that they would span an entire exon, allowing both cDNA 
and any contaminating genomic DNA to be detected. Some primers to be used 
in site-directed mutagenesis were designed using the Agilent website 
(http://www.genomics.agilent.com/primerDesignProgram.jsp). Sequence and 
details of all the primers are given in Appendix 2.  
 
2.5 Polymerase chain reaction (PCR) 
The PCR, including the reverse transcriptase RT-PCR, was normally carried 
using the standard method, but when this was not successful, the Hot-Shot 
master mix was used. Both methods are described below.  
 
2.5.1 Standard PCR 
PCR was typically performed in 25μl volumes containing 100ng genomic DNA, 
1l of 10x PCR buffer (Invitrogen), 1l of each forward and reverse primer (10M 
stock), 200 μM dATP, dGTP, dCTP and dTTP nucleotides (Invitrogen) and 0.5U 
Taq DNA polymerase (Invitrogen). Thermal cycling was performed on this mixture 
with an initial denaturing step of 95°C for 2 minutes then 40 cycles as follows: 
94°C for 30 seconds (denaturing), 50-65°C for 30 seconds (annealing) and 72°C 
for 45 seconds (extension). Following these cycles, a final extension step was 
performed at 72°C for 5 minutes. 
 
2.5.2 PCR with Hot-Shot master mix 
This reaction was prepared by adding 5 l of Hot-Shot master mix (Clent Life 
Science), 1 l of DNA, 3.5 l of water and 0.25 l of each forward and reverse 
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primers. After gentle mixing, the mixture was subjected to the same 
thermocycling conditions as in the standard PCR method, except that initial 
denaturation time was 10 minutes instead of 2 minutes. 
 
2.6 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to detect the presence and size of PCR 
products. Gels contained between 1% and 2% (w/v) of ultra-pure agarose (Fisher 
Scientific, UK). To prepare a gel, the desired amount of agarose was first 
dissolved in 0.5X TBE buffer by heating in a microwave oven. The solution was 
cooled to 55°C, mixed with ethidium bromide (Sigma-Aldrich) at a final 
concentration 0.5 μg/ml, and then poured into a gel tray, to a depth of between 5 
and 8mm. Gel combs were inserted. When the gel had solidified, the combs were 
removed to create wells, and the gel was submerged under 5 mm of 0.5X TBE 
buffer, in an electrophoresis tank. Wells were loaded with 10ul PCR products that 
had been diluted with 6X DNA loading dye (30% glycerol 0.25%  bromophenol 
blue and 0.25% xylene cyanol FF). 5μl DNA molecular weight marker (Bioline, 
UK) was also loaded into a well. The gel was then ran at 100V for 45 minutes. 
DNA bands within the gel were visualized with a ChemiDoc™ MP System (Bio-
Rad) over ultra-violet (UV) light (wave length 320nm). The image was focused 
through Image Lab™ software (Bio-Rad). 
 
2.7 Genotyping by microsatellite testing 
In order to make sure that no mixing of DNA samples had taken place, and for 
the purpose of verifying sample identity, each DNA sample within a family was 
subjected to microsatellite testing using three different markers. The markers 
were D1S478, D4S3042 and D7S483. In brief, the test was done by first carrying 
out standard PCR (section) using the marker primers (10μM each; Sigma-
Aldrich). An aliquot of the PCR products was first visualised on a 1.5% agarose 
gel by electrophoresis. Then, the PCR products were diluted between 1:10 to 
1:70, depending on the intensity of the PCR aliquot on the gel, in distilled water 
before taking 1 μl and mixing with 8.5µl Hi Di formamide (Applied Biosystems) 
and 0.5μl of ROX-500 ladder (Applied Biosystems). The diluted PCR products 
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were then run on an ABI3130xI capillary Genetic Analyser. Finally, the genotyping 
results were analysed by Gene Mapper software (v3.7). The possible allele sizes 
for each of the markers used were found on the CEPH website 
(http://www.cephb.fr/hgdp/main.php). Detailed information about the genotyping 
markers is given in Appendix 3. 
 
2.8 Clean-up of PCR products before Sanger sequencing 
The products were cleaned up using ExoSAP-IT (GE Healthcare Life Science), 
which contains both exonuclease I and shrimp alkaline phosphatase (SAP). The 
clean-up reaction was done by adding 2l of ExoSAP-IT to 5l of PCR product 
and incubating on a thermocycler for 30 minutes at 37°C, followed by a 
deactivation step of 15 minutes at 80°C.  
 
2.9 Sanger DNA sequencing 
A plate was set up for sequencing reaction using 0.5 μl of BigDye® Terminator 
Kit v1.3 (Applied Biosystems) with 1.5μl of 5x sequencing buffer and reverse or 
forward primer (1μl of 1.6μM) and 1μl of cleaned PCR product in a total volume 
of 10μl. The mixture was subjected to an initial denaturation step of 96°C for 1 
minute, followed by 25 cycles of 96°C for 10 seconds, 50°C for 5 seconds and 
60°C for 4 minutes. DNA precipitation was carried out by adding 5μl of 125mM 
EDTA (pH 8.0) and 60μl of 100% ethanol followed by centrifugation for 30 
minutes at 22°C and 3000 g. After that, the fluid contents were replaced by 60 μl 
of 70% ethanol and centrifuged for 15 minutes at 4°C and 800g. The ethanol was 
then decanted and the plate was completely dried by centrifugation in an inverted 
position (1 minute at 10g) followed by air drying of about 20 minutes at RT to 
allow evaporation of excess ethanol. 10μl of Hi Di Formamide (Applied 
Biosystems) was used to hydrate each DNA sample before putting the plate on 
the ABI3130xI Genetic Analyser (Applied Biosystems). Sequencing visualization 
and analysis was carried out against template sequences from UCSC Genome 
Browser build hg19 (February 2009) using SeqScape v2.5 and Sequence 
Analysis v5.2 softwares (Applied Biosystems). 
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2.10 Whole genome homozygosity mapping 
This method of mapping was performed on the DNA of affected family members 
using Affymetrix SNP 6.0 arrays by a commercial company (AROS 
Biotechnologies Ltd., Aarhus, Denmark). A flow diagram indicating the main 
steps involved in the protocol is outlined in Figure 2.1. Basically, this technique 
genotyped the DNA samples at numerous SNP markers spread across the 
genome. The Affymetrix® Genome-Wide Human SNP Array 6.0 included 
906,600 SNPs and 945,826 copy number probes, making it a powerful and cost-
effective tool for the identification of genes involved in rare, monogenic disorders. 
 
2.10.1 Data analysis of the genotyping data 
Affymetrix array data, received from Denmark, was analysed using IBDfinder 
software (http://dna.leeds.ac.uk/ibdfinder/), which produces a graphical plot on 
which the identical by descent (IBD) regions of all the chromosomes are clearly 
defined and highlighted. The data was also visualised by extracting SNP data 
from WES using Agile MultiIdeogram software (http://dna.leeds.ac.uk/auto-
zygosity/) which was set to detect runs of homozygosity (ROH) of 1 Mb and 
above. It generates a circular ideogram in which the genotyping data is displayed 
as an inner ring of human autosomal chromosomes next to one another. Each 
ring corresponding to the genotyping data of a single individual. . 
 
2.11 Whole exome next generation sequencing 
Library construction was done according to the protocol of 'SureSelect Target 
Enrichment System for IIIumina Paired-End Sequencing', from Agilent. Figure 2.2 
summarises the steps involved. 
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Figure 2.1. A flow diagram indicating the main steps involved in Affymetrix SNP 6.0 arrays. The process was started by setting two plates 
for Sty and Nsp digestions which were then pooled and purified. After that, the sample was fragmented in a thermocycler and labelled in ice using 
specific probes. The step of target hybridization was done by injecting each sample into an array chip (Affymetrix® Genome-Wide Human SNP 
Array 6.0) and placed it into a hybridization oven. Then, hybridization cocktails were exacted from the samples followed by washing/staining 
processes on a GeneChip® Fluidics Station 450.  The arrays were read in a GeneChip Scanner 3000 7G and the quality of the genotyping data 
was assessed by producing a metric Contract QC. Data anlysis was done using IBDfinder and AgileMultiIdeogram softwares.  
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Figure 2.2. A flow diagram showing the main steps involved in constructing library for Whole Exome Next Generation Sequencing. 
Library preparation is a multitask process and each step normally involves using various reagents. Detailed description about the steps, the used 
reagents and their quantities could be found in the written paragraphs following this figure. 
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2.11.1 DNA shearing 
In brief, 3μg of genomic DNA was diluted with 250μl 1X TE buffer and put in a 
secured glass tube (Covaris, USA) which was then inserted into a Covaris s220 
machine (Sonicator with Sonolite software, Applied Biosystems) for 5 minutes of 
sonication to shear the DNA into 150-200bp fragments. The samples were then 
purified using Agencourt AMPure XP beads (Beckman Coulter Genomics, South 
Plainfield, USA). After purification, the quality of the sheared DNA was checked 
by loading 1μl of the sample on a DNA 1000 chip and run on a 2100 Bioanalyzer 
(Agilent Technology). The results were assessed and visualized using Agilent 
2100 Expert Software which produced an electropherogram specific for each 
sample. Samples which showed a distribution curve with a peak size between 
150 to 200 nucleotides in the electropherograms (Appendix 4) were considered 
to have passed assessment and were thus ready to proceed to the next step. 
 
2.11.2 End-repairing 
End-repairing was carried out so that the fragments would have blunt-ends for 
creating overhangs. This was achieved by taking 48μl of each sample and mixing 
it with the following reagents from the SureSelect Library Prep Kit (Illumina): 
32.2μl of nuclease-free water, 10μl of 10x end repair buffer, 1.6μl of dNTP mix, 
1μl of T4 DNA polymerase, 2μl of Klenow DNA polymerase and 2.2μl of T4 
polynucleotide kinase. This mixture was incubated for 30 minutes at 20°C. The 
samples were then purified again using Agencourt AMPure XP beads. After that, 
adenosine overhangs were added to the 3’ ends of the fragments (3’-dA 
overhangs) by adding 11μl of nuclease-free water, 5μl of 10x Klenow polymerase 
buffer, 1μl of dATP and 3μl of Exo(-) Klenow to 30μl of the purified samples, and 
keeping the mixture in a thermal cycler for 30 minutes at 37°C. After that, the 
samples were purified using Agencourt AMPure XP beads. 
 
2.11.3 Adaptor ligation and library amplification 
Ligation of indexing-specific paired-end adaptor was carried out by adding the 
following reagents to 13μl of the sample: 15.5μl of nuclease-free water, 10μl of 
5x T4 DNA ligase buffer, 10μl of SureSelect adaptor oligo Mix and 1.5μl of T4 
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DNA ligase. The ligation was incubated for 15 minutes at 20°C in a thermal cycler, 
followed by purification using Agencourt AMPure XP beads. Each adaptor-ligated 
library was amplified by adding the following reagents to 15ul of the sample: 21μl 
of nuclease-free water, 1.25μl of SureSelect primer, 1.25μl of SureSelect Illumina 
Indexing pre-capture PCR reverse primer, 10μl of 5x Herculase II reaction Buffer, 
0.5μl of 100mM dNTP mix and 1μl of Herculase II fusion DNA polymerase (all 
from Agilent kits). The amplification was done using the following thermocycling 
conditions: initial denaturing step of 98°C for 2 minutes, then 6 cycles of 98°C for 
30 seconds, 65°C for 30 seconds and 72°C for 1 minute (extension), followed by 
final extension at 72°C for 10 minutes. There was then a purification step using 
Agencourt AMPure XP beads. 
 
2.11.4 Library hybridization 
Prior to the hybridization step, the samples were assessed using the DNA 1000 
chip run on an Agilent 2100 Bioanalyzer. A sample was considered to have 
passed this check when its electropherogram showed a single peak in the size 
range 250 to 275bp. After assurance that the samples had the correct quality and 
quantity, library hybridization was initiated using working reagents of hybridization 
buffer, SureSelect capture library and SureSelect block mix. The working 
hybridization buffer was prepared from four different SureSelect buffers: 25μl 
Hyb#1, 1μl Hyb#2, 10μl Hyb#3 and 13μl Hyb#4. Similarly, the SureSelect Capture 
Library, which was based on 4 Gb of targeted region, was prepared using 5μl of 
SureSelectXT Human All Exon V4 mixed with 2μl RNase Block Dilution that was 
prepared earlier by mixing 75% water with 25% RNase Block solution. The 
preparation of SureSelect Block Mix was done by mixing 2.5μl SureSelect 
Indexing Block #1, 2.5μl SureSelect Block #2 and 0.6μl SureSelect Indexing 
Block #3. After preparation of these reagents, 3.4μl of amplified DNA (750 ng) 
was mixed with 5.6μl of SureSelect Block Mix and 40μl of the capture libraries. 
This mixture was incubated for 5 minute at 95°C and then hybridized at 65°C 
overnight with a heated lid at 105°C. 
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2.11.5 Selection hybrid capture 
Once the hybridization step was complete, hybrid capture selection was done by 
taking 23μl of hybridised library, while still at 65°C, and adding it to 200μl of 
prepared magnetic beads (50μl of Dynabeads MyOne Streptavidin T1 washed 
and resuspended in 200μl SureSelect Binding Buffer). The solution (hybrid-
capture and beads) was incubated on a rotator mixer for 30 minutes at RT. During 
this time, the biotinylated capture-sequence will be attracted to the beads.  After 
that, the tubes were put on a magnetic stand which pulled down all the hybrid 
captured beads, leaving clear supernatant that was discarded. Then, 500μl of 
SureSelect Wash1 Buffer was added to the beads and incubated for 15 minutes 
at RT. Beads were washed three times, each with 500μl of SureSelect Wash2, 
and the supernatant discarded after putting the tubes on the magnetic stand. After 
the last wash, the beads were resuspended in 30μl nuclease-free water. 
 
2.11.6 Addition of index tags 
For the purpose of sample identification, a specific tag was added to each sample 
via the PCR. So, the capture library was amplified by taking 14μl of captured on-
bead DNA and mixing it with 22.5μl of nuclease-free water, 10μl of 5x Herculase 
II reaction buffer, 0.5μl 100mM dNTP mix, 1μl of Herculase II fusion DNA 
polymerase, 1μl of SureSelect Illumina Indexing post-capture forward PCR 
primer and 1μl from PCR primer Index. After thorough and gentle mixing, the 
tubes were run on a thermocycler as follows: 2 minutes denaturation at 98°C, 12 
cycles of 30 seconds at 98°C, 30 seconds at 57°C and 1 minute at 72°C, followed 
by an elongation step of 10 minutes at 72°C. There was then a purification step 
using Agencourt AMPure XP beads before the samples were assessed using a 
High Sensitivity DNA assay run on the Agilent 2100 Bioanalyzer. The samples 
which showed electropherograms with a peak in the size range of 300-400 
nucleotides were considered suitable for next generation sequencing. 
 
2.11.7 Sample pooling 
Samples were pooled in batches of six with a total volume of 50μl. The pooling 
was performed considering each index-tagged library was present in the mixture 
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at a concentration of 10 nM. Samples were combined based on the following 
formula: Volume = (V(f) x C(f)) / (6*C(i)), where V(f) is the final desired volume of 
the pool, C(f) is the desired final concentration of the pool (10 nM) and C(i) is the 
initial concentration of each index sample. Once all the samples were pooled, 
they were taken to the Leeds Sequencing Facility, at which they were prepared 
for cluster amplification and loaded on an Illumina HiSeq 2000/2500 platform. 
 
2.11.8 Cluster amplification 
This step was performed at the NGS facility (University of Leeds. Briefly, sample 
preparation was done using a TruSeq Cluster Generation kit (IIumina). To start, 
3μl (30 fmol) was removed from each pool and diluted with 16μl of Buffer EB (10 
mM Tris Cl, ph 8.5) and 1μl of HP3 (2 N NaOH). After brief mixing and pulse 
centrifugation, the HP3was allowed to denature the DNA by incubating for 5 
minutes at RT and then immediately on ice. Final dilution was done by adding 
992μl of pre-chilled HT1 (Hybridization Buffer) to 8μl of the denatured DNA. The 
samples were then treated with TruSeq SBS Kit v5-GA (36-cycle) before loading 
into an Illumina HiSeq 2500 Genome Analyzer (Illumina Inc. UK). 
 
2.11.9 Analysis of whole exome next generation sequencing 
output 
Analysis of the WES data is a multistep task that involved using certain UNIX 
console commands (Appendix 5) plus several of the online available facilities. 
The first step was to score the quality measures of the raw data obtained from 
the Illumina Higseq 2500 
 
2.11.9.1 Assessing quality 
This quality check was performed (see section)  by processing the data using 
FASTQC on the Galaxy platform (Blankenberg et al., 2010). The generated 
quality scores showed a wide range of measurements which reflected how well 
was the analysed sample. Examples of these measurement  and generated QC 
charts could be found in Appendix 4. To assure that the raw IIIumina sequencing 
data were of good quality with no problems or biases, they were loaded in bam 
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format into FastQC software (http://www.bioinformatics.babraham.ac.uk 
/projects/fastqc/) for quality checking. This gave a full report with quality scores, 
sequence length distribution and adaptor contents. In order for a sample to pass 
the quality control test, the mean of its Phred score had to be above 30, indicating 
an accuracy of >99.9%. Once the samples passed quality assessment, they were 
then taken for the main steps of exome analysis. 
 
2.11.9.2 Alignment of reads 
Once the sample passed the quality check, it was then taken to the alignment 
step at which the sequencing reads were aligned against the reference genome 
(hg19/GRCh37) using Bowtie2 (Langmead and Salzberg, 2012). It should be 
mentioned here that alignment of the samples for CNVs detection was made 
using NovoAlign software (http://www.novocraft.com/products/novoalign) as it 
was preferred for exome depth analysis. Then, the sample was treated in 
SAM/BAM format using SAMtools (Li Heng et al., 2009) in order to sort and index 
the sequencing reads. Samtools software (http://samtools.sourceforge.net/) was 
used to convert the produced SAM (Sequence Alignment/Map) files into BAM 
(the binary version of a SAM) format. This process involved viewing, sorting and 
indexing reads before the files were treated with Picard tools 
(http://broadinstitute.github.io/picard/) to remove all the duplicates. Local 
realignment was then carried out using the Genome Analysis ToolKit (GATK) 
software package (https://www.broadinstitute.org/gatk/). After that, all the indels 
and single substitution changes were called in VCF format using the Unifield 
Genotyper function of the GATK as described by Depristo et al. (2011). In order 
to visualise the aligned reads, the sample was then processed with the Integrative 
Genomics Viewer (IGV)  (http://software.broadinstitute.org/software/igv/) 
(Robinson et al., 2011). 
 
2.11.9.3 Variant annotation 
Annovar software (http://annovar.openbioinformatics.org/en/latest/) was used to 
annotate the generated list of variants (Wang Kai et al., 2010). The list would be 
in VCF format and Annovar would express the variant’s chromosome start 
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position, end position, reference allele and observed allele. Any amino acid 
change, conservation and frequency were also annotated.  
 
2.11.9.4 Variant filtering 
After all the variants were annotated, they were transferred into Microsoft Excel 
for manual filtering (Figure 2.3). As consanguineous families were being studied, 
lots of variants were removed based on their zygosity and whether they mapped 
outside the homozygous regions. The filtering also excluded any variants not 
present in the exonic regions or flanking splice sites, and variants that showed 
synonymous changes. Because of the expected scarcity in mutations causing 
rare diseases such as intellectual disability, any variants with more than 1% minor 
allele frequency (MAF) in the 1000 Genomes database were removed. All the 
variants which showed a small read depth of 10 or less were also excluded as 
they might not be true candidates. Bioinformatic scores generated by the 
prediction softwares (Polyphen, SIFT or CADD) were used to prioritize the testing 
of the variants for segregation. When an X-linked mode of inheritance was 
suggested, all the X-chromosome variants with CADD scores of >15 were tested.  
 
2.11.9.5 Compound heterozygote variant 
For the families in which the causative mutation could not be identified, the results 
of homozygosity mapping were not used. In fact, the filtering criteria for selecting 
the compound heterozygous variants involved removing all the homozygous 
variants from the exome sequencing lists. The genes which showed only one 
variant were removed from the list. Therefore, the list only included the 
heterozygous variants at which at least 2 of them are in the same gene. After 
that, all the synonymous and intronic change were removed. The list only 
included the variants with less than 1% minor allele frequency in the 1000 
Genomes database and read depth of more than 10. Again, bioinformatic scores 
generated by the prediction softwares (Polyphen, SIFT or CADD) were used to 
prioritize the testing of the variants for segregation.  
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Figure 2.3. A flow diagram showing the steps involved in filtering the variants for recessive disease with homozygous variants. It should 
be mentioned that the above steps were not necessarily done following a strict order, as the same final list is normally achieved as long as all the 
steps are carried out. 
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2.11.9.6 X-linked variants 
For the families at which their structure suggested an X-linked inheritance mode, 
all the variants located on X chromosome were first selected. The filtering criteria 
was applied to remove all the changes that were synonymous, intronic, with low 
depth of coverage (<10) or with > 1% MAF. The list included the variants in the 
exonic regions and  flanking splice sites.  The variants were then prioritised based 
on their scores, obtained by the prediction softwares (Polyphen, SIFT or CADD). 
An updated list of X-linked genes, that had been already known to be associated 
with ID, was used to highlight some of the prioritised variants. The list of the 
known X-linked ID genes is managed by the University of Colorado Denver and 
a copy of the list is attached in Appendix 8. Segregation of the candidate variants 
was then investigated by Sanger sequencing and checking if any variant was 
consistent with being the cause of ID in the studied family.     
 
2.11.9.7 Copy number variants 
The main principle of the ExomeDepth analysis is to look for structural 
rearrangements based on a comparison between the read depths of the sample 
and a small set of control samples. It is important for the used control samples to 
have been treated with the same version of library reagents and sequenced in 
the same run. The analysis was carried out as described by Plagnol et al. (2012).  
Briefly, the fastaq files of the samples were processed as for whole exome 
analysis (see Section 2.11.9) but the “removal of duplication” step was not done. 
The indexed bam file of each sample was treated by GATK using the R package 
ExomeDepth (https://cran.r-project.org/web/packages/ExomeDepth/index.html). 
The used UNIX console and R commands are shown in Appendix 5. The obtained 
CNV calls were prioritised based on Bayes factor (BF), which is the log10 of the 
likelihood ratio of data for the CNV call divided by the call of the normal copy 
number. There is no ideal threshold for BF but a higher number suggests a 
potential CNV. Zygosity of the candidate CNV was determined based on the ratio 
between the expected and observed reads.  All the heterozygous variants, with 
reads ratio of 1 and 1.5, were excluded and the final lists included only the 
homozygous variants which had read ratio of 0 and 2.  
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2.12 Download from UK10K database 
UK10K (http://www.uk10k.org/)  is a database providing whole exome sequences 
of 4000 healthy individuals and 6000 subjects with neurodevelopmental 
disorders, obesity and other rare diseases. A request was made to allow the 
members of Leeds Psychiatric Genetics Group (Appendix 1) to access the 
UK10K database. After granting the authorisation access, the related cohorts of 
data were downloaded.  Three cases cohorts were selected for the download as 
they have samples for individuals with various degree of intellectual 
disabilities/learning disabilities. These cohorts were; UK10K_NEURO_MUIR, 
UK10K_NEURO_ASD_GALLAGHER and UK10K_RARE_FIND. For the 
purpose of comparing the changes of significance in the cases, two cohorts of 
samples for healthy individuals were also included and these were 
UK10K_COHORTS_TWINSUK and UK10K_COHORT_ALSPAC. The samples 
of interest within datasets were downloaded using FileZilla download client 
(https://filezilla-project.org/download.php) in order to get VCF files. The total 
numbers of downloaded samples were 469 cases and 2432 controls. 
 
Once all the samples were downloaded, multiple analysis was carried out which 
involved using various UNIX commands (Appendix 5). For security reason, all the 
samples were only available for downloaded as encrypted data. The first step 
was to decrypt all the downloaded files and a separately supplied code was used. 
After that, vcfhacks (https://sourceforge.net/projects/vcfhacks/) was used to 
search for all the variants that were present in ANKRD2 or PDZD8. This step was 
very important as it helped to focus only in specific genomic regions of interest 
and allowing an easy manipulation of the data. The variants were then annotated 
using variant effect predictor (VEP) (http://www.ensembl.org/info/docs/tools/vep 
/index.html). After that, all the variants were scored using CADD 
(http://cadd.gs.washington.edu/) and the ones with <10 were filtered out.  Then, 
the VCF list was converted Microsoft excel and all the non-functional variants 
(synonymous, intronic, etc.) were filtered out. 
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2.13 Site-directed mutagenesis (SDM) 
A construct, containing wild-type human DFNB31 transcript 3 (UC004bja.4) 
cloned into ampicillin-resistant pDEST-733, was received from Dr Erwin van Wijk 
of Radboud University, Nijmegen, Netherlands. The full sequence of the 
construct, including an mRFP tag (Monomer Red Fluorescent Protein), is shown 
in Appendix 6. The main aim of site directed mutagenesis is  to introduce a 
substitution change into a genome (Carter Paul, 1986). The process was done 
by using QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies) to 
make a change in the DFNB31 insert so that it resembles the reported variants 
(R450C). 
 
2.13.1 Preparation of ampicillin LB (Luria Broth) 
The following components were added to 900 ml of distilled water in a 1 litre Pyrex 
bottle: 9g of tryptone, 4.5g yeast extract and 9g NaCl. These were thoroughly 
mixed and autoclaved for 15 minutes at 15 Pa pressure. When the mixture had 
cooled down, the bottle was labelled and stored at 4°C. 
 
2.13.2 Preparation of ampicillin LB agar 
The following components were added to 400ml of distilled water in a 500ml 
Pyrex bottle: 4g tryptone, 2g yeast extract, 4g NaCl and 6g agar. These were 
thoroughly mixed and autoclaved for 15 minutes at 15 Pa pressure. When the 
mixture had cooled down, but before solidification, 400μl of 100mg/ml ampicillin 
(Sigma-Aldrich) were added and mixed thoroughly. The medium was then poured 
into petri dishes, labelled and stored at 4°C. 
  
2.13.3 Protocol of SDM 
The main steps are shown Figure 2.4 and the construct sequence is shown in 
Appendix 6. Mutagenic primers (Appendix 2) were designed using the Agilent 
website (http://www.genomics.agilent.com/primerDesignProgram.jsp). PCR was 
done using 50ng of the plasmid and high-fidelity DNA polymerase (Pfu Turbo, 
Agilent Technologies). The pair of primer for the DFNB31 variants (R450C 
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mutation) was used to introduce the target changes into the wild-type transcript. 
Thermal cycling was performed with an initial denaturing step of 95°C for 30 
seconds, followed by 16 cycles of 95°C for 30 seconds (denaturing), 55°C for 1 
minute (annealing) and 68°C for 8 minutes (extension). 
 
The PCR product was then digested with a DpnI restriction enzyme (New 
England Biolabs) by adding 1μl of DpnI to the PCR product and incubating the 
reaction at 37°C for one hour. During the incubation time, DpnI recognised the  
GATC sequence but it only cut the parental DNA plasmid because its “A” was 
methylated when it was originally prepared from a stain of E.coli. To transform 
XL1-Blue supercompetent cells, 1μl of the digested PCR product was incubated 
with 50μl of XL1-Blue supercompetent cells in ice for 30 minutes before exposing 
to a heat-pulse of 42°C for 45 seconds, followed by immediate storage on ice. 
The cells were then nourished with 500μl of pre-warmed SOC medium 
(Invitrogen) and incubation with shaking (230 rpm) at 37°C for one hour. After 
that, 150μl of the mixture was spread onto ampicillin (100 μg/ml)-LB agar plates 
(see preparation above). The plates were incubated overnight at 37°C. 
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Figure 2.4. A flow diagram showing the steps involved in Site-Directed Mutagenesis assay and the purification of the produced plasmid. 
The designed mutagenic primers introduced the required change and the DpnI cleaved the methylated parental DNA. The super competent cells 
has holes that facilitated the entry of the mutated DNA. The mutated DNA was harvested from the grown cells. Plasmid purification and production 
of more mutated DNA was made after the confirmation that the change of interest was successfully introduced.   
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2.13.4 Preparation of bacteria for plasmid preps 
Aseptic techniques were followed throughout this process. Starter cultures were 
first prepared by inoculating a single colony from an ampicillin-LB agar plate into 
a tube containing 5 ml LB broth (see preparation above) with 5μl of 100 mg/ml 
ampicillin. The tube was then incubated at 37°C with shaking at 300rpm for about 
8 hours. From the starter culture, plasmids were extracted using a Qiagen 
Miniprep kit, according to the manufacturer’s instructions (Qiaprep MiniPrep 
Handbook). The protocol produced about 45μl of DNA, the concentration of which 
was quantified using a Nanodrop spectrophotometer. 
 
2.13.5 Testing the prepared plasmids for the introduced changes 
A standard PCR was first carried out using a pair of primers (5μM each; Appendix 
II) that flanked the targeted change (R450C mutation) in the DFNB31 cDNA. 
Thermal cycling was performed as follows: 94°C for 3 minutes, then 34 cycles of 
94°C for 20 seconds (denaturing), 55°C for 1 minute (annealing) and 72°C for 40 
seconds (extension), followed by a final extension step of 72°C for 10 minutes. 
 
2.13.5.1 Digestion 
8 μl of the PCR product were mixed with 9.3 μl water, 2 μl Buffer K, 0.2 μl BSA 
(10 μg/μl) and 0.5 μl ScaI enzyme (Promega, USA). The mixture was incubated 
at 37°C for 3 hours. The mixture was incubated at 37°C for 1 hour. The digestion 
was subjected to electrophoresis in a 2% agarose gel at 100V for 45 minutes. 
 
2.13.5.2 Sequencing 
Six primers (Appendix 2) were designed to cover the whole sequence of the 
DFNB31 cDNA insert. The DNA fragments amplified using these primers were 
subjected to standard Sanger sequencing, as described earlier. This step was 
not only to verify the target mutation but also to ensure that no other changes 
were introduced during the process of SDM. 
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2.13.6 Plasmid purification using HiSpeed Plasmid Maxi Kit 
A starter culture was prepared by aseptically inoculating a single colony from an 
ampicillin-LB agar plate into a tube that had 5ml LB broth with 5μl of 100 mg/ml 
ampicillin. The tube was then incubated at 37°C with shaking at 300rpm for about 
8 hours. After that, 333μl of the start culture was added to 250ml LB containing 
250μl of 100mg/ml ampicillin. The mixture was incubated at 37°C with shaking 
overnight. Cells from the culture were then harvested by centrifugation at 6000xg 
for 15 minutes at 4°C. Using a Maxiprep kit (Qiagen), the pellet was first treated 
by adding 10ml of Buffer P1 (lysis agent), followed by 10ml of Buffer P2 
(homogenising agent) and then 10ml of chilled Buffer P3 (precipitation agent). 
The lysate was then poured into a cartridge and incubated for 10 minutes at room 
temperature. Using a plunger, the lysate in the cartridge was then applied to a 
filter column (which had already been equilibrated by applying 10ml of Buffer 
QBT) and allowed to enter the resin filter by gravity flow. After that, the filter was 
washed with 60ml of Buffer QC before the DNA was eluted from the filter in 15ml 
of Buffer QF. The eluted DNA was then precipitated by adding 10.5 ml of 
isopropanol, followed by 5 minutes of incubation at room temperature. With the 
aid of a 30ml syringe and constant pressure upon the plunger, the mixture of elute 
and isopropanol was then filtered through a QIAprecipitator. Two ml of 70% 
ethanol were then applied to the QIAprecipitator via a syringe. After that, the 
syringe was twice used to push air quickly and forcefully through the 
QIAprecipitator membrane, until the membrane was dry. At this step, the DNA 
was trapped in the QIAprecipitator and ready for elution. One ml of TE buffer was 
then applied from 5ml syringe to the QIAprecipitator, and the elute was collected 
in a 1.5ml collection tube. In order to ensure that the maximum amount of DNA 
was solubilized and recovered, a re-elution step was done by taking the elute and 
pushing it through the QIAprecipitator again. This Maxiprep process usually 
produced 1ml of purified DNA with a concentration ranging from 500-1000μg/ul. 
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2.14 Immunofluorescence on fixed cells 
2.14.1 Cell line maintenance 
All the cell line culture was performed in a NuAire Labgard 437 ES Class II 
Biosafety Cabinet using the standard aseptic technique. When required, cells 
were removed from a -80°C freezer, thawed by immediate swirling in a 37°C 
water bath, and then rapidly transferred into a tube containing 19ml of Dulbecco's 
Modified Eagle Medium (DMEM), from Lonza, supplemented with 10% Fetal 
Bovine Serum (Sigma-Aldrich). The cells were then collected by centrifugation at 
3000rpm for 3 minutes, decanting the media, and resuspension in 1 ml DMEM. 
Cells were grown in T75 flasks (Corning) containing DMEM in a Sanyo MCO 
20AIC cell culture incubator set at 37°C and 5% CO2. Cells were passaged after 
their confluency by dissociating them from the surface of the flask with 10 ml of 
0.25% trypsin (Lonza) and 2-10 minutes incubation at 37°C and 5% CO2. 
Sufficient banging into the flask for about 1-2 minutes ensured the maximum 
removal of the cells attached to the inner flask wall. Using a pipette, the flask wall 
was flushed thoroughly using the same suspension of cells in the flask and all the 
cells were transferred into a new Falcon tube containing 15ml of DMEM. The tube 
containing the 25 ml cell suspension was inverted 3 times to achieve proper 
mixing of cells. Subsequently, 3 minutes centrifugation at 3000rpm was given to 
the tube and the media was discarded, leaving the cell pellet, which was 
resuspended in 1ml of DMEM. Then, the cells were vigorously mixed by pipetting 
up and down about 20 times before adding 9 ml of fresh DMEM. So, the cells at 
this stage were suspended in a total of 10ml of DMEM. 
 
2.14.2 Cell counting 
For accuracy and consistency, the resuspended cells were counted before their 
seeding into new flasks. The count was carried out by mixing 50μl of trypan blue 
stain (Thermo Fisher Scientific) with 50μl of the cell suspension, and then loading 
into a clean haemocytometer. The haemocytometer was placed under an 
Olympus CKX41 bright field microscope and cells were counted. The 
resuspended cells were then diluted based on the desired seeding density. 
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2.14.3 Transfection 
Transient DNA transfection was done to assess the over-expression of plasmids 
in cultured SHSY5Y cells. Plasmid transfection was carried out using an 
Effectene Transfection Kit (Qiagen), according to the manufacturer’s instruction. 
The cells were first plated overnight in 24-well plates containing sterile coverslips 
(Fisher Scientific) in each of the wells. The next day, transfection was done when 
the growth was about 60-80% confluency. The cells were transfected while 
growing at 37°C with 5% CO2 for 16 hours at 0.2μg concentration using 5 μl of 
Effectene Transfection Reagent and 1.6μl of Enhancer, all diluted in 400μl of 
DMEM. 
 
After 16 hours of incubation, the media (with the transfection complex) was 
removed and the cells were immediately resuspended in 500μl of fresh warm (37 
oC) DMEM media to prevent cell toxicity. 
 
2.14.4 Cell fixation 
The cells were washed three times with 500μl of warm (37 oC) Dulbecco's 
phosphate-buffered saline (DPBS, from Sigma) on a rocking platform (Roto-
Shake Genie, Qorpak, USA) for 1 minutes at RT. After that, they were fixed with 
500μl of 4% paraformaldehyde (Alfa Aesar, UK) for 10 minutes on the Roto-
Shake machine. The paraformaldehyde was immediately removed, and 1ml of 
DPBS containing 50mM NH4Cl (1.5g in 500ml) was added to the cells, which 
were then rocked for 1 minute to quench excessive fixative and prevent any 
subsequent non-specific cross-linking later. The cells were then washed three 
times with 500μl of DPBS (Lonza) and 5 minutes of rocking. 
 
2.14.5 Cell permeabilisation 
Cell permeabilisation was carried out using 0.2% triton X-100 (Sigma-Aldrich) 
with rocking for 4 minutes, then rinsing the cells twice with 500μl DPBS. The cells 
were then blocked in 500μl DPBS containing 3% donkey serum (Sigma-Aldrich) 
for 2 hours with rocking at RT. After that, the cellular coated coverslips were 
carefully transferred into a new 24-wells plate. 
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2.14.6 Immunostaining 
To each well, 250μl of the appropriate primary antibody, diluted in blocking 
solution containing 3% donkey serum, was added. Goat anti-whirlin antibody 
(Santa Cruz, sc-49787) was used at a 1:100 dilution and rabbit anti-UBR4 
antibody (Abcam, ab86738) was used at a dilution of 1:250. The plate was 
transferred into a moist chamber and incubated overnight at 4°C on a rocking 
platform. The next day, the cells were washed three times with 500μl of 0.1% 
tween solution (Bio-Rad) for 5 minutes on a rocking platform at RT. The cells 
were then incubated for 1 hour with 250μl of fluorescently conjugated secondary 
antibodies in blocking buffer with rocking at RT. Both secondary antibodies (Anti-
Goat 488 and Anti-Rabbit 488; Invitrogen) were used at a dilution of 1:500 
dilution. The cells were then washed in 500μl DPBS for 10 minutes with rocking 
before their nuclei were stained with 500μl of 1:1000 diluted DAPI (Sigma-
Aldrich). The cells were then given two final washes with 500μl DPBS for 10 
minutes with rocking at RT. 
 
2.14.7 Slide mounting 
The correct number of microscopic slides was labelled and about 50μl of 
Fluoromount-G® mounting medium (Southern Biotechnology) were added at the 
centre of each slide. Then, the correct coverslips were carefully taken from the 
24-well plate and mounted upside down on the mounting medium. Any air 
pebbles present between the slide and the coverslip were driven out by gently 
pressing on the coverslip. The slides were then kept for at least 12 hours at 4°C 
before they were taken for confocal microscopy. 
 
2.14.8 Confocal microscopy 
The slides were analysed and imaged using both Zeiss LSM510 and Nickon 
Eclipse TE2000-E microscopes. Each of them has its own associated imaging 
software. In general, confocal imaging involved using 408nM, 488nM and 543nM 
lasers for exciting DAPI, Alexa Fluor® 488 and Alexa Fluor® 563 fluorophores, 
respectively. Multiple photographs were taken for each view of interest using 
different cellular slices, and co-localization was assessed on 30 cells using the 
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ImageJ software open source image processing package (http://fiji.sc/). The 
confocal microscopy and Fiji ImageJ assessment was also independently done 
by Dr James Dachtler, faculty of biological sciences, university of Leeds.   
 
2.15 Co-immunoprecipitation 
2.15.1 Brain tissues homogenising 
For minimal disturbance of hypothesised interaction between whirlin and UBR4, 
ultrasonication was selected as the method for homogenising right brain 
hemispheres collected from three different wild type adult mice. The tissues were 
first weighed and then Protease Inhibitor Cocktail (cOmpleteTM, EDTA-free; 
Roche) was added to each tissue based on its weight, 5ml of inhibitor per 1g of 
tissue. Each sample was then placed under a sonicator tip for 40 seconds using 
7 cycles and 40% power. After that, the homogenates were transferred to new 
Eppendorf tubes on ice before they were centrifuged in a pre-chilled microfuge at 
12,000 rpm for 20 minutes at 4°C. After centrifugation, the supernatants were 
carefully transferred to new tubes and the deposits were discarded along with 
their tubes. The samples were then stored at -80°C. 
 
2.15.2 Protein quantification 
The protein level in each of the samples was measured using a Pierce BCA 
Protein Assay Kit (Thermo Fisher Scientific), following the manufacturer’s 
instructions. At the beginning, five albumin standards were prepared from 2 
mg/ml stock. In order to achieve accurate measurement, the assay was done in 
duplicate for each of the standards and the samples. The prepared standards 
were 0, 2, 4, 8 and 10mg/ml diluted in ddH2O. The samples were diluted 1:10. 
After that, the required amount of BCA working reagent was calculated 
considering that each sample or standard needed 190μl of working reagent 
containing 50 parts of solution A (sodium carbonate, sodium bicarbonate, 
bicinchoninic acid and sodium tartrate in 0.1M sodium hydroxide) and 1 part of 
solution B (4% cupric sulphate). The reaction was set up in a microplate (Thermo 
Fisher Scientific) in which each 10μl of the samples or standards were mixed with 
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190μl of the prepared BCA working reagent, and the micropate was incubated at 
37°C for 30 minutes. The plate was then loaded into an Ultrospec 3000 optic 
reader (Pharmacia Biotech) and the optical density measured at 750nm. The 
readings obtained from the different standards were plotted against their protein 
concentration in order to generate a standard curve that was used to determine 
the protein concentration of each sample. 
 
2.15.3 Immunoprecipitation 
Antibodies were diluted in PBS at a total volume 450 μl. The experiment was 
designed to include whirlin and blocked whirlin, plus Munc18 as a control 
antibody. All the antibodies were diluted 1:200 in tubes, except that the blocked 
whirlin tube also contained a specific peptide (Santa Cruz, sc-49787 P) to block 
the whirlin antibody. This peptide is the same against which the antibody had 
originally been raised, and the amount of whirlin peptide was five times the 
antibody amount in the tube, based on the manufacturer’s instructions. The tubes 
were incubated with rotation overnight at 4°C, with the expectation that the 
blocking peptide would be effective. In order to attach the prepared antibodies to 
beads, 50μl of PBS-washed magnetic beads (Novex; Life Technologies) were 
added to each tube and the mixture (500μl) was incubated with rotation at RT for 
2 hours. This preparation was called antibody-bound beads. In the middle of the 
incubation time, 350μg of protein from each sample was prepared in a total 
volume of 450μl of PBS and mixed with 50 μl of PBS-washed magnetic beads 
before being incubated with rotation at RT for 1 hour. The tubes were then placed 
on a magnetic stand for about 2 minutes until clear supernatant formed. The 
supernatants were saved and the beads were discarded. This step was done to 
remove any unwanted materials, leaving clean protein samples known as pre-
cleared protein. After that, the antibody-bound beads (500μl) were mixed with the 
pre-cleared protein (500μl) and kept rotating overnight at 4°C in order for the 
antibody-bound beads to bind to the protein of interest. The next day, the tubes 
were placed on the magnetic stand for about 2 minutes before the flow 
through/supernatant was removed from each sample and saved. The beads were 
then washed by mixing 500μl of PBST, putting the tubes in the magnetic stand 
and then removing the supernatant. The beads were then resuspended in 30μl 
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of 4X loading buffer, boiled at 65°C for 5 minutes in order to dissociate from the 
proteins, and then placed on ice. Subsequently, the beads were placed in ice and 
30μl of eluted supernatant was transferred from each sample to a new Eppendorf 
tube ready for loading on a gel. 
 
2.16 Western blotting 
2.16.1 Samples preparation 
The mouse brain lysates were first prepared for Western blotting by making 15μl 
dilutions containing 60μg of protein from each sample. After that, 5μl of Laemmli 
buffer with 5% β-mercaptoethanol (see appendix 7 for recipe) was added to each 
sample in Eppendorf tubes. A cap holder was fixed over the lid of each tube 
before the samples were boiled in a heating block at 90°C for 5 minutes, then 
placed on ice. A quick spin was then given to the tubes to bring down any sample 
that might have adhered to the tube walls during boiling. 
 
2.16.2 Polyacrylamide gel electrophoresis (PAGE) 
The samples were run on pre-cast gels of different polyacrylamide concentrations 
(Bio-Rad) depending on the molecular weight of the protein of interest. Ten 
percent polyacrylamide gels were used to detect whirlin and 5% gels were used 
to detect UBR4. The gels were carefully removed from their packaging and the 
plastic well separator was then removed before inserting the gel into a holder and 
locked. After that, the gel was placed in a tank and 200ml running buffer (see 
appendix 7 for recipe) was then added. The wells in the gel were flushed by 
pipetting running buffer up and down with a Pasteur pipette before loading the 
samples (20μl each) and 8μl of protein size maker (Hi-Mark pre-stained HMW 
protein standard, Invitrogen). The gel was then run at 80V for between 60 and 
180 minutes using a Power Pac 3000 (Bio-Rad). Meanwhile, 1000ml of transfer 
buffer (see appendix 7 for recipe) was prepared and stored at 4°C for the next 
step. 
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2.16.3 Gel blotting 
Before the electrophoresis was stopped, sheets of blotting paper (BioRad) and 
PVDF membrane (Amersham Biosciences) were cut to the size of the gel. The 
blotting paper was immersed in transfer buffer and the PVDF membrane was 
immersed in 100% methanol for 1 minute. Once the electrophoresis had run for 
the specified time, the gel was removed from its frame and placed over the PVDF 
membrane. Both the gel and the PVDF membrane were supported by sheets of 
blotting paper and sponges in the form of a sandwich, which was then fixed and 
locked in a cassette. The cassette was placed in the tank which was filled transfer 
buffer and ice blocks. The gel was allowed to transfer at 20V with agitation 
overnight at 4°C. 
  
2.16.4 Immunostaining 
The next day, the membrane was removed and placed in PBST and the correct 
amount of blocking solution was prepared. Blocking solution consisted of 5% milk 
(Marvel skimmed milk powder) for the anti-whirlin antibody and 2% BSA (Sigma) 
for the anti-UBR4 antibody. The membranes were blocked for 1 hour with shaking 
at RT. After that, the membranes were briefly washed in PBST and then the 
antibody diluted as 1:200 in the correct amount of blocking solution was added to 
the membrane and incubated rotating for one hour at RT. Subsequently, the 
membrane was washed three times in PBST with shaking for 10 minutes. HRP-
conjugated secondary antibody specific to the primary antibody, diluted 1 in 5000 
of the correct blocking solution, was incubated with the membrane for 1 hour at 
RT. Again, the membrane was washed three times in PBST with shaking for 10 
minutes before it was ready for imaging. 
 
2.16.5 Imaging 
Amersham ECL (enhanced chemiluminescent) Prime Western Blotting Detection 
Reagent (GE Health Care) was used for chemiluminescent detection of proteins. 
The membrane was covered with equal parts of solutions A (luminol) and B 
(peroxide) from the kit and left for 1 minute at RT. The membrane was then 
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removed and excess ECL reagent was drained from the membrane. The 
membrane was the wrapped with cling film and exposed to UV light.  
 
2.16.6 Membranes stripping 
To determine whether samples with no bands in the western blotting did actually 
contain proteins, membranes were stripped of antibodies using a strong antibody 
stripping solution (EMD Millipore) before re-probing with a different antibody. This 
method caused minimal disturbance to the proteins immobilized on the 
membrane. The membranes were first incubated in 20ml of 1:10 diluted stripping 
buffer for 30 minutes with rotation at room temperature, then they were washed 
three times in 20 ml PBST for 5 minutes per wash. The membrane was blocked 
by incubating it in 20 ml of 5% milk for 30 minutes with rocking at RT. The 
membranes were incubated with 1:500 diluted mouse anti--Actin antibody 
(Sigma, A5441) in 5% milk for one hour. After that, the membranes were washed 
three times in 20 ml PBST for 5 minutes before they were incubated in 1:5000 
diluted rabbit anti-mouse antibody (Sigma, A9044) in 5% milk for 1 hour at RT. 
The membranes were then washed three times in 20ml PBST for 5 minutes in 
preparation for imaging. 
 
2.17 Immunohistochemistry 
Immunohistochemistry was carried out on paraffin embedded sagittal sections of 
adult wild type mouse brain fixed in 4% PFA (obtained from Dr Christine Diggle, 
University of Leeds). The process used the Novolink Polymer Detection System 
(Leica Biosystems) and was carried out at RT unless stated otherwise. To melt 
the paraffin wax, the slides were incubated on a heat block at 70°C for 20 
minutes. The sections were then rehydrated using reduced gradient alcohol of 
100%, 90% and 70% ethanol, each for 5 minutes. Endogenous peroxidase 
activity was blocked by keeping the sections in 3-4% (v/v) hydrogen peroxide 
(H2O2) for 20 minutes. The sections were kept under running tap water for 10 
minutes in order to wash off all the H2O2 before boiling in 1:100 unmasking 
solution (Vector) for 5 minutes for antigen retrieval. After that, protein blocking 
was done by adding 100 μl of 0.4% casein to each section and keeping it in a 
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moisture chamber for 20 minutes. The casein was then removed and the sections 
were incubated overnight at 4°C in 100μl of primary antibody diluent (Invitrogen) 
with the optimised concentration of antibody. Both ANKRD2 (rabbit IgG 
polyclonal, from Santa Cruz) and PDZD8 (rabbit IgG polyclonal, from biorbyt) 
antibodies were used at 1:100 dilution. The negative slides were incubated with 
antibody diluent, supplemented with a non-immune immunoglobulin of the same 
isotype (Rabbit (DA1E) IgG XP® Isotype Control, from Cell Signalling) and 
concentration as the primary antibodies. The moisture chamber was then kept at 
RT for 1 hour before sections were washed three times with TBS (Tris-buffered 
saline) and then incubated in post primary treatment for 30 minutes. This 
treatment contains the secondary antibody (Rabbit anti Mouse IgG) which aims 
to detect mouse antibodies and their attracted tissues. The sections were again 
washed three times with TBS followed by incubation with Polymer HRP for 30 
minutes. DAB solution was prepared by mixing one part of DAB chromogen (3,3’ 
– diaminobenzidine) to 19 parts of supplied DAB substrate buffer. Each section 
was incubated in 100 μl of DAB solution for 5 minutes. The slides were then 
rinsed for 1 minute under tap water before counterstaining with haematoxylin and 
then dehydrating the section with 100% ethanol and xylene. Each slide was 
mounted with the proper coverslip and using DPX mounting medium (contains a 
mixture of distyrene, plasticiser, and xylene). The sections were then left to dry 
at RT for at least 3 hours before being examined under Nikon Eclips TE-2000-E 
light microscope. 
 
2.18 Drosophila behaviour experiments 
2.18.1 Transgenic fly lines 
CG10632 is the Drosophila melanogaster orthologue of the human gene PDZD8. 
A CG10632 RNAi Drosophila was received from the Vienna Drosophila Source 
Centre (VDSC). They are transgenic white eyed fly lines expressing RNA 
interferences (RNAi) against CG10632 which is located in chromosome X.  VDSC 
uses the GAL4 system to produce Drosophila lines for gene knockdown. The idea 
of using GAL4 system in the clinical practice goes back to 1987, when O'Kane 
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and Gehring described a way of regulating the expression of LacZ gene (encodes 
B-galactosidase) in Drosophila genome through its fusion with the P-element 
promoter (O'kane and Gehring, 1987). This success was later supported by 
Brand and Perrimon who established the GAL4 system and explained its efficient 
use as a  tool to  activate specific target gene in wide ranges of tissues (Brand 
and Perrimon, 1993). Details on how GAL4 system works are given in Figure 2.5. 
The system utilizes yeast transcriptional factor GAL4, which was found to 
maintain its potential to activate the transcription process in other species 
including human cell lines, plant, zebrafish and Drosophila (Caygill and Brand, 
2016). GAL4 has a direct interaction SAGA protein complex through Tra1 subunit, 
allowing it to recruit the Mediator (Jeong et al., 2001) and multiple components of 
the transcription machinery to generate the transcription process (Lin Ling et al., 
2012a). The principle of using GAL4 in the process of knocking down the 
expression of a gene of interest is explained further in Figure 2.5.   
 
In the experiment described here, a GAL4-actin driver line, donated by Tracey 
Chapman (University of East Anglia), was used to control CG10632 expression. 
This GAL4 driver was balancer with curly wing (cyo) to stop homologous 
recombination in the stock. When crossing to CG10632 RNAi, offspring with curly 
wings were discarded and only straight-wing males were taken forward into 
experiments. This is because straight-wing males, and not curly wings male, carry 
both copies of Actin Gal-4 and CG10632 RNAi in their genome.    
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Figure 2.5. Principle of GAL4 to supress gene expression. A yeast transcriptional 
factor GAL4 is incorporated in a driver line which also has the enhancer of the target 
gene. The target gene line is generated to contain the upstream activating sequences 
(UAS) of the GAL4 as well as an inverted repeat sequence of the target gene. The 
process of knocking the target gene down would not be initiated until both lines comes 
in contact and the GAL4 get activated by its UAS. The activation of GAL4 system causes 
the inverted repeats to fold and create a long RNA of the target gene. After that, the 
produced RNA will be processed by the cellular machinery to make multiple functional 
siRNAs that would act to repress the target gene. (Adapted from Caygill and Brand 
(2016) with a permission from Springer and Copyright Clearance Center, License 
Number: 4105940955052). 
 
 
The use of  chromosome balancers, like Cyo, FM7h and TM3, is an important 
toolbox in the field of Drosophila genetics due to their capabilities that  allow 
maintaining lethal mutations, avoiding separation of multiple alleles during mitotic 
recombination and visibility of an effect in multiple generations (Sun et al., 2012). 
Cyo is a dominant chromosome balancer for the second chromosome of 
Drosophila and once activated, it makes the wings of the flies to be curly or 
twisted (Lattao et al., 2011; Pina and Pignoni, 2012). 
 
White eye flies, obtained from Elizabeth Duncan (University of Leeds), were used 
as a control because they have the same genetic background of the RNAi line 
and would be expected to control the behaviour of physiological differences. In 
the experiment, white eye and RNAi males were crossed to virgin actin driver 
females. The crosses were done by knocking the flies down with CO2, as 
described by Artiss and Hughes (2007), and putting 5 males with 5 females in the 
prepared vials after sprinkling some yeast on top of the food (see 2.4.2). The flies 
were kept to mate and lay eggs at 25°C. After 2-3 days, they were moved into 
new vials with food and yeast for further egg laying. Larvae hatch from the eggs 
after about 6 days and then develop into the adult stage. The newly bred 
Drosophila flies were collected under cold anaesthesia (ice), as described by 
Ratterman (2003). As the CG10632 knockdown occurs at chromosome X, males 
were selected for the behavioural assays (negative geotaxis, courtship 
suppression, T-maze). All males were between 4 and 8 days old when used in 
experiments. Females were only used for the first experiment to compare the 
relative expression of CG10632 expression.  
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2.18.2 Food preparation 
A standard sugar-yeast agar (SYA) medium was prepared by adding 20g of agar 
to 1 litre of water, which was then heated in a steamer at 100°C for 90 minutes. 
Once the agar was dissolved, a smooth mixture of 100g of brewer’s yeast and 
100 g of sugar was added to the mixed agar. The mixture was stirred until it 
became homogenous and then allowed to cool to less than 70°C. Thirty ml of 
nipagin (10% w/v solution from Sigma) and 3ml of propionic acid were then added 
and mixed thoroughly. Nipagin is a methylparaben which acts as an anti-fungal 
agent and it also slows the Drosophila growth rate in the larval and pupal 
stages.   With the food mixture at about 50°C, a dispenser was used to pour 7ml 
of the prepared food into 25 x 95mm polystyrene vials. The food was allowed to 
cool at room temperature for 2 hours before the vials were capped with cotton 
balls and stored at 4°C for daily usage. 
 
2.18.3 Checking RNA knockdown through qPCR 
2.18.3.1 RNA extraction and cDNA Synthesis 
To begin with, 5 flies from wild type or RNAi crosses where put into an Eppendorf 
tube. A hole was made in the lid of each tube before placing it into liquid nitrogen, 
then transferring it to wet ice. 600μl of QIAzol Lysis Reagent (Qiagen) were added 
to each tube and flies were homogenised using a micropestle. After that, the 
tubes were centrifuged for 3 minutes at 12,000rpm and 500μl of the supernatant 
was transferred into new RNase-free Eppendorf tubes. An equal volume (500μl) 
of ethanol was then added to each tube and the solution mixed by vortexing. RNA 
extraction was then carried out following the same steps as described in section 
2.2.2 above. All the extracted RNA samples were quantified using a NanoDrop. 
In order to check the integrity of the RNA samples, they were run on a 1% agarose 
gel and examined for the appearance of the 18s RNA band. cDNA was 
synthesized from the RNA using the First Strand cDNA Synthesis method 
described in section 2.2.3. 
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2.18.3.2 Relative CG10632 expression 
In order to determine the relative expression of CG10632 in the flies, quantitative 
PCR (qPCR) was carried out using forward and reverse primers (Appendix 2). 
cDNA was first diluted 1:40 (3μl of cDNA plus 117μl water). A primer mix was 
prepared with the forward and reverse primers at a concentration of 6 μM each. 
In addition to the CG10632 primers, an eEF-1a (Eukaryotic elongation factor 1-
alpha) primer set (Appendix 2) was also used to normalise the expression. Stock 
cDNA was serially diluted at 1:10, 1:100, 1:1000 and 1:10000. The qPCR reaction 
was set by making a master mix for CG10632 and for eEF-1a. Each sample was 
tested in triplicate and each reaction would contain 10μl of SYBR Green (Sigma), 
4μl of water and 1μl of primer mix. To each well of a 96-well plate, 15μl of master 
mix and 5μl of the 1:40 diluted cDNA were then added. The plate was then sealed 
with an optical clear seal and briefly centrifuged followed by 30 second shake at 
the plate shaker. After that, the plate was loaded into the qPCR thermocycler. 
The results were analysed using Bio-Rad CFX manger software to determine the 
qPCR efficiency and the values were plotted using Microsoft Excel. 
 
2.18.4 Rapid iterative negative geotaxis (RING)  
Flies were collected in tubes in groups of 10 under short CO2 anaesthesia (about 
1-2 minutes) and then left to recover overnight. The next day, the rapid iterative 
negative geotaxis (RING) assay was carried as described by Gargano et al. 
(2005). In brief, the flies were transferred into assay vials (Figure 2.6A) and 
allowed 1 minute to rest before the tubes were rapidly tapped against the bench 
three times to stimulate geotaxis. A digital camera (Canon, EOS 1200D) affixed 
to a tripod 45cm away from the tubes (Figure 2.6B) was used to capture images 
of the flies at 3 seconds from the last tap when they starting to travel into the top 
of the tube (known as negative geotaxis). The distances travelled by the flies in 
a single vial (n=10) were averaged across to generate a single datum. They were 
250 RNAi flies and 250 wild type flies tested for RING assay. The data were 
copied into Microsoft Excel for statistical analysis and graph plotting. 
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Figure 2.6. The RING assay A. Picture of 2 vials attached to a wooden sheet. Notice 
that half of the vial’s mouth was kept free to put and remove the files. B. A schematic 
diagram about the set-up and apparatus involved in the RING assay. The taken images 
were then analysed in order to measure the travelled distance.   
 
2.18.5 Courtship suppression assay 
In this assay, female flies were allowed to be mated the day before the 
experiment. One wild type male and one RNAi male were then put in separate 
chambers (0.3cm3), each with a mated female separated by a barrier. The males 
were left for 5 minutes before the chamber barrier was removed and the flies 
were allowed to interact for 1 hour (Figure 2.7A). The fly interaction was videoed 
during the first and last 10 minutes (Figure 2.7B). Then, the mated females from 
both chambers were replaced by virgin ones and the interaction was recorded for 
10 minutes. As a control, two other chambers were run in parallel, each 
containing one wild type or RNAi male, which were left for one hour before a virgin 
female was put into each chamber and recorded for 10 minutes. The captured 
videos (n=18) were analysed using JWatcher (http://www.jwatcher.ucla.edu/), a 
powerful open source tool for the quantitative analysis of behaviour. The analysis 
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was carried out to measure the courting index base on the the time that males 
spent out of the 10 minutes.   
 
 
 
 
Figure 2.7. The courtship suppression assay. A. Picture of two courting chambers 
each containing a male and a female. The left chamber showing a non-courting male 
whereas the right chamber indicates a courting male extending and vibrating its wings 
towards the female. B. Schematic diagram about the set-up and apparatus involved the 
courtship suppression assay. The captured videos were then analysed to compare the 
courting time.     
 
2.18.6 T-maze associative learning 
2.18.6.1 Olfactory Memory Test 
Olfactory memory is the ability of the brain to link an olfactory cue  to an 
associated event and evoke episodic recollections accordingly. The study of 
olfactory memory is one of the used assessment  in exploring the cognition and 
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perception functions (Zucco et al., 2012).  Our brains process and analyse the 
different odours in the olfactory bulb which is thoroughly connected with the 
amygdala and hippocampus, which are the core regions of memory processing 
in the brain. In Drosophila, the olfactory system is equipped with about 1300 
sensory neurons located in antenna as well as in the maxillary palp (Larsson et 
al., 2004).  
 
2.18.6.2 Optimization of odour concentration 
The T-maze assay started with an optimization step to select the optimum 
concentration of the two odours used: 3-octanol (OCT) and 4-methylcyclohexanol 
(MCH) (Sigma-Aldrich). The odours were diluted in 10 ml of mineral oil and 3 
different concentrations (0.1, 0.15 and 0.3ml/l) of each odour were tested. The 
optimization was carried out using the male progeny of wild type crossed with 
actin driver. In groups of 50, the flies were given 2 minutes to choose between 
OCT and MCH that were delivered via air drawn through a vacuum pump 
connected to the T-maze apparatus.  (Figure 2.8). The optimisation step involved 
more than 2000 flies. The optimum concentration was considered to be achieved, 
as described by (Murakami et al., 2010), when about half of the flies selected one 
odour and the other half selected the other odour.  
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Figure 2.8. A picture of the used T-maze apparatus. The files were first put into the 
conditioning compartment where they get trained to remember avoiding the smell 
coupled with the shock . The movable part was then used to bring the elevator up to take 
the flies to the testing compartment at which the two smells were delivered though a 
pump.    
 
2.18.6.3 Fly conditioning 
All the fly vials were labelled by blind coded marking so that the genetic identity 
of the flies within could not be known during the testing process. The conditioning 
was performed as described by Mery and Kawecki (2002) and Frederic mery et 
al. (2007).  Each group of flies was first given 30 seconds to rest and equilibrate 
in fresh air. After that, they were supplied for 1 minute with one of the two odours 
along with simultaneous exposure to a mechanical shock (hard vortexing) every 
5 seconds that knocked them down and made them struggle. Then, 30 seconds 
of fresh air was delivered to the flies in order to allow a gap time for the other 
alternative smell which was also given for 1 minute but without any mechanical 
shock. The conditioning was exchanged between starting with and without a 
mechanical shock throughout the experiment. A final 30 seconds period was 
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allowed before the flies were moved into the testing compartment of the T-maze 
apparatus (Figure 2.8). 
 
2.18.6.4 T-maze choice test 
The testing compartment has a chamber in the middle with right and left 
connecting arms in which the two odours were supplied (Figure 2.8).  As 
described by Pitman et al. (2009),the flies were given 2 minutes to choose 
between the two odours (odour paired with the mechanical shock versus the 
odour not paired with the mechanical shock) before the path that connects the 
chamber to both arms was closed. After that, the flies from the right and left arms 
were collected in separate vials. The test was carried without bias so that the 
location of the odours was exchanged between the left and right arms after testing 
each set of flies. The number of flies in each vial was recorded in Microsoft Excel 
in order to calculate the learning index and plot the graphs. The learning index 
(LI) was calculated by subtracting the number of flies that did not learn from the 
number of flies which chose the non-risky smell, and then divided by the total 
number of flies in the test. Statistics were performed in SPSS software version 
20.   
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Chapter 3: Using whole exome sequencing and 
SNP array to identify pathogenic mutations 
causing intellectual disability in consanguineous 
Omani families 
3.1 Introduction 
Genetic factors are the most common cause of intellectual disability (ID). The 
condition is extremely heterogeneous and has, so far, been linked to more than 
800 genes (Chiurazzi and Pirozzi, 2016). ID has been known to be inherited by 
different modes including recessive, dominant and X-linked as well as 
mitochondrial. Consanguineous families in which ID is segregating, like the ones 
described here, normally have an autosomal recessive mode of inheritance 
whereas sporadic cases are mostly attributed to dominant, heterozygous de novo 
changes (Musante and Ropers, 2014; Reuter et al., 2017). ID does not always 
develop because of a single aetiology. Many times, the condition is complex 
resulting from the interaction of multiple factors. Because of this complexity 
associated with ID development, genetic screening for it is challenging. 
Furthermore, a large proportion of ID cases remain unsolved after screening, 
without a specific and clear diagnosis. 
 
This chapter describes the results of genetic analyses of Omani ID families 
ascertained by Omani collaborators (see section 2.1). DNA was extracted from 
peripheral lymphocytes using standard techniques (Section 2.2.1). Whole 
genome homozygosity mapping was undertaken using Affymetrix SNP 6.0 arrays 
(Section 2.2.10). The IIIumina platform was used for whole exome next 
generation sequencing (Section 2.2.11). All annotations and physical positions 
were recorded according to the UCSC Genome Browser GRCh37/hg19 build. 
Primer pairs for PCR amplification of the regions of interest were designed using 
Primer3 software. Sequencing of the candidate genes was carried out using the 
BigDye® Terminator Kit v1.3 and an ABI 3130xI Genetic Analyser (Section 2.2.9). 
This chapter covers the findings of the genetic analysis of six Omani families 
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diagnosed with ID. The causative genes were identified in half of the families 
studied (Families 1, 2 and 3) but could not be defined in the other half (Families 
4, 5 and 6). Table 3.1 summarizes the families studied with some details about 
their diagnosis, inheritance pattern and the number of cases sampled. 
 
Family 
ID 
Diagnosis 
Inheritance 
pattern 
Affected 
members 
Sampled 
members 
Sampled 
unaffected 
members 
Family-1 ID & ASD Recessive 4 3 4 
Family-2 ID & SHL 
Recessive / 
X-linked 
2 2 3 
Family-3 ID  Recessive 3 3 4 
Family-4 ID Recessive 5 5 2 
Family-5 ID 
Recessive / 
X-linked 
2 2 2 
Family-6 ID Recessive 2 2 3 
 
Table 3.1. Summary of the studied Omani ID families. All the families are 
consanguineous and of Omani Arab ethnicity. The expected mode of inheritance as well 
as the number of the sampled cases are detailed for each family. ID = intellectual 
disability, ASD = autistic spectrum disorder, SHL= Sensorineural hearing loss. 
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3.2 Results  
3.2.1 Intellectual disability families with identified causes 
3.2.1.1 Description and clinical details for Family-1 
This consanguineous family originates from a first-cousin marriage (Figure 3.1). 
Four of the children have been diagnosed with ID as the consensus feature. Table 
3.2 summarizes the major features and developmental profile of the affected 
members in this family. Patient V.5, a male, was reported to have obvious 
difficulties with reading and writing at school. He was referred to the clinic at 7-
years-old for short stature (below the 3rd centile) and developmental delay of 
language and motor skills. On examination, the patient was described as having 
a myopathic elongated face with pointed chin and downturned mouth with thin 
lips. His eye lids (palpebral fissures) were downslanting and the space between 
his eyes was increased, showing apparent hypertelorism. He also had very thin 
nails and bilateral fusion of the second and the third toes (syndactyly). Given the 
similarity of the child’s features to Smith–Lemli–Opitz syndrome, caused by a 
mutation in 7-dehydrocholesterol reductase, this enzyme was tested, but found 
to be within normal limits. Further investigations including chromatography of 
plasma amino acids, urine organic acids, lactate, ammonia and creatinine kinase 
were all within normal reference ranges. Magnetic resonance imaging (MRI) of 
the brain was normal. His behaviour included a fascination with the sight and 
sound of water. Family history revealed that his deceased older brother (V.I) also 
had similar clinical features (Figure 3.1 and Table 3.2) as well as camptodactyly 
of the right fingers which was confirmed by reading his hospital notes and 
reviewing family pictures. Patient V.I had also been assessed by the 
developmental team and was found to fulfil the DSM-5 diagnostic criteria for 
autism spectrum disorder (ASD). Patient V.I drowned in water at the age of 10 
years old. 
 
Patients V.8 and V.9, a female and male, respectively, share a similar 
developmental and clinical profile as patient V.5 and his deceased brother (see 
Table 3.2), though patient V.9 does not have any congenital malformations of the 
hands or toes. Patient V.8 has shown some delay of motor functions including 
 100 
 
problems with balance and a poor hand grip and was unable to hold a pencil 
between the thumb and finger, resulting in her being unable to draw a circle or a 
straight line. She has had difficulty chewing food and swallowing, and sometimes 
drools when performing a focused task. Her communication comprises a few 
single words, vowel sounds and non-verbal gestures, including pointing and facial 
expressions. It is worth highlighting that the unaffected female sibling V.10 also 
appears to have some of the facial features described in the affected patients, so 
the mild dysmorphic features described in this pedigree may not be disease-
specific. 
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Figure 3.1. Family-1 pedigree with microsatellite genotyping results. This family has multiple consanguineous loops. The three nuclear 
families in the fourth (IV) generation resulted from marriages between first-cousins. There are four ID affected children: three boys (filled squares), 
of whom one drowned in water (V.1), and a girl (V.8; filled circle). The small triangle indicates a miscarriage. Detailed clinical information is given 
in Table 3.2. Genotyping is shown for the cases from whom DNA was available. Red text indicates the alleles detected using marker D4S3042, 
and the green text indicates the alleles detected with D7S483. SNP array analysis was carried out for case V.8 and WES for case V.9. (Adapted 
from Al‐Amri et al. (2016) with a permission from John Wiley and Sons, and Copyright Clearance Center’s RightsLink® service, License number 
4055460722605). 
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ID (Gender): V.1 (M) V.5 (M) V.8 (F) V.9 (M) V.10 (F) 
TUSC3 genotype 
(status) 
M/M (affected) M/M (affected) M/M (affected) M/M (affected) M/+ (unaffected) 
Growth parameters (at 
birth) 
Wt = 50th centile 
Ht = 10th centile 
HC = 25th centile 
Wt = 3rd centile 
Ht = 10th centile 
HC = 3rd centile 
Wt = 3rd 
centile 
Ht = <3rd 
centile 
HC = <3rd 
centile 
Wt = 3rd 
centile 
Ht = <3rd 
centile 
HC = <3rd 
centile 
Wt = 90th centile 
Ht = 50th centile 
HC = 50th centile 
Congenital 
malformations 
Unilateral 
camptodactyly - 
hand 
Bilateral 2-3 
syndactyly - toes 
Bilateral 2-3 
syndactyly - 
toes 
-ve -ve 
Growth parameters 
(age) 
Wt = 3rd centile 
Ht = <3rd centile 
HC = 3rd centile 
(9 years) 
Wt = <3rd centile 
Ht = <3rd centile 
HC = 3rd centile 
(7 years) 
Wt = 50th 
centile 
Ht = 10th 
centile 
HC = 25th 
centile 
(3 years) 
Wt = 3rd 
centile 
Ht = <3rd 
centile 
HC = <3rd 
centile 
(1 year) 
Wt = 3rd centile 
Ht = 10th centile 
HC = 50th centile 
(5 years) 
Facial features 
Hypertelorism 
Long face 
Deep set eyes 
Thin philtrum 
Pointed chin 
Hypertelorism 
Long face 
Thin philtrum 
Pointed chin 
Hypertelorism 
Hypertelorism 
Thin philtrum 
Hypertelorism 
Thin philtrum 
 
Brain imaging 
NR Normal MRI NR NR Normal MRI 
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ID (Gender): V.1 (M) V.5 (M) V.8 (F) V.9 (M) V.10 (F) 
IQ NR 53 40 50 81 
Autism spectrum 
disorder 
+ve -ve -ve -ve +ve 
Developmental profile NR 
Motor and 
language skills 
delayed 
Poor reading and 
writing ability 
Motor and 
language skills 
delayed 
Walked at 20 
months 
Can say ~5 
words with 
meaning at 1 
year 
Walked at 19 months 
Single words at 2.5 years 
Current language normal 
but has delayed echolalia; 
also has hyperlaxia 
 
Table 3.2. Summary of clinical features in affected cases from Family-1. Growth parameters were measured using the World Health 
Organisation child growth standards, and IQ was measured using the Stanford Binet intelligence test (5th edition). M in genotype denotes mutation 
in TUSC3; + in genotype, wild type allele; Wt, weight; Ht, height; HC, head circumference; NR = not recorded; -ve, negative; +ve, positive. 
(Adapted from Al‐Amri et al. (2016) with a permission from John Wiley and Sons, and Copyright Clearance Center’s RightsLink® service, License 
number 4055460722605). 
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3.2.1.2 Microsatellite genotyping in Family-1 
Two polymorphic microsatellite markers (D4S3042 and D7S483) were used to 
genotype each case to ensure its correct parentage within the pedigree before 
proceeding with homozygosity mapping (Section 2.10) and exome sequencing 
(Section 2.11). Genotyping was performed using a ROX-500 ladder and 
ABI3130xI capillary Genetic Analyser (Section 2.7). An example of the analysed 
results, generated by the Gene Mapper software is shown in Appendix 3. The 
results of genotyping in this family are shown in Figure 3.1. The affected boy (V.5) 
shows a genotype pattern consistent with him being the progeny of IV.1 and IV.2. 
Similarly, genotypes of the other two affected children (V.8 & V.9) are consistent 
with them being the progeny of IV.3 and IV.4. 
 
3.2.1.3 Homozygosity mapping in Family-1 
Homozygosity mapping in this family was performed using genomic DNA on a 
SNP array for subject V.8, while WES data of subject V.9 was analysed using 
Agile MultiIdeogram software as described in section 2.10.1. The results 
presented as an ideogram are shown in Figure 3.2. Homozygosity mapping 
indicates the shared regions inherited by descent from a common ancestor, which 
would be considered most likely harbour a homozygous variant as the cause of 
disease in a family of this background. When homozygosity mapping and whole 
exome sequencing are combined (Section 2.11.9.4), this allows a huge number 
of variants located outside the homozygous regions – and thus unlikely to be the 
disease-causing mutation – to be discarded.  
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Figure 3.2. Shared homozygous region in Family-1. A. Ideogram where the outermost 
circle represents the 22 autosomal chromosomes. The middle circle plots homozygosity 
revealed in the SNP data from subject V.8, while the inner circle shows homozygous 
segments in WES data from subject V.9. The light blue areas are the homozygous 
regions within each of the individuals genomic DNA and the dark blue region on 
chromosome 8 appears to be the only homozygous region shared by both individuals. 
B. Details of the shared homozygous region. These coordinates were generated for the 
regions and the corresponding measurements were based on human genome reference 
hg19. The region measuring about 11.5 Mb in chromosome 8 is expected to contain the 
mutated gene. 
 
3.2.1.4 Exome sequencing in Family-1 
Whole exome next generation sequencing was carried out on subject V.9 using 
paired end reads on an Illumina HiSeq 2500 (Section 2.11). Before proceeding 
with the exome analysis, the quality score of the sequenced data was checked 
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using FastQC software (Section 2.11.9.1) to ensure no obvious problems or 
biases. An example of the quality score and charts are illustrated in Appendix 4. 
Table 3.3 shows the basic statistics of exome sequencing for subject V.9’s DNA. 
 
Measure Value 
File Name V.9 of Family-1 
File type  Conventional base calls 
Encoding  Sanger / Illumina 1.9 
Total reads 72326188 
Sequence flagged as poor quality 0 
Sequence length 101 
%GC 50 
 
Table 3.3. Basic statistics of V.9 exome sequencing reads. Simple statistical 
composition of the analysed sample. V.9 did not show any poor quality sequence. The 
appearance of only one value for the length of the reads (101) is an indication that all 
sequences are of the same length. The percentage of the GC content is perfect as it is 
within the target the GC content is about (49–51%).  
 
After passing the quality check, exome analysis was carried out, as described in 
section 2.11.9.1. One of the major steps in exome analysis is the removal of PCR 
duplicates and reads that have not aligned to the reference sequence; this 
discards a huge number of unwanted reads. By the end of this analysis, V.9 had 
61,905 variants that were taken forward for further selection and prioritization 
(Figure 3.3). 
 
3.2.1.5 Variant filtering and prioritization 
Among the 61905 variants, 238 were located in the shared 11.5 Mb homozygous 
region on chromosome 8 (Figure 3.2). These 238 variants were then filtered 
based on the likelihood of them being causative. By removing all the synonymous 
changes that code for the same amino acids and keeping only the exonic and 
splicing variants, the list of variants was reduced to 44. Because the causative 
mutation was expected to be rare, another filter was applied to remove all the 
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variants that were present in more than 1% of the population, based on 1000 
Genomes database. The final variant list (Table 3.4) consisted of six variants in 
SGK222, RP1L1 and TUSC3.   
 
 
 
Figure 3.3. Variants in Family-1 after analysis of exome sequencing and filtering 
steps. This flow diagram shows the reduction in the number of variants after analysing 
the exome data (case V.9) , when coupling the analysis with the homozygosity mapping 
results (case V.8) and the filtering process until getting to the final 6 candidates . All the 
238 variants are located in the shared homozygous region of chromosome 8 but the 
highlighted filtering steps excluded the unlikely causatives. 
 
•Total number of sequences in the original raw 
data = 72326188 
•Number of variants after analysing the exome 
data = 61905
•Variants located in the shared homozygous 
region = 238
•Only non-synonymous exonic variants = 44
•Variants having <1% frequency in the 
population (1000g) = 6
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Chr Position Gene 
Coding 
Effect 
cDNA Change Protein Change CADD Score 
Freq in 
1000G 
8 8234868 SGK223 exonic NM_001080826:exon2:c.1050insAGCGGC p.A351delinsSGA 0.985 0 
8 10466010 RP1L1 exonic NM_178857:exon4:c.G5598T p.E1866D 10.03 0 
8 10467637 RP1L1 exonic NM_178857:exon4:c.A3971G p.E1324G 0.79 0 
8 10467652 RP1L1 exonic NM_178857:exon4:c.C3956G p.A1319G 0.013 0 
8 10467653 RP1L1 exonic NM_178857:exon4:c.G3955A p.A1319T 7.54 0 
8 15480672 TUSC3 exonic NM_006765:exon2:c.222delA p.R74fs 31 0 
 
Table 3.4. Final list of candidate variants for Family-1. This list was generated after further filtering that removed all the synonymous changes 
and the variants that are present in more than 2% of the population. The table illustrates six variants located in three different genes: SGK222, 
RP1L1 and TUSC3. CADD suggests the most likely causative variant and thus is highlighted in light green. 
 
 
 109 
 
3.2.1.6 Segregation of candidate variants 
The six candidates were scored by CADD, a bioinformatic predictor which 
integrates diverse genome annotations to provide a metric of deleteriousness for 
the variants of interest. CADD predicts only TUSC3 variant is significant, others 
are unlikely to affect the proteins encoded (Table 3.4). Furthermore, examination 
of the literature showed that RP1L1 is involved in inherited eye disease, SGK223 
is not known to be involved in any human disease, but TUSC3 mutations are 
implicated in ID. Attention therefore focussed on the TUSC3 variant but other 
candidates in the final list were all tested for segregation.  
 
A novel homozygous single base pair deletion of an adenine nucleotide at 
position 222 (Figure 3.4) in exon 2 of TUSC3 (NM_006765:c.222delA, p.R74fs*3) 
was the only candidate variant that showed segregation and consistency with the 
ID diagnosis in Family-1. This variant followed a recessive pattern of inheritance 
as both parents were found to be heterozygous, all affected children were 
homozygous and the unaffected children were either heterozygous or wild type 
(Figure 3.5). This frameshift deletion is predicted to cause the removal of 273 
residues from the C-terminus of the predicted protein product as the premature 
termination of TUSC3 protein synthesis occurs after only 76 amino acids. 
However, it is not possible without further experiments to determine whether a 
truncated protein is produced or whether the effect is to cause nonsense 
mediated decay of the mRNA, meaning there is effectively no protein produced. 
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Figure 3.4. Electropherograms of the c.222delA deletion. This mutation occurs in 
exon 2 of TUSC3. The upper alignment highlights, in green, the position of the adenine 
(A) in the triplet encoding an arginine (R) amino acid. A. Normal wild type sequence 
found in unaffected controls. B. The pattern observed for an individual who is a 
heterozygous carrier for the mutation. The deletion in one allele has resulted in the 
observed overlapping sequencing peaks. C. Homozygous deletion seen in affected 
cases. The deletion is predicted to result in protein termination after two amino acids 
from the arginine but alternatively it may cause no protein due to nonsense mediated 
decay. The bottom alignment shows the arginine (R) highlighted in green, and the stop 
codon (taa, -) which is indicated by the red shading. 
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Figure 3.5.Segregation of c.222delA, p.R74fs*3 in Family-1. The nuclear family from 
the original extended family showing the segregation of the single base deletion mutation 
in TUSC3. + is the wild type allele and M is the deletion (c.222delA, p.R74fs*3). 
 
3.2.1.7 Population frequency of the TUSC3 mutation 
To determine the frequency of the variant, c.222delA, p.R74fs*3, in the Omani 
population, Sanger sequencing of 100 chromosomes from 50 Omani healthy 
individuals was performed. The absence of the mutation in these subjects and in 
141,353 individuals in the Genome Aggregation Database (gnomAD) suggests 
that the c.222delA is a very rare change, which is consistent with it being 
pathogenic. 
 
3.2.1.8 Description and clinical details for Family-2 
Family-2 (Figure 3.6) is also a consanguineous Omani family that originates from 
a first-cousin marriage. The family has two boys (IV.3 and IV.1) diagnosed with 
ID and sensorineural hearing loss. Prenatal, delivery and neonatal history of IV.3 
was unremarkable. He was born by Caesarean section with normal birth 
parameters and no post-delivery complications, but was noted to have low 
muscle tone at birth. At 3 years of age, IV.3 was assessed at the Genetics and 
Developmental Medicine (GDM) clinic for global developmental delay. He did not 
start sitting unsupported until 12 months of age, started walking at 2 years and 
was thus diagnosed with fine and gross motor delay. Detailed developmental 
assessment revealed language delay affecting his expressive speech. He also 
had poor social interaction and communication and significant stereotypic 
behaviours and play. Autism diagnostic interview and direct clinical observation 
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revealed that IV.3 fulfilled the DSM-5 diagnostic criteria for autism spectrum 
disorder. 
 
His 11-year-old brother (IV.1) had severe bilateral sensorineural hearing loss and 
received a cochlear implant at around 5 years of age. Assessment by the GDM 
clinic revealed that IV.1 also had autism spectrum disorder, confirmed by autism 
diagnostic interview and direct clinical observation. 
 
Both brothers were referred to the ophthalmology team and diagnosed with 
hypermetropia (long-sightedness) and astigmatism (blurred or distorted vision). 
They also had dental anomalies and similar facial features (summarised in Table 
3.5). Both parents were examined and the mother was found to have dental 
crowding with overlapping incisors and some conical shaped teeth. 
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Figure 3.6. Family-2 pedigree with microsatellite genotyping. The fourth generation (IV) progeny from a consanguineous marriage between 
first-cousins. The incidence of ID suggests an X-linked or recesssive inhertance pattern. IV.1 and IV.3 both have ID and sensorineural hearing 
loss. There is also a male with ID in the third generation (reported by III.1 & III.2) but no samples or detailed clinical information were available. 
The red genotypes are the detected alleles when tested using marker D4S3042 and the green genotypes are for marker D7S483. DNA from case 
IV.1 was analysed by SNP array and case IV.3 DNA was subject to WES. 
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ID (gender): IV.1 (male) IV.3 (male) 
Deafness (age at 
diagnosis) 
+ (5 years) + (3 years) 
Growth parameters 
(age) 
Wt = 25-50th centile 
Ht = 25-50th centile 
HC = 50th centile 
(11 years) 
Wt = 50th centile 
Ht = 50th centile 
HC = 50th centile 
(3 years) 
Visual problems 
Hypermetropia and 
astigmatism 
Hypermetropia and 
astigmatism 
Dental anomalies 
Conical shaped teeth, 
crowding and 
overlapping incisors 
Conical shaped teeth, 
crowding and 
overlapping incisors 
Skeletal/ muscular 
development 
Normal Generalised hypotonia 
Brain imaging Normal CT 
MRI: non-specific white 
matter changes in 
trigone and occipital 
lobe 
IQ 68 45 
Speech development 
Poor speech and has 
echolalia  
Language skills delayed 
LHFPL5 genotype  M/M M/M 
 
Table 3.5. Summary of clinical features in affected members of Family-2. Wt = 
weight, Ht = height, HC = head circumference, + = presence and - = absence. M 
represents the c.575T>C variant allele in LHFPL5. 
 
3.2.1.9 Microsatellite genotyping in Family-2 
Genotyping markers were used on the cases from whom DNA was available to 
verify the pedigree structure of the family. This was considered to be an important 
step before proceeding with costly next generation sequencing technology. 
Figure 3.6 indicates the tested cases and their genotypes. All the children (IV.1, 
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IV.2 & IV.3) showed genotype patterns that were consistent with III.1 and III.2 
being their parents. 
 
3.2.1.10 Homozygosity mapping in Family-2 
Homozygosity mapping of Family-2 was carried out using the results of SNP array 
analysis of subject IV.1 and SNP data extracted from WES of subject IV.3, as 
described in section 2.10.1. (Figure 3.6). Three shared homozygous regions 
could be defined (Figure 3.7), and it was assumed, based on the pedigree 
structure, that one of these ought to harbour the causative mutation. 
  
 
Figure 3.7. Shared homozygous regions in Family-2. A. An ideogram where the outer 
circle contains template segments of the 22 autosomal chromosomes. The middle circle 
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is a plot of homozygous regions in SNP data from subject IV.1 while the inner circle 
shows homozygous regions from WES data from subject IV.3. The light blue areas are 
the homozygous regions within each individual and the dark blue regions (number=3) 
are the homozygous regions shared between both affected individuals. B. Details of the 
shared homozygous regions. The coordinates were generated based on human genome 
reference hg19. The three shared regions are on different chromosomes and with 
different lengths. The biggest region, which is on chromosome 6, is highlighted in green. 
 
3.2.1.11 Exome sequencing in Family-2 
Whole exome next generation sequencing was carried out on DNA from subject 
IV.3 using the method described in section 2.11. The data for this sample, 
generated by Illumina HiSeq 2500, passed the quality check described in section 
2.11.9.1. Table 3.6 shows the basic statistics of exome sequencing of IV.3. 
 
Measure Value 
File Name IV.3 of Family-2 
File type  Conventional base calls 
Encoding  Sanger / Illumina 1.9 
Total reads 36420257 
Sequence flagged as poor quality 0 
Sequence length 101 
%GC 49 
 
Table 3.6. Basic statistics of IV.3 exome sequencing reads. Simple statistical 
composition of the analysed sample. IV.3 did not show any poor quality sequence. The 
length of the reads is showing a single value (101) suggesting that all sequences are of 
the same length. The percentage GC content is within the target (49–51%).  
 
After passing the quality check, exome analysis (Section 2.11.9) was carried out. 
The sequencing reads were aligned against the reference genome 
(hg19/GRCh37) using Bowtie2 aligner as described in section 2.11.9.2. PCR 
duplicates and reads that had not aligned to the reference sequence were 
removed using Picard tools. By the end of the analysis, IV.3 had 165753 variants 
that were taken for further selection and prioritization. 
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3.2.1.12 Variant filtering and prioritization 
Among the 165753 variants, 2166 variants were located in the three shared 
homozygous regions (Figure 3.8). These 2166 variants were then filtered based 
on the likelihood of them being causative. By removing all the variants with a low 
depth of coverage depth (<10) as well as synonymous changes that code for the 
same amino acids, and keeping only the exonic and splicing variants, the list of 
variants was reduced to 74. Further filtering removed variants that had a 
frequency higher than 1% in the population and all heterozygous changes. The 
final variant list (Table 3.7) highlighted three variants in LHFPL5, MRPS10 and 
MMP17. 
 
 
 
Figure 3.8. Variants of Family-2 after analysis of exome sequencing and filtering 
steps. This flow diagram shows the reduction in the number of the variants after 
analysing the exome data (case IV.3), when coupling the analysis with homozygosity 
mapping results (case IV.1) and after the filtering steps. All 2166 variants are located in 
the three shared homozygous regions on, chromosomes 5, 6 and 12. filtering steps 
reduced the variants to and then to only 3.   
•Total number of sequences in the original raw 
data = 36420257 
•Number of variants after doing exome analysis 
= 165753
•Variants located in the shared homozygous 
regions = 2166
•Only non-synonymous exonic variants= 74
•Variants having <1% frequency in the 
population (1000g) = 3
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Chr Position Gene 
Coding 
Effect 
cDNA Change Protein Change 
CADD 
Score 
Freq in 
1000G 
chr6 35782485 LHFPL5 exonic LHFPL5:NM_182548:exon2:c.T575C p.L192P 28 0 
chr6 42185562 MRPS10 exonic MRPS10:NM_018141:exon1:c.C26T p.A9V 8.928 0.005 
chr12 132313098 MMP17 exonic 
MMP17:NM_016155:exon1:c.59_60insGCTGCC
GCT 
p.R20delinsRLPL 1.276 0 
 
Table 3.7. The final list of candidate variants for Family-2. The table shows the details of each variant, including its pathogenicity score 
based on CADD and frequency in the 1000G database. The variant highlighted in green is the strongest candidate. 
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3.2.1.13 Segregation of candidate variants 
Based on CADD score, it is unlikely that the MRPS10 and MMP17 variants have 
any functional consequences. However the score of the LHFPL5 variant looks 
pathogenic on CADD (28). Furthermore, it fits with part of the diagnosis because 
previous researchers found link with deafness (Marková et al., 2016; Shahin et 
al., 2010). A novel homozygous missense variant (Figure 3.9) in LHFPL5 
(NM_182548:exon2:c.T575C, p.L192P) was the only candidate variant that 
showed segregation and consistency with the described phenotype in Family-2. 
This variant was consistent with a recessive pattern of inheritance, as both 
parents were found to be heterozygous, while both affected boys were 
homozygous and the unaffected boy was heterozygous (Figure 3.10). 
 
 
Figure 3.9. Electropherograms of the c.T575C variant. A. The wild type sequence 
from an ethnically matched control. The arrow indicates the exact location of the thymine 
(T), at which the substitution takes place. This trinucleotide (CTC) encodes Leucine (L). 
B. The heterozygous sequence pattern seen in case III.1 (mother), also presents in case 
III.2 (father) and case IV.2 (unaffected brother). The alternative cytosine (C) could be 
seen overlapping the reference thymine (T).  C. The homozygous variant seen in both 
affected cases, IV.1 and IV.2. So, this missense mutation resulted in replacing the CTC 
trinucleotide by CCC, which encodes Proline (P).  
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Figure 3.10. Segregation of c.T575C, p.L192P in Family-2. Segregation of the variant 
in LHFPL5 within the nuclear family taken from the original extended family. + is the wild 
type allele; M is c.T575C, p.L192P. 
 
3.2.1.14 Conservation and mutation frequency 
The LHFPL5 mutation (NM_182548:exon2:c.T575C, p.L192P) changes the 
leucine at position 192 to a proline (p.L192P). This position is conserved across 
multiple species as shown in Figure 3.11, suggesting that the residue may have 
an important function.  In order to rule out the identified variant from being a 
common SNP in the Omani population, one hundred chromosomes from 50 
Omani healthy individuals were screened for the variant, but none was found to 
carry it. Furthermore, c.T575C is not present in 141,353 unrelated individuals in 
the Genome Aggregation Database (gnomAD). These findings suggest that 
c.T575C is a very rare change, which is consistent with it being pathogenic. 
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Figure 3.11. ClustalW alignment of p.L192 conservation in LHFPL5. ClustalW alignment of LHFPL5 amino acid sequences around the 
missense mutation, p.L192P, showing a highly conserved leucine residue at position 192. Accession numbers for LHFPL5 protein are 
human NP_872354.1, rhesus XP_001112357.2, dog XP_005627321.1, Cow NP_001192875.1, mouse NP_080847.2, rat 
NP_001013928.1, chicken NP_989729.1, zebrafish XP_686620.5 and worm NP_503066.1.   
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3.2.1.15 X-linked variants in Family-2 
As both affected individuals in Family-2 (Figure 3.6) are male, this raised the 
possibility of an X-linked mode of inheritance. The existence of the affected male 
uncle would argue against this as there is no connection between siblings IV1 
and IV3 and their paternal uncle. However the clinical and genetic status of this 
individual has not been assessed, so an X-linked mode of inheritance could not 
be ruled out. Therefore, variants identified in the WES of subject IV.3 and which 
were located on the X chromosome were also analysed. Filtering criteria removed 
synonymous changes, variants with a frequency of more than 1% and those that 
have coverage depths of less than 10. This filtering shortened the list of variants 
from 5301 to 664. The remaining changes were then compared to an updated list 
of X-linked genes that are known to be associated with intellectual disability. This 
list is managed and updated by the University of Colorado, and a copy is included 
in Appendix 8. Filtering against the known genes identified three variants as 
plausible candidates (Table 3.8). 
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Chr Position Gene Coding Effect cDNA Change Protein Change 1000g CADD 
X chr 17750076 NHS exonic NHS:NM_198270:exon8:c.C4385G p.S1462C 0 23 
X chr 49846369 CLCN5 exonic CLCN5:NM_000084:exon6:c.C588G p.I196M 0 15.86 
X chr 122336600 GRIA3 exonic GRIA3:NM_001256743:exon3:c.382dupG p.G127fs 0 1.126 
 
Table 3.8. Final list of X-linked candidate variants for Family-2. This table shows the details of each variant, including its pathogenicity 
score based on CADD and frequency based on 1000G database. The variant highlighted in green is the strongest candidate. 
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By combinining the CADD score plus the partial phenotype match,  NHS variant 
was a better candidate. By performing  Sanger sequencing, a novel missense 
variant (Figure 3.12) in part of the NHS gene (NM_198270:exon8: c.C4385G, 
p.S1462C) was the only candidate variant that showed segregation within the 
family. This variant followed an X-linked pattern of inheritance, as the mother was 
found to be heterozygous and both affected boys were hemizygous due to the 
fact that the X chromosome in males has no allelic counterpart (Figure 3.13). The 
mutation was not present in 50 healthy individuals of the same ethnicity as 
Family-2 or in 141,353 unrelated individuals in the Genome Aggregation 
Database (gnomAD). 
  
 
Figure 3.12. Electropherograms of the c.C4385G variant. A. Wild type sequence from 
the father (III.2), also present in the unaffected brother (IV.2). The arrow indicates the 
exact location of the cytosine (C), at which the substitution takes place. This trinucleotide 
(TCC) encodes Serine (S). B. Heterozygous mutation found in the mother (III.1). The 
alternative guanine (G) could be seen overlapping with the reference cytosine (C) as the 
substitution occurs in one of the X chromosomes. C. Hemizygous mutation seen in both 
affected boys (IV.1 & IV.3). Therefore, this missense mutation resulted in replacing the 
TCC trinucleotide by the TGC that encodes Cysteine (C). 
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Figure 3.13. Segregation of c.C4385G, p.S1462C in Family-2. Segregation of the NHS 
variant in the nuclear family from the original extended family. + = wild type allele; Y = 
male chromosome; M = c.C4385G, p.S1462C. 
 
3.2.1.16 Description and clinical details for Family-3 
A consanguineous nuclear family is shown in the fourth generation of the 
extended family (Figure 3.14).  The nuclear family resulted from marriage 
between first-cousin members (III.1 & III.2), and three of their five children are 
affected with ID and autistic features. They also have scoliosis, myopia and 
dysmorphic features (long, thin and myopathic face, flat malar region, laxity of 
joints, bilateral ptosis, hypertelorism, and slender hands and feet). Family 
structure suggests an autosomal recessive mode of inheritance.  
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Figure 3.14. Family-3 pedigree with microsatellite genotyping. There are 7 ID affected individuals in the fourth generation of this family but 
no samples or detailed information was obtainable from cases IV.1, IV.2, IV.3 and IV.10. The nuclear family  has  three affected children, all with 
moderate-severe ID. Genotyping is shown of the cases from whom DNA was available. The red results are the detected alleles when genotyping 
with marker D1S478, the green results are for marker D4S3042 and the blue results are for the D7S483 marker. Whole exome seqencing was 
done for case IV.5 and SNP array genotyping for cases IV.8 and IV.9. 
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3.2.1.17 Microsatellite genotyping in Family-3 
Three polymorphic microsatellite markers (D1S478, D4S3042 & D7S483) were 
used to genotype each case where a DNA sample was available to ensure the 
correct parentage within the pedigree and that no mixing between samples took 
place. Figure 3.14 shows the tested cases and their genotypes. All the children 
(IV.5, IV.6, IV.8 & IV.9) have shown genotype patterns that are consistent with 
being inherited from their parents (III.1 & III.2).    
 
3.2.1.18 Homozygosity mapping in Family-3 
Homozygosity mapping of this family was analysed based on the results of the 
SNP data from subjects IV.8 and IV.9, as well as SNP data extracted from exome 
sequencing of subject IV.5. Four shared homozygous regions could be defined 
which are detailed in Figure 3.15. As the family are consanguineous and 
inheritance is recessive, it was expected that one of these regions would harbour 
the causative mutation.   
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Figure 3.15. Shared homozygous regions in Family-3. A. An ideogram where the 
outer circle contains template segments of the 22 autosomal chromosomes. The three 
inner circles plot homozygous regions in SNP data from subject IV.8 and IV.9, and WES 
data from subject IV.5. The homozygous regions within the genomic DNA of each 
individual are shown in light blue, and the shared homozygous regions (number=4) 
common to all affected individuals are shown in dark blue. B. Details of the shared 
homozygous regions. Corresponding coordinates were based on human genome 
reference hg19. The four shared regions are on different chromosomes. The biggest 
region, which is highlighted in green, is on chromosome 10; this region has the highest 
probability of harbouring the causative mutation.   
 
3.2.1.19 Exome sequencing in Family-3 
An Illumina HiSeq 2500 sequencer was used to generate whole exome next 
generation sequencing (Section 2.11) on subject IV.5. Before proceeding with 
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exome analysis, the quality score of the next generation sequence data obtained 
was checked using FastQC software (Section 2.11.9.1) to ensure that the data 
are of good quality with no problems or biases. Table 3.9 shows the basic 
statistics of exome sequencing in IV.5. 
 
 
Measure Value 
File Name IV.5 of Family-3 
File type  Conventional base calls 
Encoding  Sanger / Illumina 1.9 
Total reads 43218122 
Sequence flagged as poor quality 0 
Sequence length 101 
%GC 49 
 
Table 3.9. Basic statistics of IV.5 exome sequencing reads. NGS analysis of DNA 
from IV.5 did not show any sequence of poor quality. The single reported value for the 
length of sequence and the percentage of the GC content suggest that the sample is of 
good quality.  
 
Exome analysis was carried out using Bowtie2 aligner and hg19/GRCh37 
reference genome. IV.5 sample was treated by SAMtools  to sort and index the 
sequencing reads and then to convert into BAM format. Removal of all duplicates 
was done using  Picard tools and Unifield Genotyper was used for calling the 
variants. Variants annotation was performed by using Annovar software as 
described in section 2.11.9.3. By the end of the analysis task, had 55491 variants 
that were taken for further selection and prioritization. 
 
3.2.1.20 Variant selection, filtering and prioritization 
The total number of variants (554891) was reduced to 9032 by removing the 
unlikely causatives which are not located in the four shared homozygous regions 
(Figure 3.16). The exclusion of those variants was due to the fact that the  study 
was based on a consanguineous family with a rare recessively inherited disorder 
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(ID), which highly suggest  that the disease is caused by a homozygous variant 
that resides within shared homozygous regions.  
 
  
 
Figure 3.16. Variants of Family-3 after analysis of exome sequencing and 
homozygosity mapping. This flow diagram shows the reduction in numbers of the 
variants after analysing the exome data (case IV.1) after coupling the analysis with the 
homozygosity mapping results (cases IV.8 and IV.9). The power of utilising the results 
of homozygosity mapping can be seen in the marked reduction in the number of variants. 
All 9032 variants are located in the four shared homozygous regions on chr6, chr10, 
chr13 and chr17. 
 
 
3.2.1.21 Filtering and variant prioritization   
The 9032 variants were further filtered by taking out all those with coverage depth 
<10 as well as synonymous changes that encode the same amino acids, and 
keeping only exonic and splicing variants. This filtering step brought the list down 
to 1434 variants. Further filtering involved removing the variants with a frequency 
more than 1%, and all the heterozygous changes, leaving only 6 candidates 
(Table 3.10). 
•Total number of sequences in the original raw 
data = 43218122 
•Number of variants after doing exome analysis 
= 554891
•Variants located in the shared homozygous 
regions = 9032
•Only non-synonymous exonic variants= 1434
•Variants having <1% frequency in the 
population (1000g) =  6
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Chr Position  Gene 
Coding 
Effect 
cDNA Change  Protein Change CADD 1000G 
chr10 98155678 TLL2 exonic TLL2:NM_012465:exon12:c.C1484T p.T495M 17.83 0.02 
chr10 99343381 ANKRD2 exonic ANKRD2:NM_001129981:exon8:c.C883T p.R295W 34 0 
chr10 102258991 SEC31B exonic SEC31B:NM_015490:exon13:c.G1510A p.V504M 12.80 0.01 
chr10 119044044 PDZD8 exonic PDZD8:NM_173791:exon5:c.2197_2200del p.733_734del 35 0 
chr13 35747681 NBEA exonic NBEA:NM_015678:exon27:c.A4504G p.S1502G 15.85 0.02 
chr17 17039562 MPRIP exonic MPRIP:NM_015134:exon6:c.534_539del p.178_180del 18.20 0 
 
Table 3.10. Final list of candidate variants for Family-3. This table shows the details of each variant, including its pathogenicity score 
based on CADD and frequency based on the 1000G database. The variants highlighted in green are the two strongest candidates. 
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3.2.1.22 Segregation of candidate variants in Family-3 
One of the candidate variants that appeared in the final list is in NBEA, which is 
a well-established autism gene but this candidate did not segregate within the 
ASD and ID of Family-3. In addition, none of the finally prioritised candidates have 
a known evidence of involvement in ID. However, the obtained CADD scores as 
well as literature search about the known functions of these genes indicated that 
ANKRD2 and PDZD8 are probably the most important among the proposed 
candidates. Upon Sanger sequencing, both of the variants showed segregation 
and consistency with the ID diagnosis in Family-3. The first was a missense 
mutation in ANKRD2 (NM_001129981:exon8:c.C883T, p.R295W) (Figure 3.17) 
and the second was a frameshift deletion of four base pairs in PDZD8 
(NM_173791:exon5: c.2197_2200del, p.733_734del) (Figure 3.18). Both 
mutations followed the suggested recessive pattern of inheritance, as both 
parents were heterozygous, both affected children were homozygous, and the 
unaffected children were either heterozygous or wild type (Figure 3.19). These 
mutations are novel and they are predicted to be pathogenic (CADD score of 34 
for c.C883T; 35 for c.2197_2200del). 
 
 
Figure 3.17. Electropherograms of the c.C883T mutation. This mutation occurs in 
exon 8 of ANKRD2 and the arrow indicates the location of the substituted base; 
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CGG encodes arginine (R). A. The normal wild type found in an unaffected case. B. Both 
parents were heterozygous with cytosine (C) to thymine (T) substitution in one copy of 
ANKRD2. C. All the affected cases have a homozygous substitution replacing a C base 
with a T. The newly produced trinucleotide (TGG) encodes tryptophan (W).   
 
 
Figure 3.18. Electropherograms of the c.2197_2200del deletion. The upper 
alignment highlights, in green, the location of the 4-bp deletion (agtt) that forms part of 
the Serine (S) and Leucine (L) amino acids. A. Wild type PDZD8 in an unaffected case. 
B. Both parents were heterozygous with the 4-bp deletion in one copy of PDZD8. 
Deletion in one copy of chromosome 10 causes the overlapping frameshift in the 
sequencing peaks. C. All the affected cases are homozygous for the frameshift 4-bp 
deletion, which induces a premature stop mutation that is highlighted in red.   
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Figure 3.19. Segregation of c.C883T, p.R295W in ANKRD2 and c.2197_2200del, 
p.733_734del in PDZD8 in Family-3. This is only the nuclear family taken from the 
original extended family. The co-segregation of homozygosity for the mutations in 
ANKRD2 and PDZD8 and ID diagnosis is shown. Red text is ANKRD2: c.C883T, 
p.R295W. Green text is PDZD8: c.2197_2200del, p.733_734del. + is wild type allele; M 
is mutated allele. 
 
3.2.1.23 Conservation and mutation frequency  
Measurement of conservation is applied to understand the impact of variation at 
a given region and it provides an indication as to whether the variation would be 
damaging or not (Cooper Gregory M and Shendure, 2011). Sequence of a range 
of species through evolution was observed for the p.R295 position (Figure 3.20) 
reported in ANKRD2 and the alternative tryptophan amino acid (W) was found to 
be present in spiny softshell turtle.  Although this type of turtle has the same 
ANKRD2 variant reported in Family-3, it still function normally. In fact, this finding 
argues against the ANKRD2 variant being the causative of the described 
phenotypes in this family.    
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Figure 3.20. ClustalW alignment of the normal amino acid sequence of ANKRD2. ClustalW alignment of ANKRD2 amino acid 
sequences around the missense mutation, p.R295W, showing a highly conserved arginine residue at position 295 and presence of the 
tryptophan amino acid (W) in the normal sequence at position 295 in the spiny softshell turtle. Accession numbers for ANKRD2 protein are 
human NP_001123453.1, gorilla ENSGGOP00000014859, chimpanzee XP_507964.3, rhesus XP_001095517.2, dog XP_850948.2, Cow 
XP_003587918.2, horse ENSECAP00000007038, mouse NP_064417.1, rat NP_001101059.1, chicken XP_004942257.1, cave fish 
ENSAMXP00000002269, zebrafish XP_005157118.1, spiny softshell turtle APJP00000000.1 and frog NP_001090801.1. 
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Both the ANKRD2 c.C883T variant and the PDZD8 c.2197_2200del variant were 
screened for in 100 chromosomes from ethnically-matched healthy controls and 
neither of them was found. They were also not present in 141,353 unrelated 
individuals in the Genome Aggregation Database (gnomAD).  
 
To search for additional cases with mutations in either of these genes, 11 Belgian 
ID cases with similar phenotypes were obtained by collaboration from Professor 
Paul Coucke, Department of Medical Genetics, Ghent University Hospital, 
Belgium. The exons of both genes were fully screened by Sanger-sequencing. 
Details of the PCR primers used are shown in Appendix 2. No mutation was found 
in PDZD8, but a homozygous ANKRD2 variant (NM_001129981:exon1:c.C272T, 
p.A2V) was found in one Belgian ID case (Figure 3.21), with a CADD score of 
20.9.  
 
 
Figure 3.21. Electropherograms of the c.C272T variant in ANKRD2. This variant 
occurs in exon 1 and the arrow indicates the location of the substitution. A. Wild type 
sequence found in an unaffected case showing the GCA that encodes alanine (A). B. 
The affected Belgian case showed homozygous substitution of a C to a T. This variant 
causes the trinucleotide to change resulting in GTA that encodes valine (V).  No 
heterozygous mutation was found for this variant. 
 137 
 
Multiple contacts were made with Dr.Coucke to try to get further clinical details 
about this case and additional family samples so that segregation could be 
checked, but unfortunately, no reply was received. The identification of this 
ANKRD2 variant, but no PDZD8 variants, in the Belgian ID cases suggests that 
ANKRD2 has a role in the phenotypes descried for the affected members of  
Family-3. However, the fact that segregation testing could not be studied in the 
Belgian case make this not a strong assumption!.       
 
3.2.1.24 ANKRD2 and PDZD8 mutation load in the UK10K database 
For the purpose of checking various mutations and comparing their enrichment 
in the two genes, vcf files from 469 moderate to severe ID cases and 2432 control 
samples were downloaded from the UK10K, as described in section 2.12. After 
downloading, vcfhacks programme was used to search for variants of ANKRD2 
and PDZD8 in the samples.  The identified variants were then annotated using 
variant effect predictor (VEP) and scored with CADD.  Variants with >10 CADD 
located in ANKRD2 and PDZD8 were checked and the mutation load was 
compared with healthy controls. A total of 93 mutations were found among the ID 
cases. Details about the identified mutations, including the ones in the control 
samples, are summarised in Table 3.11. 
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Gene  Variant  Frequency CADD 
No. of mutations in 
938 ID cases alleles  
No. of mutations in 
4864 control alleles  
ANKRD2 
ENSP00000306163.5:p.Pro146Leu_rs36020819 0.004264995 26.7 13 heterozygous 11 heterozygous 
ENSP00000306163.5:p.Arg292Cys_rs149812913 0.001613611 33 5 heterozygous 10 heterozygous 
ENSP00000306163.5:p.Val229Leu_n/a 3.96181E-06 24.5 1 heterozygous 0  
PDZD8 
ENSP00000334642.5:p.Arg897Gln_rs363294 0.047812872 17.34 
1 homozygous, 38 
heterozygous  
4 homozygous, 262 
heterozygous 
ENSP00000334642.5:p.Ala11Val_rs78645354 0.051904249 21.1 33 heterozygous 358 heterozygous 
ENSP00000334642.5:p.Ile364Leu_rs138899307 0.000743079 14.46 2 heterozygous 6 heterozygous 
Compound heterozygous rs363294 & rs78645354   3 22 
 
Table 3.11. ANKRD2 and PDZD8 mutation load. This list was generated based on 469 ID cases and 2432 control samples in the UK10K 
database. It contains only plausible mutations based on CADD scores >10. The frequency was based in the Genome Aggregation Database 
(gnomAD). The number of the heterozygous and homozygous mutations found is indicated for each variant. Student T-test showed no 
statistically significant difference for ANKRD2 and PDZD8, p value was 0.2367 and 0.5393, respectively.  
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3.2.1.25 Constraint metrics in the ExAC database 
Constraint metrics are comparative measurements that could be attained from 
the ExAC database. For the missense, synonymous changes and CNV changes, 
a quantification, called a Z score, is created to indicate the deviation in numbers 
of the found variants from the expected ones (Samocha et al., 2014). An 
increased Z score (>3.9) means that the gene of interest has recorded a 
significantly (p-value of 10-3) lower number of variants than the expected, 
suggesting that disruptive changes in this gene are not tolerated and do have a 
functional consequence. On the other hand, a gene with a decreased negative Z 
score is considered as under “low-constraint”, suggesting variations are well 
tolerated. For the loss of function variants (LOF), the number of the observed and 
expected variants is utilized to calculate a score called pLI (the proportion of 
genes that are very likely intolerant) (Samocha et al., 2014). When the pLI score 
for a given gene is high, close to 1, it means that the gene is extremely intolerant 
to the LOF changes. The constraint metric is thus a useful tool for recognising 
diseases-causing variants as it provides a valuable indication about the 
significance of different genetic changes to a given gene (Lek et al., 2016). 
 
The results of constraint metrics for both ANKRD2 and PDZD8 genes are 
summarised in Table 3.12. It was found that ANKRD2 had observed values that 
were close to the expected values for all missense, CNVs and LOF variants, and 
its constraint metrics were not significant. However, PDZD8 has a significant 
constraint metric for LOF (pLI = 1.000), which is the nature of the mutation reported 
in this family. 
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Gene Name Changes Type Expected variants Observed variants Constraint Metric 
ANKRD2 
 
Synonymous 58.4 51 Z = 0.60 
Missense 119 114 Z = 0.22 
CNV 3.1 1 Z = 0.44 
LOF 11.4 10 pLI = 0.00 
PDZD8 
 
Synonymous 189.3 168 Z = 0.96 
Missense 411 322 Z = 2.15 
CNV 2.6 4 Z = 0.25 
LOF 21.5 1 pLI = 1.00 
 
Table 3.12 Constraint metrics of ANKRD2 and PDZD8. These comparative measurements were obtained from the ExAC database. 
ANKRD2 has observed values that are close to the expected values but PDZD8 looks more constrained, especially with loss of function 
(LOF) mutations, as it showed only one variant compared with the 21.5 expected. The score of 1 in pLI for PDZD8 means that it is extremely 
intolerant to the LOF changes. This gives more weight and significance to the PDZD8 mutation but does not rule out the ANKRD2 mutation. 
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3.2.1.26 ANKRD2 and PDZD8 expression in human tissues 
Reverse transcriptase PCR was done on a human tissue panel (Section 2.5). The 
primers (Appendix 2) were designed to span at least one exon, allowing both 
cDNA and any contaminating genomic DNA to be detected. Primers of ANKRD2 
were designed to amplify exons 4 and 5 of the cDNA sequence giving a product 
size of 355pb. For PDZD8, the primers were chosen to amplify exons 2, 3 and 4 
across cDNA sequence producing a product size of 406pb. The expression 
studies. P53 was used as a control housekeeping gene and its primers were 
selected to produce 408pb cDNA band or 1057bp genomic band. The expression 
study showed that ANKRD2 is expressed in all the tested tissues but more 
abundant in brain, kidney, prostate, salivary gland and skeletal muscle, while 
PDZD8 is just ubiquitously expressed in all the tested tissues (Figure 3.22). 
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Figure 3.22. Expression of ANKRD2 and PDZD8 mRNA in various human tissues. 
A. ANKRD2 expression. B. PDZD8 expression. C. P53 housekeeping gene expression 
(control). Lane 1, 100-bp ladder; 2, Adrenal gland; 3, Bone marrow; 4, Brain 
(cerebellum); 5, Brain (whole); 6, Fetal brain; 7, Fetal liver; 8, Kidney; 9, Liver; 10, Lung; 
11, Placenta; 12, Prostate; 13, Salivary gland; 14, Skeletal muscle; 15, Spleen; 16, 
Testis; 17, Genomic DNA;18, Negative Control. 
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3.2.1.27 Immunolocalisation in mouse brain regions 
The localisation of ANKRD2 and PDZD8 proteins in sagittal sections of mouse 
brain was studied using immunohistochemistry (IHC). The antibodies were rabbit 
IgG polyclonal anti-mouse ANKRD2 (from Santa Cruz) and rabbit IgG polyclonal 
anti-mouse PDZD8 (from biorbyt), both were used at 1:100 dilution. For the 
negative slides, a non-immune immunoglobulin of the same isotype was as 
described in Section 2.17. Both ANKRD2 and PDZD8 were found to be 
moderately expressed in various brain regions including hippocampus and 
cerebrum (see Figure 3.23 and Table 3.13). In particular, there was strong 
staining of ANKRD2 in the substantia innominata (Figure 3.23C) and of PDZD8 
in the choroid plexus (Figure 3.23F). 
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Figure 3.23. Examples of ANKRD2 and PDZD8 localization in regions of mouse brain. A. Strong positive localization of PDZD8 in the 
cerebellum. B. Moderate staining of ANKRD2 in the hippocampus. C. Strong positive localization of ANKRD2 in the substantia innominata 
(x40). D. Negative isotype control for cerebellum. E. Negative isotype control for hippocampus. F. Strong PDZD8 staining in the choroid 
plexus. For more details on the localization, refer to Table 3.13.  
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Brain Region ANKRD2 localisation PDZD8 localisation 
Choroid plexus None Strong 
Substantia innominata Strong Very mild 
Hippocampus 
Moderate in both the 
granular layer and 
Pyramidal neurons 
Moderate in both the 
granular layer and 
Pyramidal neurons 
Cerebral cortex None 
Mild in the Neocortical 
neurons 
Cerebellum 
Strong in molecular 
layer; 
no localisation in the 
Purkinje cell layer and 
granular layer 
Strong in the molecular 
layer; 
moderate localisation in 
the Purkinje cell layer; 
no localisation in 
granular layer 
Pontine neurons Strong Strong 
Basal ganglia Neurons Mild Mild 
White matter tracts None None 
 
Table 3.13. Localization of ANKRD2 and PDZD8 in regions of mouse brain. The 
degree of staining for ANKRD2 and PDZD8 in the main brain regions is indicated. 
Choroid plexus and substantial innominata showed a marked difference in localization 
between these two proteins. 
 
3.2.1.28 Behaviour studies in PDZD8 knock down Drosophila 
3.2.1.28.1 Background 
The equivalent of the Homo sapiens ANKRD2 in Drosophila is CG44001 but a 
mutant line with confident and direct orthologue of ANKRD2 was not available. 
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Given that the mutation in ANKRD2 in Family-3 is a missense mutation, knock 
down of CG44001 in Drosophila would be an inadequate model of the human 
mutation. However, the PDZD8 orthologue in Drosophila is a single gene called 
CG10632 and a mutant line was available. Drosophila in which CG10632 could 
be knocked down were obtained by collaboration from the Vienna Drosophila 
Source Centre (VDSC). These flies are RNAi responder transgenic flies. The 
process of knocking down CG10632 was activated by crossing RNAi responder 
flies with a special type of Drosophila which had been created to express GAL4 
throughout their bodies, as shown in Figure 3.24. Each of these lines had been 
created in white-eyed flies. 
 
 
Figure 3.24. Activating the GAL4 system to knock down CG10632 expression. The 
flies with the GAL4-actin driver were crossed with the RNAi Responder flies. The driver 
flies also have the promoter/enhancer and the RNAi flies contain the inverted repeat 
sequence of CG10632 beside GAL4 upstream activating sequences (UAS). The process 
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that cause CG10632 knock down is silent in the absence of GAL4. However, GAL4 binds 
to its UAS in the produced progeny, leading to the activation of the GAL4 system, which 
initiates the transcription of CG10632. The activation of the GAL4 system causes the 
inverted repeats to create RNA that would be processed by the cellular machinery to 
make functional siRNAs. The mission of the produced siRNA is to repress CG10632. 
(Adapted from Caygill and Brand (2016) with a permission from  Springer and Copyright 
Clearance Center, License Number 4106030489352).  
 
3.2.1.28.2 CG10362 expression  
White eye flies (W*) were used as a control in the experiment because they have 
the same genetic background as the RNAi responder line and would be expected 
to control for behavioural and physiological differences. The RNAi responder and 
the wild type (W*) were separately crossed to virgin GAL4-Actin driver females, 
as described in section 2.18.1. RNA extraction and cDNA synthesis was made 
from the progeny of different types of flies (Section 2.18.3.1). The relative 
expression of CG10362 was measured by quantitative PCR (qPCR) as described 
in section 2.8.3.2 and the assay was normalised against eEF-1a (Eukaryotic 
elongation factor 1-alpha) which is a housekeeping gene. Figure 3.25 shows the 
CG10362 expression in male Drosophila. Female progeny were, however, 
excluded from the behaviour study because they showed increased expression 
of CG10632 due to compensation. CG10632 expression following RNAi in males 
and females is shown in Appendix 9. To explain more, the responder line had the 
transgenic RNAi against CG10362 on chromosome X. The knockdown process 
was activated when these responder flies were mated with GAL4 driver. The 
RNAi has, therefore, worked to reduce CG10632 expression but because female 
flies have two copies of X chromosome, they could maintain a balanced CG10632 
expression by amplifying the transcriptional yield of the intact active X 
chromosome (Heard and Disteche, 2006). Because of the compensation effect 
of CG10362 expression in females, only male flies showed CG10632 knock down 
(Figure 3.25) and were selected for behaviour studies. 
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Figure 3.25. Relative expression of CG10632 in Drosophila. The expression was 
normalised against housekeeping eEF-1a. The flies with knocked down CG10632, that 
resulted from crossing CG10632 RNAi responder with the Gal4 Actin driver, showed a 
reduced expression of CG10632 compared with both CG10632 (RNAi responder) and 
wild-type flies (W*).  
 
The expression of CG10362 was markedly reduced in the progeny of CG10632 
RNAi responder flies crossed with Gal4 Actin flies (the middle block in Figure 
3.25). The process appeared to knock down the  CG10362 levels to around 40% 
of the wild type  (W*). Therefore, it was confirmed that the knockdown of 
CG10362 was working and behaviour assays could be undertaken.  
 
3.2.1.28.3 Olfactory learning T-maize assay  
An experiment was first carried to select the optimum concentrations of 4-
methylcyclohexanol (MCH) and 3-octanol (OCT), at which the naïve flies, which 
had not previously been exposed to these two smells, had no preference to follow 
one of the odour more than the other and flies were evenly distributed in the T-
maze. For this experiment, male progeny of wild type flies (W*) crossed with actin 
driver flies were used as described Section 2.18.6.2.  The flies were put in the T-
maze apparatus, in groups of 50, and allowed 2 minutes to choose between OCT 
and MCH. The experiment was done using more than 2000 flies against 0.1, 0.15 
and 0.3ml/l concentrations for each smell, and the result was achieved with 
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0.1ml/l MCH and 0.15ml/l OCT. Figure 3.26 indicates the percentage of flies that 
moved to each smell. 
 
 
Figure 3.26. Percentage of the flies that moved towards MCH and OCT. The 
percentage of flies for a smell was calculated by counting the number of flies that 
selected to follow that particular smell, and dividing this by the total number of flies tested, 
then multiplying by 100.  
 
The olfactory learning assay was done after training the flies to associate one 
smell with a shock but not the other. The training (also called conditioning) was 
carried against the two odours and was exchanged between having OCT or MCH 
as a safe smell, as described in section 2.18.6.3. After training the flies to 
remember avoiding one of the smell, because it was coupled with a mechanical 
shock, and to select the other safe smell, the olfactory learning test was done. 
This test indicated the associative memory of the flies if they learned from the 
training and could then avoid the “shock” smell. The assay involved training and 
testing 800 wild type flies and 800 CG10362 knock down flies. The flies were 
given 2 minutes in a T-maze apparatus to choose between the two odours 
(Section 2.18.6.4) and their learning index was calculated. Learning index 
represents the immediate memory of the flies and its calculation obtained 
performed using the following equation: 
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Li is the Learning index. 
A is the number of flies that chose the correct/safe smell. 
B is the number of flies that chose the incorrect/shock smell. 
C is the total number of flies in the test.  
 
 
 
Table 3.14 shows the average Li, the standard deviation as well as the standard 
error of the mean (SEM) for both wild type and CG10362 knock down flies. The 
CG10362 knock down flies, that resulted from crossing the CG10632 RNAi 
responder line with the GAL4 driver line, showed no significant difference in the 
leaning index (P=0.159) compared with the wild type flies (Figure 3.27).  
 
 CG10632 RNAi Line x Gal4 Actin Wild Type (W*) x Gal4 Actin 
Average 0.18665318 0.063518043 
St.dev 0.15040407 0.179160439 
S.E.M 0.053175869 0.063342781 
 
Table 3.14. The average of learning index (Li) in the olfactory learning assay. 
 
 
Although it might suggest that the wild type (W*) flies would achieve a learning 
index (Li) of 1, this was not the case (Figure 3.27). This is because the used wild 
type (W*) flies were of white eyed background, which might have interfered with 
the learning ability of the flies (see Section 3.3.3). It should be also mentioned 
that there were always some flies which remained in the area between the two 
smells until the end of the testing period but these flies were not included in the 
calculation.   
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Figure 3.27. Learning index of olfactory learning assay. The CG10362 knock down 
flies (CG10632 x Gal4 Actin) appeared to have a higher learning index compared with 
wild type flies (W* x Gal4), but this difference was not significant.  
 
 
In this assay, the CG10632 knockdown flies show a non-significant trend (T-test: 
t = -1.489, df = 14, p = 0.159) towards higher ability to remember the mechanical 
shock and choose the smell that avoids it.  
 
3.2.1.28.4 Rapid iterative negative geotaxis (RING) assay 
The rapid iterative negative geotaxis (RING) assay examines the locomotor ability 
of flies. When flies are startled and knocked down to the bottom of their container 
by rapid tapping against the bench, normal flies are expected to immediately act 
and move upward (Section 2.18.4). The measurements in this assay were done 
based on a total number of 250 CG10362 knock down flies compared with 250 
wild type flies. Photographs taken during the test (example in Figure 3.28) clearly 
indicated the slower movement of the CG10362 knock down flies compared with 
the wild type flies, which progressed quickly to the top of the tube. 
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Figure 3.28. Example of RING assay. A. Tube containing the CG10362 knock down 
flies (CG10632 x Gal4 Actin). B. Tube containing wild type flies (W* x Gal4 Actin). The 
picture was taken with a digital camera (Canon, EOS 1200D) at 3 seconds after the last 
tap. The wild-type flies moved significantly faster upward than the knock down flies. 
 
 
Figure 3.29. Negative geotaxis index. The CG10362 knocked down flies (CG10632 x 
Gal4 Actin) showed a lower negative geotaxis index compared with wild type flies. 
**<0.01.  
 
The difference in the negative geotaxis index (Figure 3.29), measured as a mean 
of distances from the bottom in cm, was analysed using independent sample t-
test and found to be significant (p=0.002). This finding is indicative of a loss of 
locomotor behaviour and could point to CG10362 being important in neurological 
or physical control of movement. This motor deficit, obtained through RING 
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assay, also suggests that there is a confounding effect on behavioural measures 
that require fly movement.  
 
3.2.1.28.5 Courtship suppression assay 
Courtship suppression is one of the studies that have been utilised to test the 
learning paradigm in Drosophila. The courtship suppression assay measures the 
courtship behaviour of male flies after one-hour exposure to mated females. The 
development of courting suppression is attributed to the presence of what is so 
called as conditioned and unconditioned stimuli. To explain more, all female 
drosophila have the conditioned stimuli, like 9-pentacosene, which would enable 
the males to recognise the female Drosophila and start courting them (Siwicki et 
al., 2005). Once a female is get mated, it would have unconditioned stimuli, like 
7-trocosene and cis-vaccenyl acetate (cVA), that arise from male cuticular 
hydrocarbon during copulation process (Lacaille et al., 2007). The unconditioned 
stimuli last for different times depending on their type but they collectively act to 
train the male to suppress its courtship for few hours (Ejima A. et al., 2007). 
Normal male flies are reported to have  suppressed courting tendency for four 
hours after an hour exposure to a mated female (Ejima Aki and Griffith, 2011).  
 
The assay was carried out as described in Section 2.18.5. Male progenies of the 
CG10632 RNAi responder line crossed with the GAL4-Actin driver as well as of 
the wild type (W*) x GAL4-Actin driver were kept with mated females for one hour. 
Their courting activity was videoed during the first and last 10 minutes. The 
females were then replaced by virgin females and the courting activity of the 
males was videoed. To compare the courting activity of the males towards the 
newly placed females, sham-trained males were also exposed to virgin females 
and videoed. The experiment outlines and different time points, at which videos 
were recorded, are highlighted in Figure 3.30. 
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Figure 3.30. A timeline of the experimental procedure and video sample points in 
the courtship suppression assay. The assay was carried out to measure the courting 
activity of CG10632 RNAi males on mated flies and compare it with the one of wild type 
(W*) males. A sham-trained female of either CG10632 RNAi or wild type (W*) flies was 
used to compare the courting activity of the males towards virgin females that were put 
instead of the mated ones.  
 
Two indices were calculated based on this assay: the learning index (Figure 3.31) 
and the memory index (Figure 3.32). The learning index (LI) is the immediate 
memory of the flies and it was calculated using the equation below. On the other 
hand, the memory index (Mi) is the one-hour memory that was calculated using 
the same courting measures but after 60-minutes gap from the training time.  
 
 155 
 
 
A is the percentage of courting over 10 minutes for trained males 
B is the percentage of courting over 10 minutes for sham males  
 
The average Li in the courtship suppression assay is shown in Table 3.15 and 
Figure 3.31 whereas Table 3.16 and Figure 3.32 illustrate the Mi results.    
 
 CG10632 RNAi Line x Gal4 Actin Wild Type (W*) x Gal4 Actin 
Average 0.169472271 0.178209024 
St.dev 0.155299082 0.175962431 
S.E.M 0.058697536 0.058654144 
Table 3.15. The average of learning index (Li) in the courtship suppression assay. 
 
 
Figure 3.31. Learning index in the courtship suppression assay. This is an indication 
of the immediate memory of the tested flies. The index is calculated based on the mean 
time that males spent on courting mated females during the last 10 minutes in 
comparison with the first 10 minutes of the experiment. Both CG10362 knock down and 
wild type flies had a similar learning index during the courtship suppression assay. 
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 CG10632 RNAi Line x Gal4 Actin Wild Type (W*) x Gal4 Actin 
Average 1.004327506 0.90535309 
St.dev 0.258936486 0.230636222 
S.E.M 0.097868793 0.076878741 
Table 3.16. The average of memory index (Li) in the courtship suppression assay. 
 
 
 
Figure 3.32. Memory index in the courtship suppression assay. This is an indication 
of the one-hour memory of the tested flies. The index is calculated based on the mean 
time that experienced males spent in courting virgin females in comparison with the time 
spent by naive males in courting virgin females. Both CG10362 knock down and wild 
type flies had a similar memory index during the courtship suppression assay. 
 
In comparison with the courtship index of sham-trained males, who were placed 
individually in empty chambers, the courtship behaviour of both the CG10362 
knock down males and the wild type males was not supressed after one-hour of 
exposure to mated females (Figure 3.32). The fact that the wild type males have 
not shown courtship suppression after one hour exposure to mated females rise 
a question about the validity of the used wild type. This issue and the interference 
caused by using white-eyed Drosophila in the outcome of courtship suppression 
assay is discussed in Section 3.3.3. On the other hand, the unsuppressed 
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courting activity in the CG10362 knock down males, does support the importance 
of the PDZD8 in cognitive and memory activities.  
 
3.2.2 Intellectual disabilities families with unidentified causes 
3.2.2.1 Clinical features and genetic analysis of Family-4 
Family-4 originates from a first-cousin consanguineous marriage (Figure 3.33). 
The father (case III.1) died of prostate cancer aged 65 years and the mother was 
reported as healthy. The couple had ten children; two of them (IV.2 and IV.3) died 
in a road traffic accident. Five of the children were diagnosed with intellectual 
disability: three (IV.6, IV.8 & IV.10) had moderate level of ID, and the other two 
(IV.1 & IV.9) had a mild form of ID. Case IV.6 was referred to the Genetic and 
Developmental Medicine Clinic for speech delay and dysmorphic features. The 
child was born with normal growth parameters and no history of delivery or 
neonatal complications. Family history reported that the other four siblings had 
learning problems. Examination of case IV.6, at the age of 6 years, revealed 
dysmorphic features including hypertelorism, mild upslanting of palpebral 
fissures, epicanthal folds, broad nasal tip, brachydactyly of fingers and toes. Brain 
MRI was reported to be normal. 
 
Microsatellite genotyping was performed to verify the pedigree structure of the 
family (Figure 3.33) using the methods described in section 2.7. Homozygosity 
mapping of Family-4 was performed on Affymetrix SNP array data and WES data 
generated as in section 2.10.1. The data generated were plotted using the Agile 
MultiIdeogram programme. Results are based on the affected subjects; IV.6, IV.9 
and IV.10. These three shared three homozygous regions more than 1Mb in size 
(Figure 3.34).  
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Figure 3.33. Family-4 pedigree with microsatellite genotyping. A consanguineous family from a first-cousin marriage. There are five ID 
affected individuals: IV.1, 1V.6, IV.8, IV.9 and IV.10. The pattern suggests a recessive inheritance. Genotyping is shown for the cases from whom 
DNA was available. Red text indicates the alleles for marker D4S3042 and green text indicates the alleles for D7S483. All the affected children 
(IV.1, IV.6, IV8, IV.9 and IV.10) have shown a genotype pattern that is consistent with being inherited from their parents (III.1 and III.2).  WES 
was done for case IV.6 and SNP array for cases IV.9 and IV.10. 
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Figure 3.34. Shared homozygous regions in Family-4. A. An ideogram where the 
outer circle contains template segments of the 22 autosomal chromosomes. The three 
inner circles are as follows: the SNP data from subjects IV.9 and IV.10 and WES data 
from subject IV.6. The light blue areas are the homozygous regions within each individual 
and the dark blue regions (number=3) are the shared homozygous regions between 
individuals. B. Details of the shared homozygous regions. The coordinates for the 
regions are based on human genome reference hg19. Two of the shared regions are on 
chromosome 5 and there is one bigger region on chromosome 12. 
 
Exome sequencing was carried out on case IV.6. After annotation by ANNOVAR 
and exome analysis, 57996 variants were identified, of which 293 variants were 
mapped in the homozygous regions shared by the affected members of this 
family. Only one homozygous variant in the GPR151 gene on chromosome 5 
remained after filtering according to the strategy described in (Section 2.11.9.4, 
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Table 3.17). This variant did not segregate with the disease in additional family 
members.  
 
The possibility of compound heterozygous variants in the rest of the genome 
underlying the ID in Family-4 was also investigated. 393 genes which had more 
than one variant were selected, but only 9 variants in four genes (Table 3.17) 
passed the filtering process according to methods described in Section 2.11.9.5. 
When these were tested in additional family members none of them fully 
segregated with the disease phenotype. 
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Chr Position Gene Coding 
Effect 
cDNA Change Protein Change 1000g CADD Zygosity 
chr5 145895285 GPR151 exonic GPR151:NM_194251:exon1:c.390_392del p.130_131del 0 0.897 Homo 
chr11 6411936 SMPD1 exonic SMPD1:NM_000543:exon1:c.108_113del p.36_38del 0 12.79 Het 
chr11 6415259 SMPD1 exonic SMPD1:NM_000543:exon5:c.G1474A p.G492S 0.0023 9.451 Het 
chr12 4735968 AKAP3 exonic AKAP3:NM_006422:exon5:c.T2100G p.D700E 0 0.001 Het 
chr12 4735969 AKAP3 exonic AKAP3:NM_006422:exon5:c.A2099T p.D700V 0 22 Het 
chr12 4736150 AKAP3 exonic AKAP3:NM_006422:exon5:c.T1918G p.X640E 0 0.001 Het 
chr12 58017860 SLC26A10 exonic SLC26A10:NM_133489:exon9:c.G1206A p.W402X 0.0018 39 Het 
chr12 58018668 SLC26A10 exonic SLC26A10:NM_133489:exon10:c.T1247G p.L416R 0.0032 27.5 Het 
chr17 79094162 AATK exonic AATK:NM_004920:exon10:c.C3265T p.P1089S 0.0046 0.072 Het 
chr17 79094694 AATK exonic AATK:NM_004920:exon10:c.2731_2733del p.911_911del 0 8.607 Het 
 
Table 3.17. Final list of homozygous and compound heterozygous candidate variants for Family-4. This table shows one homozygous 
and 9 heterozygous variants, each with its pathogenicity score based on CADD and frequency based on the 1000G database. Homo= 
homozygous; Het= heterozygous. 
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ExomeDepth is a piece of software that searches in genomic ngs data (WES or 
WGS) for CNVs by using the read depth data from exome sequencing 
experiments. It works by comparing the exome depth of a given exome in the 
sample of interest against a set of control samples that have been loaded in the 
same sequencing run. In this analysis, the control sets comprised 5 samples. The 
analysis was performed on the exome sequencing results of case IV.6 using the 
method of Plagnol et al. (2012).  The obtained CNV calls were prioritised based 
on Bayes factor (BF), as described in section 2.11.9.7. This identified a final list 
of seven putative homozygous CNVs (Table 3.18) that could be involved in the 
pathogenicity of the ID in Family-4. All the highlighted variants were tested for 
validation by PCR and IGV (Integrative Genomics Viewer). They were either 
found to be artefacts or did not segregate within the family. A representative 
example of the variant validation was a deletion on chromosome 3 that maps 
within a gene called EFCAB12. The deletion appears to remove the full gene.  
Primers were designed to amplify 356 bp of exon 7 of EFCAB12 (Appendix 2). 
All members showed a normal PCR product amplified, like the +ve control 
sample. The fact that a band was amplified from DNA from all family members, 
including those affected by ID, suggests this deletion might not be genuine 
(Figure 3.35). 
 
 
chr start end Exp Read Obs Read Type BF 
chr3 129120437 129127701 163 2 deletion 36.9 
chr22 24376424 24384231 228 402 duplication 23.5 
chr1 113126595 113126748 68 1 deletion 14.6 
chr5 147553798 147553933 66 0 deletion 14.5 
chr1 152573209 152586574 43 0 deletion 10.3 
chr4 69433480 69434202 25 0 deletion 6.14 
chr20 1569207 1569278 18 0 deletion 4.52 
 
Table 3.18. CNVs in case IV.6 of Family-4. This is the final list of seven putative 
homozygous CNVs that was generated with the programme ExomeDepth after 
comparing the reads of case IV.6 with a reference set of samples that were run in the 
same batch on the Illumina 2500 high seq. ‘Exp’ is the expected reads and ‘Obs’ is the 
observed reads. The candidates were prioritised based on Bayes factor (BF). 
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Figure 3.35. Investigation of EFCAB12 deletion in Family-4. In order to validate the 
first candidate of the CNVs, DNA samples from family members were tested by PCR for 
the presence of exon 7 of EFCAB12. Lane 1, 100-bp ladder; lane 2, III.2; lane 3, IV.6; 
lane 4, IV.7; lane 5, IV.8; lane 6, IV.9; lane 7, IV.10; lane 8, +ve control; lane 9, -ve control  
 
3.2.2.2 Clinical features and genetic analysis of family-5. 
Family-5 (Figure 3.36) originated from a first-cousin consanguineous marriage. 
Both parents were reported to be healthy. Two of the children (IV.2 and IV.3) had 
been diagnosed with moderate ID, ASD and microcephaly. The pedigree 
structure was verified by microsatellite genotyping (Figure 3.36). Homozygosity 
mapping was carried out using Affymetrix SNP array data (Section 2.10) 
generated from genomic DNA in individual IV-3, and from SNP genotypes 
extracted from WES (section 2.11) from subject IV.2 using the programme Agile 
MultiIdeogram programme. Five shared homozygous regions were identified 
(Figure 3.37). Combining the exome sequence in case IV.2 with the 
homozygosity mapping data identified 538 variants in the shared homozygous 
regions. Three candidate variants remained after filtering as described in section 
2.11.9.4, shown in Table 3.19. However, none showed complete segregation. 
 
Therefore, a further search was undertaken to find possible compound 
heterozygous variants elsewhere in the exome that could underlie the described 
phenotypes. 547 variants as possible compound heterozygotes were detected in 
case IV.2. Only 17 variants in 8 genes passed the filtering process (Table 3.19). 
However, none of these variants showed complete segregation within the family. 
The fact that both affected individuals in this family were male (cases IV.2 and 
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IV.3 in Figure 3.36) suggested possibly an X-linked mode of inheritance for the 
disease. Therefore, variants located on the X-chromosome were also analysed 
and 14 variants were highlighted after the filtering and prioritization step (Section 
2.11.95). Three of them were in known genes for ID (the full list of known ID genes 
is shown in Appendix 8). However, all the X-chromosome candidates for this 
family (Table 3.20) were checked for segregation with the ID in this family and 
none of them was found to show a complete pattern of co-segregation. 
 
Exome depth, performed on case IV.2, identified 4 putative homozygous CNVs 
that could be potentially involved in the ID pathogenicity (Table 3.21). PCR, 
Sanger sequencing and examination on IGV were used as validation methods. 
None of the tested candidates was consistent with being causative.  A 
representative example using the IGV platform to examine a duplication variant 
on chromosome 3 in case IV.2 compared with the control is shown in Figure 3.38. 
The results showed an increased read pattern in the analysed sample. 
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Figure 3.36. Family-5 pedigree with microsatellite genotyping. A consanguineous family originating from a first-cousin marriage. The small 
triangle indicates a miscarriage. The parents are unaffected but two of the children (IV.2 and IV.3) have ID and this pattern suggests recessive 
inheritance. Genotyping is shown for the cases from whom DNA was available. Red text indicates the alleles for marker D4S3042 and green text 
indicates the alleles for D7S483. Both affected cases (IV.2 and IV.3) showed a genotype pattern consistent with being inherited from their parents 
(III.1 and III.2). Case IV.2 was exome sequenced and case IV.3 SNP genotyped using an Affymetrix SNP chip.  
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Figure 3.37. Shared homozygous regions in Family-5. A. An ideogram in which the 
outer circle contains template segments of the 22 autosomal chromosomes. The middle 
circle is SNP data from subject IV.3 and the inner circle is WES data from subject IV.2. 
The light blue regions are the homozygous regions within each individual and the dark 
blue regions (number=5) are shared between the affected individuals. B. Details of the 
shared homozygous regions. The coordinates were based on human genome reference 
hg19. The five-shared regions are on different chromosomes and have different lengths. 
The largest region is on chromosome 5.  
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Chr Start Gene Coding Effect cDNA Change Protein Change 1000g CADD Zygosity 
chr5 94749787 FAM81B exonic FAM81B:NM_152548:exon4:c.C430T p.Q144X 0.02 37 Homo 
chr11 405937 SIGIRR exonic SIGIRR:NM_001135053:exon10:c.C1192G p.R398G 0 32 Homo 
chr11 1298430 TOLLIP exonic TOLLIP:NM_019009:exon6:c.G664T p.A222S 0.02 13.98 Homo 
chr6 35086272 TCP11 Exonic TCP11:NM_001261818:exon9:c.G1187A p.R396Q 0 32 Het 
chr6 35086275 TCP11 Exonic TCP11:NM_001261818:exon9:c.A1184G p.Q395R 0 23.8 Het 
chr7 100345978 ZAN Exonic UNKNOWN ? 0 8.718 Het 
chr7 100385593 ZAN Exonic UNKNOWN ? 0 12.85 Het 
chr7 100385595 ZAN Exonic UNKNOWN ? 0 22.5 Het 
chr9 140772669 CACNA1B Exonic 
CACNA1B:NM_000718:exon1:c.284_ 
285insTCCATTCGAGT 
p.P95fs 
0 32 Het 
chr9 140777306 CACNA1B Exonic CACNA1B:NM_000718:exon3:c.C501G p.N167K 0 14.39 Het 
chr11 62400108 GANAB Exonic GANAB:NM_198334:exon9:c.A925T p.T309S 0 34 Het 
chr11 62400570 GANAB Exonic GANAB:NM_198334:exon8:c.G722T p.R241M 0 27.3 Het 
chr13 24798712 SPATA13 Exonic SPATA13:NM_001166271:exon2:c.A1645G p.K549E 0 0.005 Het 
chr13 24871664 SPATA13 Exonic SPATA13:NM_153023:exon10:c.G1499A p.G500D 0 27.8 Het 
chr15 31521506 LOC283710 Exonic LOC283710:NM_001243538:exon2:c.75_76del p.25_26del 0 1.944 Het 
chr15 31521507 LOC283710 Exonic LOC283710:NM_001243538:exon2:c.75delC p.P25fs 0 2.124 Het 
chr17 39346593 KRTAP9-1 Exonic KRTAP9-1:NM_001190460:exon1:c.455_457del p.152_153del 0 10.64 Het 
chr17 39346622 KRTAP9-1 Exonic KRTAP9-1:NM_001190460:exon1:c.T484A p.C162S 0 0.623 Het 
chr17 67145191 ABCA10 Exonic ABCA10:NM_080282:exon39:c.4515_4516del p.1505_1506del 0 35 Het 
chr17 67149973 ABCA10 Exonic ABCA10:NM_080282:exon33:c.C3964T p.R1322X 0 28 Het 
 
Table 3.19. Final list of homozygous and heterozygous candidate variants for Family-5. This shows 3 homozygous and 17 heterozygous 
variants, each with its pathogenicity score based on CADD, and frequency based on the 1000G database.  
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Chr Position Gene cDNA Change Protein Change 1000g CADD 
chrX 18917338 PHKA2 PHKA2:NM_000292:exon29:c.T3064A p.S1022T 0 9.778 
chrX 26157773 MAGEB18 MAGEB18:NM_173699:exon2:c.A671G p.N224S 0 15.92 
chrX 31645821 DMD DMD:NM_004013:exon12:c.A806G p.K269R 0 21.4 
chrX 32404432 DMD DMD:NM_004011:exon5:c.G646A p.A216T 0 28.9 
chrX 35820384 MAGEB16 MAGEB16:NM_001099921:exon2:c.G71A p.S24N 0 0.033 
chrX 44088950 EFHC2 EFHC2:NM_025184:exon11:c.G1696A p.V566I 0.0006 0.005 
chrX 50121146 DGKK UNKNOWN ? 0 13.01 
chrX 53263460 IQSEC2 IQSEC2:NM_001111125:exon15:c.G4408A p.A1470T 0.01 14.64 
chrX 69478801 P2RY4 P2RY4:NM_002565:exon1:c.G674C p.R225P 0 25 
chrX 70330790 IL2RG IL2RG:NM_000206:exon2:c.A226G p.S76G 0 13.87 
chrX 74494304 UPRT UPRT:NM_145052:exon1:c.C215T p.S72F 0 14 
chrX 108868163 KCNE1L KCNE1L:NM_012282:exon1:c.G87T p.L29F 0 22.9 
chrX 114425217 RBMXL3 RBMXL3:NM_001145346:exon1:c.A1213C p.N405H 0 14.22 
chrX 153762634 G6PD G6PD:NM_000402:exon6:c.C653T p.S218F 0 24.2 
 
Table 3.20. X-Linked variants in Family-5. This table shows 14 variants, each with its pathogenicity score based on CADD, and frequency 
based on the 1000G database. The three variants highlighted in green are in two genes known to be associated with X-linked ID. 
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Chr start end Exp Read Obs Read Type BF 
chr22 24376424 24384231 173 0 deletion  40.2 
chr3 129120437 129127701 124 261 duplication 19.8 
chr1 113126595 113126748 51 108 duplication 7.77 
chr6 147635401 147635467 46 17 deletion 5.75 
 
Table 3.21. Candidate CNVs in Family-5. This list was generated after comparing the 
reads of case IV.2 with a reference set of samples that were run in the same batch on 
the Illumina 2500 high seq. ‘Exp’ is the expected reads and ‘Obs’ is the observed reads. 
The candidates were prioritised based on Bayes factor (BF).  
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Figure 3.38. Visualisation of chr3 duplication in Family-5. These representations, made by IGV software, cover part of chromosome 3 
(129120719-129123765) within which the duplication was expected to occur in ID-affected individuals in Family-5. A. Sequence reads for a 
control sample that was tested in the same sequencing run as IV.2. B. The sequence of case IV.2 in Family-5. This is an example indicating 
the duplication CNVs found in the analysed sample but this candidate did not segregate in Family-5 .  
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3.2.2.3 Clinical features and genetic analysis of Family-6 
Family-6 originated from a first-cousin consanguineous marriage (Figure 3.39). 
There are six children in this family, two (both girls; V.2 & V.5) with severe ID and 
microcephaly. Genotyping (Section 2.7) was done as a confirmatory step to 
indicate that no mixing between the samples had occurred. Members of Family-
6 were genotyped using two markers (D4S3042 and D7S483) and their results 
are illustrated in Figure 3.39. Homozygosity mapping of Family-6 was based on 
subjects V.2 and V.5. Thirteen shared homozygous regions were identified 
(Figure 3.40 and Table 3.22).  
 
For this family, case V.2 was exome sequenced. Combining SNP data extracted 
from the exome sequence of case V.2 with the Affymetrix SNP chip data of the 
case V.5 in homozygosity mapping resulted in thirteen shared regions, within 
which 10,275 variants were identified in the WES data from case V.2. Only six 
candidate variants remained (Table 3.23) after carrying out the filtering steps 
described in Section 2.11.9.4. However, none of the six candidate variants 
showed complete segregation with ID in this family.  
 
Searching the entire exome for compound heterozygous variants that could 
possibly underlie the described phenotypes showed 283 variants in case V.2, and 
8 variants in four genes were taken forward for segregation testing after they 
passed the filtering criteria detailed in section 2.11.9.4. Upon testing, none of the 
proposed compound heterozygous variants showed segregation with ID within 
the family. 
  
Exome depth was performed as described in section 2.11.9.7 on the exome 
results of case V.2, based on the method of Plagnol et al. (2012). This procedure 
identified 5 putative homozygous CNVs that could be involved in the 
pathogenicity of ID in Family-6 (Table 3.24). All of the proposed CNVs were 
investigated further using PCR and Sanger sequencing as well as viewing the 
sequence by eye using IGV software. They were either found to be artefacts or 
did not segregated within the family. The first ranked homozygous CNV was 
tested for validation of a representative example and is shown in Figure 3.41. The 
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putative deletion was found to delete the PCDHA7 gene. Primers were therefore 
designed to amplify exon 1 of this gene. The fact that the PCR amplified a normal 
band from DNA of affected individuals suggests the deletion might not be 
genuine.  
 173 
 
 
Figure 3.39. Family-6 pedigree: a consanguineous family from a first-cousin marriage. There are six children in this family, of which two 
(both girls; V.2 & V.5) have severe ID and microcephaly. The pattern suggests recessive inheritance. Genotyping is shown for the cases from 
whom DNA was available. Red text indicates the detected alleles for marker D4S3042 and green text indicates the alleles for D7S483. All the 
children including both affected cases (V.2 and V.5) show a genotype pattern consistent with being inherited from their parents (IV.1 and IV.2). 
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Figure 3.40. Shared homozygous regions in Family-6. An ideogram in which the outer 
circle contains template segments of the 22 autosomal chromosomes. The middle circle 
is SNP data from subject V.5 and the inner circle is SNP genotypes extracted from WES 
data from subject V.2. The light blue areas are homozygous regions within each 
individual and the dark blue regions (number=13) are the homozygous regions shared 
between the affected individuals. Chromosome 12 had the largest shared homozygous 
region. 
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Chr Start End Length (bp) 
1 162504246 169512039 7007793 
2 179600563 187487160 7886597 
4 146825552 149155928 2330376 
5 85682624 93731985 8049361 
5 96244638 97442526 1197888 
6 28269663 29312762 1043099 
8 28452799 29927321 1474522 
8 142146708 144779718 2633010 
11 37131957 46744925 9612968 
11 107895836 110035301 2139465 
12 31139966 56928777 25788811 
18 62537601 70517206 7979605 
20 55436718 60712511 5275793 
 
Table 3.22. Shared homozygous regions in Family-6. Coordinates of the shared 
homozygous regions between cases V.2 and V.5, based on human genome reference 
hg19. There are 13-shared regions and the largest region is on chromosome 12. 
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Chr Position Gene 
Coding 
Effect 
cDNA Change 
Protein 
Change 
1000g CADD Zygosity 
chr11 46342259 CREB3L1 splicing CREB3L1:NM_052854:exon12:c.1524-1->G ? 0 34 Homo 
chr12 48167179 SLC48A1 exonic SLC48A1:NM_017842:exon1:c.T92A p.V31E 0 23 Homo 
chr12 49373410 WNT1 exonic WNT1:NM_005430:exon2:c.T264A p.S88R 0.01 13.78 Homo 
chr12 51678502 BIN2 exonic BIN2:NM_016293:exon12:c.G1666C p.E556Q 0 24.7 Homo 
chr12 51759296 GALNT6 exonic GALNT6:NM_007210:exon5:c.G732T p.E244D 0 19.07 Homo 
chr12 53009992 KRT73 exonic KRT73:NM_175068:exon2:c.A620G p.E207G 0 23 Homo 
chr5 112868579 YTHDC2 exonic YTHDC2:NM_022828:exon5:c.C679T p.P227S 0 29.5 Het 
chr5 112903526 YTHDC2 exonic YTHDC2:NM_022828:exon23:c.A3224G p.Q1075R 0 17.34 Het 
chr11 48286231 OR4X1 Stopgain OR4X1:NM_001004726:exon1:c.T819A p.Y273X 0.66 35 Het 
chr11 48286256 OR4X1 exonic OR4X1:NM_001004726:exon1:c.C844T p.P282S 0.46 24.1 Het 
chr13 25670868 PABPC3 exonic PABPC3:NM_030979:exon1:c.G532A p.E178K 0 32.2 Het 
chr13 25670877 PABPC3 exonic PABPC3:NM_030979:exon1:c.G541A: p.A181T 0 14.99 Het 
chr19 56515447 NLRP5 exonic NLRP5:NM_153447:exon2:c.G428A p.R143Q 0 23.5 Het 
chr19 56544970 NLRP5 exonic NLRP5:NM_153447:exon9:c.G2510A p.R837H 0.0005 9.27 Het 
 
Table 3.23. Homozygous and heterozygous candidate variants for Family-6. This table shows the six homozygous variants, and the 
eight heterozygous variants in 4 genes, each with its pathogenicity score based on CADD and frequency based on the 1000G database. 
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Chr start end Exp Read Obs Read type BF 
5 140228082 140238021 209 5 deletion 17 
19 1978442 1987252 182 305 duplication 8.36 
11 65413928 65422471 191 321 duplication 8.22 
19 55603019 55606166 127 223 duplication 7.74 
1 43917320 43919464 109 205 duplication 6.4 
 
Table 3.24. CNVs in Family-6. The final list of putative CNVs predicted by the 
ExomeDepth software after comparing the reads of case IV.2 from family-6 with a 
reference set of samples that were run in the same batch on the Illumina 2500 high seq. 
‘Exp’ is the expected number of reads and ‘Obs’ is the observed reads. The candidates 
were prioritised based on Bayes factor (BF).  
 
 
Figure 3.41. Checking for Chr5 deletion in Family-6. This putative deletion predicted 
by ExomeDepth analysis of WES data from individual IV-2 was found on the genome 
browser to include a gene called PCDHA7. An experiment was carried out to check if it 
was possible to amplify exon 1 of PCDHA7 from DNA from the family members. Lane 1, 
100 bp ladder; lane 2, IV.1; lane 3, IV.2; lane 4, V.1; lane 5, V.2; lane 6, V.5; lane 7, +ve 
control; lane 8, -ve control. All members, including the affected cases, showed the normal 
PCDHA7 band (394 bp), like the +ve control sample.  
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3.3 Discussion  
3.3.1 Family-1 with TUSC3 Mutation 
Affected individuals from Family-1 presented with developmental, motor and 
language delay, syndactyly, facial dysmorphology and low IQ. Homozygosity 
mapping and WES analysis revealed a nonsense mutation in the TUSC3 gene 
that cosegregated with the condition in a manner consistent with it being the 
causative mutation. This mutation would be expected to lead to a truncated 
protein, but may alternatively lead to nonsense mediated decay, meaning 
effectively that no protein is produced. Furthermore, previous published reports 
have shown that other mutations in the same gene have caused similar 
phenoptypes, detailed below. It was therefore concluded that this mutation is the 
cause of the condition observed in this family.  
 
TUSC3 is the tumour suppressor candidate-3 gene and is also known as N33 or 
OST3A (oligosaccharyl transferase 3 homolog A). The gene encodes a 348-
amino acid protein comprising a membrane-anchored thioredoxin signal peptide 
with four transmembrane domains (Figure 3.42). 
 
The TUSC3 protein has been found to participate in the multimeric oligosaccharyl 
transferase complex (OTC) in the endoplasmic reticulum. The OTC is likely to be 
involved in post-translational glycosylation of selected proteins essential for 
normal brain development (Kelleher and Gilmore, 2006; Mohorko et al., 2014). 
Glycosylation is a sophisticated but very important step for protein modification 
and without it, a newly synthesised protein would have difficulty with folding and 
stability (Shental-Bechor and Levy, 2008). Figure 3.43 gives more explanation of 
the glycosylation process and highlights the step in which TUSC3 is involved. 
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Figure 3.42. Topology prediction of TUSC3 structure. The four transmembrane 
domains of the protein are shown as clusters of amino acids within the orange-shaded 
membrane. The amino acid at which the premature truncation occurs due to the 
c.222delA mutation in Family-1 is indicated with a red arrow. The image was generated 
using the Protter prediction tool. 
 
It has been suggested that TUSC3 may also play a role as a magnesium 
transporter (Zhou and Clapham, 2009) but this could be clarified by the fact that 
TUSC3 could control the efficiency of glycosylation in a membrane transporter. 
Furthermore, It has previously been found that deletion of the human 
chromosome 8p22 region, which contains the TUSC3 gene, is common in cases 
of prostate (Bergerheim et al., 1991) and ovarian cancers (Pribill et al., 2001). 
Silencing TUSC3 in ovarian cancer cell lines was also documented to support the  
proliferation and migration of the cancer cell, which points to the fact that TUSC3 
could be a tumour suppressor protein (Vanhara et al., 2013). Because all ID 
patients in Family-1 are still in their childhood, it is too early to assess the relation 
of the found variant to tumour development. Although it may be appropriate to 
monitor these individuals for the presence of tumours in the future, it should also 
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be noted that the full TUSC3 deletions described in cancer cells are quite different 
from the likely premature termination of protein synthesis reported in Family-1. 
On the other hand, if nonsense mediated decay destroys all truncated mRNAs 
then this mutation will be an effective knockout just like the situation in tumour 
cases. 
 
There have been various reports on ID patients, also with speech delay as the 
prominent features, who have biallelic TUSC3 mutations (El Chehadeh et al., 
2015; Garshasbi Masoud et al., 2008; Garshasbi M. et al., 2011; Khan M. A. et 
al., 2011; Loddo et al., 2013; Molinari et al., 2008). The affected individuals in 
Family-1 have symptoms matching the phenotypes described in these reports 
and the findings are consistent with each other. Moreover, the vast majority of the 
additional characteristics that have been found in previously reported cases, like 
short stature, microcephaly and moderate facial dysmorphism, were also present 
in some of the patients in Family-1 (Table 3.2). In the study of Loddo and 
colleagues (Loddo et al., 2013), one of the descripted ID case had congenital 
malformations in the phalanges and this sign has been observed in three of the 
four patients in Family-1. Therefore, it seems there is no recognisable genotype-
phenotype correlation between the different variants and the additional 
comorbidity signs  (El Chehadeh et al., 2015). 
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Figure 3.43. The protein glycosylation process and the stage of TUSC3 involvement. The process is started at the cytosolic face of 
the ER at which mannose-rich oligosaccharide is synthesized. When the newly synthesized protein comes from the ribosomes and starts 
entering the ER, the developed oligosaccharide chain is transferred from dolichol (a lipid molecule) to the protein and this step is mediated 
by glycosyltransferases. TUSC3 is involved in the glycosyltransferase complex, facilitating the association of the established oligosaccharide 
into newly produced protein before it is directed to the Golgi apparatus for further processing and transportation sorting to their final 
destinations. (Adapted from  Wang Yu-Chieh et al. (2014), no permission required).  
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The previously published studies have reported a premature stop codon mutation 
(Garshasbi M. et al., 2011), frameshift insertion (Molinari et al., 2008), gross 
deletion (Garshasbi Masoud et al., 2008; Khan M. A. et al., 2011; Loddo et al., 
2013) and an intragenic duplication (El Chehadeh et al., 2015) in TUSC3. All of 
these would be predicated either to yield TUSC3 protein which is not functional, 
or to lead to complete loss of protein, either through deletion of the gene or 
nonsense mediated decay. The mutation reported in this current research is a 
frameshift mutation that could initiate nonsense mediated decay (NMD) of the 
RNA transcript that leads to its total elimination, or may give rise to a truncated, 
non-functional protein. Given the published spectrum of TUSC3 mutations 
reported in various ID patients, it seems likely that the ID condition in Family-1 is 
the result of absence of functional TUSC3 protein during neurodevelopment 
rather than due to the presence of defective mutated protein.  
 
It is worth highlighting that some recent work on primary fibroblast cell cultures 
derived from patients with a null homozygous mutation in TUSC3 showed no 
significant difference from controls in glycosylation of selected proteins (El 
Chehadeh et al., 2015). This may argue against the key role of TUSC3 in 
glycosylation of extracerebral proteins.  
 
The finding of a novel TUSC3 mutation in the consanguineous Family-1 from 
Oman contributes further data on the spectrum of mutations causing this form of 
ID and the phenotype associated with it. This is the seventh family with a TUSC3 
mutation causing syndromic or non-syndromic ID that has been identified (Figure 
3.44). 
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Figure 3.44. Diagram showing the reported TUSC3 mutations to date. The representation is mapped onto the GRCh38 reference 
genomic DNA sequence, with exons highlighted according to the transcript with accession code, NM_006765.3. ‘n’ denotes the number of 
patients with that mutation. So far, a total of 25 patients have been described with TUSC3 mutations. The superscript notation assigns the 
reference that reports the mutation as follows: 1. Molinari et al., 2008; 2. Garshasbi et al., 2008; 3. Khan et al., 2011; 4. Garshasbi et al., 
2011; 5. Loddo et al., 2013; 6. El Chehadeh et al., 2015, and # represents the mutation reported in the current study. (Adapted from Al‐Amri 
et al. (2016) with a permission from John Wiley and Sons, and Copyright Clearance Center’s RightsLink® service, License number 
4055460722605).  
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3.3.2 Family-2 with LHFPL5 mutation 
The affected members in this family had autistic spectrum disorder, tooth 
abnormalities and sensorineural deafness as a profound feature. Homozygosity 
mapping and WES analysis revealed a novel homozygous missense mutation in 
LHFPL5 (NM_182548:exon2:c.T575C, p.L192P), co-segregating with the 
condition in an autosomal recessive fashion, consistent the pattern of inheritance 
seen in the family and with being involved with the phenotype. In addition, given 
that both affected individuals are male, an X-linked mode of inheritance was 
possible. Variants on the X chromosome were therefore identified, filtered and 
compared to a list of X-linked genes known to be mutated in cases of ID. This 
identified a missense variant in the NHS gene as a strong candidate for 
involvement in the phenotype seen in this family.   
 
Mutations in LHFPL5 are known to cause hearing loss, with eight different 
mutations already published as causing recessive sensorineural hearing loss 
(SNHL). The finding in Family-2 is the ninth mutation identified in LHFPL5 that 
has been implicated in deafness (Figure 3.45).  Different types of LHFPL5 
mutations have been reported and these include a biallelic mutation in the start 
codon (Shahin et a.l, 2010; Sloan-Heggen et al., 2015) and frameshift mutations 
(Bensaïd et al., 2011; Kalay et al., 2006; Shabbir et al., 2006), all of which are 
expected to induce a premature termination in the production of LHFPL5 mRNA, 
which might lead to a truncated protein or might cause loss of protein through 
nonsense mediated decay. Pathogenic mutations that cause missense changes 
(Ammar-Khodja et al., 2015; Kalay et al., 2006; Marková et al., 2016; Shabbir et 
al., 2006; Sloan-Heggen et al., 2015); this thesis) and an in-frame deletion (Sloan-
Heggen et al., 2015) have also been reported and the protein that is produced as 
a results of these mutations  is not normally functional. By looking at the published 
reports, there do not seem to be distinct phenotypic differences between the 
effect of null alleles and missense changes, as all patients had non-syndromic 
hearing loss, with no reports of the additional symptoms observed in Family-2. 
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Figure 3.45. Representation of LHFPL5 protein showing the pathogenic mutations 
identified to date. The protein has four-transmembrane domains. There have been a 
total of nine LHFPL5 mutations described up to date, including the one reported here. 
Missense and in-frame mutations are highlighted in red while frameshift, nonsense and 
splice mutations are in black. The superscript notation assigns the reference that reports 
the mutation as follows: 1. Kalay et al, 2006; 2. Shabbir et al, 2006; 3. Shahin et al, 2010; 
4. Bensaid et al, 2011; 5. Ammar-Khodja et al, 2015; 6. Sloan-Heggen et al, 2015; 7. 
Markova et al, 2016 and #  represents the mutation reported in the current study. The 
image was generated from accession code NP_872354.1 using the Protter prediction 
tool. 
 
LHFPL5 is also known by other aliases including TMHS (tetraspan membrane 
protein of hair cell stereocilia) and DFNB67 (deafness, autosomal recessive 67). 
The deduced 219-amino acid protein has four transmembrane domains that form 
a major part of the mechano-electrical transduction machinery for perception of 
sound. It is localised to the stereocilia, which are microvilli-like projections of 
different sizes that are arranged in bundles to make up the hair cells of the inner 
ear (Longo-Guess et al., 2005; Longo-Guess et al., 2007). LHFPL5 forms a 
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complex with other transmembrane proteins, TMC1 and TMIE, near the lower 
end of the stereocilia tip (Fettiplace, 2016). LHFPL5 has also been reported to 
cooperate with the amino-terminus of PCDH15, which interacts with the top end 
of the tip where the transduction channel, of unknown identity, is located (Beurg 
et al., 2015; Zhao B. et al., 2014). LHFPL5 has an important role as a modifier 
protein since it regulates the localisation of PCDH15 to the stereocilia tip, the 
formation of the tip-link assembly, and channel conductance (Xiong et al., 2012). 
Figure 3.46 shows the structure of hair cells and the main molecular components 
involved in the tip-link assembly. It would be interesting to know the protein 
interactions that are disturbed by the pathogenic changes in LHFPL5 that cause 
human deafness. 
 
Figure 3.46.The structure of mechano-electrical transduction machinery in hair 
cells of the inner ear. A. Electron microscope capture of the outer hair cells in V-shaped 
arrangement.  The micrograph is showing compact clusters of stereocilia, each 
measuring about 2-4 um, projecting in three rows. B. Representation of tip link 
organisation within the stereocilia and the essentially involved molecular participants. Tip 
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links, which tie successive stereocilia to each other, are fundamentally made of upper 
and lower ends. The upper ends consist of homodimers of cadherin 23 (CDH23) whereas 
the lower ends are formed by homodimers of protocadherin 15 (PCDH15). Components 
of Usher protein complex (MYO7a, SANS, Harmonin, Whirlin, CIB2) play a role in holding 
both ends in place. Interconnection of PCDH15, at the lower end of the links, with the 
mechano-electrical transducer (MET) channel is achieved through its interaction  with 
LHFPL5, along with TMIE and TMC1/2. (Adapted from Fettiplace (2016), no permission 
required).   
 
LHFPL5 mutations have so far been identified in patients with deafness from 
Central Europe (Markova et al., 2016), Algeria (Ammar-Khodja et al., 2015), 
Tunisia , Turkey (Kalay et al., 2006), Palestine (Shahin et al., 2010), Iran (Sloan-
Heggen et al., 2015), Pakistan and India (Shabbir et al., 2006), totalling 12 
families. Most of the mutations are unique to one family, though it is interesting 
to note that families were identified with the same mutation in Palestine and Iran 
(c.1A>G, p.-), Turkey and Central Europe (c.494C>T, p.T165M) and India, Iran 
and Central Europe (c.380A>G, p.Y127C). Though these findings could reflect 
mutation hot spots in LHFPL5, it is more likely that they represent common 
founder alleles reflecting population migration over the years. The family 
described in this report is the 13th with biallelic LHFPL5 mutations and represents 
the first time that mutations in this gene have been described in the Arabian 
Peninsula. 
 
The NHS variants reported in Family-2 could not be excluded from being the 
underlying cause of mental disability in the family especially when considering 
the fact that about 30-50% of individuals with Nance-Horan syndrome have 
intellectual disability (Brooks et al., 2010). However, the principle features of 
Nance-Horan syndrome, including congenital cataract and small mis-shaped 
hypoplastic teeth, have not been reported in Family-2. The only reported ocular 
phenotypes in the affected members are hypermetropia and astigmatism, and the 
tooth anomalies observed were crowding and overlapping incisors (Figure 3.47). 
Therefore, the affected members do have some tooth abnormalities are but they 
are not the ones normally seen with NHS mutations. Although a considerable 
variability of clinical phenotype within Nance-Horan syndrome is known, no case 
has been so far reported without the characteristic ophthalmic and dental 
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abnormalities (Liao et al., 2011; Tug et al., 2013). This is also the first time an 
NHS mutation has been reported in the Arabian Peninsula. 
 
 
Figure 3.47. Dental features of Nance-Horan syndrome. A. Characteristic screwdriver 
shaped incisors and diastema in a child with Nance-Horan syndrome (Tug et al. (2013). 
B. Case IV.3 in Omani Family-2 with mild teeth anomalies including conical shaped teeth, 
crowding and overlapping incisors. Part of a cochlear implant device is also visible on 
the left of the picture. 
 
The NHS gene encodes10 exons and is located at Xp22.31–p22.13 (Ding et al., 
2009). The biological structure of the NHS protein is unclear but a recent study 
suggests that there are, at least, four isoforms derived from alternative splicing, 
the two major isoforms being NHS-A and NHS-1A. (Tian et al., 2017). The 
pathogenicity of Nance-Horan syndrome is predominantly caused by defects in 
these two isoforms, which could be due to the functional WAVE homology domain 
at their N-termini (Brooks et al., 2010). The protein is highly conserved among 
vertebrates and is expressed in the retina as well as neuronal tissues (Figure 
3.48). Although published studies have shown its importance in the development 
of eye and neural tissues (Burdon et al., 2003; Sharma et al., 2006), the precise 
function of NHS is still unknown. 
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Figure 3.48. Expression of NHS in ocular and neuronal tissue. A. A gel image of 
reverse-transcriptase PCR on mRNA from human adult brain, fetal brain, retina, and 
lens, showing the existence of NHS transcript in all tested tissues . B. A coronal section 
of adult mouse brain stained for NHS. The mouse was transgenic for a lacZ reporter-
gene cassette inserted in the Nhs locus. The blue-green colour staining occurred after 
using β-galactosidase. Co, cortex; Hi , hippocampus; AN, amygdaloid nuclei; Hy, 
hypothalamus. (Adapted from Burdon et al. (2003), no permission required). 
 
In this family, two novel mutations were discovered: one in LHFPL5 and the other 
in NHS. It is true that the ultimate significance of the identified NHS variant could 
not be assuredly confirmed in the described phenotype. The ID phenotype in this 
family cannot therefore be accounted for by genetic findings. It remains possible 
that this particular LHFPL5 variant also causes ID, as the protein is expressed in 
the brain, or that the NHS variant or an undetected variant in another gene is 
causing this condition. Alternatively, the ID in this family may be the result of an 
undetected environmental factor such as poor maternal nutrition (Abu-Saad and 
Fraser, 2010; Purandare, 2012) or intrauterine viral infection (Cheeran et al., 
2009).  
 
However, the LHFPL5 mutation is likely to account for the deafness phenotype in 
this family, and family members would be expected to benefit from this finding, 
through genetic counselling and carrier screening of additional family members 
and/or potential marriage partners. Affected children within the family can now be 
identified earlier and appropriate intervention offered, such as cochlear implants, 
to help with the child’s speech and language development. 
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3.3.3 Family-3 with ANKRD2 and PDZD8 mutations 
The three affected individuals in Family-3 presented with cognitive deficit, autistic 
features, scoliosis, myopia and some dysmorphic features. Homozygosity 
mapping and WES analysis indentified two novel homozygous variants; a 
missense mutation in ANKRD2 and a nonsense mutation in PDZD8, which co-
segregated with the described phenotypes in an autosomal recessive mode of 
inheritance. Both variants are located within the biggest identified homozygous 
region (28.3 Mb) on chromosome 10 and they could individually or together be 
the cause of intellectual disability. 
 
ANKRD2 is a member of the muscle ankyrin repeat protein (MARP) family and is 
involved in various pathways including muscle stress response, myogenic 
differentiation and apoptosis (Bean C. et al., 2008; Jasnic-Savovic et al., 2015). 
Studies have shown that ANKRD2 plays an anti-inflammatory role through a 
direct interaction with p50 subunit in NF-kB-mediated response (Bean C et al., 
2014). Tsukamato et al. (Tsukamoto et al., 2002) described the expression of 
mouse ANKRD2 in cerebrum and cerebellum. PDZD8, on the other hand, is a 
cellular cytoskeletal regulator with a poorly understood function. It is known to be 
a moesin-interacting protein involved in microtubule cross-linking (Henning 
Matthew S et al., 2011). PDZD8 has also been shown to support human retrovirus 
infection (HIV-1) via its Gag region which facilitates the interaction with the virus 
(Henning Matthew S. et al., 2010). Based on this role, PDZD8 has been studied 
as a potential target for intervention in retrovirus infection, but it was recently 
shown to be not always required for the infection (Zhang Shijian and Sodroski, 
2015). PDZD8 protein was selected as one of the best five candidates (Figure 
3.49) for specific interaction with IL13Rα2, a receptor that is overexpressed in 
various human tumours and associated with poor prognosis (Bartolomé et al., 
2015). PDZD8 was identified as one of the strongest candidates, along with 
NRAP and HSPA12A, for a forelimb muscular anomaly in Japanese black cattle 
(Masoudi et al., 2008) but it was then brought to our knowledge, based on a follow 
up contact with the author of this paper, that PDZD8 was ruled out. Recently, 
significantly reduced PDZD8 expression in the amygdala has been associated 
with posttraumatic stress disorder in humans (Bharadwaj et al., 2016). 
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Figure 3.49. PDZD8 in the interaction network for IL13Rα2. Bartolome and 
colleagues carried out a proteomic approach using colon cancer cells in order to identify 
the protein partners of IL13Rα2. After precipitating IL13Rα2 from KM12SM cell lysate 
and fractioning the pulled-down proteins by SDS-PAGE, mass spectrometry was carried 
out. The analysis was followed by a filtering process at which all the proteins which have 
no means of contact with the membrane IL13Rα2 (like mitochondrial proteins) or have 
no relevant protein-protein interactions (like chaperons) were excluded. The final 
identified IL13Rα2 partners were FAM120A, EPHB4, CMTM6, PDZD8 and  ACTB 
proteins, which are highlighted in this representation. The colour scale indicates the 
known biological function for each of  these proteins. (Adapted from  Bartolomé et al. 
(2015), with a permission from the American Association for Cancer Research and 
Copyright Clearance Center, License number 4127721023107).    
 
Additional screening of ANKRD2 and PDZD8 in 100 chromosomes from healthy 
individuals of matching ethnicity revealed no homozygous or heterozygous 
mutations. Both mutations were also absent from 60,706 subjects in the ExAC 
database, indicating their extreme scarcity. Examination of the data available on 
ExAC also suggested that, of the two genes, PDZD8 has by far the most 
interesting constraint metrics (Table 3.12). This suggests that PDZD8 is much 
more constrained (especially for loss-of-function alleles like the one described 
here) than ANKRD2. This does not exclude ANKRD2 but it gives support to the 
loss-of-function mutation in PDZD8 as the possible cause of the ID in Family-3. 
 
Hoischen et al. (2014) mentioned that consideration of suggested candidate 
genes needs to be investigated for various factors including the location of the 
mutation, its load in healthy controls, pathogenicity predictions and whether the 
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gene is a known component in one of the networks that are associated with the 
disease in question. Conservation measures give an indication of the importance 
and stability of the affected amino acid in different species. A highly conserved 
position suggests that a mutation could have functional consequences (David 
and Sternberg, 2015). The location of R295W in ANKRD2 is evolutionarily 
conserved but the corresponding position in the soft-shelled turtle is occupied by 
a tryptophan (W), the same residue introduced by the mutation in Family-3 
(Figure 3.20). This raises a question as to its significance. This finding suggests 
that the R295W mutation may not have adverse functional effects since ANKRD2 
apparently functions normally in soft-shelled turtles. It is not easy to defend this 
assumption as, unfortunately, turtle intelligence is not a subject that has been 
much studied, which could be probably true for most reptiles. 
 
In fact, there are few studies but most of them are in the form of controlling the 
movements of the animal utilising various cues. For example, in an experiment 
by Lee and colleagues (Lee Serin et al., 2013), turtles were successful at 
following a visual stimulus and performing a specific non-linear movement 
trajectory. Furthermore, red-footed tortoise was also capable of learning and 
mastering an eight-arm radial maze, at which they  needed to remember various 
different cues (Mueller-Paul et al., 2012). On the other hand, there are also some 
findings that might suggest turtles are not good at facing navigation challenges. 
For instance, painted turtles were not able return to their pond when they kept a 
mile away but they did very well  in reaching their pond quickly when they were 
released 100 meters from home (Emlen, 1969). 
 
It is true that sequence conservation measures have played a significant role in 
assessing and ranking candidate protein coding and non-coding variants 
(Adzhubei et al., 2010). However the value of such analyses are impacted by the 
power of the sequence alignments used to determine conservation. Therefore, it 
is generally considered best not to depend solely on conservation measures for 
evidence about the pathogenicity of a particular variant (Macarthur et al., 2014).     
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It was a shame not to be able to track the segregation of the homozygous 
ANKRD2 mutation (NM_001129981:exon1:c.C272T) that was found in one of 
these Belgian cases (Figure 3.12). The analysis of the ANKRD2 and PDZD8 
mutation load, based on UK10K cohorts, has not shown a conclusive result, 
although it could be argued to have favoured the candidacy of ANKRD2 
somewhat (Table 3.11). Furthermore, the strong staining of ANKRD2 in the 
substantia innominata suggests an important role for this protein in this brain 
region. The substantia innominata (also known as the nucleus of Meynert) is part 
of the basal forebrain and is located below the anterior part of the thalamus and 
contains telencephalic structures (Haines and Ard, 2013). The substantia 
innominata is believed to have a major role in the neural processing of signals 
(Noback et al., 2005; Zhu Qiong-Bin et al., 2016). This could be due to the fact 
that the substantia innominata is enriched in the cholinergic neurons which form 
extensive connections to the entire neocortex (Zhang Jin-Ping et al., 2006). 
Moreover, the substantia innominata is also connected to control centres such as 
the amygdala, hippocampus and hypothalamus, which provide significant 
network interactions important for electrical activation, recognition of reality, 
navigation and perception analysis (Kissin, 2012). It has been shown that 
individuals with Alzheimer’s disease (AD) have major cell loss and degradation 
in the substantia innominata (Zarow et al., 2003). Significant associations have 
also been reported in AD patients between volumetric loss of the grey matter in 
substantia innominate and the levels of cognitive impairment (Colloby et al., 
2016). 
 
The localization of PDZD8 in the choroid plexus could indicate that PDZD8 has 
some role in this part of blood-brain barrier. The structure of choroid plexus acts 
as functional hurdle between the cerebrospinal fluid (CSF) and blood. It is also 
considered as an access window for immune cells entry into the CNS (Lun et al., 
2015). The epithelial cells in the choroid plexus are responsible for certain 
processes that are crucial for normal embryo development, particularly the ones 
related to production of CSF, ensuring brain fluid homeostasis (Saunders et al., 
2008). Therefore, even a minor disruption to this brain barrier could contribute to 
development of  neurological conditions (Liddelow, 2015). 
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Drosophila  is a simple animal model that has been used in genetic research for 
more than a century (Morgan, 1910). There are various features of Drosophila  
that make it a good option to be used for experimental studies and these features 
include the short lifespan (~120 days), the low number of chromosomes (only 4) 
and sharing some cognition/behaviour aspects with mammals (Prüßing et al., 
2013). Moreover, Drosophila was one the of the first creatures to have its  full 
genome sequenced and available for research (Adams et al., 2000). Drosophila 
was used in this thesis to study the effect of knocking down CG10362, which is 
the PDZD8 orthologue in Drosophila, on behaviour. Drosophila has a wide range 
of behaviour that could be studied, like learning, memory and decision making 
(Bellen et al., 2010; Guo et al., 2010).   
 
Three behaviour assays were done for the CG10362 knocked-down Drosophila 
in order to measure their olfactory learning, negative geotaxis and courtship 
suppression. Surprisingly, the wild type flies used in this experiment (W118) 
appeared to show reduced learning ability (p = 0.159) to choose the odour that 
was not paired with the mechanical shock (olfactory learning assay, Section 
2.18.6), though this reduction was not statistically significant. Similarly, courtship 
activity was not suppressed after one hour of courting females in CG10362 
knocked-down flies (courtship supression assay, Section 2.18.5). However, the 
wild type flies used in this experiment (W118)  were not the most appropriate 
reference, as the white-eyed background on which the knock down flies were 
bred are not technically wild-type flies. The colour of Drosophila eyes is brick-red 
which is determined by two key pigments, the brown ‘ommochromes’ and red 
‘drosopterins’ (Kim et al., 2006). Drosophila with no eye pigmentation are referred 
as “white-eyed” which is caused by a mutated white (W) gene (Mackenzie et al., 
1999) that encodes the  transmembrane ABC transporter (Ewart and Howells, 
1998). Therefore, the obtained findings may in fact be the result of presence of 
the white locus (W) mutation, which has been found to have an impact on various 
aspects of courting behaviour (Krstic et al., 2013). On the other hand, white locus 
(W) caused no impact on the rapid iterative negative geotaxis (RING) assay 
(Section 2.18.4). The significantly lower geotaxis index (p=0.002) in the produced 
male progeny, compared to wild-type males, is indicative of a loss of locomotor 
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behaviour and could point to CG10362 being important in controlling physical 
movement. It is worth mentioning here that the experiment has since been 
repeated by others with correct controls, and an impact on negative geotaxis and 
long term memory has been confirmed.  
 
In comparison with invertebrate models such as flies and worms, mice are a 
better model to study human diseases, especially when studying complex 
biological systems like immune, cardiovascular and nervous systems. Mice are 
mammals and have anatomical, physiological and genetic similarities with 
humans  (Rosenthal and Brown, 2007). Moreover, various features, like cheap 
cost and ease of maintenance, make them the most widely used animal model in 
research (Eisen, 2005; Justice and Dhillon, 2016). After getting the results from 
the Drosophila experiments, an inquiry was made to the Wellcome Trust Sanger 
Institute (WTSI) on whether they had a Pdzd8 knock out (KO) mouse that we 
could use for behaviour testing. It was found that Pdzd8tm1b(EUCOMM)Wtsi line was 
available. Phenotyping of the Pdzd8tm1b(EUCOMM)Wtsi line in the WTSI pipeline 
(White et al., 2013) indicated that both males and females have reduced body 
weight, body length and body mass (A. Galli, personal communication). This is 
biological evidence that KO of PDZD8 does indeed have phenotypic effects in 
mammals. An arrangement has, therefore, been made to import some of these 
mice to Leeds in order to do some learning and memory tests (Kirshenbaum et 
al., 2015). If homozygosity for the PDZD8 truncation mutation really is responsible 
for the intellectual disability in Family-3, Pdzd8tm1b(EUCOMM)Wtsi mice would be 
expected to show cognitive deficits. 
 
Based on the genetic analysis of the Omani Family-3, as well the different 
experimental analyses, mutations in both ANKRD2 and PDZD8 remain plausible 
underlying causes of the ID phenotype in the family. ANKRD2 is a known 
myogenic factor, and may therefore account for the join laxity described in the 
affected members of the family. In addition, its contribution to the neurological 
pathology cannot be excluded. In fact, the ANKRD2 homozygous mutation found 
in the Belgian ID case, the substantia innominata localisation, as well as the 
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enrichment of ANKRD2 variants in the UK10K ID cohort are all supportive of a 
role of the ANKRD2 mutation in this phenotype. Importantly, Tsukamoto  and 
colleagues have already pointed out that ANKRD2 could have an operative role 
in brain according to their findings on expression of mArpp, a murine gene 
identical to  the human ANKRD2, in neurons of the cerebellum and cerebrum 
(Tsukamoto et al., 2002).  
 
On the other hand, the gene encoding the cytoskeleton regulator PDZD8 showed 
significant constraint metrics from ExAC, is expressed in the brain, the mutation 
found is more likely to affect protein function given sequence conservation and 
the nature of the mutation observed, and the PDZD8 knock-down Drosophila had 
significantly reduced geotaxis. Thus while it is not possible to discount the 
possibility that mutations in both genes are causing the condition in Family-3, 
PDZD8 seems the stronger candidate for causing the ID phenotype. This is the 
first time that either ANKRD2 or PDZD8 have been linked to intellectual disability; 
it would be interesting to see whether other supportive evidence arises in the 
future. 
 
3.3.4 Families-4, 5 and 6 with unidentified causes 
There are several reasons why genetic testing is a good option for differential 
diagnosis in certain families. Important factors include having more than one 
individual within the family affected with the same diagnosis and the presence of 
particular developmental delay with congenital abnormalities (Trattler et al., 
2012). The correct diagnosis of disease conditions is valuable and would aid in 
finding the casual variant (Rabbani et al., 2014). However, correct identification 
of the causative gene requires good physical examination, detailed medical 
family history and clinical laboratory findings. It might not be always possible to 
make a confident diagnosis for particular cases, especially with subtle 
phenotypes which might not have been previously associated with the disease of 
interest (Ropers H, 2006). 
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Technological advances in DNA sequencing have significantly helped in 
identifying the causes of various genetic diseases in humans. In intellectual 
disability, the positive impact of high-throughput sequencing can be seen in the 
growing number of the newly discovered ID genes and publications; ID papers 
have increased from <20 in 2006 to around 190 in 2015 (Chiurazzi and Pirozzi, 
2016). Despite these successes, there is still a large proportion of about 50% of 
ID cases that have unidentified causes (Alexander-Bloch et al., 2016). 
 
Families-4, 5 and 6 have all been generally diagnosed with ID but each of them 
has a different number of affected individuals with different manifestations. 
Cognitive impairment is not a direct diagnosis, especially with the presence of 
certain comorbidities which make a correct diagnosis more challenging (Kaufman 
et al., 2010). The families were all subjected to homozygosity mapping and whole 
exome sequencing. Testing of all the filtered homozygous and compound 
heterozygous variants did not reveal any candidate that could be considered as 
the underlying cause. ExomeDepth also did not reveal any underlying CNVs in 
these families. 
 
One potential reason for the inability to find the underlying variants in these three 
families is the possibility that some of the family members were not diagnosed 
correctly. It is known that incorrect attribution of disease status among family 
members can misguide researchers, resulting in failure to identify the underlying 
causative factors (Duncan et al., 2014). This could occur when a family member 
who is actually unaffected, but within a borderline status showing features of very 
mild ID, is erroneously classified as affected. A causative mutation could then be 
excluded because it is not carried by that particular individual, even if it shows 
complete co-segregation with ID the rest of the family. 
 
Incorrect attribution of disease status could also involve the opposite scenario 
whereby an affected individual is classified as unaffected, which could negatively 
affect the ability to find the causative variants. For example, this could occur in 
cases of reduced or incomplete penetrance, when an affected person fails to 
express most features of the disease in question (Cooper David N. et al., 2013). 
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In fact, various studies have shown that ID could be caused by disease risk 
variants that display incomplete penetrance (Ehret et al., 2015; Kuechler et al., 
2015; Ropers H and Wienker, 2015; Vorstman and Ophoff, 2013); finding this 
type of variant is a challenge and would require larger data sets for statistical 
significance (Wang Jian and Shen, 2014). 
 
Another possible reason for the failure to identify causative variants in these 
families is that they may not be detected by the technologies utilised. If the 
mutations are present in the middle of an intron, or in a promoter or enhancer, it 
is not possible for exome sequencing to detect them, as this test focuses on 
exons (Warr et al., 2015). Such mutations would require whole genome 
sequencing in order to identify them (Belkadi et al., 2015) because they are not 
conventionally captured by whole exome sequencing (Warr et al., 2015). 
 
During the recent few years, somatic mutations have been found to play a 
pathogenicity role in human diseases other than cancer (Frank, 2014; Kennedy 
et al., 2012). Somatic mutations, that arise in the germ cell lineage during the 
early eight to fourteen divisions after fertilization, may not be detected using 
offspring blood or  saliva (Acuna-Hidalgo et al., 2016). These genetic variations 
are not originally present neither in the parent’s germs (ovum or sperm) nor in the 
fertilized egg but they take place later. So, a somatic mutation that occurs, for 
example, to a neuronal cell during the time of prenatal brain development could 
lead to mosaicism since not all divided cells will have this mutation (Biesecker 
and Spinner, 2013). The ultimate result about whether this somatic mutation 
would alter the function of the associated gene causing a human disease is based 
on the number of the affected cells as mutation can still remain restricted to small 
number of cells which are not phenotypically significant (Acuna-Hidalgo et al., 
2016). Assessment of somatic mutation causing neurodevelopmental disorders 
would always require highly sensitive technologies (Poduri et al., 2013). A study 
based on high-coverage whole-genome sequencing (WGS) and single-cell 
sequencing (SCS) from the cerebral cortex of three normal individuals found 
thousands of somatic single nucleotide variations, that tends to occur during 
transcription process rather than due to errors in DNA replication (Lodato et al., 
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2015). This high enrichment of somatic mutations and their predominance in the 
brain has pointed out that they could be at the source of developing psychiatric 
disorders (Insel, 2014; Poduri et al., 2013).
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Chapter 4: Genetic and functional studies to 
assess the implication of Mendelian alleles in 
causing Schizophrenia in consanguineous UK 
families 
4.1 Introduction  
Psychiatric disorders are among the top causes of disability in all countries, 
regardless of their living standard. More disability cases are caused by 
depression than by HIV infection or dietary problems (Lopez and Murray, 1996). 
As a result, psychiatric disorders have been increasingly the focus of new medical 
approaches and research throughout the world. In the UK, there has been a 
radical change in approach to these conditions, with mental health services 
shifting from an asylum-based care towards care in a community setting (Herring 
et al., 2006). 
 
Psychotic disorders include a wide range of conditions, but the most common are 
schizophrenia (SZ) and bipolar disorder (BPD), both with a largely unknown aetio-
pathogenesis. Patients with a psychotic condition frequently meet criteria of more 
than one particular disorder, as many of the associated signs and symptoms 
overlap between disorder categories (Paris, 2007). Schizophrenia patients 
normally have positive as well as negative symptoms. Positive symptoms include 
delusions, hallucinations and paranoid thoughts, whereas negative symptoms 
include lack of interest, inability to enjoy fun activities and social withdrawal (Patel 
et al., 2014). Accumulating evidence suggests a shared genetic architecture 
among psychotic disorders (Doherty and Owen, 2014); and some of the 
implicated overlapping genes have already been mentioned in Chapter 1 (Section 
1.4). 
 
The influence of consanguinity, when a marriage occurs between two individuals 
belonging to a recent common ancestor, on human diseases has been well-
documented (Bittles and Black, 2010; Hamamy, 2012; Modell and Darr, 2002; 
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Mokhtari and Bagga, 2003; Shawky et al., 2013) and also highlighted in Chapter 
1 (Section  1.1). The Pakistani population of West Yorkshire, comprises 189,000 
individuals, the vast majority of whom derive from Mirpur in Azad Kashmir, 
Pakistan (Shaw, 2014). Marriage is normally within the community and 
approximately 70% of marriages are between relatives (Darr and Modell, 1988). 
As a result, this community is both endogamous and consanguineous, leading to 
enrichment for homozygosity of recessive alleles, high background autozygosity 
(Woods et al., 2006) and recessive disease. SZ and other psychoses are 
common in this population, with a higher prevalence of mental disorders than the 
general population (Mcgrath et al., 2004).  
 
One hypothesis proposed for this increase is the change of culture associated 
with immigration (Bhugra, 2004; Bhugra and Becker, 2005; Hollander et al., 2016; 
Shekunov, 2016), as discussed in Section 1.3.3 of Chapter 1. Based on the 2001 
Census, Pakistanis (747,000) comprised the second biggest group, after Indians 
(over one million), of immigrants living in the UK (Charsley, 2013; Schierup et al., 
2006). We hypothesise that a proportion of the higher prevalence of mental 
disorders is caused by recessive alleles of major effect predisposing to psychosis 
in the Pakistani population of West Yorkshire. The existence of Mendelian SZ 
alleles has been discussed in Section 1.3.5 of Chapter 1. 
 
This chapter describes research in two families in which a psychotic disorder 
appears to be segregating in a Mendelian fashion. Both families were collected 
along with others in 2012 for a project entitled “Genetic investigation of 
schizophrenia in the Pakistani population of West Yorkshire”. Both had been the 
subject of prior research by others, which the author sought to extend as part of 
this project. The first family (Family-7) has a putative mutation in WHRN that 
appears to co-segregate with psychosis. In previous work detailed in Section 
1.2.1, others had carried out both genetic and functional assessment of that 
variant, revealing that it weakens binding between whirlin (encoded by WHRN) 
and the ubiquitin-ligase UBR4. The second family (Family-8) is consanguineous 
and has multiple cases of schizophrenia, a pattern of inheritance highly 
suggestive of a recessively inherited Mendelian allele. Homozygosity mapping 
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suggests that one or more genes in a locus on chromosome 13q31 is a plausible 
underlying cause of the increased incidence of schizophrenia observed in this 
family. Previous work on Family-8 is detailed in Section 1.3.1. 
 
4.2 Family-7: the possible involvement of a WHRN 
variant in psychotic disorder 
4.2.1 Work done previously 
The initial genetic work was undertaken by Dr Jose Ivorra Martinez (Formerly of 
Leeds University but now moved back to his country Spain), who showed that the 
two brothers affected with psychosis (IV.7 & IV.8) in Family-7 (Figure 4.1) were 
homozygous for a mutation in WHRN. The clinical information and the work 
performed before this doctoral research was initiated are explained below. In-
silico modelling was carried out by Dr Jonathan Mullins of Swansea University, 
while protein-protein interaction studies were carried out by Dr Erwin van Wijk, 
Radboud University, Nijmegen. 
 
4.2.1.1 Family collection and diagnosis 
Family-7 is a consanguineous family derived from a first cousin marriage (Figure 
4.1). The family lives in Bradford but originates from Mirpur in Pakistan-
administered Kashmir. All the members were initially assessed by Dr Qadeer 
Nazar at Lynfield Mount Hospital, Bradford and the affected individuals were 
diagnosed based on the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-4). The diagnosis was confirmed by Dr Alastair G Cardno of the Academic 
Unit of Psychiatry and Behavioural Sciences, University of Leeds.
 203 
 
 
Figure 4.1. Pedigree of Family-7. A consanguineous marriage between first-cousins in the third generation (III.2 and III.3) resulted in eight 
children. There are six unaffected sisters in this family (IV.1-IV.6) and two sons affected with psychosis: one with schizophrenia (IV.7) and the 
other one with schizoaffective disorder (IV.8). The mode of inheritance in this family is suggestive of X-linked inheritance, given that only males 
are affected and all females are unaffected. However, this does not exclude autosomal recessive inheritance. 
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4.2.1.2 WHRN as a causative gene 
To originally identify putative causative mutations in the family, Dr Jose Ivorra 
Martinez used homozygosity mapping combined with whole-exome sequencing. 
Microarray analysis of individuals IV.7 and IV.8 was performed using an 
Affymetrix Genome-Wide SNP 6.0 Array, and the results were analysed for 
identity-by-descent (IBD). Two shared homozygous regions were found on 
chromosomes 5 and 9 (Figure 4.2). 
 
 
Figure 4.2. Shared homozygous regions in Family-7. An ideogram where the outer 
circle contains template segments of the 22 autosomal chromosomes. The middle circle 
is the SNP data from subject IV.7 and the inner circle is SNP data from subject IV.8. The 
light blue areas are the homozygous regions within each of the individuals and the dark 
blue regions on chromosomes 5 and 9 are the homozygous regions shared between 
both affected individuals. The region in chromosome 13 is small, less than 1mb.  
 
Whole-exome sequencing was carried out in one of the affected individuals (IV.8) 
using an Illumina HiSeq 2500 platform according to the standard Agilent 
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SureSelect Library Preparation protocol. Data were filtered to select only 
homozygous splicing, missense, nonsense or frameshift variants with a minimum 
depth coverage of 20, less than 1% frequency in the 1000 Genomes or 6500 
Exomes projects, and predicted to be pathogenic according SIFT and Polyphen2 
scores. After checking the segregation of the candidate changes in the parents 
and six unaffected siblings under autosomal recessive or X-linked models, only 
the WHRN variant appeared to co-segregate with psychosis in the family. The 
unaffected parents were heterozygous, the affected sons were homozygous, and 
the unaffected daughters were a mixture of heterozygous and wild-type. This 
mutation, in exon 6 of  NM_015404 WHRN (cDNA, c.C1348T), is a substitution 
of an arginine by a cysteine (p.R450C). PhyloP score (Pollard et al., 2010)  
indicated  that the arginine at position 450 is conserved (0.999), which suggests 
that a change at this position could have functional consequences (David and 
Sternberg, 2015) 
 
WHRN is a gene with 12 exons located on chromosome 9q32, and encodes a 
protein, whirlin, the structure of which is shown in Figure 4.3. Like other PDZ 
domain containing proteins, whirlin is involved in protein-protein interactions 
(Green et al., 2013). Whirlin has two main isoforms: short (NM_001083885) and 
long (NM_015404; NM_001173425) and their protein measures 49kDa and 
97kDa, respectively. The main difference between them is that the first 5 exons 
are missing in the short isoform, so that it has only one PDZ domain (PDZ3) and 
a proline-rich domain (Aller et al., 2010). Both short and long isoforms of whirlin 
are expressed in brain, retina and cochlea of fetal and adult tissues (Van Wijk E. 
et al., 2006b). 
 
 
 
Figure 4.3. Structure of long and short forms of Whirlin. Whirlin is composed of three 
PDZ domains (yellow) and a proline-rich region (blue/green). The short form of 49 kDa 
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has alternative transcriptional start sites (asterisks). The exons are indicated by 
alternately shaded boxes scaled according to their lengths. Full-length whirlin is 110 kDa. 
(Adapted from Green et al. (2013), no permission required). 
 
Homozygous mutations that cause premature termination of the protein near the 
N-terminus of whirlin have been found to cause the deaf-blindness condition, type 
2D Usher syndrome (Ebermann et al., 2006). On the other hand, truncating 
mutations near the C-terminus have been reported to cause autosomal recessive 
deafness (Mustapha et al., 2002). As far as we know, no mutation has, so far, 
been identified in the middle domain of whirlin, where R450 is located. None of 
the patients in Family-7 have any obvious problems with hearing, vision or 
vestibular function.  
 
GWAS studies have already suggested that WHRN is a candidate for 
involvement in bipolar disorder (Baum et al., 2008; Sklar et al., 2008). The gene 
was also independently replicated in a Finnish bipolar disorder cohort (Ollila et 
al., 2009). In addition, the chromosome region where WHRN is located (9q31-32) 
has been identified as a linked region for bipolar disorder (Detera-Wadleigh 
Sevilla D. et al., 1997; Liu J. et al., 2003; Venken et al., 2005) and schizophrenia 
(Freedman et al., 2001; Kaufmann et al., 1998) in family studies. Therefore, 
evidence is already available to support the hypothesis that variants in WHRN 
increase the risk of developing psychotic disorders. 
 
4.2.1.3 Screening for the R450C mutation 
In light of this preliminary evidence suggesting that the WHRN R450C variant 
might be a Mendelian allele predisposing to schizophrenia, it was then screened 
for in DNA from 28 Pakistani and 58 Caucasian local schizophrenia patients but 
no further variants were identified. Further scanning of online sources also 
excluded this variant from 1,442 schizophrenia/psychosis cases available via the 
UK10K resource. A number of control cohorts containing a total of 10,047 healthy 
individuals were scanned (Table 4.1) and an unaffected Afro-American individual 
from the NHLBI GO Exome Sequencing Project was found to be a WHRN R450C 
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heterozygote. These findings, detailed in Table 4.1, suggest the scarcity of the 
R450C mutation. 
 
 
Used cohort Type of 
sample 
Number of 
samples 
Ethnicity 
Leeds/Bradford 
(DNA) 
Patients 80 Caucasian/British 
Pakistanis 
UK10K (Online) Patients 1442 Caucasian 
UK10K (Online) Controls 2453 Caucasian 
NHLBI GO ESP 
(Online) 
Controls 6502 
American-
European 
1000 Genomes 
Project (Online) 
Controls 1092 
Various origins 
 
Table 4.1. Samples screened for the WHRN R450C variant. A total of 1,522 patients 
with various psychoses were checked for the R450C variant. The control samples used 
were available via online sources from different databases, and the total number of 
screened samples was 10,047. 
 
In order to investigate the middle region of whirlin and to check its relation to 
schizophrenia risk, an association study was done with rs4978584 (c.G1318A; 
p.A440T), a common missense polymorphism located only 10 amino acid 
residues away from R450 (Figure 4.4). Genotyping of rs4978584 in the patient 
and control cohorts revealed that it is in Hardy-Weinberg equilibrium, and is 
significantly associated with schizophrenia (p = 0.017) under both additive (odds 
ratio for minor allele: 1.22; p = 0.017) and codominant models (p=0.027). 
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Figure 4.4. Association of rs4978584 in schizophrenia. The association was done 
using cases and controls from UK10K database. The reference genotype (C/C) is more 
in the controls whereas both heterozygous (C/T) and homozygous (T/T) are more in 
cases with significant association.  
 
4.2.1.4 Structural modelling of the R450C whirlin variant 
Given the apparent linkage of the R450C whirlin variant with psychotic disorder 
in Family-7, the association of rs4978584 with psychosis in the cohorts in Table 
4.1, and the published evidence of a link between WHRN variants and bipolar 
disorder (Baum et al., 2008; Ollila et al., 2009; Sklar et al., 2008; Venken et al., 
2005), in-silico analysis was used to predict the effect of R450C mutation on 
whirlin protein structure to assess its likely pathogenicity. This analysis was 
carried out by Dr Jonathan Mullins of Swansea University, who used the program, 
I-Tasser (Roy et al., 2010) to model the R450C variant (Figure 4.5). 
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Figure 4.5. Structural modelling of the R450C variant in whirlin. Left: wild type (WT) whirlin protein showing an approximately equal 
distribution of positively and negatively charged residues around the R450 residue, all in highly accessible positions. Right: whirlin with the R450C 
mutation, which results in severe disruption of the organisation of adjacent residues and withdrawal from their highly accessible peripheral 
location. (This image was produced by Dr Jonathan Mullins and is used with his permission). 
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When the wild type and R450C models of whirlin were compared, the regions 
surrounding the R450 position were found to undergo substantial conformational 
rearrangement in the R450C variant, particularly with regard to reorganisation of 
positively charged outward facing regions that may form interaction surfaces for 
other proteins to bind with whirlin. In contrast, other parts of the protein remain 
largely unchanged. The apparent withdrawal of loops from their highly accessible 
peripheral locations suggests that interactions between this region of whirlin and 
other proteins are likely to be greatly impaired. 
 
4.2.1.5 Whirlin interaction with UBR4 is disrupted by the R450C mutation 
After the structural modelling suggested that the R450C mutation disrupt the 
binding ability of whirlin, members of the Leeds Psychosis Group contacted a 
research team in Nijmegen who had published on whirlin protein structure and 
function. Dr Erwin van Wijk of Radboud University, Nijmegen informed the Leeds 
group that a yeast two-hybrid assay (Coates and Hall, 2003) had identified UBR4 
as interacting with the middle portion of whirlin containing the R450 residue. The 
Netherlands group investigated this protein-protein interaction assay using 
constructs containing the middle domain (MD) of both wild-type and R450C 
mutant whirlin, screened against a human brain cDNA library. An interaction of 
wild-type whirlin with UBR4 was identified, and found to be weakened by the 
R450C mutation. 
 
4.2.2 Follow-up work 
A number of lines of evidence, both genetic and protein modelling, suggested the 
involvement of WHRN variants in psychoses, and more specifically that the 
R450C mutation is likely to have an impact on whirlin function. The author 
therefore carried out further experiments, as detailed below, to investigate this 
link. 
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4.2.2.1 Screening more schizophrenia patients for the WHRN R450C variant 
To increase the sample size for R450C screening and to look for other possible 
mutations, Sanger sequencing of the key exon 6 of WHRN was undertaken 
(Section 2.9 in Chapter 2) on a further 200 Caucasian schizophrenia patients 
ascertained and sampled in Glasgow. R450C was not found in these patients. 
Because Family-7 is of Pakistani ethnicity, it was also important to check the 
frequency of the R450C variant in the unaffected Pakistani population. Therefore, 
154 unaffected Pakistani controls collected in the Leeds/Bradford area were also 
sequenced. All the tested healthy controls showed normal sequences, and the 
R450C mutation was not found in any of these samples either. Results are shown 
in Table 4.2. 
 
 
Used cohort Type of 
sample 
Number of 
samples 
Ethnicity 
Glasgow (DNA) Patients  200 Caucasian 
Leeds/Bradford 
(DNA) 
Controls  154 Asian 
 
 
Table 4.2. Screening of extra patient and control samples for WHRN R450C. 200 
Caucasian schizophrenia patients ascertained in Glasgow and 154 normal Pakistani 
control samples collected from the Leeds/Bradford area were screened for variants in 
exon 6 of WHRN, including the R450C variant. No variants were found in any of the 
tested samples. 
 
 
4.2.2.2 WHRN expression in human tissues 
In order to determine which tissues express WHRN, reverse transcriptase PCR 
was carried out as described in Sections 2.3-2.5 on cDNA prepared from samples 
of 20 different human tissues. The results showed that WHRN is expressed in a 
large number of tissues, and is particularly highly expressed in fetal and adult 
brain (Figure 4.6). 
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Figure 4.6. Expression of WHRN in human tissues. WHRN expression was assessed 
in a Human Total RNA Master Panel II (Clontech Laboratories, Inc) containing cDNA 
from 20 different human tissues. The amplification products were size fractionated on a 
1.5% ultra-pure agarose gel (Fisher Scientific, UK), stained with ethidium bromide and 
visualized with a ChemiDoc™ MP System (Bio-Rad) over ultra-violet (UV) light (wave 
length 320 nm). The image was focused through Image Lab™ software (Bio-Rad). This 
analysis revealed that WHRN is expressed in all tissues but at widely varying levels, with 
particularly clear expression in fetal and adult brain. 
 
4.2.2.3 Site directed mutagenesis 
For the purpose of carrying out further functional analyses of the in vitro effect of 
the R450C mutation on subcellular localisation and protein interactions of whirlin, 
a WHRN construct was obtained as a gift from Dr Erwin van Wijk. This construct 
contains wild-type human WHRN transcript 3 (UC004bja.4) that has been cloned 
by Gateway destination cloning (Katzen, 2007) into an ampicillin-resistant 
pDEST-733 mammalian expression vector (Invitrogen) (Van Wijk Erwin et al., 
2006a). The map of the pDEST-733 is shown in Figure 4.7. A monomer Red 
Fluorescent Protein (mRFP) tag (Campbell et al., 2002) was already fused 
upstream of the attB1 recombination site of the vector. 
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Figure 4.7. Map of pDEST-733 vector. WHRN transcript 3 (2748 bp) was cloned into 
this vector. The full sequence of the construct, including the mRFP tag, is shown in 
Appendix 6. 
 
In order to compare the wild-type 450R and mutant 450C proteins, site directed 
mutagenesis (SDM) was carried out to generate the 450C clone. The 
mutagenesis experiment was specially designed to target base number 1348 in 
WHRN and change the wild-type “C” nucleotide into a “T” base. The method used 
is detailed in Figure 4.8, and two 450C clones were generated. 
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Figure 4.8. The major steps to introduce the 450C mutation into the WHRN gene 
construct. The use of mutagenic primers and pfuTurbo DNA polymerase results in the 
introduction of the change of interest into both stands of the newly-synthesised DNA 
plasmid. DpnI, which recognises GATC, will cleave the sequence only if the “A” is 
methylated. The in vitro-synthesised DNA plasmid (the new plasmid with the mutation) 
will not be methylated and remains intact, while the parental DNA plasmid originally 
prepared from a strain of E. coli is methylated and will be digested by DpnI. For the 
transformation, XL1-Blue supercompetent cells were used. Because of the increased 
membrane permeability, these cells facilitate the entry of the plasmid. (Adapted from 
(Smith, 2007) with permission from Nature Publishing Group, License Number: 
4078900153135). 
 
4.2.2.3.1 Confirming SDM by enzymatic digestion 
The clones (two wild-type with 450R and two mutants with 450C) were selected 
for growth on agar plates using ampicillin, as explained in Section 2.14. Plasmids 
were then extracted and standard PCR was carried out using a pair of primers (5 
μM) that flanked the targeted change in WHRN, as described in Section 2.14.5. 
To ensure that the site-directed mutagenesis was successful, WHRN cDNA 
clones were tested for the presence of a restriction fragment length polymorphism 
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(RFLP). The ScaI restriction enzyme cut the mutant 450C clone but not wild-type 
WHRN (Figure 4.9). 
 
 
Figure 4.9. ScaI digestion of R450C mutant WHRN. ‘L’ indicates is a 100-bp ladder. 
Lanes 1 and 2 are the mutated R450C WHRN and lanes 3 and 4 are wild-type (450R) 
WHRN. ScaI recognises the AGTACT sequence and cuts the mutated product, giving 
two bands of 238 bp and 157 bp (lanes 1 and 2). The wild-type was not digested, leaving 
the 395 bp band intact (lanes 3 and 4). 
 
4.2.2.3.2 Confirmation of SDM by Sanger sequencing 
Sanger sequencing was carried out as described in Section 2.9, not only to 
confirm that the SDM was successful but also to find out if there had been any 
other mutations introduced during the SDM process. It was confirmed that the 
required change had been inserted at the correct location (Figure 4.10) and that 
no other change was present. 
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Figure 4.10. Sequencing of the site of the targeted R450C mutation in WHRN. The 
upper sequence is the wild-type and the lower sequence is the mutated WHRN. The 
wild-type blue “C” base has been changed to red “T”, indicated by the arrows. Apart from 
the deliberately introduced change (R450C), the full insert was found to match the normal 
wild-type sequence. 
 
4.2.2.4 Whirlin over-expression and its effect on UBR4 
Transfection studies were undertaken to see whether the presence of the 450C 
mutation in whirlin affected the cellular localisation of the tagged protein when it 
was overexpressed in a human neuroblastoma cell line (SH-SY5Y), as described 
in Section 2.14.3. This experiment also tested whether the localisation of 
endogenous UBR4 was altered by overexpression of the mutant versus the wild-
type construct. Based on independent analyses by two different individuals, the 
transfection studies showed no localisation difference between the 450C mutant 
and wild-type whirlin. It was also found that strong co-localisation existed between 
whirlin and UBR4 (Figure 4.11). 
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Figure 4.11. Co-localisation of whirlin and UBR4. Thirty SH-SY5Y cells transfected with wild-type (WT) or mutant 450C whirlin were captured 
and independently analysed by two individuals. SH-SY5Y cells transfected with wild-type whirlin (upper panel) or R450C mutant whirlin (lower 
panel) construct with a red fluorescent tag are shown. The nuclei are stained blue with DAPI stain and endogenous UBR4 is stained in green. 
Both WT and mutant whirlin show consistent co-localisation with the green UBR4. 
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The hypothesis proposed as a result of the findings of the Nijmegen group were 
that the 450C mutation weakens but does not abolish binding between whirlin 
and UBR4. It might not be possible to detect a subtle difference in UBR4 co-
localisation by simple visual examination of cells transfected with wild-type or 
mutant whirlin. Therefore, the ratio of UBR4-whirlin co-localisation to non-co-
localisation in SH-SY5Y cells transfected with either the WT or 450C mutant 
whirlin constructs was assessed using Fiji ImageJ (Schindelin et al., 2012) 
software. This software allows the user to measure each pattern of cellular 
fluorescence separately and then calculate the extent to which two different 
signals overlap, in order to obtain a measure of the extent of co-localisation in the 
form of a Pearson R square value (Mukaka, 2012). The analysis revealed that 
whirlin and UBR4 co-localisation is strong in the perinuclear area but weaker at 
the membrane. Co-localisation values for UBR4 with wild type and 450C mutant 
whirlin are given in Table 4.3. The mean co-localisation values and significance 
value are shown in Figure 4.12. 
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Image No Pearson R square WT Pearson R square R450C 
1 0.78 0.49 
2 0.78 0.61 
3 0.56 0.52 
4 0.48 0.65 
5 0.83 0.46 
6 0.63 0.56 
7 0.59 0.55 
8 0.6 0.62 
9 0.8 0.63 
10 0.71 0.6 
11 0.62 0.46 
12 0.5 0.59 
13 0.53 0.6 
14 0.55 0.61 
15 0.54 0.58 
Mean  0.633333333 0.568666667 
STD 0.112999508 0.058636356 
t-test 0.067694391 
 
Table 4.3. Co-localisation of tagged whirlin and endogenous UBR4 in SH-SY5Y 
cells overexpressing WT or mutant 450C tagged whirlin. Thirty cells, half transfected 
with wild-type (WT) whirlin and the other half transfected with 450C mutant (R450C) 
whirlin, were assessed. Co-localisation with UBR4 was measured using the Pearson R 
square values in Fiji ImageJ software. The results suggest a difference, as shown in 
Figure 5.10. 
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Figure 4.12. Pearson’s correlation coefficient measurement of whirlin and UBR4 
co-localisation in whirlin construct-transfected SH-SY5Y cells. The extent of co-
localisation between endogenous UBR4 and overexpressed tagged wild-type (WT) or 
450C mutant (R450C) whirlin. The difference in co-localisation is not significant (P = 
0.067). 
 
4.2.2.5 Further testing to investigate that whirlin interacts with UBR4 
Yeast two-hybrid (Y2H) analyses carried out by colleagues in Nijmegen 
(described in Section 4.2.1.5) suggested that whirlin interacts with UBR4. 
Furthermore, comparison of co-localisation of WT and mutant 450C whirlin with 
endogenous UBR4 in SH-SY5Y cells suggested a trend of some reduction in 
UBR4 co-localisation with mutant 450C whirlin, though this difference did not 
reach statistical significance. It should be, however, mentioned that Y2H can 
sometimes give false positives that could result due to various reasons including 
nonspecific interactions, inefficient filtering criteria and considering the test 
outcome with out carrying out replicates under alternative conditions (Serebriiskii 
and Golemis, 2001). The overexpression of baits/preys in Y2H is potential for 
nonspecific interaction and should be considered. Excluding the proteins that 
normally show multiple interactions, such as chaperones, and carrying out 
replicates using different settings, such as using different reporters, are also 
crucial to minimise false positive results in Y2H (Koegl and Uetz, 2007). In order     
to provide further independent evidence of WHRN/UBR4 interaction, a mouse 
0
0.1
0.2
0.3
0.4
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0.8
P = 0.06 
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whirlin antibody was used to pull down whirlin from mouse brain lysate, then the 
resulting protein complex was tested to determine whether it contained Ubr4. 
 
4.2.2.5.1 Checking the whirlin antibody 
Protein extracts were prepared from brain hemispheres from three different wild-
type mice. These were subjected to western blotting to test the ability of the 
whirlin antibody to detect whirlin protein. Western blot analysis was carried out 
using whirlin antibody (1 in 200 dilution) and it showed the expected band size of 
97-kDa (Figure 4.13). 
 
 
Figure 4.13. Western blot of whirlin in mouse brain. A. Image taken from whirlin 
antibody datasheet (Santa Cruz, sc-49787) showing a marker as well as the expected 
97-kDa band of whirlin. B. Image of western blot of three samples showing the 
corresponding whirlin bands. A lower molecular weight band appears in each of the 
samples and is also present in the image from the whirlin antibody datasheet. This could 
indicate a shorter isoform of the protein. 
 
4.2.2.5.2 Peptide blocking check 
As a control for the specificity of the whirlin antibody (Santa Cruz, sc-49787), 
western blotting was carried out on two of the previously tested mouse brain 
hemispheres. The experiment was started by performing whirlin antibody 
blocking using the specific peptide against which it was raised, referred to as 
Santa Cruz, sc-49787P, as described in Section 2.16.3. Western blotting was 
then done on the two samples using blocked and unblocked whirlin antibody. The 
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absence of bands when the antibody was peptide-blocked and the appearance 
of bands with the normal unblocked antibody (Figure 4.14) indicated the good 
quality and specificity of the antibody used. 
 
Figure 4.14. Peptide blocking to confirm the specificity of the whirlin antibody. A. 
Western blot with size marker Hi-Mark pre-stained HMW protein standard (Invitrogen) in 
the first and last lanes, in between two samples of mouse brain extract (WT1 and WT2) 
were loaded and size fractionated. This was then probed with whirlin antibody after 
peptide blocking. B. An identically loaded western blot membrane probed with the normal 
unblocked whirlin antibody showing bands of the expected size for whirlin (~97-kDa). 
The failure of the peptide-blocked antibody to detect whirlin and its successful detection 
when the antibody was not blocked suggests that the antibody used has good specificity. 
 
4.2.2.5.3 Detection of β-Actin 
In order to exclude the possibility that the disappearance of bands on the 
membrane probed with peptide-blocked whirlin antibody was not due to a loading 
artefact or a difference in the samples or methods used to prepare the western 
blots, both membranes were stripped and stained for mouse β-Actin (Sigma, 
A5441) (Figure 4.15). A band of the expected size and of equal intensity was 
detected in both membranes. 
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Figure 4.15. Detection of β-Actin as a loading control. The same membranes shown 
in Figure 4.14 after stripping with antibody stripping solution (Section 2.16.6) and then 
staining for β-Actin (1:500, Sigma, A5441). Both membranes showed bands of the 
expected size for β-Actin (42-kDa). 
 
4.2.2.6 Co-immunoprecipitation to investigate Whrn and Ubr4 interaction 
Co-immunoprecipitation analysis was carried out in an attempt to further 
investigate Whrn/Ubr4 interaction in mouse brain lysates (Section 2.15.1). As a 
control, another antibody (Munc18) was also used in the same assay. Munc18 is 
a member of the Sec1/Munc18 protein family and is a neuron-specific protein of 
67-kDa that is abundant in the brain (Kalidas et al., 2000). It has been found that 
Munc18 interacts with syntaxin-1 and enhances its stability (Toonen et al., 2005). 
The antibody for Munc18 protein has been tested and verified previously by 
Dachtler et al. (2015). There were no expectations that this protein will interact 
with Ubr4 and it was therefore included as a control in this experiment. 
 
Whirlin antibody and Munc18 antibody (both 1:200 dilution) were attached 
separately to magnetic beads. During incubation with purified brain samples, 
each antibody was expected to bind specifically to its corresponding protein. 
Before eluting the materials from the beads, the complex of antibodies binding to 
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their proteins was washed to remove the unbound protein portion. This material 
was saved and called “unbound”. The proteins, which were bound to their 
antibodies, were then eluted from the beads as described in Section 2.16.3. The 
material eluted from the beads of whirlin antibody was called “whirlin bound” and 
the material eluted from the beads of Munc18 antibody was called “Munc18 
bound”. Beside the bound and unbound materials, the experiment also included 
the starting material of the samples, which was an untreated mouse brain lysate 
expected to have all the protein contents. The buffer (PBST), used in the washing 
steps, was also included in the test to give an indication if amount of the whirlin 
bound got lost during the washing steps. The elutes were then processed for 
western blot (2.16) followed by immunostaining for Ubr4 using 1:200 rabbit anti-
Ubr4 antibody (Abcam, ab86738) 
 
Although a light band of 574-kDa, which is equivalent to Ubr4 size, was observed 
when the WB membrane was viewed under the UV, the printed image hardly 
show anything in that position. Furthermore, the appearance nonspecific bands 
suggests poor quality of Ubr4 antibody. Therefore, it has not been possible to 
draw a firm conclusion based on the obtained image (Figure 4.16). The full 
experiment, therefore, needs to be repeated after getting a better Ubr4 antibody 
and testing its specificity though peptide blocking assay. Another possible 
experiment would be to use a cell line that does not have endogenous WHRN 
and UBR4, such as HEK293, to transfect human WT WHRN and UBR4 into the 
cells and do immunoprecipitation while, in parallel transfecting human mutant 
WHRN and UBR4 into other cells and doing pull-down immunoprecipitation. If our 
hypothesis, that WHRN/UBR4 interaction is present but  disturbed with mutated 
WHRN, is correct, then a normal UBR4 band will be detected in the first case but 
the intensity of the band will be smaller in the second case. Such finding will, 
therefore, support the raised hypothesis and would also point out that R450C is 
probably a functional/pathological mutation.  
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Figure 4.16. Testing Ub4 in protein pulled-down by whirlin antibody from mouse 
brain lysate. The lane labelled “Supernatant” is the untreated mouse brain lysate which 
forms the starting material. The lane labelled “wash” is the PBST used to wash the 
material that was not captured by the antibody in the beads. The “unbound” lane contains 
the material that was not held by the antibody bound to beads, and “bound” is the lysate 
generated from the beads holding the antibody. A Ubr4 band of the expected size was 
not clearly detected and the appearance of non-specific bands argues about the quality 
of the used Ubr4 antibody. No confirmed result has been considered and this experiment 
would, therefore, need further validation and repeating.   
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4.3 Family-8: a Mendelian allele for schizophrenia on 
chromosome 13q? 
4.3.1 Preliminary work 
Family-8 was ascertained by Dr Tariq Mahmood after affected family members 
attended clinics and respite care at the Becklin Centre, St James’s University 
Hospital, Leeds. The initial genetic analyses described below were undertaken 
by Prof. Chris Inglehearn (homozygosity mapping) and Dr Jose Ivorra-Martinez 
(whole exome sequencing). 
 
4.3.1.1 Family description 
A large extended consanguineous family (Figure 4.17) with multiple individuals 
diagnosed with schizophrenia by DSM-IV criteria was identified and ascertained 
when family members attended clinics in the Becklin Centre, St James’s Hospital, 
Leeds. Six affected members of the fourth generation had been monitored for up 
to 15 years by Dr Mahmood. The family consisted of four nuclear families, each 
formed by intermarriages of first cousins from the same two related families in the 
previous generation. Three of these nuclear families live in Yorkshire and the 
fourth in northern Pakistan. The six affected individuals in the fourth generation 
were diagnosed with schizophrenia and are indicated by the filled symbols in 
Figure 5.15. This pedigree structure is highly suggestive of recessive inheritance 
for an allele causing or predisposing to schizophrenia. 
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Figure 4.17. Pedigree structure of Family-8. A large family with four consanguineous marriages between first-cousins in the third 
generation and six cases of schizophrenia. One of the consanguineous families (marriage between III.1 and III.2) lives in northern Pakistan 
but the other three live in Yorkshire. The pattern of inheritance in this family suggests an autosomal recessive mode. 
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The onset of the disorder in the six affected individuals was in the late teens and 
early twenties. At the beginning, these individuals had positive symptoms such 
as auditory hallucinations, paranoid delusions and disordered thoughts. 
However, in later stages they developed negative symptoms, and cognitive 
decline was evident in cases IV.4, IV.5, IV.6 and IV.9. The three males have 
shown marked sensitivity to cannabis, one reported to become extremely thought 
disordered with minute quantities of cannabis. The females have not been 
exposed to cannabis. One affected female (IV.14) has shown some affective 
features such as grandiose ideas in post-natal relapses. Four of the affected 
cases are being treated with and are responsive to clozapine. Table 4.4 
summarises the clinical findings in this family and the drug treatments used. 
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Case ID Sex 
Age of 
onset 
Delusions 
Auditory 
hallucinations 
Thought 
disorder 
Grandiose 
ideas 
Negative 
symptoms 
Drug 
treatment 
IV.4 M 19 y + + n/a n/a + Clozapine 
IV.5 F 23 y + + n/a n/a + Clozapine 
IV.6 F 17 y + n/a n/a n/a n/a Olanzapine 
IV.9 M 22 y + + + n/a ++ Clozapine 
IV.11 M 21 y + + ++ n/a + Clozapine 
IV.14 F 23 y + n/a n/a + n/a Quetiapine 
 
Table 4.4. Symptoms of the affected cases in Family-8. Symptoms and current treatments for the six affected individuals diagnosed with 
schizophrenia from Family-8. n/a = not available.
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4.3.1.2 Homozygosity mapping results 
Homozygosity mapping of this family was carried out using SNP genotypes 
generated on an Affymetrix 6.0 Whole genome SNP array. DNA from four 
affected family members, IV4, IV.5, IV.9 and IV.11, was sent to AROS Applied 
Biotechnology (Aarhus, Denmark) for genotyping. Data were analysed using the 
Agile ideogram software available via http://dna.leeds.ac.uk/autozygosity. 
Results revealed only one homozygous region shared between these affected 
individuals, on chromosome 13q, shown in Figure 4.18. It was therefore 
hypothesised that a gene in this region would be found to carry a mutation of 
recessive effect causing or predisposing to schizophrenia. 
 
Figure 4.18. Shared homozygous region in Family-8. Ideogram plotting SNP data 
from the four affected genotyped members of Family-8. The outer circle contains 
template segments of the 22 autosomal chromosomes. The four inner circles plot the 
SNP data from affected subjects IV.4, IV.5, IV.9 and IV.11. The light blue areas are the 
homozygous regions in each individual and the dark blue region on chromosome 13 is 
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the homozygous region shared between all four individuals. This region, 
chr13:75367473-81504615, measures about 5 Mb. 
 
The relationship between the chromosome13q region and neuropsychiatric 
disorders is not new. Early evidence from a linkage study of 540 individuals with 
bipolar disorder from 97 families, assessed by National Institute of Mental Health 
(NIMH) Diagnostic Centres, suggested 13q32, besides two more regions on 
chromosome Xp, as interesting regions that need further investigation (Stine et 
al., 1997). Subsequently, further support has come from linkage studies by 
Detera-Wadleigh Sevilla D et al. (1999), Badenhop et al. (2001), Badenhop et al. 
(2002) and Ferraren et al. (2005). Association studies have also provided 
evidence implicating 13q in BPD. For example, (Hattori et al., 2003) found an 
association between the G72/G30 gene locus, located at 13q33, and bipolar 
disorder, after performing transmission/disequilibrium testing (TDT) and 
haplotype analysis on two independent pedigree sets, from Clinical 
Neurogenetics (CNG) (22 families) and the National Institute of Mental Health 
(NIMH) Genetics Initiative (152 families). A 65-kb genomic region at 13q32-33 
had already been associated with schizophrenia (Chumakov et al., 2002). The 
13q32 locus has, therefore, been a potential locus of susceptibility for both bipolar 
disorder and schizophrenia (Berrettini, 2003). 
 
4.3.1.3 Exome Sequencing in Family-8 
Whole exome next generation sequencing was carried out on subject IV.6 using 
paired end reads on an Illumina HiSeq 2500 (Section 2.12). The shared 
homozgous region contains some likely neuronal candidates, including CLN5, 
which is associated with neuronal ceroid lipofuscinoses (NCL), also known as  
Batten disease (Williams et al., 2006); SLAIN, which is implicated in susceptibility 
to schizophrenia (Curtis, 2016a) and intellectual disability (Harripaul et al., 2017); 
and SPRY2, which has a known regulatory role in neurogenesis (Dow et al., 
2015). However, after doing all the exome analysis, combining it with the result 
of homozygosity mapping and applying the filtering criteria, no obvious candidate 
variant was identified. 
 
 232 
 
4.3.2 Follow-up work 
After the finding of a homozygous region on chromosome 13q, followed by exome 
sequencing that identified a list of candidate variants in the region but was unable 
to highlight any obvious causative variant, the author undertook follow-up work in 
the search for an underlying causative recessive allele in Family-8, as detailed 
below. 
  
4.3.2.1 13q region under investigation 
Because no obvious candidate variant was identified by whole exome analysis, it 
was hypothesised that a variant could be in a non-coding region such as a 
promoter, UTR, intron or intergenic region. Therefore, all the genes located in the 
region (chr13:76,482,752-82,585,964) were interrogated by genome sequencing. 
Table 4.5 lists the RefSeq annotated coding genes located in the 13q region. A 
full list, including the pseudogenes and microRNA genes, is shown in Appendix 
10
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No Start Stop Symbol Description 
1 77454304 77460540 KCTD12 Potassium channel tetramerization domain containing 12 
2 77522694 77532777 ACOD1 Aconitate decarboxylase 1 
3 77566059 77576652 CLN5 Ceroid-lipofuscinosis, neuronal 5 
4 77579389 77601331 FBXL3 F-box and leucine rich repeat protein 3 
5 77618792 77901177 MYCBP2 MYC binding protein 2, E3 ubiquitin protein ligase 
6 78109809 78219398 SCEL Sciellin 
7 78271989 78338377 SLAIN1 SLAIN motif family member 1 
8 78469616 78549664 EDNRB Endothelin receptor type B 
9 79173227 79177695 POU4F1 POU class 4 homeobox 1 
10 79188421 79233314 RNF219 Ring finger protein 219 
11 79885962 79980393 RBM26 RNA binding motif protein 26 
12 80055259 80130212 NDFIP2 Nedd4 family interacting protein 2 
13 80910111 80915086 SPRY2 sprouty RTK signaling antagonist 2 
 
Table 4.5. Fully annotated RefSeq genes located in the 13q region implicated by homozygosity mapping in Family-8.
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Non-coding variants missed in the whole exome sequencing could have many 
possible consequences. One possible effect might be to decrease or increase the 
transcription of one or more of the 13 genes in the region, leading to a change in 
the level of one or more mRNAs from these genes in the brain. Such variants 
might be more likely to be in promotor regions but could be in 5’ or 3’ UTRs, 
introns or intergenic DNA. Another possible consequence, particularly of intronic 
variants, is that splicing might be altered to include a cryptic exon or cause exon 
skipping. This would manifest as variation in the sequence and possibly affect the 
length of the mRNA from one or more of these 13 genes. 
 
To screen for both of these possibilities, RT-PCR was carried out on each of the 
genes located in the 13q31 locus. PCR of a near full-length mRNA could reveal 
length variants implying mis-splicing, while semi-quantitative RT-PCR (Section 
2.3) could reveal large differences in the level of one or more RNAs. Ideally, this 
work would be carried out on patient brain tissue, but this was not available. Fresh 
lymphocytes or fibroblasts can be obtained from the patients, so a preliminary 
test on control samples was done to assess whether transcripts could be 
amplified from these tissues. Sets of primers (Appendix 2) were designed as 
described in Section 2.4. RT-PCR products were ran through 1.5% agarose gels 
and visualised over ultra-violet (UV) light (Figure 4.19). It was found that cDNA 
from lymphocytes and fibroblasts were equally likely to express the genes in the 
13q31 locus. Based on this experiment, blood lymphocytes were selected as a 
source of cDNA for transcript analysis. 
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Figure 4.19. Reverse transcriptase RT-PCR to assess whether transcripts in the 
13q region could be amplified from lymphocytes or fibroblasts. A. 1, KCTD12; 2, 
ACOD1; 3, CLN5; 4, FBXL3. B. 5, MYCBP2; 6, SCEL; 7, SLAIN1; 8, EDNRB. C. 9, 
POU4F1; 10, RNF219; 11, RBM26; 12, NDFIP2; 13, SPRY2. Each row has a 100-bp 
marker in the first lane. For each gene, 1st lane, lymphocyte cDNA; 2nd lane, fibroblast 
cDNA; 3rd lane, ddH2O as a negative control. 
 
Since RT-PCR did not amplify any band for some of the tested genes (such as 
CLN5, MYCBP2, and SCEL), while those bands present were rather weak, RT-
PCR with Hot-Shot master mix was tried on cDNA from blood lymphocytes, as 
described in Section 2.3. Figure 4.20 illustrates the amplified bands after 
visualisation over ultra-violet (UV) light. The HotShot master mix resulted in 
clearer, more intense bands. Furthermore, CLN5, which did not work in the 
previous experiment, now showed a band. 
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Figure 4.20. Reverse transcriptase-PCR with HotShot master mix. For each gene, 
1st lane, lymphoblast cDNA; 2nd lane, negative control. The genes were loaded in the 
same order as in Figure 4.17. Most of the transcripts could be detected in blood but there 
were still some that could not be amplified. 
 
4.4 Discussion 
Investigating the causes of genetically complex neuropsychiatric disorders is a 
challenging task. Individuals with schizophrenia have abnormalities in several 
brain regions and the condition is extremely heterogeneous, with both genetic 
and environmental factors influencing clinical outcome. Some neuropsychiatric 
disorders, however, follow a Mendelian pattern of inheritance (Huang Yue et al., 
2014), such that their underlying genetic causes could be determined relatively 
simply using family studies. The pedigree structures of Family-7 and Family-8 
described here suggested the possibility that a Mendelian allele might account 
for inheritance of schizophrenia in them; if true, this might mean that a similar 
approach in these families could reveal new insights into schizophrenia. 
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4.4.1 Putative involvement of a WHRN variant in schizophrenia 
in Family-7 
This family has two affected males with six unaffected sisters and unaffected 
parents. At first glance the pedigree might suggest either autosomal recessive or 
X-linked inheritance. Genetic testing did identify a candidate variant in the TENM1 
gene on the X chromosome present in both affected brothers, but segregation 
analyses excluded the TENM1 variant (analysis by Dr Jose Ivorra Martinez). The 
alternative hypothesis is that the disorder is the result of an autosomal recessive 
allele that is homozygous in the affected brothers. 
 
The initial work of a colleague (Dr Jose Ivorra Martinez) implicated WHRN variant 
in schizophrenia in Family-7 (see Section 4.2.1.2). Homozygosity mapping in the 
affected individuals identified two homozygous regions, and within these a 
missense mutation, c.C1348T:p.R450C in the WHRN gene encoding whirlin, was 
found to segregate in a manner consistent with it having a causative role in 
psychosis. Based on the preliminary work on this family, additional genetic 
studies were carried out to further test the involvement of WHRN variants in 
schizophrenia. Furthermore, functional studies of the identified WHRN coding 
variant was initiated. 
 
In a genetic study, it is important to screen as large a number of patients as 
possible to achieve significance, and include age and ethnicity matched controls. 
The control genotypes used in the preliminary study were largely of Caucasian 
origin and it was therefore important to check the frequency of the variant in 
samples from the same ethnic background. Under-representation of an ethnic 
group in particular databases could lead researchers to overstate the significance 
of their findings, and this needed to be ruled out by using controls from the same 
ethnic group. If the variant occurs in unaffected controls from the same ethnic 
group, it is likely to be ethnic group specific and not associated with the disease 
phenotype (Casanova et al., 2014). Screening of additional cohorts of 
schizophrenia patients and control samples, including ethnically matched 
controls, did not identify the WHRN R450C variant or any similar changes within 
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the region. This suggests that this variant is rare and is a “private mutation” in this 
family. 
 
WHRN encodes the protein whirlin, which is involved in the formation of 
scaffolding protein complexes in the central nervous system (Yap et al., 2003) 
and photoreceptor synapses (Van Wijk E. et al., 2006b). The protein has also 
been found to play an essential role in actin filament packing and stereocilia 
elongation in the hair cells of the inner ear (Mogensen et al., 2007). Figure 4.21 
demonstrates the stereocilia interactome, in which whirlin exerts a central role 
among other proteins involved in the growth and cohesion of stereocillia. Hair 
cells have highly organised synaptic sites, like the ones in photoreceptor cells, 
called ribbon synapses (Khimich et al., 2005). These are essential for neurons 
that transmit graded signals. Ribbon synapses are characterized by an electron-
dense structure of tight calcium channels and vesicles to enhance immediate 
release of the associated neurotransmitters (Sterling and Matthews, 2005). 
 
 
 
 
Figure 4.21. The role of whirlin within the 'stereocilia interactome'. The left circle 
contains the proteins that are involved in the growth of the stereocillia and the 
right circle contains the proteins that are crucial for the stereocillia cohesion. 
Whirlin is a scaffolding protein, located in the overlapping region of the two circles, 
required to establish a connection between these two groups, and forming a 
complex that is crucial for actin polymerization and stereocilia elongation. 
Evidence for this complex interactome comes from mouse genetic and protein 
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interaction studies. (Adapted from Brown Steve D. M. et al. (2008) and used with 
permission from Nature Publishing Group, License Number: 4078241032964). 
 
The C1348T:p.R450C change is a missense variant located in the central portion 
of WHRN, encoding a Harmonin-N-like domain which is a putative protein binding 
domain (Pan et al., 2009). In contrast, the variants causing Usher syndrome or 
non-syndromic sensorineural deafness are nonsense mutations, clustered at the 
N-terminus or C-terminus, respectively. The N- and C-terminal PDZ domains are 
thought to be sites through which the protein interacts with other known 
components of the Usher protein network (Van Wijk E. et al., 2006b). For these 
reasons, research on the function of this protein has tended to focus on the N- 
and C-terminal domains, while the central region has not been extensively 
studied. The genetic findings in Family-7 suggest that missense variants in the 
central part of whirlin could predispose to psychiatric disorders such as bipolar 
disorder and schizophrenia. Nonsense mutations in the N- and C-termini are 
known to cause Usher syndrome and deafness, respectively. 
 
It was previously found that whirlin is expressed in a large number of mouse 
tissues, with predominant expression in the brain, the eye and the inner ear (Van 
Wijk Erwin et al., 2006a). Whirlin expression in human tissues, carried out in this 
thesis (Figure 4.5), showed a similar finding. Whirlin was expressed in a wide 
range of tissues, particularly neuronal tissues of fetal and adult brain. A construct 
carrying the 450C variant was made as described in Section 2.14 and it was used 
to study the localisation of the 450C mutant in comparison with wild type whirlin. 
The R450C mutation did not appear to affect the cellular localization of the protein 
in overexpression studies (Section 4.2.2.4). However, structural modelling 
(Section 4.2.1.4) predicted that the change disrupts protein conformation, 
specifically disrupting two clusters of peripheral charged residues with potential 
protein binding properties. It was found, through yeast two-hybrid assay (Section 
2.4.1.5), that the central region of whirlin, where the R450 residue is located, 
interacts with UBR4 in an interaction not previously described in the literature, 
and that the R450C mutation weakens this interaction. 
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UBR4 is an E3 ubiquitin-protein ligase of 5,183 amino acids that has been shown 
to interact with the smooth endoplasmic reticulum, a major intracellular calcium 
store, in neurons (Shim et al., 2008). It has also been shown to interact with 
calmodulin, a calcium sensor protein, in the cytoplasm (Nakatani et al., 2005), 
highlighting a potential role for UBR4 in calcium signalling. Consistent with the 
known role of UBR4 in neurogenesis (Parsons et al., 2015), neuronal migration 
(Shim et al., 2008) and neuronal Ca2+ signalling (Nakatani et al., 2005), an 
R5091H mutation in UBR4 is reported to co-segregate with a novel form of 
autosomal dominant episodic ataxia in a large three-generation Irish family 
(Conroy et al., 2014). Interestingly, UBR4 is also a time-of-day-dependent and 
light-inducible protein in the suprachiasmatic nucleus of the mouse brain during 
circadian rhythm (Ling et al., 2014). Circadian rhythm disruption is a common 
feature in many neuropsychiatric diseases including schizophrenia, bipolar 
disorder and depression (Wulff et al., 2010). Although the precise mechanisms 
remain unclear, recent evidence suggests that circadian rhythm disruption is not 
simply a product of medication or an absence of social routine, but instead 
reflects commonly affected underlying pathways and mechanisms (Jagannath et 
al., 2013; Monti et al., 2013). 
 
Based on the experiments and assays carried out, it is concluded that whirlin is 
highly expressed in neuronal tissue and that the R450C mutation observed in 
Family-7 is rare. Preliminary data suggest that the interaction of whirlin with UBR4 
is affected by the R450C mutation, but further experiments are needed to confirm 
this. The R450C mutation might cause some alteration to the surrounding 
residues in whirlin, thus reducing but not abolishing the binding to UBR4. 
Therefore, a small disruption of UBR4 function, caused by reduced binding to 
whirlin, could conceivably confer risk for mental disorders. 
 
4.4.2 Family-8 with a putative Mendelian allele in a homozygous 
region on chromosome 13q 
The structure of this large consanguineous Pakistani family, with six 
schizophrenia cases across multiple first cousin marriages, is suggestive of a 
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recessive mode of inheritance. Although homozygosity mapping suggests a 
single shared region at chromosome 13 (13q31), the analysis of whole exome 
sequencing (WES) in this family has not been able to identify a single clear 
causative mutation. Despite its known power in diagnostic genetics, WES still has 
some limitations and is not always the best application (Klein Hanns-Georg et al., 
2014; Warr et al., 2015). Indeed, there have been some cases where the 
underlying genetic causes were missed by WES, and other techniques were 
more useful. For example, a study of Inherited Retinal Dystrophy (IRD) did not 
detect a splicing mutation in the CDHR1 gene (c.439-17G>A) by the standard 
WES analysis. This is because the mutation was filtered out due to not being in 
a coding region or obvious splice site. However, transcript analysis of cDNA from 
a patient’s fibroblasts indicated the splicing of CDHR1 by a mutation activating a 
cryptic splice-acceptor site (Tiwari et al., 2016). 
 
In order to further investigate the genes located in the 13q locus, additional 
biological samples are required from the family members. Availability of samples 
is dependent on the consent of family members, and the feasibility of collection. 
For example, neuropsychistric disorders would ideally be investigated by 
determining the expression of the genes in the 13q homozygous region in brain 
samples. However, as brain samples are not available, other tissues were 
considered. Blood is one of the most easily accessible tissues (Kukurba and 
Montgomery, 2015). Rollins et al. (2010) found that majority of the brain 
transcripts (about 90%) are also expressed in blood. Peripheral blood 
mononuclear cells (PBMCs) have therefore been suggested as a good tissue in 
which to study gene expression in individuals with psychiatric disorders. The 
present study found that fibroblasts and blood lymphocytes gave similar results 
in the amplification of the 13 genes in the 13q31 locus (Figure 4.18). RT-PCR 
showed that most of the transcripts could be amplified from blood lymphocyte 
cDNA (Section 4.3.2.1), but it was not possible to amplify the transcripts of SCEL, 
SLAIN1 and EDNRB. 
 
A mutation in any one of the 13 genes located on 13q31-32 could potentially be 
a plausible cause of schizophrenia in this family. Some of the genes have already 
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been linked to some types of neuropsychiatric disorder. For example, mutations 
in CLN5, encoding a soluble lysosomal protein, have been associated with 
neuronal ceroid lipofuscinosis, an autosomal recessive, progressive 
encephalopathy in children (Jalanko and Braulke, 2009; Lyly, 2008). SPRY2 
encodes a protein belonging to the sprouty family that is involved in signal 
transduction in multiple processes, including axon growth and brain development. 
Decreased expression of SPRY2 has been observed in post-mortem samples of 
dorsolateral prefrontal cortex (DLPFC) from schizophrenia patients (Pillai, 2008). 
 
Genetic analysis indicated 13q31 as the region most likely linked to the 
schizophrenia in Family-8, and all the genes within it require thorough 
investigation. Further sampling of blood for transcript analysis is thus necessary. 
Whole genome sequencing could also be done, as it might reveal a hidden 
mutation in this family. Experimental studies have shown the capability of genome 
sequencing to detect causative mutations missed by techniques such as exome 
sequencing and genomic microarrays (Gilissen et al., 2014a; Lupski James R et 
al., 2010). 
 
One further planned investigation in Family-8 is neuroimaging to obtain images 
of brain structure and activation patterns (Wen Wei et al., 2011). Neuroimaging 
is a non-invasive method to obtain information on brain structure and function in 
living subjects (Rumsey and Ernst, 2009). Magnetic resonance imaging (MRI) 
technique, which is based on using various magnetic fields, radio waves and 
fields gradients, has been used to attain such valuable information. 
 
There are two main neuroimaging techniques to study brain structure. Structural 
MRI (sMRI) utilises three-dimensional weighted scans to measure the thickness 
of the cortical regions (Barton and Harvey, 2000) and to illustrate the distribution 
of anatomical networks in the human brain (He et al., 2007). Diffusion tensor 
imaging (DTI) of grey matter is used to reconstruct the anatomical connections 
between entire brain regions, permitting the study of the highly complex network 
properties of the brain and the production of detailed 3D maps (Hagmann et al., 
2007). Diffusion spectrum imaging (DSI) followed by computational tractography 
 243 
 
has been used to study the structural core of cortical networks (Hagmann et al., 
2008). 
 
Functional magnetic resonance imaging (fMRI) is also a method for studying 
brain networks. fMRI has been used to show the changes in the functional 
organization of the brain in Alzheimer's disease (Kivistö et al., 2014; Sperling, 
2011) and schizophrenia (Liu Y et al., 2008), indicating specific alterations in the 
frontal, parietal and temporal lobes. With technical advances to provide a higher 
anatomical resolution and improved quantitation, fMRI has become the dominant 
technique to investigate brain networks (Dauvermann et al., 2014; Gur and Gur, 
2010; Karlsgodt et al., 2010). By fMRI, schizophrenia subjects have been shown 
to have a characteristic physiological response of the synaptic activity within the 
dorsolateral prefrontal cortex (DLPFC) and anterior cingulate cortex (ACC) 
(Thermenos et al., 2013). In a study by (Wagner et al., 2013), schizophrenia 
patients (n=36) showed a significant reduction (p < 0.001) in the functional 
activation of the DLPFC and ACC compared with healthy control subjects (n=36) 
(Figure 4.22). 
   
Figure 4.22. Brain regions that have reduced functional activity in schizophrenia 
patients. The orange-yellow scale represents the degree of hypoactivity in 
schizophrenia patients compared with healthy control subjects. Significantly lower 
activation was found in cerebellum, mediodorsal thalamus, dorsal anterior cingulate 
cortex (dACC), dorsolateral prefrontal cortex (DLPFC) and ventrolateral prefrontal cortex 
(VLPFC). (Adapted from Wagner et al. (2013); no permission required). 
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Certain tasks might require more concentration and longer time from the brain 
networks, depending on the task’s difficulty (Gómez et al., 2014). A normal 
person requires a certain period of elapsed time to do daily routine activities, but 
schizophrenia patients have timing disturbance that negatively impacts on their 
cognition and daily behaviours (Alústiza et al., 2016). Various neuroimaging 
studies have shown that dysfunctional neural timing is the core deficiency in 
schizophrenia patients (Macar and Vidal, 2009; Volz et al., 2001). (Alústiza et al., 
2016) carried out a multimodal analysis using data from 43 fMRI studies of 
schizophrenia patients. They concluded that schizophrenia patients have 
overloaded networks, resulting in a broad range of task-related timing and 
response deficits (Figure 4.23). 
 
Neuroimaging of Family-8 would help to determine whether the affected cases 
have a pattern of brain region activation similar to the patterns seen in unaffected 
family members who are also homozygous for the 13q31 region, and in other, 
unrelated schizophrenia patients. 
 
Four of the affected in Family-8 are responding to clozapine without any reported 
resistance or major side effects. Clozapine is normally used to treat schizophrenia 
when other antipsychotics are ineffective, but an estimated 40-70% of 
schizophrenia patients show resistance to clozapine (Papetti et al., 2007). 
Clozapine is reported to be helpful in reducing self-harming and suicidal 
behaviour (Meltzer et al., 2003; Zarzar and Mcevoy, 2013), but is also associated 
with the development of agranulocytosis, a life-threating side effect (Abanmy et 
al., 2014). The usage of clozapine has, therefore, become restricted and the 
haematological parameters of patients treated with clozapine are monitored 
(Miyamoto et al., 2004). 
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Figure 4.23. Neuroimaging of schizophrenia patients showing brain regions 
involved in cognitive tasks. Alústiza et al. (2016) carried out a signed differential 
mapping (SDM) meta-analysis on 954 schizophrenia patients and 999 healthy volunteers 
from 43 fMRI studies. The blue scale indicates the level of hypoactivity whereas the 
orange scale represents the degree of hyperactivity in schizophrenia patients. Bilateral 
inferior frontal and superior occipital gyri, right supplementary motor area, left inferior 
parietal gyri, left cuneus, and red nucleus all showed reduced activity. Hyperactivity was 
recorded in right postcentral and fusiform gyri. (Adapted from Alústiza et al. (2016); no 
permission required). 
 
Affected individuals in Family-7 and Family-8 are reported to use cannabis, which 
can cause a wide range of psychiatric symptoms (Van Gastel et al., 2013). The 
active compound in cannabis is called ∆9-tetrahydrocannabinol (∆9-THC), which 
produces behavioural effects within minutes (Anderson Beth M. et al., 2010; Khan 
Masood A. and Akella, 2009). When smoking cannabis, the psychoactive agent 
∆9-THC gets immediately absorbed into the blood stream and then rapidly 
delivered to the brain. Being extremely lipid soluble, the ∆9-THC accumulates 
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within the fatty tissues and then is slowly released back into the body areas. After 
smoking cannabis, a high concentration is found in the brain and sensory and 
motor parts of the body (Ashton, 2001). Cannabis has not been approved by the 
US Food and Drug Administration (FDA), though there is still some conflict 
between federal and state laws about its legal status in the USA. In the UK, 
cannabis was made illegal in 1925 (Chadwick, 2008). Despite it having potentially 
harmful effects, cannabis has gradually become the most commonly used illicit 
drug, accounting for 80% of worldwide drug abuse (Jha et al., 2006; Macleod et 
al., 2004). 
 
Hearing impairment (Carvill S., 2001; Stefanis et al., 2006) and Usher syndrome 
(Dammeyer, 2012; Domanico et al., 2015) are believed to be risk factors for the 
development of mental disorders, with a reported frequency of 23% of Usher 
syndrome patients presenting psychiatric conditions (Dammeyer, 2012). This 
could be the result of sensory deprivation, but alternatively it may imply a common 
pathology linking defects of hearing and vision with psychotic disorders. The 
involvement of the central nervous system (CNS) in Usher syndrome (Koizumi et 
al., 1988; Schaefer et al., 1998) supports this hypothesis. 
 
To conclude, the follow up work on Family-7 has contributed further findings 
supporting our hypothesis that a proportion of the increased psychosis in the 
Pakistani population is caused by recessive alleles. In Family-8, it was not 
possible to progress the project further due to lack of the tissue samples from the 
family, but the preliminary results obtained should help when those samples 
become available in the future.
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5. General Discussion 
 
5.1 Summary of key findings 
The research described herein used NGS technology to identify the genetic 
causes of intellectual disability (ID) in six consanguineous Omani families. It also 
includes some follow-up functional work on loci identified in two consanguineous 
families in the UK with schizophrenia. 
 
The combination of whole genome homozygosity mapping and whole exome 
sequencing (WES) revealed mutations underlying ID in Omani families. 
Homozygosity mapping identified homozygous regions shared between the ID 
affected members in each family. The shared homozygous-by-descent (HBD) 
regions potentially could contain the mutation that causes the recessive ID 
phenotype in each family (Woods et al., 2006). To investigate an X-linked mode 
of inheritance, the affected cases in each family were checked for X chromosome 
variants. Families in which the underlying mutations could not be identified by the 
above strategy were also tested for possible copy number variants (CNVs) using 
the method of Plagnol et al. (2012). CNVs are a major cause of neurological 
disease and their estimated prevalence in ID is about 10-30% (Vissers Lisenka 
Elm et al., 2010). NGS technology was able to identify the causative mutation in 
three of the six ID families studied, a detection rate of 50%. Detection rates vary 
widely in the reported literature. For example, in 50 patients with ataxia, Nemeth 
et al. (Németh et al., 2013) reported a detection rate of 8.3% for patients with an 
adult onset progressive disorder, and 40% for patients with a childhood or 
adolescent onset progressive disorder. This suggests that applying NGS on 
samples of early onset disorders might increase the detection rate, which is not 
surprising as early-onset phenotypes are more likely to have a genetic basis 
(Acuna-Hidalgo et al., 2016; Ropers H, 2010; Zou et al., 2014). A WES study of 
an ID cohort of 100 trios (patients and their healthy parents) had a detection rate 
of 16% (De Ligt et al., 2012). A rate of 55% was achieved by the study of Rauch 
et al. (2012) on ID children and their parents from Germany and Switzerland. By 
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comparison, a WES study of 17 families with inherited retinal disorders achieved 
a mutation detection rate of 57% (Audo et al., 2012). 
 
The mutations reported in this thesis are all novel, although some of them occur 
in genes previously associated with ID. The known ID genes in which novel 
mutations were identified are TUSC3 and NHS. TUSC3 is a known ID gene with 
various reported mutations but the variant identified in Family-1 
(NM_006765:exon2:c.222delA, p.R74 fs) has not been reported before. This is 
the first time that a mutation in TUSC3 has been identified in an Arab population. 
The family are expected to benefit from this knowledge through genetic 
counselling and carrier screening of additional family members and/or potential 
marriage partners. The reported NHS change (NM_198270:exon8:c.C4385G, 
p.S1462C) might not be the cause of the cognitive impairment in Family-2 
because the affected members do not have the ophthalmological and dental 
anomalies characteristic of Nance-Horan syndrome (NHS). One of the patients 
has some very mild teeth anomalies, including conical shaped teeth, crowding 
and overlapping incisors, but the NHS characteristic abnormalities are not seen 
in ID affected siblings. Moreover, as only about 30% of patients with pathogenic 
NHS mutations have intellectual disability, Nance-Horan syndrome is not 
necessarily the cause of ID in Family-2. The possibility remains that the NHS 
mutation reported in this study could be a SNP in the Omani population, even 
though none of the 50 tested ethnically-matched controls had this change. The 
significance of the NHS variant to the cognitive deficit in Family-2 thus remains 
uncertain. LHFPL5 is a gene that has been previously reported to be mutated in 
hearing loss. However, the LHFPL5 variant identified in this thesis 
(NM_182548:exon2:c.T575C, p.L192P) is novel, and could not be excluded from 
being the cause of intellectual disability in Family-2. In Family-3, two new mutated 
genes – ANKRD2 and PDZD8 – were identified as being potentially associated 
with ID. The subsequent analysis and screening suggested that a mutation in 
either, or both, of them could be the underlying cause of the phenotype in Family-
3. 
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The genetic cause of ID in the remaining three families could not be solved even 
after searching for possible compound heterozygous mutations. These families 
were also tested for CNVs, which are a common genetic cause of neurological 
diseases. CNVs are genetic regions of more than 50bp that are duplicated or 
deleted in comparison with the reference genome sequence (Tattini et al., 2015). 
During the last decade, the importance of CNVs in risk of diseases has become 
increasingly apparent and is expected to be important in the development of 
personalized medicine in the future (Love et al., 2011; Sharp et al., 2005). 
 
Numerous logarithmic and statistical tools exist for discovering CNVs from array 
intensities and next generation sequencing data. The review of Pirooznia et al. 
(2015) suggests appropriate methods, such as read depth and combined 
approach,  to detect CNVs in whole genome sequencing data. Examples of 
commonly used tools are HMM-Hidden Markov models (Fromer et al., 2012; Love 
et al., 2011), CoNIFER-copy number inference from exome reads (Krumm et al., 
2012) and EXCAVATOR (D'aurizio et al., 2016; Magi et al., 2013). An evaluation 
of 37 available tools concluded that a combination of different tools would help in 
detecting CNVs with higher confidence (Zhao Min et al. (2013). An analysis tool 
called ExomeDepth (Section 2.11.9.7) was used in the present study to look for 
possible CNVs in the families for which the causative mutation was not identified 
by homozygosity mapping and whole exome sequencing. ExomeDepth has 
shown a higher sensitivity than five other tools (ExomeCNV, CONTRA, 
ExomeCopy, CoNIFER and HMM) for detecting rare CNVs (Samarakoon et al., 
2014), but did not identify any CNVs in the present study. In consequence, three 
families remain unsolved, and there are various potential reasons for these 
negative findings (explained in Chapter 3, Section 3.3.4). 
 
Follow-up work was undertaken based on previous findings in two SZ families 
(Family-7 & Family-8). In Family-7, a variant in DFNB31 (R450C) was previously 
identified by a University of Leeds colleague, post-doctoral fellow Dr Jose Ivorra 
Martinez. Whirlin, the protein which encoded by DFNB31, was over-expressed in 
SH-SY5Y cells. A pull-down assay has not shown a conclusive evidence that 
whirlin interacts with UBR4 and it is, therefore, important to repeat the 
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experiment, using good quality of UBR4 antibody. UBR4/WHRN interaction need 
to be further tested and once that is confirmed, then it would be interesting to find 
out if the R450C mutant whirlin have reduced binding to UBR4, as this partial loss 
of function could potentially underlie the schizophrenia in Family-7. In Family-8, 
a single homozygous locus at chromosome 13q31 was previously found to be 
shared by six affected members. Whole exome sequencing did not find any 
potentially causative mutations in the coding regions, so the expression of the 13 
genes in the shared region was analysed as the next step. Transcript analysis 
using control samples showed no difference in transcript amplification between 
fibroblasts and lymphocytes. Sample collection from Family-8 is the next step 
required for further transcript analysis. Other types of analysis of Family-8 could 
include neuroimaging and whole genome sequencing (WGS). 
 
5.2 Implications for the diagnosis of ID and neuro-
psychiatric disorders 
Mental illnesses and intellectual disabilities are overlapping cognitive disorders 
that cause a high proportion of disability in the world. It has been estimated that 
mental disorders occur in 10–20% of teenagers in the world, and half of these 
conditions start before 14 years of age (Charara et al., 2017). People with mental 
illness/intellectual disability have limitations in their daily life and less opportunity 
for a good quality of life (Lecroy and Holschuh, 2012). As such, they need 
appropriate attention and health care. However, the study of mental illnesses has 
various challenges in terms of diagnosis and treatment (Wittchen et al., 2003). 
 
Depending on the severity of the illness, patients with ID or mental diseases may 
appear normal if their condition is mild. For example, it could be hard for a 
specialist clinician to confidently diagnose a person with mild ID, when their IQ 
score is 69. Conversely, a normal person who does not perform well in IQ tests 
could be diagnosed with intellectual disability. The score of IQ is not a reflection 
of every aspect of a person’s intellectual capacity, so caution is required before 
making a diagnosis based solely on the IQ test (Richardson Ken and Norgate, 
2015; Strauss et al., 2006). Similarly, it can be difficult to recognize small changes 
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that occur in an individual with schizophrenia before the condition manifests in its 
complete form. Some of the first signs in young adults, like occasional 
spontaneous movements, sleep problems, and much time doing nothing, are not 
specific to SZ and could be misguiding. Furthermore, evaluating the negative 
symptoms, like lack of interest and social withdrawal, is hard because they are 
not as grossly abnormal as positives ones, like hallucinations and delusions, and 
thus could sometimes be missed by the patients and their relatives (Sarkar et al., 
2015; Stahl and Buckley, 2007). Therefore, a definite diagnosis can sometimes 
not be easily achieved through observing the symptoms. In fact, this type of 
uncertainty about diagnosis is considered one of the major problems that 
psychiatrists face (Aboraya et al., 2006). 
 
Despite the fact that mental illnesses can affect many areas of life, most affected 
individuals hesitate to seek medical help for various reasons. One of the more 
obvious reasons is poor awareness of the condition. A person with poor insight 
might think that nothing is wrong with them and the situation is not so bad as to 
require treatment (Reddy, 2016). The negative stigma and discrimination 
associated with having a mental illness is another reason for people not getting 
treatment (Corrigan and Watson, 2002). There is a fear of being labelled as 
“mentally retarded” or “mad”, which could bring shame and unwanted attention. 
Another reason is the avoidance of sharing personal information, known as 
“distrust” (Henderson et al., 2015; Suite et al., 2007). Distrust could involve worry 
about maintaining confidentiality of the provided information or it could be 
attributed to hearing about others’ bad experiences of treatment (Armstrong et 
al., 2013). Other factors documented to form barriers to achieving medical help 
include limited access to the professional centres that provide mental health care 
(Caldas and Killaspy, 2011; Ofori-Atta et al., 2010), as well as the cost of 
treatment (Mccrone et al., 2008; Trachtenberg et al., 2013). 
 
Numerous studies have been done in the field of neurogenetics, including those 
on intellectual disability, schizophrenia and bipolar disorder. The findings of these 
studies have generally resulted in a better understanding of the biology and 
genes underlying these conditions (Chiurazzi and Pirozzi, 2016). For example, 
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Najmabadi et al. (2011) studied 136 consanguineous families with autosomal 
recessive ID and found mutations in 23 genes that were already linked to ID, plus 
50 novel candidate genes. Similarly, De Ligt et al. (2012) used exome sequencing 
to identify de novo mutations in 12 previously known ID genes and 24 novel 
candidate genes amongst 100 trios in which the affected individuals had 
unexplained severe ID. Furthermore, WGS enabled the identification of 33 novel 
candidate genes in 143 multiplex families mainly with ID (Alazami et al., 2015). 
Likewise, a study of 53 schizophrenia sporadic cases, 22 unaffected controls and 
their parents resulted in the identification of de novo germ-line mutations in 40 
genes (Xu Bin et al., 2011). A recent study of 192 consanguineous families with 
autosomal recessive ID from Pakistan and Iran identified 46 known ID genes and 
26 new ID genes (Harripaul et al., 2017). 
 
One of the genetic advances that has been introduced in the clinical setting to 
diagnose ID and neurodevelopmental diseases is targeted gene capture 
technology. Unlike standard NGS technology, at which all genomic regions have 
an equal chance to be sequenced, gene capture technology works by creating 
an enriched DNA capture to significantly increase the chance for a particular 
region or gene to be sequenced (Lin Xi et al., 2012b). There has been a range of 
diagnostic testing panels offered by different commercial companies. One 
example is a panel designed for detecting >90 X-linked genes of ID, presented 
by Eurofins Clinical Diagnostics (http://www.egl-eurofins.com/tests/MXLI1). 
Another example is the devACT® Clinical Management Panel by Courtagen 
(http://www.courtagen.com/test-menu-genetic-testing-devseek-clinical-
management-panel.htm) which is a panel of 226 genes for patients with 
developmental delay, intellectual disability and Autism Spectrum Disorders 
(ASD). The results are normally received from Courtagen in less than three 
weeks at a cost of about $300. Given their reasonably acceptable cost as well as 
short handling time, the diagnostic panels offered by different vendors have been 
of increased use (Schnekenberg and Németh, 2013). In a study by Lim et al. 
(2015), a panel called Haloplex ICCG (International Collaboration for Clinical 
Genomics) was used to screen 180 genes associated with congenital 
neuromuscular and neurodevelopmental disorders. This panel achieved >97% 
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breadth of coverage at which the targeted bases are sequenced >20x average 
depth, and a 40% detection rate of an abnormality in one of the 180 genes. A 
limitation of diagnostic panels is that they screen only a particular set of genes, 
and thus are not suitable for identifying novel mutated genes (Winkler and 
Wiemann, 2016). For a panel to be efficient, it needs to be updated with more 
and more genes as they are identified and validated, but these are expensive and 
time consuming processes (Watson Christopher M et al., 2014). These panels 
are also not the best option to use in cases where the patients do not show a 
previously described disease phenotype. 
 
Because of the limitations associated with the pre-designed panels, there has 
been a lot of interest in the use of whole genome sequencing (WGS) technology 
for mutation detection. WGS has several advantages that make it the method of 
choice in DNA sequencing (Pollack, 2014; Van El et al., 2013). These advantages 
include its consistent coverage as well as its greater capability to identify 
structural variants, in comparison with WES (Belkadi et al., 2015; Ekblom and 
Wolf, 2014). Some biases commonly take place in WES due to artifacts formed 
during library preparation (Aird et al., 2011), but these are eliminated with WGS, 
as no PCR step is involved in library preparation (Meynert et al., 2014). 
Furthermore, WGS has the capability to sequence regions that are difficult to 
sequence, such as GC-rich (Marx, 2013) and repetitive regions (Sipos et al., 
2012). The cost of WGS is also gradually reducing and it now costs less than 
$1000 (Nagasaki et al., 2015; Warr et al., 2015). However, WGS still has some 
limitations, including difficulty in bioinformatic analysis, the interpretation of 
findings, the need of massive servers for data storage, and the security of stored 
data (Christensen et al., 2015). 
 
Limitations and dilemmas are also present in NGS technologies. For instance, 
WES in the present study resulted in the identification of the NHS variant in 
Family-2 but it was not possible to confirm its causation of the phenotype based 
on the existing information and samples. Interpretation of variant lists obtained 
from NGS analysis is one of the biggest challenges (Dienstmann et al., 2014) and 
the availability of broad knowledge, about the affected patients, and resources, 
 254 
 
about the candidate variants, would significantly help in making the appropriate 
interpretation of variants. Another important issue in the use of NGS is whether 
to report secondary or incidental findings that are unexpectedly observed by 
researchers (Wolf et al., 2008). During a particular study, researchers might 
surprisingly come across a finding that is not related to the purposed study but is 
important and needs medical action. For example, mutations in BRCA1 or 
BRCA2 predispose to cancer risk (Petrucelli et al., 2013) and it would be 
significantly valuable to report such findings to the clinicians who might 
consequently consider life-saving mastectomy for the patient (Metcalfe et al., 
2014). Despite the obvious benefits of reporting such incidental findings, various 
issues related to confidentiality, discrimination and health insurance need to be 
considered (Clift et al., 2015; Meacham et al., 2010; Simon et al., 2011). Certain 
measures related to reporting incidental findings are being discussed by patient 
groups, researchers and clinicians. The American College of Medical Genetics 
(ACMG) has made regulations and guidelines to ensure best practice in reporting 
incidental findings (Jorde et al., 2015; Kalia et al., 2017). 
 
Single cell sequencing (SCS) studies DNA or RNA taken from one cell rather than 
from a whole tissue sample (Gawad et al., 2016; Wang Yong and Navin, 2015). 
Neurobiology has shown increased utilization of SCS, after the fields of cancer, 
embryonic development and microbiology (Wang Jian and Song, 2017). 
Examples of its uses in neurobiology include neuron classification and neuronal 
diversity (Wang Yong and Navin, 2015). RNA sequencing in a single neuron, for 
exploring neuronal morphology, is one of the earliest applications of SCS (Qiu et 
al., 2012). LINE-1 retrotransposition is one of the processes believed to 
participate prominently in causing genomic variation among neuronal cells 
(Singer et al., 2010). Evrony et al. (2012) studied LINE-1 retrotransposition in 
neurons of the cerebral cortex, and found an occurrence of 0.6 insertion events 
in each neuron, which could be relevant to the neuronal diversity within the 
genome. Another study using SCS in normal and diseased brains reported that 
CNVs occur during the normal developmental stages in about 5% of the neuronal 
cell population (Cai et al., 2014). 
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The diagnostic services for mental health are underdeveloped in developing 
countries (Ngui et al., 2010). Since Sultan Qaboos acceded to the throne in Oman 
in 1970, enormous improvement the number of clinical centres/laboratories and 
experienced personnel dedicated to mental illness has occurred (Al-Azri et al., 
2013). Mental health services were first founded in Oman through Al-Rahama 
Hospital which was opened in Muscat in the mid-1970s. There were also some 
out-patient services in different parts of the country during the late 1970s. The 
Ibn Sina hospital, opened in 1983, was the second specialised hospital to offer a 
high-standard of service for mental illnesses. The Royal Hospital, opened in 1987 
with 630 beds, is now the largest hospital in the country that provides tertiary 
health care with genetic services (Al-Gazali et al., 2006). This was later followed 
by psychiatric services at the Sultan Qaboos University Hospital (SQUH) in 1991. 
By 2005, the World Health Organisation (WHO) ranked the service offered by the 
health institutions in Oman as “the most well-organized in the world” (Ghodse, 
2011). The National Genetic Centre, inaugurated in 2013 as a supportive 
department for the genetic service of the Royal Hospital, is a recent development 
by the Ministry of Health. The centre has cytogenetic and molecular laboratories 
facilitated with advanced genetic analysis including NGS (Rajab Anna et al., 
2015). 
 
5.3 Future direction in ID and neuropsychiatric disorder 
treatment 
Most individuals with ID have major complications not only in terms of the 
cognitive impairment but also with comorbid psychiatric disorders (Brown Julie F. 
et al., 2013) as well as stereotypic and aggressive behaviours (Medeiros, 2015). 
For example, a study based in the counties of Leicestershire and Rutland found 
that ID patients had 14% aggression rate, >3 times episodes of severe physical 
episodes towards other people, and about 3% of the population reported major 
injuries from ID patients that required medical attention (Tyrer F et al., 2006). 
Studies have also shown that people with ID have an increased incidence of 
psychological stress (Bramston and Fogarty, 2000; Janssen et al., 2002), mental 
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health illness and antisocial tendencies (Crocker et al., 2007; Wheeler et al., 
2013). 
 
Treatment of the manifestations associated with ID patients have been 
considered an important and effective target and there have been many studies 
(Luyben, 2009; Prout H Thompson and Nowak-Drabik, 2003; Willner, 2005) 
reporting the positive effect of implementing concurrent psychosocial 
interventions to decrease the rate of these complications. However, the study of 
ID populations is associated with certain restrictions. Beside their nonrandomized 
designs, most of the studies in this field have limitations in measuring the 
outcomes, as no indication is normally given about whether there has been a 
reduction in the rate or severity of the manifestations (Brown Julie F. et al., 2013). 
Therefore, it might be too early to objectively judge how useful these sequential 
interventions are in reducing the abnormal behaviours in ID individuals, especially 
in the absence of solid clinical evidence. 
 
Another approach that has been in wide use as a treatment intervention to reduce 
the challenging behaviours in ID patients is called Applied Behaviour Analysis 
(ABA). This technique was described about 50 years ago (Baer et al., 1968) and 
its attributed mainly on the utilisation of social background and surroundings to 
sort out a social issue. “ABA has produced remarkably powerful interventions in 
fields such as education, developmental disabilities and autism, clinical 
psychology, behavioural medicine, organizational behaviour management, and a 
host of other fields and populations” (Slocum et al., 2014). There is a huge 
amount of evidence on the success of ABA in improving the challenges of ID 
individuals (Borrero and Vollmer, 2006; Hassiotis et al., 2009; Medeiros, 2015; 
Neef, 2001; Robertson et al., 2005). Despite the large number of studies that 
collectively demonstrate the effectiveness of the ABA procedure, some 
researchers have proposed certain arguments related to this discipline. 
Examples of their valid arguments include that the therapy is based on a cruel 
premise, the stimuli in the real life are not like in application, the difficulty to notice 
low-frequency behaviour and no clear measurements for relaxation that occurs 
after the treatment (Brown Julie F. et al., 2013; Sigafoos and Schlosser, 2008). 
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Dialectical Behaviour Therapy (DBT) is also a treatment approach that has been 
used in cases of ID and mental illnesses including conditions of borderline 
personality disorder (BPD). DBT was initially developed to help women with 
biopolar disorder and a previous history of a suicide attempt (Linehan, 1993). 
DBT is a type of cognitive-behavioural approach at which comprehensive life 
skills are incorporated in a programme and used to help the person to control 
their challenging emotions and behaviours (Chapman, 2006). The method 
showed promising results when applied in a pilot study of six individuals with ID, 
as general progress was recorded in all the studied functional measures 
(Sakdalan et al., 2010). Promising results were also reported for six adolescents, 
with features of biploar disorder (BPD), after receiving DBT treatment for a period 
of 26 weeks (Geddes et al., 2013). DBT intervention has also been used to 
reduce the manifestations associated with sucidal thoughts (Luoma and Villatte, 
2012) as well as depression (Berking et al., 2009). 
 
Apart from the cognitive and behavioural therapies, psychodynamic therapy 
(PDT) is one of the more recent approaches that has been researched to improve 
the condition of individuals with mental illness (Prout Tracy A and Wadkins, 2014; 
Wittenberg, 2006). PDT, which is also sometimes called insight-oriented therapy, 
is based on considering the negative impact of past occurrences to help the client 
understand their influence on present behaviours and thus control them 
(Schnyder and Cloitre, 2015). An investigative analysis on 528 individuals with 
schizophrenia and severe mental illness from four randomized trials (Malmberg 
et al., 2001) showed less hospitalization and medication after using PDT. 
Although there have been also some other studies suggesting the helpful value 
of PDT for psychosis, there is little evidence of longer term benefits and cost-
effectiveness (Fonagy, 2015). 
 
Because ID patients have 4-5 times the rate psychiatric illness compared with the 
general population, the use of antipsychotic drugs to treat ID patients is not 
uncommon (Rush et al., 2004). Various studies have reported that inappropriate 
use of antipsychotic drugs by ID patients is a concern (Branford, 1994; Nyunt Tin 
et al., 2008; Shah, 2017). Public Health England reports that 58% of ID and/or 
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autism patients are receiving antipsychotics but have no definite diagnosis of 
mental illness (Glover et al., 2015). The inappropriate use of antipsychotics also 
includes their overuse and extreme dosage without checking their adverse effects 
(Deb et al., 2009; Mcgillivray and Mccabe, 2004; Tyrer Peter et al., 2014). About 
22.5% of ID and/or autism individuals have been issued with more than one 
antipsychotic, and 5.5% of them have been found with doses higher than the 
maximum (Glover et al., 2015). Over the last three decades, there has not been 
remarkable improvement in the development of new antipsychotics. Most of the 
currently used antipsychotics are more than 40 years old, and majority of the 
newly introduced drugs are either in the same category as the old ones or have 
no better effects (Gelenberg et al., 2013). The issue of not having an efficient 
antipsychotic and the fact that a gap is present between the currently available 
knowledge and the offered therapy is discussed further in section 5.4. 
 
From the genetic point of view, there have been a number of therapeutic 
strategies that could potentially be applied to ID individuals. For example, the use 
of siRNAs to reduce the expression of the candidate gene (Rondal Jean-Adolphe 
and Rasore-Quartino, 2007), the use of immunoglobulins to target the product of 
the candidate gene (Pritchard and Kola, 2007), and the use of certain biochemical 
compounds that could alter either the activity of the associated protein or a step 
in its associated pathway (Korenberg et al., 1996) have all been tried in 
experimental animals as possible therapeutic approaches (Picker and Walsh, 
2013; Rondal Jean-A and Lang, 2010). Hayashi et al. (2017) have described a 
novel approach to restore many of the cellular and behavioural failures seen in 
Fragile X syndrome (FXS). In their method, they focused on obstructing the 
catalytic activity of p21-activated kinase (PAK) in FMR1 knockout (KO) mice by 
crossing them with transgenic mice with a dominant negative form of the kinase 
(dnPAK transgene) specifically expressed in the postnatal forebrain (Hayashi et 
al., 2004). A wide range of abnormalities and FXS phenotypes were rescued in 
the offspring, including phenotypes associated with synaptic defects, cortical 
spine abnormalities, locomotor activity, stereotypy and anxiety. A successful 
therapeutic strategy has been described via introducing an extra copy of MECP2, 
a gene mutated in a neurodevelopmental disorder called Rett syndrome (RTT), 
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in a mouse model with a knock-in nonsense mutation (p.R255X) (Pitcher et al., 
2015). 
 
The technologies of genome editing systems like zinc finger nucleases (ZFNs), 
TALEN (Transcription Activator-Like Effector Nucleases) and CRISPR/Cas9 
(Clustered Regulatory Interspaced Short Palindromic Repeats) offer great 
therapeutic potential. Their direct interventions to the genome are expected to 
yield a considerable influence on the treatment of various inherited conditions in 
humans (Carroll Dana, 2016; Nemudryi et al., 2014). ZFNs are being used in 
mice to develop a cure for Duchenne muscular dystrophy (DMD), a disease that 
occurs due to lose of dystrophin expression. Ousterout et al. (2015) demonstrated 
the strategy of ZFNs to remove particular sequences of dystrophin in order to skip 
exon 51 and thus repair the reading frame for the expression in mice. Similarly, 
the use of CRISPR-Cas9 to cut the full CGG-repeats of FMR1 in several cell lines, 
including human FXS iPS cells, is believed to restore the activity of this gene and 
maybe an effective treatment for individuals with FXS in the future (Xie et al., 
2016). 
 
The employment of stem cells, which have incredible potential to differentiate into 
other cell types and remarkable self-renew capacity, has also been explored as 
a possible therapeutic means for various brain conditions, including 
neuropsychiatric diseases (Benninghoff, 2009). The utilisation of stem cell 
technologies has been applied to many of human degenerative diseases 
including stroke, Parkinson's and Huntington's diseases (Lindvall and Kokaia, 
2010; Lindvall et al., 2004). One of the great implications of this approach is the 
modelling that has been successfully done for various neuropsychiatric diseases 
of monogenic as well as non-monogenic causes (Soliman et al., 2017). For 
instance, published work describes the generation of neurons from iPS cells from 
patients with bipolar disorder (Madison et al., 2015; Mertens et al., 2015) and 
schizophrenia (Brennand et al., 2011; Chiang et al., 2011). Wen et al. (2014) 
generated iPS cells from four patients of a psychiatric disorder family with 
mutated DISC1 (Sachs et al., 2005); these cells showed various synaptic 
abnormalities and provide a cellular model on which to test potential therapies. 
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The biology of ID/neuropsychiatric diseases is being increasingly revealed by 
such studies, paving the way towards better therapies for these conditions. 
 
5.4 The impact of up-to-date findings on the success of 
therapy 
Great progress has been achieved in revealing the underlying genetic causes of 
intellectual disability, with more than 800 genes being linked to the condition 
(Chiurazzi and Pirozzi, 2016). Twin studies, adoption studies, linkage studies as 
well as association studies have collectively highlighted that neuropsychiatric 
diseases have at least a partial genetic basis (Cardno Alastair G, 2014; Kremen 
et al., 2016; O’donovan et al., 2009; Pepper and G Cardno, 2014; Ronald, 2015). 
The substantial progress in gene identification, coupled with advances in brain 
imaging techniques, has implicated multiple biological mechanisms/pathways. 
Furthermore, knowledge of the cellular functions of proteins in the brain has 
improved. The expectation of an effective therapy for ID has increased with 
encouraging research outcomes in recent years. For example, Cachón-González 
and colleagues (Cachón-González et al., 2012) have used gene transfer and 
reported promising results on treating mouse model of Tay- Tay-Sachs disease, 
a neurodegenerative disorder caused mutations in HEXA gene that resulted to 
no functional  β-hexosaminidase A. In their experiments, Cachón-González and 
colleagues infused recombinant adeno-associated viral vectors encoding human 
β-hexosaminidase α and β subunits (rAAVα and rAAVβ) into the brain cranial of 
the mouse model at 1 month of age and they could rescue GM2 gangliosidosis 
in the CNS for up to 2 years.  Similarly, it has become possible to prevent the 
occurrence of conditions like phenylketonuria and hyperthyroidism (Menolascino 
and Stark, 2012). 
 
Despite the massive improvement in the identified genes and the comprehensive 
knowledge of many associated pathways, there is still a gap between 
identification of the affected gene and the availability of technology to eradicate 
the causes or to establish an efficient therapy, particularly for neuropsychiatric 
disorders (Krystal and State, 2014). Barely any antipsychotics were discovered 
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between 1975 and the introduction of second generation drugs in 1990s (Krystal 
and State, 2014; Tamminga, 2000). Later, some newer psychiatric medications 
have been discovered but none of the currently available drugs has demonstrated 
an improvement in the symptoms of cognitive deficits in schizophrenia patients 
(Stolzer, 2016). Furthermore, the newly introduced drugs have their own 
limitations, including a high price, major side effects and increased body weight 
(Hoffman et al., 2011; Stolzer, 2016). A randomised controlled trial (Kahn et al., 
2008) comparing the typical antipsychotic haloperidol versus four newer second 
generation drugs (amisulpride, olanzapine, quetiapine and ziprasidone) in 498 
patients with first episode SZ did not indicate any better response for the new 
drugs, as both groups showed a similar cessation rate. Similarly, Leucht et al. 
(2009) found no major differences in a wide range of aspects, including efficacy, 
side effects and sedation, between first-generation and second-generation drugs 
in their meta-analysis of 21,533 patients with SZ. Leucht et al. (2009) also pointed 
out that there is a huge variation among the antipsychotic drugs, and their 
classification might be confusing. Gøtzsche (2015) state that: “The drug industry 
has invented catchy terms such as ‘second generation antipsychotics’ and 
‘atypical antipsychotics’ but there is nothing special about the new drugs”. 
 
It is believed that the deficiency in getting and providing adequate drug therapy 
for ID and neuropsychiatric diseases could be partially attributed to various 
limitations when researching this area of medicine. Moreover, the incomplete 
understanding of the underlying biology at the current time and the existing 
management measures are not of great help to select the best treatment option. 
In other words, they do not really direct whether treating a patient with some 
cognitive, behavioural or psychodynamic therapies would be advantageous, or 
the patient is not likely to benefit. According to Professor Helen Mayberg of Emory 
University, "Syndromes are so nonspecific by our current criteria that the best we 
can do now is flip a coin” (Weir, 2012). Many studies are being carried out using 
revolutionary technologies, such that the current gap in knowledge is closing and 
the underlying biology is being better elucidated. As knowledge increases, 
personalized medicine (PM) could be one of the best options. 
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Personalized medicine (PM) has been has been put forward as an alternative to 
the “one-size-fits-all” approach that has been ineffective in many conditions 
(Pavelić et al., 2015). There are certain factors, specific for each patient, which 
play a significant role in determining his/her likely response to the prescribed 
drugs. These factors include the age, health status and diet of the person, but 
genetic make-up is also a main contributor. PM works by considering the 
knowledge of  molecular basis underlies drug response in order search for the 
best option of drugs that would give maximum benefit to the patients (Vogenberg 
et al., 2010). PM also allows pharmaceutical companies to take a forward step in 
producing some medicines that are tailored for particular groups of patients who 
no not seem to mprove with the available agents. The positive impact of knowing 
the patient’s genetic variation on the treatment strategy could be in the form of 
choosing alternative drugs with less side effects or considering a preventive 
monitoring plan to avoid the occurrence of susceptible diseases. One good 
example of PM is HER2 (human epidermal growth factor) testing for women 
diagnosed with breast cancer. The best treatment is based on finding out whether 
the tumour is HER2 positive, as this is known to propagate more rapidly and 
would thus needs more attention (Lidgren et al., 2008; Weigel and Dowsett, 
2010). In the field of neurology, PM has been utilised for some conditions and 
promising outcomes are expected with Alzheimer’s disease and Parkinson’s 
disease (Huang Xuemei et al., 2004), as well as in psychiatric diseases (Cutter 
and Liu, 2012). Progress in PM has already been made in various areas, as an 
approach to selecting the best treatment for each individual patient (Pavelić et 
al., 2015; Schee Genannt Halfmann et al., 2017). 
 
In order to benefit from the PM strategy, it is important for the patients to have 
their genetic profile uploaded into a system, like the Personal Health Record 
(PHR), that allows the integration and retrieval of critically complex data in a 
practically easy manner (Van Gorp and Comuzzi, 2014). The newly introduced 
smart cards, like electronic health records (EHR) (Latha et al., 2012) and Genome 
(G) cards (Jauhari and Rizvi, 2015), are examples of the applications that have 
been developed to facilitate PM work. Besides the DNA sequencing profile, the 
electronic system needs to contain some lifestyle information, like details related 
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to exercise, sleep, diet and medication, which is entered by the patients 
themselves. It has been realised that patient engagement is very advantages and 
a routine review of their electronic medical records would allow them to check 
and update the information simultaneously (Harman et al., 2012; Mishuris et al., 
2016). Documentation of any other information would be good and might be vital 
for certain analysis in the future. Physicians can access the records and utilize 
the stored information in order to select the best treatment strategy that could be 
used for the patients. These records are also important for clinical research as 
they facilitate the ultimate aim of delivering innovative medicines to society 
(Beresniak et al., 2015). 
 
5.5 Concluding remarks and future work 
Homozygosity mapping has considerably contributed to identifying recessive 
mutations in consanguineous families. Combining homozygosity mapping with 
next generation sequencing is a powerful strategy, applied in this current 
research that enables researchers to map the locus and identify the underlying 
mutation. Although next generation sequencing is still a relatively new 
technology, it has already made a potential impact on many diverse fields. In this 
thesis different novel variants, including the ones in TUSC3, LHFPL5 and PDZD8, 
have been identified in families with intellectual disabilities and the implication of 
WHRN and 13q region in psychiatric diseases has also been further 
strengthened. The clinicians, who are treating the studied families, have already 
been updated with these findings. It is expected that the members of the families 
would benefit from the feedback as it imparts knowledge and makes them more 
aware of their genetic make-up to help make informed choices such as facilitating 
carrier testing in cases were  interrelated marriages are intended. Furthermore, it 
helps them to consider prenatal or pre-implantation testing for future pregnancy. 
 
In the field of neuroscience, NGS has revolutionized approaches of genetic 
analysis and allowed the detection of many rare and de novo mutations. 
Furthermore, a huge number of novel neurological disease genes have been 
discovered, resulting in the elucidation of their principle aetiologies. The great 
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wealth of the obtained data has provided greater insights into understanding the 
biology of intellectual disability and psychiatric diseases. Much greater 
knowledge is now available about the mechanisms involved in these complex 
disorders and the susceptibility risks to their development. Despite the great 
success of next generation sequencing technologies, some difficulties still exist 
with regard to bioinformatic analysis, result interpretation and ethical dilemmas. 
 
There is no doubt that the mutations identified in this thesis have generally 
extended the information related to the causes of the diseases but it is too early 
to consider any therapy based on these findings. For example, TUSC3 is involved 
in the glycosylation process which belongs to the metabolic pathways of the 
genes implicated in ID. It might be worth doing a future study to find out more 
about the exact role of TUSC3 in glycosylation, particularly in relation to the 
proteins that are known to have a role in the brain. TUSC3 gene is also known 
as a tumour suppressor and it would be good to monitor the affected members of 
Family-1 for the presence of tumours in the future. The variant identified in NHS 
gene was reported in patients who did not have the characteristic 
ophthalmological features seen in Nance-Horan syndrome. Although it would be 
useful to follow and re-evaluate the vision of affected members in the family, more 
work needs to be also done to further assess the pathogenic significance of the 
reported NHS variant.  
 
The implication of new ID genes, like PDZD8, in this small set of families suggests 
that the field of neurological diseases is probably still enriched with numerous 
undiscovered mutations It would be interesting to see if cognitive deficits are 
present in PDZD8 KO mice (Pdzd8tm1b(EUCOMM)Wtsi ) that have already been 
arranged to be imported to Leeds from the Wellcome Trust Sanger Institute 
(Hinxton, UK). PDZD8 is a cytoskeletal regulator but not much information is 
available for this protein. The fact that PDZD8 is of poorly understood function 
makes it difficult to predict the exact pathways that links it to the ID. Because of 
that, functional characterisation is actually needed to follow the exact role of 
PDZD8. One of the follow up work for the three unsolved ID families is to do whole 
genome sequencing (WGS), which might identify some underlying mutations that 
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have not been possible to be picked by the performed strategies. For the studied 
psychosis families, mutated WHRN appears to have a role in the development of 
schizophrenia and evidence of mutations from other future reports would be 
important for its implication to this disorder. Similarly, the identified 13q region 
have strengthened the importance of this region in the occurrence of psychiatric 
diseases and reverse transcriptase RT-PCR on patients’ lymphocytes for  the 13 
genes in this region could suggest the presence of an underlying mutations. 
Sanger sequencing could then identify large deletion/insertion, promotor variant 
or intronic mutation  in one of the genes.    
 
In terms of therapy, a considerable impact has generally been achieved and the 
commonly prevailing view that no treatment is available for cognitively impaired 
individuals has been changed in recent years. Different types of therapies have 
been utilised to improve the intellectual ability of patients, including cognitive, 
behavioural and psychodynamic therapies. Although not much improvement has 
occurred in the medication side, the application of siRNAs and CRISPR/Cas9 has 
proved the possibility to restore the action of the mutated gene using cells or 
animal models. Furthermore, stem-cell technology is another exciting application 
and its advances have already allowed modelling conditions like schizophrenia 
and bipolar disorder, providing important information for their therapy. The move 
to personalised medicine, which is facilitated by smart cards and electronic 
records, is a pronounced evolution that would allow selecting the best treatment 
option that matches the patient’s need. It is therefore obvious that research has 
the potential to yield massive outcomes in both technology and treatment but the 
demand is still there for lives to be free from disease. 
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Appendix 2- Details of the primers used in this study 
 
F= Family, temp= temperature, S= standard, HS= hot-shot master mix, PCR= polymerase chain reaction, RT= reverse transcriptase, Q= 
quantitative, CNV= copy number variation, CH= compound heterozygous, BLG= Belgian sample and SDM= site directed mutagenesis.      
 
Oligo  
name 
Forward primer (5’-3’) Reverse primer (5’-3’) 
Annealing 
temp (oC) 
Product 
size (BP) 
Remarks 
OR4L1 TTTTTGGACGATGGGAACTT CAGCTTGTGGCTCATGATTG 57 371 F4, S-PCR 
HSH2D CAAAGCCAGTCCTGTGTCAC GGCTTTTGAGAGATGTGGCC 57 349 F4, S-PCR 
TUSC3 GAAATTCAAACAAAAGGACTTTGA ACATGCCCCCAATAAAAGAA 56 424 F1, S-PCR 
ALOX5AP CACACCTCCTCTCATCTCCC TAGATCCTGGGGCCACTCTA 57 391 F1, S-PCR 
LTBP4 ATGGTCCCGAGATTTGTGGA CCACAACCCGAAAATTCCCA 60 419 F1, S-PCR 
CREB3L1 CAGATGGCTGGGAAATCAAC GGAGAGTTTGATGGTGGTGTT 56 395 F6, S-PCR 
DIXDC1 ACCTGAACCTGTGAACGCTA ACAAGGGCAAACTACAAGGG 56 269 F6, S-PCR 
LHFPL5 AGCCACAGGCCTAATGATTG TGATTTCAGGGAGGACAAGG 57 392 F2, S-PCR 
DEFB126 AAAGAATGGTTGGGCAATGT AAGCCTCTTTGCTTTAATGAGTCA 57 260 F2, S-PCR 
SIGIRR AACTTCCTGGGCCTCACAG ATTTTCTGGCACTGGGAGGC 59 442 F5, S-PCR 
SLC35C1 TTCATGTGGAGTGCTTTGC CAGCTGGGCAAAGTCACG 60 433 F5, S-PCR 
CLCA4 GCCAACTCCAAGGAAAGCTT TGAGTTTATGATCACACATGGGA 58 422 F5, S-PCR 
DLX6 AAACCCGGGAGAAGGCTTT TAGGACTGGAGGTAAGGGCT 57 432 F5, S-PCR 
MUC17 ACTCAGGTGGCCACTTCTAC GCCTCAGGACTGGTCACC 57 320 F5, S-PCR 
MMP12 GCACAGAACAGCCCAGACTA GCCACGTATGTCATCAGCAG 57 330 F5, S-PCR 
CELA1 TGTGATTTTCCCTGCCTTGC TCCAGGAGAGTAAAGGACGC 59 325 F5, S-PCR 
RBPJ ACCTACACACCAGAACCAGG CCAACCAACCAACAAAACAGC 57 447 F3, S-PCR 
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Oligo  
name 
Forward primer (5’-3’) Reverse primer (5’-3’) 
Annealing 
temp (oC) 
Product 
size (BP) 
Remarks 
PODXL AGCGGCAGGGAGGAAGAG GTGGATGGTGCAAGGTCAG 57 431 F3, S-PCR 
AKR1B10 GCGATTGTACCTGAAGCCAC TCCCTGGGCTGGAAAATGAT 57 335 F3, S-PCR 
TRPV6 CTTCCTCTGGTTCTGCAGGA CACTGGCCTAAAGTCCCTGA 60 366 F3, S-PCR 
TRPV5 GGACAGGGTAAGGAGTGGAG GGAATAGGAAGCAAGGGACC 57 438 F3, S-PCR 
OR2A14 CCAGGAAAGCACCATCTCCT CAAGTAGGAGACCAGCACCA 57 450 F3, S-PCR 
CYP2C9 ACCCCTGAATTGCTACAACA CCCGGTGATGGTAGAGGTTT 57 345 F3, S-PCR 
ANKRD2 CCCATCCCCTAGTGTGACAA TGCTCCTGGATCATGCAGAA 57 430 F3, S-PCR 
PDZD8 TAAGGACAGTTCGGACGACC ACATGGTGGTCTGATTCTCCT 57 408 F3, S-PCR 
ALOX5AP CACACCTCCTCTCATCTCCC CTGGGAGCCTCGGTTCTTAA 62 354 F3, S-PCR 
KBTBD6 ATCTCCACCATGCAGTCCC TCACTGAGAGACACACGACC 60 422 F3, S-PCR 
MYH8 GTGTGTGTGTAAAGCCTGCA AGCTTCAGTAACATGGTGCA 58 448 F3, S-PCR 
CENPV CCCTGGGCCTGAAGACTG GAACGTCTCCCAGCGCTC 58 447 F3, HS-PCR 
MPRIP CTGACATTGTGTAGCTGGCC CATTCCCGTGCATACAAGCC 57 384 F3, S-PCR 
KCNJ18 GAGGAGGGCGAGTACATCC TGTGGAAGTGCGAGTAGTCA 55 325 F3, S-PCR 
MUC16 GCAAGGCAGCCCAACATATT ACAAACCTGCACATGTTCCC 58 424 F5, S-PCR 
ANKLE1 CTCCTTGTCTTCCTGGCTGA GCTTCCCTTCTTGTCCTCCT 57 344 F5, S-PCR 
FAM47C CCCACGGAGCCTGGTAAATA CCAGGCAGAGATCAGGCAC 59 403 F5, S-PCR 
DGKK ACATCCTTTCCAGTCCTGCT GGCACACAGACCTCCTTTTG 57 360 F5, S-PCR 
IL2RG GTCTCAAACTCCTGGCCTCT TGGTCTCTGATCCAACCCAC 57 355 F5, S-PCR 
FAM171B CTTCCTCCTGCCGGTGAG GAGGCCCTAAGAGATCGCC 59 439 F6, S-PCR 
OR4C45 GCACAGACACTCACACCTTG AGGTGTAAATAGGGTGCAAAACA 57 273 F6, S-PCR 
NR1H2 GATGAGGGAGCAGTGTGAGT CCGTCACACTCAAGGTTGTG 55 404 F6, S-PCR 
ZNF654 TGTTCAGACAGACTCAAATCCT TTTGGTTTGGAAGGTGCCTG 57 432 F4, S-PCR 
MYH6 CCCTCTTTGTCTCTCGCTCT ATTCCCCACCTCAGTTCTGG 58 381 F4, S-PCR 
NGDN GAACTTGGGAAGGGATGCTG GGAGCTGTGGGACCTTAGAG 57 349 F4, S-PCR 
FLJ22148 CTCCGAGTTCTGGGAGCTG GACTCTGTGACGCTAACCCT 57 417 F4, S-PCR 
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Oligo  
name 
Forward primer (5’-3’) Reverse primer (5’-3’) 
Annealing 
temp (oC) 
Product 
size (BP) 
Remarks 
PS3 ACTTGCCTCTGGAACACCTT TTATCAAATGTCCGTCGGCA 57 352 F2, S-PCR 
TTC30B GGATGCCAGGCCTACAGAA ATCCCTGCTAGCCCATCAAG 59 420 F2, S-PCR 
MSX2 TTACCACATCCCAGCTCCTC TGGGAAGCACAGGTCTATGG 58 393 F2, S-PCR 
KRT6A TCTTAGGCTCTCTGTGGCAG TGCCAATTCTCCTCTCCCAG 59 294 F2, S-PCR 
LRCOL1 ACATTCCCTTTCTCAGCCCC GCACTGCAGGAAGATGGTCT 56 341 F2, S-PCR 
RFPL2 GGATATGGGCATGCAGAACG GAGCGTTCCTAAGTCTACCCA 57 276 F2, S-PCR 
NHS TGAGTGAGATGTTTGCCCCA CAGGATCTCAGTGGCAGACA 58 310 F2, S-PCR 
CLCN5 CTTCTTAGCCTTGTTGACTTCCT CGCTTGGCTTCATTCTTCCT 57 259 F2, S-PCR 
PSMD10 CTCCTTGCTAACCCTTCCTAAA CCGCCTTCCAGTAACATGAC 60 356 F2, S-PCR 
MAMLD1 GAATTTTCACCTCCAGCCCC CTTGGCTGAGGGGTGTTTTC 60 288 F2, S-PCR 
MAGEC1 GATTTCTCAGAGCCCTCCTGA GTGGAGGAGAAGGAGCGG 61 288 F2, S-PCR 
GPR151 TGTGTGATTGGCATCCTCCT TCCACACCTTCATGATGCCT 57 389 F2, S-PCR 
ACIN1 ATTCATCCTCTAGCCGGTCC GGGGCTGAAATGAAAACCACT 58 306 F4, S-PCR 
HOMEZ CACCAACAGCTACGGGAAAC ACCCACCCTGAAGAACACAA 58 370 F4, S-PCR 
FSIP2 GCCAGTGCCATTTTGAAGCT GGCCTGTGACTTCCCTTACT 57 445 F6, S-PCR 
ASB8 ATTATGGCGCAGAGGTCAGA AGGAGTACTGCAGGGACAAC 57 417 F6, S-PCR 
WNT1 CTCCTCCACGAACCTGCTTA AACGCCTGGTAGAAGTCTGG 59 410 F6, S-PCR 
BIN2 TGAGAGGCTGGAAAGGTTGA TAGGAAAATGGGCACGGAGA 60 318 F6, S-PCR 
CELA1 AGTGATGGATGACAAGGGGT ATAAAGGACCAGGGTTGCGA 62 379 F5, HS-PCR 
EFHC2 GTGTGAAGTCCCTTTGCTGG CCTTGAGGGGAAAACAGGTG 59 276 F5, S-PCR 
IQSEC2 CCAGTCACCATTGTCACCAC ACATGGGGAGGAGGACATTG 61 333 F5, S-PCR 
UPRT GTTACAGTGTCCGGACTCCA ATGATGGTCTGTAGCTCCCG 62 366 F5, S-PCR 
GPR98 AGCAGCATGAGAATGGACCA CCGATGAGATTCTGGGTGGA- 57 301 F5, S-PCR 
FAM81B GATTCTAGTTCTGGTTCCTGGC TTTGACGATGCTGGTGATGG 57 300 F5, S-PCR 
HLA-DRB5 TCGGGGTTATGGTTGGGATC TTCCAGTACTCAGCGTCAGG 62 303 F5, S-PCR 
TOLLIP GACTGGTGTTTGCTGAGACC GATGGCGGCATCCTTGTTC 57 322 F5, S-PCR 
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Oligo  
name 
Forward primer (5’-3’) Reverse primer (5’-3’) 
Annealing 
temp (oC) 
Product 
size (BP) 
Remarks 
SUPT20HL1 AGGGCATTGCTGGACTACTT TACAGAGGGCCACGAATACC 57 414 F5, S-PCR 
GRIA3 CTTCCCCTCACCTTGTCACC AACTCTGGGCTAAGGGGTTC 57 364 F2, S-PCR 
KCNK17 CTCTCCCGCTATGTACCGAC TTCCCGACGTTTCCCTGAA 60 376 F2, S-PCR 
MRPS10 GCACAGGTTCATGTCTCTATGG ACTAGCCCCTTTCTCGTCAC 62 331 F2, S-PCR 
TMEM132D TTTTCCTTGCTGCCCACCTA CCGGCTCAGGTAGACTTTGT 62 309 F2, S-PCR 
MMP17 GCCCATGTGAGCGCCATG TGCACTGCTGGGGTCTTC 62 270 F2, S-PCR 
ANKRD2_1 CAGCCAGCAGTTCCCTTTTG GATCTCCCTCCCCTTGACAG 60 494 BLG, S-PCR 
ANKRD2_2 GATGTCTCTGTGGGGTGTCC AGATTCTGCAGGGCTAGCAA 60 327 BLG, S-PCR 
ANKRD2_3 GCTTAGCTCAGAGGTCTCCC GGTCTCCTCATCCACAGGG 60 356 BLG, S-PCR 
ANKRD2_4 TCCAGAACCTCATCGAGCTG GGTCAATTCCTGTACGGGGA 60 476 BLG, S-PCR 
ANKRD2_5 TAGAGCATAAGGGAGCTGGC GGAGGAGAAGGGGCTTACTC 60 417 BLG, S-PCR 
ANKRD2_6 ACTTTCTTCCCTGCAGCTCT TGCAGCCAGAAACCAGACTA 57 269 BLG, S-PCR 
ANKRD2_7 TGTACCATTCTCTGCCCCTC CACTCACTATGGCCCTTGTG 60 421 BLG, S-PCR 
ANKRD2_8 CCTGGGCCTGGAAATCAATG ATAGAGAATGGGGCGGACAG 57 500 BLG, S-PCR 
ANKRD2_9 CTGGTGGTGTCAATGAGGGT AGTTTCCCTCCTCCCCAAAC 60 492 BLG, S-PCR 
PDZD8_1 AAGGGCCGCAGAGAAGTAAA GGAAGAACTGGGCGAGGAG 57 353 BLG, S-PCR 
PDZD8_2 GCCCGATGTCCTCAAAATGG ATGGTGGCGTTGAGGAAGTA 57 402 BLG, S-PCR 
PDZD8_3 GACGCGGGAGACTTGCTA CCCGTTGTACTCCACCTCC 57 298 BLG, S-PCR 
PDZD8_4 GCCCTTCATCAAGACCATCC TCCCCGACCTCCAGCTCA 57 450 BLG, S-PCR 
PDZD8_5 TGTAGAGCACGTGTAGTATTAGG TTTTCACTGCACTGTTCTTCCC 57 472 BLG, S-PCR 
PDZD8_6 ACAGGTATGATACTCTCCCTTGT TGAAAGGAAAGCTAGTCGGACT 57 327 BLG, S-PCR 
PDZD8_7 ATCAGCCATGGTGCTCTCTG GAAGGTGGGAAGGGAAGGAT 59 400 BLG, S-PCR 
PDZD8_8 TCAGCACATTCAGGGTTTGA ATCTACTGTCAACCCGGCAG 57 411 BLG, S-PCR 
PDZD8_9 GGCCAGAGTAATCAAGGTGC TGGCACAGGTGGTTTGAAAG 57 388 BLG, S-PCR 
PDZD8_10 AGCTGTAGGAAGTCACCCAC GGTCGTCCGAACTGTCCTTA 57 290 BLG, S-PCR 
PDZD8_11 GTGCCACCTCCTCTTGTAGA CCGTGTTTGATGTAGCTAGGC 57 502 BLG, S-PCR 
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Oligo  
name 
Forward primer (5’-3’) Reverse primer (5’-3’) 
Annealing 
temp (oC) 
Product 
size (BP) 
Remarks 
PDZD8_12 TGGTGCAGGGATCCTTTCAA CTGTTAAACCCATCTGTCCAACA 60 320 BLG, S-PCR 
PDZD8_13 AGGAGAATCAGACCACCATGT TCCTGTCCTTCCAGCCTAAG 55 346 BLG, S-PCR 
PDZD8_14 TGGAGCAACTGATAGGCGAA CCCTGTACAGATCACGACCA 57 473 BLG, S-PCR 
PDZD8_15 CAGACAACGAAGGCAGTGAC TGCCTGCTCTGTAGTGAATCA 57 426 BLG, S-PCR 
PDZD8_16 TCACTTCTTTCTGCTGCCTT AGTAACTGGAGAAGCAGGCC 57 279 BLG, S-PCR 
PDZD8_17 ATCCTCGTATGCACTCTGGC TTGTCAGTTTGGGCATGCAG 59 354 BLG, S-PCR 
A2ML GGAGACATTATGGGCACAGC TACCCTGGGAAGCCAAATGT 58 348 F4, S-PCR, CH 
BZRAP GAATGGGGAGCTGCGACA GCATGGGCCAAGTTGCTATT 60 255 F4, S-PCR, CH 
CACNA1B GAACTGCTTCACCGTCAACC CGCACTCACGGAAATGCTC 58 270 F4, S-PCR, CH 
HSPB7 AACCTCTTCCACCTTCCGAG ACATCTGTCTTGGTGGCCA 58 334 F4, S-PCR, CH 
SLC26A9 ACACACACACACACACACAC GGAGAGAGGAACCCAAGCTC 57 319 F4, S-PCR, CH 
ZAN AGGCTGGTCTCAAACTCCTG GGATCCATCTTGTTGCGTCC 60 281 F4, S-PCR, CH 
NLRP5 CAACGTGGAATGTCTGGCAC CCCATTTCTCCCTCCTCCAT 62 336 F6, S-PCR, CH 
OR4X1 AATTGGAGTGAGCAGAGGGT ATTCGCTGGTTCATGATGGC 58 362 F6, S-PCR, CH 
PABPC3 CGTGGTTTGTGATGAAAATGGT CTTTCACACTTAAGGCGGGC 60 278 F6, S-PCR, CH 
YTHDC2 CAGCATTGATTATCCCCATCCA TTGACCAATCCTTTCCCGTC 61 474 F6, S-PCR, CH 
FUCA1 TCCCTTCTTGAGCACCAGAG GATGAACACCCCGAACTTGG 59 360 F5, S-PCR, CH 
KIAA0040 TCAGTGCCTTCTTCAGCTCT TGGTCAGAAGGAGGCTTAGC 57 343 F5, S-PCR, CH 
KRT4 AGAAGCCTCTACAACCTCAGG ACAGCTCACCTTGTCGATGA 57 324 F5, S-PCR, CH 
MROH8 ACTCCCACCAGCTCGCAG TTAGAACTCATCCTGGCCCG 55 320 F5, S-PCR, CH 
MYO18B CCACTGCTTTGCCACCTAAG GGGAGGGACAGCAATTCTCT 57 274 F5, S-PCR, CH 
MYO5C ACACGCAACGCTGTAATTGT GTTTCCTTAGCAGCGACACA 57 259 F5, S-PCR, CH 
PABPC3 GACGGAACTTAAGCGCACAT GTGGCCACAATTCTACCGTT 57 261 F5, S-PCR, CH 
SGSM2 TCTCATCCCACTGTGAGCTG GTAGTGGCCAAGCAGAAAGG 60 274 F5, S-PCR, CH 
SPATA13 GGGGAGCTGACCAAAATCAC CCTCGTCTGTGGTCCTACTG 60 235 F5, S-PCR, CH 
SYNE1 CCCGGCCCTAAACCAATTTT GAAAAGTGCAGTCCTGAGCC 60 394 F5, S-PCR, CH 
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Oligo  
name 
Forward primer (5’-3’) Reverse primer (5’-3’) 
Annealing 
temp (oC) 
Product 
size (BP) 
Remarks 
SLC26A9 CCTCTCCGAGTCCTTCATCC TGAAGGAGGAGGGATGGAGA 59 425 F5, S-PCR, CH 
CACNA1B-a GGGTCCTCTACAAGCAATCG CGCACTCACGGAAATGCTC 57 343 F5, S-PCR, CH 
CACNA1B-b CAGTTGTCTCAGCCCCTCC TGTTCTCAGGCACAGACCAT 57 305 F5, S-PCR, CH 
CACNA1B-c TGGAGAATCTGCAGGGTGTT AGCTTGCCTACCCTGTGAG 60 309 F5, S-PCR, CH 
ZAN-a GATTACAGGCACGCACCAC GGATCCATCTTGTTGCGTCC 58 355 F5, S-PCR, CH 
ZAN-b CCTCACATCCCTTTCTCCCA GGGAAGGAGAACAGGCGAA 59 342 F5, S-PCR, CH 
MROH8 GAGCGGCGACTAGTAACCTC AACTGCAAGGCCCTGTGA 57 299 F5, S-PCR, CH 
NBPF4 TCTCACTTGTGGATGGTGCT GCATTGCTCATACTCTGCCC 58 568 F4, S-PCR, CNV 
DMD GCCTAAGCCTTGGTTTAGCG AAAGTAGCCTCCCCTCAACC 58 598 F4, S-PCR, CNV 
C3ORF33 CGTAGAAAAGGGTGAAACGGT AGAATCGCTTGAACCCAGGA 58 461 F6, S-PCR, CNV 
ARNT2 TCTGTAGGTCTCCAGCTCCT GGTTCCCTTGTCTGCCTTTG 55 600 F5, S-PCR, CNV 
TCF4 GCCATTGCCATTTCCAAAAGG GAGATGGGGAGAAGGCCATT 62 440 F5, S-PCR, CNV 
LAMA2 CTTGCCAGCTCCACTTTCTC CAGTAACAACCCGATTAACTGGA 58 410 F5, S-PCR, CNV 
EFCAB12 CAGAGGCTTAGGGAGGGATG CCCACACTGAAGGGATAGCA 58 287 F4, S-PCR, CNV 
SPINK14 AATGGAACGGTCAACCCCT AGGGCTCAGATACCAGAACG 60 333 F4, S-PCR, CNV 
LCE3C CTGCAAAGATGTCCTGCCAG TCATCAGGATCCAGGTCAGC 60 308 F4, S-PCR, CNV 
UGT2B17 TCCAATAGCTCCTGACTTTCTCA TCATTTAGTAGCCATCCACAGTT 55 277 F4, S-PCR, CNV 
SIRPB1 AGGTAGCCTCAGATGGGGTA GGTTCCCTGAGACTCCTGAG 55 536 F4, S-PCR, CNV 
GSTT1 AGAATCACTTGAACCCGGGA AAGAGACTGGTGCCTGAACA 57 389 F5, S-PCR, CNV 
PCDHA7 CTGACTGGCACCGTTCAATT TGAGAGTCAACTGTGGAGCA 57 394 F6, S-PCR, CNV 
DFNB31-1 GCCACTGTACCCGTGCTC CTGCCTGTAGGGGGTGGT 57 517 F7, S-PCR, SDM  
DFNB31-2 TGCTCTTCGACCAATACACG CCTTTTTCTCATCCCCTCCT 57 528 F7, S-PCR, SDM  
DFNB31-3 AGGAGGGGATGAGAAAAAGG GGGTGTTGAGCAGCTTGAA 57 590 F7, S-PCR, SDM  
DFNB31-4 CCCTGTTCAAGCTGCTCAA AGGCATAGATGGGGGAAGAG 57 573 F7, S-PCR, SDM  
DFNB31-5 TCTTCTCGGCTCCACAGAAC- GCAGCTCCTTGCTACTCCTG 60 522 F7, S-PCR, SDM  
DFNB31-6 CCACCAAGAGCAGGAGTAGC CCCAGTACAGCACCAGTTCC 57 592 F7, S-PCR, SDM  
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Oligo  
name 
Forward primer (5’-3’) Reverse primer (5’-3’) 
Annealing 
temp (oC) 
Product 
size (BP) 
Remarks 
ANKRD2 TCCAGAACCTCATCGAGCTG CCACAGTGGCCCCATTATCT 61 288 F3, RT-PCR 
PDZD8 CAAGCACACCCTACCGAATT CGAGTTTGGAGCCACAGTTT 61 367 F3, RT-PCR 
TP53 GTACTCCCCTGCCCTCAACA CTGGAGTCTTCCAGTGTGA 61 600 F3, RT-PCR 
CG10632 GACCTTCTGCTGGACATCAAC CAGTGCGTGTAGGGCTTTCT 60 152 F3, Q-PCR 
eEF-1a  GTCTGGAGGCAATGTGCTTT AATATGATGTCGCCCTGGTT 60 97 F3, Q-PCR 
KCTD12 GAGCGCACTGGAACTCAAG TGTAGCGGAAGAGGAAGCC 57 500 F8, RT-PCR 
ACOD1 CCATGGCTTGAAAGTGGGAC GTAATCGGCCTTGCACTTCA 60 600 F8, RT-PCR 
CLN5 GAGAGGCTCCGGAAGTACTG CCATTGTGTAGTTCTTGCCAGT 60 431 F8, RT-PCR 
FBXL3 AAAGCTTCTTTCTGGGCAGC TCTCCACAAGTCAGGCATGT 60 450 F8, RT-PCR 
MYCBP2 GTCGTTGGAAAAGGGCTGTG TCAGACTTGCTTCTTGTCTTCAC 60 472 F8, RT-PCR 
SCEL TACTGGAAGGCAGCATGTCC GTGTTGGAGGTGTTGGCATT 60 451 F8, RT-PCR 
SLAIN1 GCCCTTCGTCTACTTCAAGC CTTGCAGACGAGCCATGATC 60 476 F8, RT-PCR 
EDNRB GCTGAACACTGGGAAGGAAC AACACAAGGCAGGACACAAC 60 437 F8, RT-PCR 
POU4F1 TCCAGCTCCGAGGCCATC ATATGCGGGTGAGGGTGC 60 500 F8, RT-PCR 
RNF219 GAAGAGTAGCGGTAGGTCGG CCCTGCACCAAGGTTAAAGG 60 463 F8, RT-PCR 
RBM26 ACCACCCATGCCAAAGAAAC GGAGGAGGCTGGTGATGAAT 60 393 F8, RT-PCR 
NDFIP2 CAGGAACGGAGGCGGAAG AGCCTTCTCAGCTTCATCGT 60 409 F8, RT-PCR 
SPRY2 GTGTTCATCAGCGGGGAATC GTGTTTGTGCTGAGTGGAGG 60 471 F8, RT-PCR 
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Appendix 3- Genotyping microsatellites.  
The genotyping markers used in this thesis were D1S478, D4S3042 and D7S483. 
The following is a representative example of the analysis report obtained from 
Gene-Mapper software version 3.7. This reading was generated for sample IV.6 
of family-3 when tested with D4S3042 marker. The image shows the double 
alleles 220/220.   
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Appendix 4- QC measures of NGS 
 
Various QC check was performed during the library preparation for the NGS samples. 
This is one example of the quality check and it was done after DNA shearing step, at 
which 1μl of the sample was loaded on a DNA 1000 chip and run on a 2100 Bioanalyzer. 
This report was generated by Agilent 2100 Expert Software, and it shows the expected 
distribution curves for two samples, with a peak size between 150 to 200 nucleotides in 
their electropherograms.   
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The quality check charts are examples of the quality measures that were investigated after getting the results of exome sequencing and 
before doing the analysis process.  The scores which are shown here belongs to the case V.9 in Family-1, at which the data was processed   
using FASTQC on the Galaxy platform. A. whisker-type plot showing a general overview of bases positions. Green area is for the very good 
quality calls, orange area is for the acceptable calls and red area is for the unacceptable poor quality calls. B. plot of the average quality per 
read. C. Plot of the average sequence content for the four DNA bases (A, T, G and C). D. Plot of the GC content distribution compared to 
a reference. This sample showed a very good quality calls as its reads were located in the green area. The sample has 72,326,188 reads 
and none of them was flagged as poor quality. The average quality per read is 39 and the distribution of GC content is slightly different than 
the reference distribution but still within the expected range.   
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Appendix 5: UNIX console  commands  
 
A) Whole exome analysis  
 
1.1 Alignment (Novoalign/Bowtie2) 
$ novoalign -c 12 -d <path> b37/human_g1k_v37.nix -f sample_R1_001.fastq.gz 
sample_R2_001.fastq .gz -o SAM $'@RG\tID:sample_novoID\tSM:sample\tPL: ILLUMINA\tLB: 
sample_ exome' -k –K mismatches_sample_novoID.txt 2> novostats_sample_novoID.txt > 
sample_novoID.sam 
$ <path> /bowtie2- version no /bowtie2 -x <path> /ucsc.hg19.idx -p 6 -q -1 <path> 
Sample_R1.fastq -2 <path> Sample_R2.fastq -S <path> Sample.sam --sam-rg ID: IN--sam-rg 
SM:IN --sam-rg PL:Illumina --sam-rg PU:HiSeq  
 
1.2 Remove reads which don’t map uniquely 
$ sed '/XS:/d' <path> Sample.sam >  <path> Sample_uniqueAlignment.sam   
 
1.3 Sorting and idexing alignment sam file (Samtools or Picard) 
$ <path> /samtools-version no/samtools view -bt <path> /DataFiles/ucsc.hg19.fasta.fai <path> 
Sample_ uniqueAlignment.sam > Sample_uniqueAlignment.bam 
$ <path> /samtools-version no/samtools sort <path> Sample_uniqueAlignment.bam <path> 
Sample_ uniqueAlignment_sort 
$ <path> /samtools-version no/samtools index <path> Sample_uniqueAlignment_sort.bam  
$ java –Xmx8g -jar <path> /picard/picard-tools- version no/SortSam.jar I= 
Sample_uniqueAlignment .sam O= Sample_uniqueAlignment_sort.bam SO=coordinate 
CREATE_INDEX=TRUE 
 
1.4 Remove duplicates (Picard) 
$ java –Xmx8g -jar <path> /picard/picard-tools- version no/MarkDuplicates.jar I= <path> 
Sample_unique Alignment_sort.bam O= <path>  Sample_uniqueAlignment_sort.rmdups.bam 
M=Sample. rmdups. metrics CREATE_INDEX=TRUE 
Alternative 
$ java -Xmx8g -jar <path> /picard/picard-tools- version no/MarkDuplicates.jar INPUT= <path> 
Sample_ uniqueAlignment_sort.bam REMOVE_DUPLICATES=true 
VALIDATION_STRINGENCY =LENIENT AS=true METRICS_FILE= 
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Sample_uniqueAlignment_sort_metrics_file.dups OUTPUT= <path> Sample 
_uniqueAlignment_sort.rmdups.bam  
 
1.5 Create indel realigner targets (GATK) 
$ java -Xmx8g -jar <path>/GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T Realigner 
TargetCreator -R <path> /human_g1k_ v37.fasta –known <path> /b37/1000G_phase1. 
indels.b37.vcf -known <path> /Mills_and_1000G_gold_standard.indels.b37.sites.vcf -I <path> 
Sample_uniqueAlignment _sort.rmdups.bam -o <path> Sample_uniqueAlignment_sort.rmdups. 
indelrealign.intervals 
Alternative 
$ java -Xmx8g -jar <path>/GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T 
RealignerTargetCreator -R <path> /ucsc.hg19.fasta -I <path> Sample_uniqueAlignment_sort. 
rmdups.bam -known <path> /1000G_biallelic.indels.hg19.vcf -log <path> 
Sample_uniqueAlignment _sort.rmdups. indelrealign.intervals.log -o <path> 
Sample_uniqueAlignment_sort.rmdups.indelrealign.intervals 
 
1.6 Perform indel realignment 
$ java –Xmx8g -jar <path>/GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T 
IndelRealigner –R <path> / human_g1k_v37.fasta –known <path> /1000G_phase1.indels.b37.vcf 
–known <path> /Mills_and_1000G_ gold_standard.indels.b37.sites.vcf –I <path>  
Sample_uniqueAlignment_sort. Rmdups.bam -targetIntervals <path> 
Sample_uniqueAlignment_sort.rmdups.indelrealign.intervals –o <path> 
Sample_uniqueAlignment_sort.rmdups.indelrealign.bam 
Alternative 
$ java -Xmx8g -jar <path>/GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T 
IndelRealigner -R <path> /ucsc.hg19.fasta -I <path> Sample_uniqueAlignment_sort. 
rmdups.bam -targetIntervals path> Sample_uniqueAlignment_sort.rmdups.indelrealign.intervals 
-log <path> Sample_uniqueAlignment _sort .rmdups. indelrealign.intervals.log –o <path> 
Sample_uniqueAlignment_sort.rmdups.indelrealign .bam 
 
1.7. Recalibrate base quality scores (GATK) 
1.7.1 Get the recalibration model 
 $ java  -Xmx8g -jar <path>/GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T 
BaseRecalibrator –I <path> Sample_uniqueAlignment_sort.rmdups.indelrealign.bam -R <path> 
/human_g1k_v37.fasta –o <path> Sample_uniqueAlignment_sort.rmdups.indelrealign.recal.grp 
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–knownSites <path> /dbSnp version no.b37.vcf.gz –knownSites <path> 
/1000G_phase1.indels.b37.vcf –knownSites <path> /Mills_and_1000G 
_gold_standard.indels.b37.sites.vcf -nct [no.threads (8)] 
 
1.7.2 Check the recalibration model  
$ java –Xmx8g -jar <path>/GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T 
BaseRecalibrator –I <path> Sample_uniqueAlignment_sort.rmdups.indelrealign.bam -R <path> 
/human_g1k_v37.fasta –BQSR <path> 
Sample_uniqueAlignment_sort.rmdups.indelrealign.recal.grp -o <path> Sample_unique 
Alignment_sort.rmdups.indelrealign.postrecal.grp -knownSites <path> /dbSnp version 
no.b37.vcf.gz –knownSites <path> /1000G_phase1.indels.b37.vcf –knownSites <path> 
/Mills_and_1000G_gold_ standard.indels .b37.sites.vcf –nct 8 
 
$ java –Xmx8g -jar <path>/GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T  Analyze 
Covariates–R <path> /human_g1k_v37. fasta -before  <path> Sample_uniqueAlignment_sort. 
rmdups. indelrealign.recal.grp –after <path> 
Sample_uniqueAlignment_sort.rmdups.indelrealign.postrecal.grp–plots <path> 
Sample_uniqueAlignment_sort.rmdups.indelrealign.postrecal.plots.pdf 
1.7.3 Apply the recalibration 
$ java –Xmx8g -jar <path> /GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T 
PrintReads –R <path> /human_g1k_v37.fasta -o <path> 
Sample_uniqueAlignment_sort.rmdups.indelrealign.recal.bam –I <path> 
Sample_uniqueAlignment_sort.rmdups.indelrealign.bam –BQSR <path> Sample_unique 
Alignment_sort.rmdups.indelrealign.recal.grp –nct 8 
 
1.8 Variant Calling (SNVs and indels) (UnifiedGenotyper/HaplotypeCaller) 
$ java -Xmx4g -jar <path> /GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T 
HaplotypeCaller –R <path> /human_g1k_v37.fasta -D <path> /dbSnp version no.b37.vcf.gz -
stand_call_conf 30 -stand_ emit_conf 10 –I <path> Sample_uniqueAlignment_ 
sort.rmdups.indelrealign.recal –o <path>  Sample_ 
uniqueAlignment_sort.rmdups.indelrealign.recal.raw.vcf 
 
$ java -Xmx8g -jar <path> /GenomeAnalysisTK- version no/GenomeAnalysisTK.jar –T 
UnifiedGenotyper -R <path> /ucsc.hg19.fasta –I <path>  Sample_uniqueAlignment_ sort.rmdups. 
indelrealign.recal –D <path> /dbsnp_version no.hg19.vcf -L <path> /hg19_exome.interval_list -nt 
8 -stand_call_conf 50.0 -stand_emit_conf 10.0 -dcov 200 -l INFO -A AlleleBalance -A 
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FisherStrand –log <path> Sample_uniqueAlignment_sort. rmdups.indelrealign.recal.SNP.log –o 
<path> Sample_unique Alignment_ sort.rmdups.indelrealign.recal.variants.SNP.vcf    
 
$ java -Xmx8g -jar <path> /GenomeAnalysisTK- version no/GenomeAnalysisTK.jar –T 
UnifiedGenotyper -R <path> /ucsc.hg19.fasta –I <path>  Sample_uniqueAlignment_ sort.rmdups. 
indelrealign.recal –D <path> /dbsnp_version no.hg19.vcf -L <path> /hg19_exome.interval_list -nt 
8 -stand_call_conf 50.0 -stand_emit_conf 10.0 -dcov 200 -l INFO -A AlleleBalance -A 
FisherStrand –log <path> Sample_uniqueAlignment_sort. rmdups.indelrealign.recal.Indel.log –o 
<path> Sample_unique Alignment_ sort.rmdups.indelrealign.recal.variants.Indel.vcf -glm INDEL 
 
1.9 Variant recalibration/ Hard filtering (GATK) 
$ java -Xmx8g -jar <path> /GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T 
VariantRecalibrator -R <path> /ucsc.hg19.fasta -input Sample_uniqueAlignment_sort.rmdups. 
indelrealign. SNP.vcf resource:hapmap,VCF,known=false,training=true,truth=true,prior=15.0 
<path> hapmap_3.3.hg19.vcf -
resource:omni,VCF,known=false,training=true,truth=false,prior=12.0 <path> 
/1000G_omni2.5.hg19.vcf -resource:dbsnp,VCF,known=true,training=false,truth=false,prior=8.0 
<path> DataFiles/dbsnp_version no.hg19.vcf -an QD -an HaplotypeScore -an MQRankSum -an 
ReadPosRankSum -an FS -an MQ --maxGaussians 6 -nt 8 -log <path> 
Sample_uniqueAlignment_sort. rmdups.indelrealign.recal.log -recalFile <path> 
Sample_uniqueAlignment_sort.rmdups.indelrealign. recal.recal -tranchesFile <path> 
Sample_uniqueAlignment_sort.rmdups.indelrealign.recal.tranches -rscriptFile <path> 
Sample_uniqueAlignment_sort.rmdups.indelrealign.recal.plot.R 
 
$ java -Xmx8g -jar <path> /GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T 
ApplyRecalibration -R <path> /ucsc.hg19.fasta -input Sample_uniqueAlignment_sort.rmdups. 
indelrealign.SNP -recalFile <path> Sample_uniqueAlignment_sort.rmdups.indelrealign. 
recal.recal -tranchesFile <path> 
Sample_uniqueAlignment_sort.rmdups.indelrealign.recal.tranches -ts_filter_level 99.0 -log 
Sample_uniqueAlignment_sort. rmdups.indelrealign.recal.log -o Sample_uniqueAlignment_ 
sort.rmdups.indelrealign.recal.vcf 
    
$ java –Xmx8g - jar <path> /GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T Variant 
Filtration -R <path> /human_g1k_v37.fasta -V <path> Sample_uniqueAlignment_sort.rmdups 
.indelrealign .recal.variants.SNP.vcf --filterExpression “QD < 2.0 || FS > 60.0 || MQ < 40.0 || 
HaplotypeScore > 13.0 || MappingQualityRankSum < -12.5 || ReadPosRankSum < -8.0” --
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filterName “snp_hard_filter” -o <path> Sample_uniqueAlignment_sort.rmdups .indelrealign 
.recal.variants.filtered. SNP.vcf  
 
$ java –Xmx8g - jar <path> /GenomeAnalysisTK- version no /GenomeAnalysisTK.jar -T 
VariantFiltration -R <path> /human_g1k_v37.fasta -V <path> 
Sample_uniqueAlignment_sort.rmdups .indelrealign .recal.variants.Indel.vcf --filterExpression 
“QD < 2.0 || FS > 200.0 || ReadPosRankSum < -20.0” --filterName “indel_hard_filter” -o <path> 
Sample_uniqueAlignment_sort.rmdups .indelrealign .recal.variants.filtered.Indel.vcf 
 
 
1.10 Combine variant lists (SNP and Indel) (GATK) 
$ java –Xmx8g - jar <path> /GenomeAnalysisTK- version no /GenomeAnalysisTK.jar –T Combine 
Variants -R <path> /ucsc.hg19.fasta (<path> /human_g1k_v37.fasta) --variant <path> 
Sample_unique Alignment_ sort.rmdups.indelrealign.recal.variants.SNP.vcf --variant <path> 
Sample_ unique Alignment_ sort.rmdups.indelrealign.recal.variants.Indel.vcf -o <path> 
Sample_unique Alignment_ sort.rmdups.indelrealign.recal.variants. combined.vcf. 
 
1.11 Variant filtering  
 
1.11.1 dbSNP 
$ perl <path> /vcfhacks/annotateSnps.pl -d <path> /dbSnp version no.b37.vcf.gz <path>/ clinvar_ 
20150330.vcf.gz -b 129 -f 1 -pathogenic –i <path> Sample_unique Alignment_ 
sort.rmdups.indelrealign .recal.variants. combined.vcf -o <path> Sample_unique Alignment_ 
sort.rmdups.indelrealign.recal. variants. Combined_1pc.vcf 
 
1.11.2 EVS 
$ perl <path> /vcfhacks/filterOnEvsMaf.pl -d <path> /evs/ -f 1 --progress –I <path> 
Sample_unique Alignment_ sort.rmdups.indelrealign.recal.variants.combined.vcf_notindbSNP 
version no or 1pc –o <path> 
Sample_uniqueAlignment_sort.rmdups.indelrealign.recal.variants.combined_1pc_evs.vcf 
 
1.11.3 ExAC  
$ perl <path> /vcfhacks/filterVcfOnVcf.pl -f <path> /ExAC.Version no /sites.vep.vcf.gz -w -y 0.01 
-i <path> 
Sample_uniqueAlignment_sort.rmdups.indelrealign.recal.variants.combined.vcf_1pc_evs –o 
<path> 
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Sample_uniqueAlignment_sort.rmdups.indelrealign.recal.variants.combined_1pc_evs_ExAC 
.vcf 
 
1.11.4 Control samples (3222 exomes of British Pakistani adults) 
$ perl <path> /vcfhacks/filterVcfOnSample.pl -i <path> Sample_uniqueAlignment_sort.rmdups. 
indelrealign.recal.variants.combined.vcf_1pc_evs_ExAC -r <path> /bib/BUILD-2014-19-
05/8.BB.anno .vcf. gz -o <path> Sample_uniqueAlignment_sort.rmdups. 
indelrealign.recal.variants.combined_1pc_ evs_ExAC_CF.vcf 
 
1.12 Variant annotation (ANNOVAR) 
$ perl <path> annovar/convert2annovar.pl  <path> Sample_uniqueAlignment_sort.rmdups. 
indelrealign. recal.variants.combined.vcf_1pc_evs_ExAC_CF –outfile <path> 
Sample_uniqueAlignment_sort.rmdups. indelrealign. 
recal.variants.combined_1pc_evs_ExAC_CF.annovar.vcf  
 
$ perl <path> annovar/table_annovar.pl <path> Sample_uniqueAlignment_sort.rmdups. 
indelrealign. recal.variants.combined_1pc_evs_ExAC_CF.annovar.vcf <path> 
/annovar/humandb -buildver hg19 -
protocolrefGene,phastConsElements46way,genomicSuperDups,esp6500si_all,1000gVersion 
no apr_all ,snpversion no,ljb2_all -operation g,r,r,f,f,f,f  -outfile <path> 
Sample_uniqueAlignment_sort.rmdups. indelrealign. 
recal.variants.combined_1pc_evs_ExAC_CF.annovar.vcf 
 
B) Exome depth analysis 
 
$ R 
> library(ExomeDepth) 
> data(exons.hg19) 
> print(head(exons.hg19)) 
> Mohammed_bam_files <- c (“Sample_indelrealign_recal(File1).bam”, “File2.bam”,”File3.bam”, 
etc.) 
> Mohammed_counts<-getBamCounts(bed.frame=exons.hg19, bam.files=Mohammed_bams, 
include.chr=FALSE, referenceFasta=" <path> /human_g1k_v37.fasta") 
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> ExomeCount.dafr <- as(my.counts[, colnames(my.counts)], 'data.frame') 
> print(head(ExomeCount.dafr)) 
> Moh_counts.dafr<-as(Mohammed_counts[, colnames(Mohammed_counts)], 'data.frame') 
> print(head(Moh_counts.dafr)) 
> Sample.test <- Moh.counts$ Sample_indelrealign_recal(File1).bam 
> Moh.ref.samples <-c(File2.bam',File3.bam', etc. ) 
> Moh.reference.set<-as.matrix(Moh_Count.dafr[,Moh.ref.samples]) 
> Moh.choice<-select.reference.set 
(test.counts=Sample.test,reference.counts=Moh.reference.set,bin.length=(Moh_Count.dafr$end 
Moh_Count.dafr$start)/1000,n.bins.reduced=10000) 
> print(Sample_choice[[1]]) 
> Moh.matrix <-as.matrix( Moh_Count.dafr[, Moh.choice$reference.choice, drop = FALSE]) 
> Moh.reference.selected<-apply(X=Moh.matrix,MAR=1,FUN=sum) 
> Sample.all.exons <-new('ExomeDepth',test=Sample.test, 
reference=Moh.reference.selected,formula ='cbind(test, reference)~1') 
> Sample.all.exons<-CallCNVs(x=sample_all.exons,transition.probability=10^-4, chromosome 
=Moh_ 
Count.dafr$space,start=Moh_Count.dafr$start,end=Moh_Count.dafr$end,name=moh_Count.daf
r$names) 
> head(Sample.all.exons@CNV.calls) 
> data(Conrad.hg19) 
> head(Conrad.hg19.common.CNVs) 
> Sample.all.exons<-AnnotateExtra(x=Sample.all.exons, 
reference.annotation=Conrad.hg19.common. CNVs, min.overlap=0.5, 
column.name='Conrad.hg19') 
> print(head(Sample.all.exons@CNV.calls)) 
> exons.hg19.GRanges <- 
GenomicRanges::GRanges(seqnames=exons.hg19$chromosome,IRanges::I 
Ranges(start=exons.hg19$start,end=exons.hg19$end),names=exons.hg19$name) 
> Sample.all.exons <- AnnotateExtra(x=Sample.all.exons, 
reference.annotation=exons.hg19.GRanges, min.overlap =0.0001, column.name='exons.hg19') 
> Sample.all.exons@CNV.calls[3:6,] 
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> output.file <- 'Sample_calls_File1CNVs.csv' 
> write.csv(file=output.file,x=Sample.all.exons@CNV.calls,row.names=FALSE) 
 
C) ANKRD2 and PDZD8 in UK10K analysis 
 
-Download the specific data stets from the UK10K using FileZilla 
-Decrypt the files  Openssl enc  -aes-256-cbc –d in  
-Search for variants present in ANKRD2 or PDZD8 (vcfhacks) 
perl vcfhacks/getVariantsByLocation.pl  
–i UK10K_input_file.vcf  
–o filtered_output_file.vcf  
–r 10:99332256-99343641 10:119042606-119134937 
(-i = input file, -o = output file, -r = regions to filter for) 
 
-Annotate variants using variant effect predictor (VEP) 
perl variant_effect_predictor.pl --offline --vcf --everything  
--dir_cache /home/variant_effect_predictor/vep_cache  
--dir_plugins /home/variant_effect_predictor/vep_cache/Plugins  
--plugin Condel,/home/variant_effect_predictor/vep_cache/Plugins/config/Condel/config/  
--plugin ExAC,/home/ref/ExAC/ExAC.r0.3.sites.vep.vcf.gz  
--plugin SpliceConsensus  
--fasta 
/home/variant_effect_predictor/fasta/Homo_sapiens.GRCh38.dna.primary_assembly.fa.gz  
-input filtered_output_file.vcf 
-o filtered_output_file.vep.vcf 
(-input = input file, -o = output file, all other options are telling VEP how to annotate your file) 
 
-CADD score the variants (version 1.3) and filter out anything with CADD < 10. 
perl vcfhacks/rankonCaddScore.pl  -d 
-c /data/shared/cadd/v1.3/*.gz  
-i filtered_output_file.vep.vcf  
-o filtered_output_file.vep.cadd1.3.vcf 
(-c = location of files containing cadd scores, -i = input file, -o = output file) 
 
-Convert to excel and remove anything that isn’t functional (synonymous, 
intronic, etc.) 
perl vcfhacks/annovcfToSimple.pl 
-i filtered_output_file.vep.cadd1.3.vcf 
-o filtered_output_file.vep.cadd1.3.xlsx 
-v –f –u --canonical_only 
 
(-i = input file, -o = output file, -v = file has been annotated with vep, -f = only show functional 
variants, -u = summarise variant data, X = show who has non-reference genotype
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Appendix 6- Sequence of pDEST-733 vector with DFNB31 insert  
 
cttgtacaaagtggttcgatctagaatggctagcttgggatctttgtgaaggaaccttacttctgtggtg
tgacataattggacaaactacctacagagatttaaagctctaaggtaaatataaaatttttaagtgtata
atgtgttaaactagctgcatatgcttgctgcttgagagttttgcttactgagtatgatttatgaaaatat
tatacacaggagctagtgattctaattgtttgtgtattttagattcacagtcccaaggctcatttcaggc
ccctcagtcctcacagtctgttcatgatcataatcagccataccacatttgtagaggttttacttgcttt
aaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgttt
attgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcac
tgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggatcgatcctgcattaat
gaatcggccaacgcgcggggagaggcggtttgcgtattggctggcgtaatagcgaagaggcccgcaccga
tcgcccttcccaacagttgcgcagcctgaatggcgaatgggacgcgccctgtagcggcgcattaagcgcg
gcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctcctttcgctt
tcttcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggctccctttagg
gttccgatttagtgctttacggcacctcgaccccaaaaaacttgattagggtgatggttcacgtagtggg
ccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgt
tccaaactggaacaacactcaaccctatctcggtctattcttttgatttataagggattttgccgatttc
ggcctattggttaaaaaatgagctgatttaacaaatatttaacgcgaattttaacaaaatattaacgttt
acaatttcgcctgatgcggtattttctccttacgcatctgtgcggtatttcacaccgcatacgcggatct
gcgcagcaccatggcctgaaataacctctgaaagaggaacttggttaggtaccttctgaggcggaaagaa
ccagctgtggaatgtgtgtcagttagggtgtggaaagtccccaggctccccagcaggcagaagtatgcaa
agcatgcatctcaattagtcagcaaccaggtgtggaaagtccccaggctccccagcaggcagaagtatgc
aaagcatgcatctcaattagtcagcaaccatagtcccgcccctaactccgcccatcccgcccctaactcc
gcccagttccgcccattctccgccccatggctgactaattttttttatttatgcagaggccgaggccgcc
tcggcctctgagctattccagaagtagtgaggaggcttttttggaggcctaggcttttgcaaaaagcttg
attcttctgacacaacagtctcgaacttaaggctagagccaccatgattgaacaagatggattgcacgca
ggttctccggccgcttgggtggagaggctattcggctatgactgggcacaacagacaatcggctgctctg
atgccgccgtgttccggctgtcagcgcaggggcgcccggttctttttgtcaagaccgacctgtccggtgc
cctgaatgaactgcaggacgaggcagcgcggctatcgtggctggccacgacgggcgttccttgcgcagct
gtgctcgacgttgtcactgaagcgggaagggactggctgctattgggcgaagtgccggggcaggatctcc
tgtcatctcaccttgctcctgccgagaaagtatccatcatggctgatgcaatgcggcggctgcatacgct
tgatccggctacctgcccattcgaccaccaagcgaaacatcgcatcgagcgagcacgtactcggatggaa
gccggtcttgtcgatcaggatgatctggacgaagagcatcaggggctcgcgccagccgaactgttcgcca
ggctcaaggcgcgcatgcccgacggcgaggatctcgtcgtgacccatggcgatgcctgcttgccgaatat
catggtggaaaatggccgcttttctggattcatcgactgtggccggctgggtgtggcggaccgctatcag
gacatagcgttggctacccgtgatattgctgaagagcttggcggcgaatgggctgaccgcttcctcgtgc
tttacggtatcgccgctcccgattcgcagcgcatcgccttctatcgccttcttgacgagttcttctgagc
gggactctggggttcgaaatgaccgaccaagcgacgcccaacctgccatcacgatggccgcaataaaata
tctttattttcattacatctgtgtgttggttttttgtgtgaatcgatagcgataaggatccgcgtatggt
gcactctcagtacaatctgctctgatgccgcatagttaagccagccccgacacccgccaacacccgctga
cgcgccctgacgggcttgtctgctcccggcatccgcttacagacaagctgtgaccgtctccgggagctgc
atgtgtcagaggttttcaccgtcatcaccgaaacgcgcgagacgaaagggcctcgtgatacgcctatttt
tataggttaatgtcatgataataatggtttcttagacgtcaggtggcacttttcggggaaatgtgcgcgg
aacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataa
atgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgcccttattccctttt
ttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatca
gttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgcccc
gaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtattgacg
ccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcac
agaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataac
actgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgg
gggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtga
caccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagct
tcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttc
cggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcact
ggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaa
cgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaactgtcagaccaagtttact
catatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttga
taatctcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatc
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aaaggatcttcttgagatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctac
cagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagagc
gcagataccaaatactgtccttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccg
cctacatacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccg
ggttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcacaca
gcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagcattgagaaagcgccacg
cttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgaggg
agcttccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcg
atttttgtgatgctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggcctttttacggttc
ctggccttttgctggccttttgctcacatgttctttcctgcgttatcccctgattctgtggataaccgta
ttaccgcctttgagtgagctgataccgctcgccgcagccgaacgaccgagcgcagcgagtcagtgagcga
ggaagcggaagagcgcccaatacgcaaaccgcctctccccgcgcgttggccgattcattaatgcagagct
tgcaattcgcgcgtttttcaatattattgaagcatttatcagggttattgtctcatgagcggatacatat
ttgaatgtatttagaaaaataaacaaataggggttccgcgcacatttccccgaaaagtgccacctgacgt
ctaagaaaccattattatcatgacattaacctataaaaataggcgtagtacgaggccctttcactcatta
gatgcatgtcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccattg
acgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagt
atttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgt
caatgacggtaaatggcccgcctggcattatgcccagtacatgaccttatgggactttcctacttggcag
tacatctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggat
agcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcacca
aaatcaacgggactttccaaaatgtcgtaacaactccgccccattgacgcaaatgggcggtaggcgtgta
cggtgggaggtctatataagcagagctctccctatcagtgatagagatctccctatcagtgatagagatc
gtcgacgagctcgtttagtgaaccgtcagatcgcctggagacgccatccacgctgttttgacctccatag
aagacaccgggaccgatccagcctccggactctagaggatccctaccggtgatatcctcgagaccatggc
ctcctccgaggacgtcatcaaggagttcatgcgcttcaaggtgcgcatggagggctccgtgaacggccac
gagttcgagatcgagggcgagggcgagggccgcccctacgagggcacccagaccgccaagctgaaggtga
ccaagggcggccccctgcccttcgcctgggacatcctgtcccctcagttccagtacggctccaaggccta
cgtgaagcaccccgccgacatccccgactacttgaagctgtccttccccgagggcttcaagtgggagcgc
gtgatgaacttcgaggacggcggcgtggtgaccgtgacccaggactcctccctgcaggacggcgagttca
tctacaaggtgaagctgcgcggcaccaacttcccctccgacggccccgtaatgcagaagaagaccatggg
ctgggaggcctccaccgagcggatgtaccccgaggacggcgccctgaagggcgagatcaagatgaggctg
aagctgaaggacggcggccactacgacgccgaggtcaagaccacctacatggccaagaagcccgtgcagc
tgcccggcgcctacaagaccgacatcaagctggacatcacctcccacaacgaggactacaccatcgtgga
acagtacgagcgcgccgagggccgccactccaccggcgcctcgagcccatcaacaagtttgtacaaaaaa
gcaggcttcaacgcgccgctggacggcctgtcggtgagctcgtcctccaccggctcgctgggctcggcgg
ccggggcgggcggcggcgggggcgcggggctgcggttactgtctgccaacgtgcgccagctgcaccaagc
gctgaccgcgctgctgagcgaggcggagcgggagcagttcacccactgcctgaacgcttaccacgcgcgc
cgcaacgtcttcgacctggtgcgcaccctgcgcgtgctgctggacagtccggtcaagcggcgcctgctgc
ccatgcttcgtctggtcatcccgcgctccgaccagctgctcttcgaccaatacacggccgagggcctcta
cctgcccgccaccaccccctacaggcagcccgcctggggcggccccgacagcgcggggccaggggaggtg
cgcctggtgagtttgcggcgtgccaaggcccacgagggcttgggcttcagcatccgtgggggctcggagc
acggcgtgggcatctacgtgtctctggtggaaccaggctctctagctgagaaggaaggactgcgggtcgg
ggaccagattctgcgcgtcaacgacaaatccctggcccgggtgacccacgcggaggccgtcaaggctctg
aagggctccaagaagctggtgctgtctgtgtactcagcagggcgcatccctgggggctacgtcaccaacc
acatctacacctgggtggacccgcagggccgcagcatctccccaccctcgggcctgccccagccccacgg
tggtgccctgaggcagcaggagggtgaccggaggagcaccctgcacctcctgcaaggaggggatgagaaa
aaggtgaacctggtgctgggggacggccggtccctgggcctcacgatccgtgggggagctgagtacggcc
ttggcatttacatcactggcgtggacccaggctctgaagcagaaggcagcgggctcaaggttggggacca
gattctagaagtgaatgggcggagctttctcaacatcctacacgacgaggctgtcaggctgcttaagtca
tctcggcacctcatcctgacagtgaaggacgtcgggaggctgccccatgcccgcaccactgtggacgaga
ccaagtggatcgccagttcccggatcagggagaccatggcgaactcggcagggtttcttggcgatctcac
aacagaaggaataaacaagccaggattttacaagggcccagccggctcccaggtgaccctgagcagcctg
gggaaccagacacgagtgctgctggaggagcaggctcggcacctgctgaacgagcaggaacacgccacca
tggcctactacctggatgagtaccgtggcggcagcgtctctgtggaggccctcgtcatggccctgttcaa
gctgctcaacacccacgccaagttctcactcctctctgaggtgagaggcaccatttccccgcaagaccta
gaacgcttcgaccacctggtgctgaggcgtgagattgagtccatgaaggcgcggcagcccccaggccccg
gggctggggacacctactccatggtctcctacagtgacacgggttcatccacaggcagccacggcacctc
caccaccgtcagctcggccaggaacactctggacctggaggaaactggcgaggctgtccagggcaatatc
aacgccctcccagatgtgtccgtggatgatgtcagatccacctcccaggggctgtcaagcttcaagccac
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tgcctcgcccaccacctctggcccaaggcaacgacctcccactaggccagccaaggaagctggggagaga
ggacctccagccaccttcctccacgccttcctgctcgggcactgtcttctcggctccacagaaccgcagc
ccgccagcgggcaccgcacccaccccagggacctcctctgcacaggacttgccctcttcccccatctatg
cctccgtctcccctgccaaccccagctccaagaggccgctggacgcccatctggccctggtcaaccaaca
ccccatcggccccttcccacgggtccagtcacccccgcacctgaaaagcccctctgcagaggccacagtg
gctgggggctgccttctgcccccatcaccctctggccacccagaccagacaggcacaaaccagcactttg
tcatggtggaggtccaccgccccgacagcgagccagacgtcaatgaagtgagggcgctgccccagacgcg
cacctctacgctctcccagctctcggacagcgggcagactctaagcgaggacagtggtgtggatgctggc
gaggcagaggccagcgccccaggccgaggaaggcagtcggcgtccaccaagagcaggagtagcaaggagc
tgcctcggaacgagaggcccacagatggggccaacaaaccgcctggacttctggagcccacgtccactct
ggtccgtgtgaagaaaagtgcggccaccctgggcatcgccatcgagggtggcgccaacacccgccagccc
ctgcctaggattgtcactattcagagaggcggctcagctcacaactgtgggcagctcaaggtgggccacg
tgattctggaagtgaatgggctgacgcttcggggcaaggagcaccgggaggccgcccgcattatcgccga
ggccttcaagactaaggaccgtgactacattgactttctggtcactgagttcaatgtgatgctctagcac
ccagcttt 
 
red: mRFP tag 
blue: whirlin cDNA
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Appendix 7- Recipe of used buffers and reagents   
 
Running buffer (X5 stock): 
15.135g Tris-Base 
71.315g glycine 
0.5g SDS (0.1%) 
Make up to 1L using dH2O. 
For x1, dilute 1:5 with dH2O 
 
Transfer buffer: 
15.135g Tris-Base 
71.315g glycine 
Make up to 1L using dH2O. 
For X1, add 20% methanol: 
 
PBST: add 500ul of Tween to 1L DPBS.  
 
Stripping buffer: 
3.8gTris-Base 
10g SDS  
3500ul β-mercaptoethanol 
Make up to 500ml using dH2O. 
Correct pH to 6.8 using HCl.  
 
Laemmli Buffer: 
3.75 ml of 1M Tris-HCl pH 6.8 
15ml  of 100% glycerol 
0.6ml of 1% bromophenol blue 
6ml of 20% SDS 
Make up to 30ml using dH2O. 
Add β-mercaptoethanol before use (200ul to 800ul sample buffer) 
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Appendix 8- List of X-linked genes known to be associated with ID.  
 
This list is based on updated information from University of Colorado Denver, 
(http://gfuncpathdb.ucdenver.edu/iddrc/iddrc/data/IDgenelist_chr.html) 
 
No 
Gene 
Symbol 
Gene Names 
1 ABCD1 ATP-binding cassette, sub-family D (ALD), member 1 
2 ACSL4 acyl-CoA synthetase long-chain family member 4 
3 AFF2 AF4/FMR2 family, member 2 
4 AGTR2 angiotensin II receptor, type 2 
5 AP1S2 adaptor-related protein complex 1, sigma 2 subunit 
6 ARHGEF6 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 
7 ARHGEF9 Cdc42 guanine nucleotide exchange factor (GEF) 9 
8 ARX aristaless related homeobox 
9 ATP6AP2 ATPase, H+ transporting, lysosomal accessory protein 2 
10 ATP7A ATPase, Cu++ transporting, alpha polypeptide 
11 ATRX alpha thalassemia/mental retardation syndrome X-linked 
12 AVPR2 arginine vasopressin receptor 2 
13 BCOR BCL6 corepressor 
14 BRWD3 bromodomain and WD repeat domain containing 3 
15 CACNA1F calcium channel, voltage-dependent, L type, alpha 1F subunit 
16 CASK calcium/calmodulin-dependent serine protein kinase (MAGUK family) 
17 CDKL5 cyclin-dependent kinase-like 5 
18 CUL4B cullin 4B 
19 DCX doublecortin 
20 DKC1 dyskeratosis congenita 1, dyskerin 
21 DLG3 discs, large homolog 3 (Drosophila) 
22 DMD dystrophin 
23 FANCB Fanconi anemia, complementation group B 
24 FGD1 FYVE, RhoGEF and PH domain containing 1 
25 FLNA filamin A, alpha 
26 FMR1 fragile X mental retardation 1 
27 FRAXE fragile site, folic acid type, rare, fra(X)(q28) E 
28 FTSJ1 FtsJ homolog 1 (E. coli) 
29 G6PD glucose-6-phosphate dehydrogenase 
30 GDI1 GDP dissociation inhibitor 1 
31 GK glycerol kinase 
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No 
Gene 
Symbol 
Gene Names 
32 GPC3 glypican 3 
33 GRIA3 glutamate receptor, ionotrophic, AMPA 3 
34 HCCS holocytochrome c synthase 
35 HPRT1 hypoxanthine phosphoribosyltransferase 1 
36 HSD17B10 hydroxysteroid (17-beta) dehydrogenase 10 
37 HUWE1 HECT, UBA and WWE domain containing 1 
38 IDS iduronate 2-sulfatase 
39 IGBP1 immunoglobulin (CD79A) binding protein 1 
40 IKBKG inhibitor of kappa light polypeptide gene enhancer in B-cells 
41 IL1RAPL1 interleukin 1 receptor accessory protein-like 1 
42 IQSEC2 IQ motif and Sec7 domain 2 
43 KDM5C lysine (K)-specific demethylase 5C 
44 KIAA2022 KIAA2022 
45 KLF8 Kruppel-like factor 8 
46 L1CAM L1 cell adhesion molecule 
47 LAMP2 lysosomal-associated membrane protein 2 
48 MAGT1 magnesium transporter 1 
49 MAOA monoamine oxidase A 
50 MECP2 methyl CpG binding protein 2 (Rett syndrome) 
51 MED12 mediator complex subunit 12 
52 MID1 midline 1 (Opitz/BBB syndrome) 
53 NDP Norrie disease (pseudoglioma) 
54 NDUFA1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1 
55 NHS Nance-Horan syndrome  
56 NLGN3 neuroligin 3 
57 NLGN4X neuroligin 4, X-linked 
58 OCRL oculocerebrorenal syndrome of Lowe 
59 OFD1 oral-facial-digital syndrome 1 
60 OPHN1 oligophrenin 1 
61 OTC ornithine carbamoyltransferase 
62 PAK3 p21 protein (Cdc42/Rac)-activated kinase 3 
63 PCDH19 protocadherin 19 
64 PDHA1 pyruvate dehydrogenase (lipoamide) alpha 1 
65 PGK1 phosphoglycerate kinase 1 
66 PHF6 PHD finger protein 6 
67 PHF8 PHD finger protein 8 
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No 
Gene 
Symbol 
Gene Names 
68 PLP1 proteolipid protein 1 
69 PORCN porcupine homolog (Drosophila) 
70 PQBP1 polyglutamine binding protein 1 
71 PRPS1 phosphoribosyl pyrophosphate synthetase 1 
72 PTCHD1 patched domain containing 1 
73 RAB39B RAB39B, member RAS oncogene family 
74 RAB40AL RAB40A, member RAS oncogene family-like 
75 RPS6KA3 ribosomal protein S6 kinase, 90kDa, polypeptide 3 
76 SHROOM4 shroom family member 4 
77 SLC16A2 solute carrier family 16, member 2 (monocarboxylic acid transporter 8) 
78 SLC6A8 
solute carrier family 6 (neurotransmitter transporter, creatine), 
member 8 
79 SLC9A6 solute carrier family 9 (sodium/hydrogen exchanger), member 6 
80 SMC1A structural maintenance of chromosomes 1A 
81 SMS spermine synthase 
82 SOX3 SRY (sex determining region Y)-box 3 
83 SRPX2 sushi-repeat containing protein, X-linked 2 
84 SYN1 synapsin I 
85 SYP synaptophysin 
86 TIMM8A translocase of inner mitochondrial membrane 8 homolog A (yeast) 
87 TSPAN7 tetraspanin 7 
88 UBE2A ubiquitin-conjugating enzyme E2A 
89 UPF3B UPF3 regulator of nonsense transcripts homolog B (yeast) 
90 ZDHHC15 zinc finger, DHHC-type containing 15 
91 ZDHHC9 zinc finger, DHHC-type containing 9 
92 ZNF41 zinc finger protein 41 
93 ZNF674 zinc finger protein 674 
94 ZNF711 zinc finger protein 711 
95 ZNF81 zinc finger protein 81 
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Appendix 9- CG10362 expression following RNAi in males and females 
These charts were generated from the qPCR that was done to measure the 
expression of CG10632.  The expression was normalised by expression of eEF-
1a (Eukaryotic elongation factor 1-alpha). The upper chart (Figure A) indicates 
the CG10632 expression in different geneotypes of Drosophila. Comparing with 
the RNAi responder and wild type (WT) flies, the progeny of RNAi responde and 
actin driver show  an obvious CG10632 reduction. Figure B shows the 
compensation effect in CG10632 expression, at which the female progeny of 
RNAi responder and actin driver cross has an incresed expression of  CG10632. 
This expreiment was only done once and no error bars could be generated.  
 
Figure A 
 
Figure B 
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 Appendix 10: List of the genes located in the 13q region (76,482,752..82,585,964) 
 
start stop Symbol Description 
77454304 77460540 KCTD12 
potassium channel tetramerization domain 
containing 12 
77502585 77503224 BTF3P11 basic transcription factor 3 pseudogene 11 
77522694 77532777 ACOD1 aconitate decarboxylase 1 
77555247 77556072 RPL7P44 ribosomal protein L7 pseudogene 44 
77558877 77563104 DHX9P1 DEAH-box helicase 9 pseudogene 1 
77566059 77576652 CLN5 ceroid-lipofuscinosis, neuronal 5 
77579389 77601331 FBXL3 F-box and leucine rich repeat protein 3 
77618792 77901177 MYCBP2 
MYC binding protein 2, E3 ubiquitin protein 
ligase 
77649649 77661911 MYCBP2-AS1 MYCBP2 antisense RNA 1 
78109809 78219398 SCEL sciellin 
78197507 78197607 RNY3P7 RNA, Ro-associated Y3 pseudogene 7 
78233548 78233808 SPTLC1P5 
serine palmitoyltransferase long chain base 
subunit 1 pseudogene 5 
78235511 78236536 LOC100129307 putative UPF0607 protein ENSP00000383144 
78271989 78338377 SLAIN1 SLAIN motif family member 1 
78272147 78272251 MIR3665 microRNA 3665 
78393072 78482577 EDNRB-AS1 EDNRB antisense RNA 1 
78469616 78549664 EDNRB endothelin receptor type B 
78555981 78571963 LINC01069 long intergenic non-protein coding RNA 1069 
78587018 78627730 LINC00446 long intergenic non-protein coding RNA 446 
78628990 79191460 RNF219-AS1 RNF219 antisense RNA 1 
78996958 78997309 RPL31P54 ribosomal protein L31 pseudogene 54 
79062317 79062647 TCEB1P23 
transcription elongation factor B subunit 1 
pseudogene 23 
79173227 79177695 POU4F1 POU class 4 homeobox 1 
79188421 79233314 RNF219 ring finger protein 219 
79335269 79335821 RPL21P111 ribosomal protein L21 pseudogene 111 
79361454 79398991 LINC00331 long intergenic non-protein coding RNA 331 
79423366 79425343 HSPD1P8 
heat shock protein family D (Hsp60) member 1 
pseudogene 8 
79483065 79484682 CCT5P2 
chaperonin containing TCP1 subunit 5 
pseudogene 2 
79484857 79484966 CCT5-2P 
chaperonin containing TCP1, subunit 5 (epsilon) 
pseudogene 2 
79664900 79665309 NIPA2P5 
non imprinted in Prader-Willi/Angelman 
syndrome 2 pseudogene 5 
79740362 79741024 BCAS2P3 
breast carcinoma amplified sequence 2 
pseudogene 3 
79885962 79980393 RBM26 RNA binding motif protein 26 
79963669 79963766 RNA5SP33 RNA, 5S ribosomal pseudogene 33 
79980444 79998471 RBM26-AS1 RBM26 antisense RNA 1 
80051499 80055366 NDFIP2-AS1 NDFIP2 antisense RNA 1 
80055259 80130212 NDFIP2 Nedd4 family interacting protein 2 
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start stop Symbol Description 
80446721 80492171 LINC00382 long intergenic non-protein coding RNA 382 
80616827 80624465 LOC101927216 uncharacterized LOC101927216 
80774284 80785454 LOC101927238 uncharacterized LOC101927238 
80910111 80915086 SPRY2 sprouty RTK signaling antagonist 2 
81192905 81194261 HNRNPA1P31 
heterogeneous nuclear ribonucleoprotein A1 
pseudogene 31 
81228890 81231137 PWWP2AP1 PWWP domain containing 2A pseudogene 1 
81455698 81463020 ARF4P4 ADP ribosylation factor 4 pseudogene 4 
81847005 81847302 HIGD1AP2 
HIG1 hypoxia inducible domain family member 
1A pseudogene 2 
82264031 82265215 PTMAP5 prothymosin, alpha pseudogene 5 
 
 
